CA2591963A1 - Tricyclic o-opioid modulators - Google Patents
Tricyclic o-opioid modulators Download PDFInfo
- Publication number
- CA2591963A1 CA2591963A1 CA002591963A CA2591963A CA2591963A1 CA 2591963 A1 CA2591963 A1 CA 2591963A1 CA 002591963 A CA002591963 A CA 002591963A CA 2591963 A CA2591963 A CA 2591963A CA 2591963 A1 CA2591963 A1 CA 2591963A1
- Authority
- CA
- Canada
- Prior art keywords
- aza
- bicyclo
- oct
- phenyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 448
- 239000000203 mixture Substances 0.000 claims abstract description 185
- -1 tetrahydropyrimidinyl Chemical group 0.000 claims description 468
- 125000001424 substituent group Chemical group 0.000 claims description 247
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 202
- 229910052739 hydrogen Inorganic materials 0.000 claims description 158
- 239000001257 hydrogen Substances 0.000 claims description 156
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 148
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 claims description 114
- 150000002431 hydrogen Chemical group 0.000 claims description 95
- 229910052736 halogen Inorganic materials 0.000 claims description 77
- 150000002367 halogens Chemical class 0.000 claims description 75
- 125000004076 pyridyl group Chemical group 0.000 claims description 69
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 66
- 125000001072 heteroaryl group Chemical group 0.000 claims description 66
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 66
- 125000001544 thienyl group Chemical group 0.000 claims description 65
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 60
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 59
- 125000001153 fluoro group Chemical group F* 0.000 claims description 58
- 229910052757 nitrogen Inorganic materials 0.000 claims description 58
- 125000002883 imidazolyl group Chemical group 0.000 claims description 57
- 150000003839 salts Chemical class 0.000 claims description 54
- 125000002541 furyl group Chemical group 0.000 claims description 53
- 125000000623 heterocyclic group Chemical group 0.000 claims description 52
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 50
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 46
- 239000012453 solvate Substances 0.000 claims description 46
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 45
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 44
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 43
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 38
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 37
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 37
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 36
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 125000002971 oxazolyl group Chemical group 0.000 claims description 32
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 32
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 31
- 125000001041 indolyl group Chemical group 0.000 claims description 31
- 125000003342 alkenyl group Chemical group 0.000 claims description 30
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 30
- 125000000304 alkynyl group Chemical group 0.000 claims description 29
- 229910052760 oxygen Inorganic materials 0.000 claims description 28
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 28
- 239000003085 diluting agent Substances 0.000 claims description 27
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 27
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 27
- 125000000335 thiazolyl group Chemical group 0.000 claims description 27
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 26
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 25
- 125000003386 piperidinyl group Chemical group 0.000 claims description 25
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 23
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 23
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 22
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 21
- RIFHJAODNHLCBH-UHFFFAOYSA-N methanethione Chemical group S=[CH] RIFHJAODNHLCBH-UHFFFAOYSA-N 0.000 claims description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 17
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 17
- 125000004682 aminothiocarbonyl group Chemical group NC(=S)* 0.000 claims description 16
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 16
- 125000004316 oxathiadiazolyl group Chemical group O1SNN=C1* 0.000 claims description 16
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 15
- 239000003937 drug carrier Substances 0.000 claims description 15
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 15
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 12
- 125000004122 cyclic group Chemical group 0.000 claims description 12
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 12
- 125000004306 triazinyl group Chemical group 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 125000001246 bromo group Chemical group Br* 0.000 claims description 10
- 125000004372 methylthioethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])* 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 108010036895 endo-alpha-sialidase Proteins 0.000 claims description 9
- IQJUMHCOVVWODY-UHFFFAOYSA-N n,n-diethyl-10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenoxazine-3-carboxamide Chemical compound C12=CC=CC=C2OC2=CC(C(=O)N(CC)CC)=CC=C2N1C1CC(N2C)CCC2C1 IQJUMHCOVVWODY-UHFFFAOYSA-N 0.000 claims description 9
- 125000001624 naphthyl group Chemical group 0.000 claims description 9
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 8
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 8
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims description 8
- 125000005394 methallyl group Chemical group 0.000 claims description 8
- YXUADZBMAKQMDY-UHFFFAOYSA-N n,n-diethyl-6-methoxy-10-[8-(2-phenylethyl)-8-azabicyclo[3.2.1]octan-3-yl]phenoxazine-3-carboxamide Chemical compound C12=CC=CC(OC)=C2OC2=CC(C(=O)N(CC)CC)=CC=C2N1C(C1)CC2CCC1N2CCC1=CC=CC=C1 YXUADZBMAKQMDY-UHFFFAOYSA-N 0.000 claims description 8
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 8
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 8
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 8
- 125000001425 triazolyl group Chemical group 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 6
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 6
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- GAZIVHWUTJBTSX-UHFFFAOYSA-N 10-(8-azabicyclo[3.2.1]octan-3-yl)-n,n-diethyl-6-methoxyphenothiazine-3-carboxamide Chemical compound C12=CC=CC(OC)=C2SC2=CC(C(=O)N(CC)CC)=CC=C2N1C1CC(N2)CCC2C1 GAZIVHWUTJBTSX-UHFFFAOYSA-N 0.000 claims description 4
- PMSZBCJFAJMFFU-UHFFFAOYSA-N 10-[8-(pyridin-2-ylmethyl)-8-azabicyclo[3.2.1]octan-3-yl]-3-(2h-tetrazol-5-yl)phenothiazine Chemical compound C=1C=CC=NC=1CN1C(C2)CCC1CC2N(C1=CC=2)C3=CC=CC=C3SC1=CC=2C=1N=NNN=1 PMSZBCJFAJMFFU-UHFFFAOYSA-N 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims description 4
- GDTKTCUECBMQJB-UHFFFAOYSA-N n-[2-[10-(8-azabicyclo[3.2.1]octan-3-yl)phenothiazin-3-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C1=CC=C(N(C2CC3CCC(N3)C2)C=2C(=CC=CC=2)S2)C2=C1 GDTKTCUECBMQJB-UHFFFAOYSA-N 0.000 claims description 4
- ACBBGYHLLZZZNA-UHFFFAOYSA-N n-[2-[10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenothiazin-3-yl]phenyl]acetamide Chemical compound CN1C(C2)CCC1CC2N(C1=CC=2)C3=CC=CC=C3SC1=CC=2C1=CC=CC=C1NC(C)=O ACBBGYHLLZZZNA-UHFFFAOYSA-N 0.000 claims description 4
- FWPXPWLXZLOILZ-UHFFFAOYSA-N 10-(8-azabicyclo[3.2.1]octan-3-yl)-3-(2h-tetrazol-5-yl)phenothiazine Chemical compound C1C(N2)CCC2CC1N(C1=CC=2)C3=CC=CC=C3SC1=CC=2C=1N=NNN=1 FWPXPWLXZLOILZ-UHFFFAOYSA-N 0.000 claims description 3
- NEPRXTXEQLOPPD-UHFFFAOYSA-N 10-(8-azabicyclo[3.2.1]octan-3-yl)-7-pyridin-3-ylphenothiazin-4-ol Chemical compound C1=C2SC=3C(O)=CC=CC=3N(C3CC4CCC(N4)C3)C2=CC=C1C1=CC=CN=C1 NEPRXTXEQLOPPD-UHFFFAOYSA-N 0.000 claims description 3
- YQIRQOWQIHMBAJ-UHFFFAOYSA-N 10-(8-azabicyclo[3.2.1]octan-3-yl)-n,n-diethyl-6-methoxyphenoxazine-3-carboxamide Chemical compound C12=CC=CC(OC)=C2OC2=CC(C(=O)N(CC)CC)=CC=C2N1C1CC(N2)CCC2C1 YQIRQOWQIHMBAJ-UHFFFAOYSA-N 0.000 claims description 3
- XBDIEUMCRJHLDE-UHFFFAOYSA-N 10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-3-(2h-tetrazol-5-yl)phenothiazine Chemical compound CN1C(C2)CCC1CC2N(C1=CC=2)C3=CC=CC=C3SC1=CC=2C=1N=NNN=1 XBDIEUMCRJHLDE-UHFFFAOYSA-N 0.000 claims description 3
- SZRDBMPFELOGSL-UHFFFAOYSA-N 10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-3-(2h-tetrazol-5-yl)phenoxazine Chemical compound CN1C(C2)CCC1CC2N(C1=CC=2)C3=CC=CC=C3OC1=CC=2C=1N=NNN=1 SZRDBMPFELOGSL-UHFFFAOYSA-N 0.000 claims description 3
- YPZDPDVDYHVSJU-UHFFFAOYSA-N 10-[8-(2-phenylethyl)-8-azabicyclo[3.2.1]octan-3-yl]-3-(2h-tetrazol-5-yl)phenothiazine Chemical compound C1C(N2C3=CC=C(C=C3SC3=CC=CC=C32)C2=NNN=N2)CC2CCC1N2CCC1=CC=CC=C1 YPZDPDVDYHVSJU-UHFFFAOYSA-N 0.000 claims description 3
- BAIRRGJMVPUERJ-UHFFFAOYSA-N 10-[8-(furan-3-ylmethyl)-8-azabicyclo[3.2.1]octan-3-yl]-3-pyridin-3-ylphenothiazine Chemical compound C1=COC=C1CN1C(C2)CCC1CC2N(C1=CC=2)C3=CC=CC=C3SC1=CC=2C1=CC=CN=C1 BAIRRGJMVPUERJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 claims description 3
- FQQQABYDYFQIIV-UHFFFAOYSA-N 3-[10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenoxazin-3-yl]-2h-1,2,4-oxadiazol-5-one Chemical compound CN1C(C2)CCC1CC2N(C1=CC=2)C3=CC=CC=C3OC1=CC=2C1=NC(=O)ON1 FQQQABYDYFQIIV-UHFFFAOYSA-N 0.000 claims description 3
- LUKRWHSSNWXFBF-UHFFFAOYSA-N 3-pyridin-4-yl-10-[8-(thiophen-2-ylmethyl)-8-azabicyclo[3.2.1]octan-3-yl]phenothiazine Chemical compound C=1C=CSC=1CN1C(C2)CCC1CC2N(C1=CC=2)C3=CC=CC=C3SC1=CC=2C1=CC=NC=C1 LUKRWHSSNWXFBF-UHFFFAOYSA-N 0.000 claims description 3
- DPADQLSYPGNRMT-UHFFFAOYSA-N [10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenothiazin-3-yl]-pyrrolidin-1-ylmethanone Chemical compound CN1C(C2)CCC1CC2N(C1=CC=2)C3=CC=CC=C3SC1=CC=2C(=O)N1CCCC1 DPADQLSYPGNRMT-UHFFFAOYSA-N 0.000 claims description 3
- LZJHHBUWJJTNCB-UHFFFAOYSA-N [10-[8-(3-methylbut-2-enyl)-8-azabicyclo[3.2.1]octan-3-yl]phenothiazin-3-yl]-(3-methylpyrrolidin-1-yl)methanone Chemical compound C1C(C)CCN1C(=O)C1=CC=C(N(C2CC3CCC(N3CC=C(C)C)C2)C=2C(=CC=CC=2)S2)C2=C1 LZJHHBUWJJTNCB-UHFFFAOYSA-N 0.000 claims description 3
- WSLCJCHTYMOWBU-UHFFFAOYSA-N [10-[8-(furan-3-ylmethyl)-8-azabicyclo[3.2.1]octan-3-yl]phenothiazin-3-yl]-pyrrolidin-1-ylmethanone Chemical compound C=1C=C2N(C3CC4CCC(N4CC4=COC=C4)C3)C3=CC=CC=C3SC2=CC=1C(=O)N1CCCC1 WSLCJCHTYMOWBU-UHFFFAOYSA-N 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- OFPALBUEFXLSDS-UHFFFAOYSA-N n,n-diethyl-10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenoxazine-3-carboximidamide Chemical compound C12=CC=CC=C2OC2=CC(C(=N)N(CC)CC)=CC=C2N1C1CC(N2C)CCC2C1 OFPALBUEFXLSDS-UHFFFAOYSA-N 0.000 claims description 3
- AVQLWWKIFVTYQP-UHFFFAOYSA-N n,n-diethyl-6-hydroxy-10-[8-(2-phenylethyl)-8-azabicyclo[3.2.1]octan-3-yl]phenoxazine-3-carboxamide Chemical compound C12=CC=CC(O)=C2OC2=CC(C(=O)N(CC)CC)=CC=C2N1C(C1)CC2CCC1N2CCC1=CC=CC=C1 AVQLWWKIFVTYQP-UHFFFAOYSA-N 0.000 claims description 3
- JQHJEJVFPXNISD-UHFFFAOYSA-N n,n-diethyl-6-methoxy-10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenothiazine-3-carboxamide Chemical compound C12=CC=CC(OC)=C2SC2=CC(C(=O)N(CC)CC)=CC=C2N1C1CC(N2C)CCC2C1 JQHJEJVFPXNISD-UHFFFAOYSA-N 0.000 claims description 3
- XBMSEPVJBNPWNZ-UHFFFAOYSA-N n-[2-[10-[8-(1h-imidazol-2-ylmethyl)-8-azabicyclo[3.2.1]octan-3-yl]phenothiazin-3-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C1=CC=C(N(C2CC3CCC(N3CC=3NC=CN=3)C2)C=2C(=CC=CC=2)S2)C2=C1 XBMSEPVJBNPWNZ-UHFFFAOYSA-N 0.000 claims description 3
- WGFGTYPVGRSKMM-UHFFFAOYSA-N n-[2-[10-[8-(2-phenylethyl)-8-azabicyclo[3.2.1]octan-3-yl]phenothiazin-3-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C1=CC=C(N(C2CC3CCC(N3CCC=3C=CC=CC=3)C2)C=2C(=CC=CC=2)S2)C2=C1 WGFGTYPVGRSKMM-UHFFFAOYSA-N 0.000 claims description 3
- JZDTZSGLBSSNIG-UHFFFAOYSA-N n-[2-[10-[8-(furan-3-ylmethyl)-8-azabicyclo[3.2.1]octan-3-yl]phenothiazin-3-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C1=CC=C(N(C2CC3CCC(N3CC3=COC=C3)C2)C=2C(=CC=CC=2)S2)C2=C1 JZDTZSGLBSSNIG-UHFFFAOYSA-N 0.000 claims description 3
- GQPBCWLLSZWEML-UHFFFAOYSA-N n-ethyl-10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenothiazine-3-carboxamide Chemical compound C12=CC=CC=C2SC2=CC(C(=O)NCC)=CC=C2N1C1CC(N2C)CCC2C1 GQPBCWLLSZWEML-UHFFFAOYSA-N 0.000 claims description 3
- QBLSUTOIYIFNJG-UHFFFAOYSA-N n-methyl-10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-n-(2-phenylethyl)phenoxazine-3-carboxamide Chemical compound C=1C=C2N(C3CC4CCC(N4C)C3)C3=CC=CC=C3OC2=CC=1C(=O)N(C)CCC1=CC=CC=C1 QBLSUTOIYIFNJG-UHFFFAOYSA-N 0.000 claims description 3
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 3
- ITGXPHWIBDIWIN-UHFFFAOYSA-N (3-hydroxypyrrolidin-1-yl)-[10-[8-(2-phenylethyl)-8-azabicyclo[3.2.1]octan-3-yl]phenothiazin-3-yl]methanone Chemical compound C1C(O)CCN1C(=O)C1=CC=C(N(C2CC3CCC(N3CCC=3C=CC=CC=3)C2)C=2C(=CC=CC=2)S2)C2=C1 ITGXPHWIBDIWIN-UHFFFAOYSA-N 0.000 claims description 2
- NDBVZPWMWRLYNK-UHFFFAOYSA-N 10-(8-azabicyclo[3.2.1]octan-3-yl)-6-methoxy-3-pyridin-3-ylphenothiazine Chemical compound C1=C2SC=3C(OC)=CC=CC=3N(C3CC4CCC(N4)C3)C2=CC=C1C1=CC=CN=C1 NDBVZPWMWRLYNK-UHFFFAOYSA-N 0.000 claims description 2
- MGRSFDALNXDFPR-UHFFFAOYSA-N 10-[8-(3-methylbut-2-enyl)-8-azabicyclo[3.2.1]octan-3-yl]-3-pyridin-3-ylphenothiazine Chemical compound CC(C)=CCN1C(C2)CCC1CC2N(C1=CC=2)C3=CC=CC=C3SC1=CC=2C1=CC=CN=C1 MGRSFDALNXDFPR-UHFFFAOYSA-N 0.000 claims description 2
- QKWPCCGOJRUJCU-UHFFFAOYSA-N 3-pyridin-3-yl-10-[8-(pyridin-2-ylmethyl)-8-azabicyclo[3.2.1]octan-3-yl]phenothiazine Chemical compound C=1C=CC=NC=1CN1C(C2)CCC1CC2N(C1=CC=2)C3=CC=CC=C3SC1=CC=2C1=CC=CN=C1 QKWPCCGOJRUJCU-UHFFFAOYSA-N 0.000 claims description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- YARPVGVUZQSQGI-UHFFFAOYSA-N [10-[8-(2-phenylethyl)-8-azabicyclo[3.2.1]octan-3-yl]phenothiazin-3-yl]-pyrrolidin-1-ylmethanone Chemical compound C=1C=C2N(C3CC4CCC(N4CCC=4C=CC=CC=4)C3)C3=CC=CC=C3SC2=CC=1C(=O)N1CCCC1 YARPVGVUZQSQGI-UHFFFAOYSA-N 0.000 claims description 2
- OIXHYHKXJZYQMD-UHFFFAOYSA-N [10-[8-(3-methylbut-2-enyl)-8-azabicyclo[3.2.1]octan-3-yl]phenothiazin-3-yl]-pyrrolidin-1-ylmethanone Chemical compound CC(C)=CCN1C(C2)CCC1CC2N(C1=CC=2)C3=CC=CC=C3SC1=CC=2C(=O)N1CCCC1 OIXHYHKXJZYQMD-UHFFFAOYSA-N 0.000 claims description 2
- LCKGNWDPNOBKTF-UHFFFAOYSA-N [10-[8-(furan-3-ylmethyl)-8-azabicyclo[3.2.1]octan-3-yl]phenothiazin-3-yl]-(3-hydroxypyrrolidin-1-yl)methanone Chemical compound C1C(O)CCN1C(=O)C1=CC=C(N(C2CC3CCC(N3CC3=COC=C3)C2)C=2C(=CC=CC=2)S2)C2=C1 LCKGNWDPNOBKTF-UHFFFAOYSA-N 0.000 claims description 2
- NHMCEZAAYYQMAX-UHFFFAOYSA-N n,n-diethyl-10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenothiazine-3-carboximidamide Chemical compound C12=CC=CC=C2SC2=CC(C(=N)N(CC)CC)=CC=C2N1C1CC(N2C)CCC2C1 NHMCEZAAYYQMAX-UHFFFAOYSA-N 0.000 claims description 2
- NOGSJGLGTSVADD-UHFFFAOYSA-N n,n-diethyl-10-[8-(2-phenylethyl)-8-azabicyclo[3.2.1]octan-3-yl]phenothiazine-3-carboximidamide Chemical compound C12=CC=CC=C2SC2=CC(C(=N)N(CC)CC)=CC=C2N1C(C1)CC2CCC1N2CCC1=CC=CC=C1 NOGSJGLGTSVADD-UHFFFAOYSA-N 0.000 claims description 2
- HLUTYKTZQLCFCL-UHFFFAOYSA-N n,n-diethyl-10-[8-(pyridin-2-ylmethyl)-8-azabicyclo[3.2.1]octan-3-yl]phenothiazine-3-carboximidamide Chemical compound C12=CC=CC=C2SC2=CC(C(=N)N(CC)CC)=CC=C2N1C(C1)CC2CCC1N2CC1=CC=CC=N1 HLUTYKTZQLCFCL-UHFFFAOYSA-N 0.000 claims description 2
- AWFPWGPEQHMHGZ-UHFFFAOYSA-N n,n-diethyl-6-methoxy-10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenoxazine-3-carboxamide Chemical compound C12=CC=CC(OC)=C2OC2=CC(C(=O)N(CC)CC)=CC=C2N1C1CC(N2C)CCC2C1 AWFPWGPEQHMHGZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- IUKUSCZCHHAPIZ-UHFFFAOYSA-N (3-hydroxypyrrolidin-1-yl)-[10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenothiazin-3-yl]methanone Chemical compound CN1C(C2)CCC1CC2N(C1=CC=2)C3=CC=CC=C3SC1=CC=2C(=O)N1CCC(O)C1 IUKUSCZCHHAPIZ-UHFFFAOYSA-N 0.000 claims 1
- LPVIKCYZXPWBSI-UHFFFAOYSA-N (3-hydroxypyrrolidin-1-yl)-[10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenoxazin-3-yl]methanone Chemical compound CN1C(C2)CCC1CC2N(C1=CC=2)C3=CC=CC=C3OC1=CC=2C(=O)N1CCC(O)C1 LPVIKCYZXPWBSI-UHFFFAOYSA-N 0.000 claims 1
- OWACVAYLWFWVGJ-UHFFFAOYSA-N 10-(8-azabicyclo[3.2.1]octan-3-yl)-3-pyridin-3-ylphenothiazine Chemical compound C1C(N2)CCC2CC1N(C1=CC=2)C3=CC=CC=C3SC1=CC=2C1=CC=CN=C1 OWACVAYLWFWVGJ-UHFFFAOYSA-N 0.000 claims 1
- YCVHCJJBOOQVKB-UHFFFAOYSA-N 10-(8-azabicyclo[3.2.1]octan-3-yl)-n,n-diethyl-6-hydroxyphenothiazine-3-carboxamide Chemical compound C12=CC=CC(O)=C2SC2=CC(C(=O)N(CC)CC)=CC=C2N1C1CC(N2)CCC2C1 YCVHCJJBOOQVKB-UHFFFAOYSA-N 0.000 claims 1
- TYECQOQYUPMIPP-UHFFFAOYSA-N 10-[8-(3-methylbut-2-enyl)-8-azabicyclo[3.2.1]octan-3-yl]-3-pyridin-4-ylphenothiazine Chemical compound CC(C)=CCN1C(C2)CCC1CC2N(C1=CC=2)C3=CC=CC=C3SC1=CC=2C1=CC=NC=C1 TYECQOQYUPMIPP-UHFFFAOYSA-N 0.000 claims 1
- AQQDIQUFCVBRPM-UHFFFAOYSA-N 3-pyridin-4-yl-10-[8-(pyridin-2-ylmethyl)-8-azabicyclo[3.2.1]octan-3-yl]phenothiazine Chemical compound C=1C=CC=NC=1CN1C(C2)CCC1CC2N(C1=CC=2)C3=CC=CC=C3SC1=CC=2C1=CC=NC=C1 AQQDIQUFCVBRPM-UHFFFAOYSA-N 0.000 claims 1
- 125000004650 C1-C8 alkynyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 279
- 208000002193 Pain Diseases 0.000 abstract description 19
- 230000036407 pain Effects 0.000 abstract description 15
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 abstract description 7
- 108700023159 delta Opioid Receptors Proteins 0.000 abstract description 7
- 102000048124 delta Opioid Receptors Human genes 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 238000004949 mass spectrometry Methods 0.000 description 142
- 230000006978 adaptation Effects 0.000 description 135
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 102
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 101
- 229910001868 water Inorganic materials 0.000 description 98
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 97
- 239000003480 eluent Substances 0.000 description 92
- 238000000746 purification Methods 0.000 description 68
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 61
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 58
- 238000004007 reversed phase HPLC Methods 0.000 description 54
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 48
- 239000000243 solution Substances 0.000 description 48
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 41
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 229910000027 potassium carbonate Inorganic materials 0.000 description 28
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 25
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 24
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 22
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 21
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 17
- DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 14
- 150000002923 oximes Chemical class 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- QQXLDOJGLXJCSE-KNVOCYPGSA-N tropinone Chemical compound C1C(=O)C[C@H]2CC[C@@H]1N2C QQXLDOJGLXJCSE-KNVOCYPGSA-N 0.000 description 14
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 13
- 238000005859 coupling reaction Methods 0.000 description 13
- 235000011181 potassium carbonates Nutrition 0.000 description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 12
- 150000001721 carbon Chemical group 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 12
- 208000004296 neuralgia Diseases 0.000 description 12
- 229910052763 palladium Inorganic materials 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 12
- QLORFFBWDKEFEL-UHFFFAOYSA-N 10-(8-azabicyclo[3.2.1]octan-3-yl)-3-(2h-tetrazol-5-yl)phenoxazine Chemical compound C1C(N2)CCC2CC1N(C1=CC=2)C3=CC=CC=C3OC1=CC=2C=1N=NNN=1 QLORFFBWDKEFEL-UHFFFAOYSA-N 0.000 description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 11
- 239000003054 catalyst Substances 0.000 description 11
- OCZXDVNSNDITBS-UHFFFAOYSA-N methyl 4-amino-3-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(N)C(O)=C1 OCZXDVNSNDITBS-UHFFFAOYSA-N 0.000 description 11
- 235000015320 potassium carbonate Nutrition 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 10
- 239000007983 Tris buffer Substances 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 150000002990 phenothiazines Chemical class 0.000 description 10
- 150000002991 phenoxazines Chemical class 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 10
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 10
- 238000013459 approach Methods 0.000 description 9
- 125000003710 aryl alkyl group Chemical group 0.000 description 9
- 238000009833 condensation Methods 0.000 description 9
- 230000005494 condensation Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 230000009466 transformation Effects 0.000 description 9
- AZVSIHIBYRHSLB-UHFFFAOYSA-N 3-furaldehyde Chemical compound O=CC=1C=COC=1 AZVSIHIBYRHSLB-UHFFFAOYSA-N 0.000 description 8
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 8
- 239000012131 assay buffer Substances 0.000 description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
- 229940100595 phenylacetaldehyde Drugs 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- ZWDIRSNPOHYFMZ-UHFFFAOYSA-N 3-bromo-10-[8-(furan-3-ylmethyl)-8-azabicyclo[3.2.1]octan-3-yl]phenothiazine Chemical compound C12=CC=CC=C2SC2=CC(Br)=CC=C2N1C(C1)CC2CCC1N2CC=1C=COC=1 ZWDIRSNPOHYFMZ-UHFFFAOYSA-N 0.000 description 7
- 229910015845 BBr3 Inorganic materials 0.000 description 7
- 206010029240 Neuritis Diseases 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- FVUOHQGPUWBISX-UHFFFAOYSA-N methyl 3-hydroxy-4-[(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)amino]benzoate Chemical compound OC1=CC(C(=O)OC)=CC=C1NC1CC(N2C)CCC2C1 FVUOHQGPUWBISX-UHFFFAOYSA-N 0.000 description 7
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- UMOPBIVXPOETPG-UHFFFAOYSA-N (2-acetamidophenyl)boronic acid Chemical group CC(=O)NC1=CC=CC=C1B(O)O UMOPBIVXPOETPG-UHFFFAOYSA-N 0.000 description 6
- GMWOSSBFNSZKAH-UHFFFAOYSA-N 1-fluoro-3-methoxy-2-nitrobenzene Chemical compound COC1=CC=CC(F)=C1[N+]([O-])=O GMWOSSBFNSZKAH-UHFFFAOYSA-N 0.000 description 6
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 108090000137 Opioid Receptors Proteins 0.000 description 6
- 102000003840 Opioid Receptors Human genes 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000020335 dealkylation Effects 0.000 description 6
- 238000006900 dealkylation reaction Methods 0.000 description 6
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthene Chemical compound C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 6
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical group O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 229960005181 morphine Drugs 0.000 description 6
- 150000002825 nitriles Chemical class 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 229940127240 opiate Drugs 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000004129 prosencephalon Anatomy 0.000 description 6
- 238000000159 protein binding assay Methods 0.000 description 6
- 150000003335 secondary amines Chemical class 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000000844 transformation Methods 0.000 description 6
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 6
- KIAPWMKFHIKQOZ-UHFFFAOYSA-N 2-[[(4-fluorophenyl)-oxomethyl]amino]benzoic acid methyl ester Chemical compound COC(=O)C1=CC=CC=C1NC(=O)C1=CC=C(F)C=C1 KIAPWMKFHIKQOZ-UHFFFAOYSA-N 0.000 description 5
- NYACFGCUJOARLR-UHFFFAOYSA-N 3-bromo-10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenothiazine Chemical compound C12=CC=CC=C2SC2=CC(Br)=CC=C2N1C(C1)CC2CCC1N2C NYACFGCUJOARLR-UHFFFAOYSA-N 0.000 description 5
- HOYPWHYABVULFC-UHFFFAOYSA-N 3-bromo-10-piperidin-4-ylphenothiazine Chemical compound C12=CC=CC=C2SC2=CC(Br)=CC=C2N1C1CCNCC1 HOYPWHYABVULFC-UHFFFAOYSA-N 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical group OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 150000003413 spiro compounds Chemical class 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229910052723 transition metal Inorganic materials 0.000 description 5
- 150000003624 transition metals Chemical class 0.000 description 5
- BSZGPQFFXUCDQU-UHFFFAOYSA-N 10-(8-azabicyclo[3.2.1]octan-3-yl)-3-bromo-6-methoxyphenothiazine Chemical compound C1C(N2)CCC2CC1N1C2=CC=C(Br)C=C2SC2=C1C=CC=C2OC BSZGPQFFXUCDQU-UHFFFAOYSA-N 0.000 description 4
- ZLIUSFDKSBRMBH-UHFFFAOYSA-N 10-(8-azabicyclo[3.2.1]octan-3-yl)phenothiazine-3-carbonitrile Chemical compound C12=CC=CC=C2SC2=CC(C#N)=CC=C2N1C1CC(N2)CCC2C1 ZLIUSFDKSBRMBH-UHFFFAOYSA-N 0.000 description 4
- VRYFKURYSJVVJG-UHFFFAOYSA-N 10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenoxazine-3-carbonitrile Chemical compound C12=CC=CC=C2OC2=CC(C#N)=CC=C2N1C(C1)CC2CCC1N2C VRYFKURYSJVVJG-UHFFFAOYSA-N 0.000 description 4
- FCSPXEQCZGDGQE-UHFFFAOYSA-N 10-[8-(2-phenylethyl)-8-azabicyclo[3.2.1]octan-3-yl]phenothiazine-3-carbonitrile Chemical compound C12=CC=CC=C2SC2=CC(C#N)=CC=C2N1C(C1)CC2CCC1N2CCC1=CC=CC=C1 FCSPXEQCZGDGQE-UHFFFAOYSA-N 0.000 description 4
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical class NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 4
- SEPQTYODOKLVSB-UHFFFAOYSA-N 3-methylbut-2-enal Chemical group CC(C)=CC=O SEPQTYODOKLVSB-UHFFFAOYSA-N 0.000 description 4
- OQEUNGDYFJAGQP-UHFFFAOYSA-N 6-methoxy-10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenoxazine-3-carbonitrile Chemical compound C1C(N2C)CCC2CC1N1C2=CC=C(C#N)C=C2OC2=C1C=CC=C2OC OQEUNGDYFJAGQP-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical group C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- 229910004373 HOAc Inorganic materials 0.000 description 4
- 229910017333 Mo(CO)6 Inorganic materials 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 150000005215 alkyl ethers Chemical class 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- 125000005605 benzo group Chemical group 0.000 description 4
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 4
- 229910052796 boron Inorganic materials 0.000 description 4
- 150000001728 carbonyl compounds Chemical class 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 4
- VPUGDVKSAQVFFS-UHFFFAOYSA-N coronene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3)C4=C4C3=CC=C(C=C3)C4=C2C3=C1 VPUGDVKSAQVFFS-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical group C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 206010027599 migraine Diseases 0.000 description 4
- CCFPJWHFLLRIJV-UHFFFAOYSA-N n-[2-(4-bromo-2-nitrophenyl)sulfanylphenyl]-8-methyl-8-azabicyclo[3.2.1]octan-3-amine Chemical compound CN1C(C2)CCC1CC2NC1=CC=CC=C1SC1=CC=C(Br)C=C1[N+]([O-])=O CCFPJWHFLLRIJV-UHFFFAOYSA-N 0.000 description 4
- 229940005483 opioid analgesics Drugs 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 4
- 150000002989 phenols Chemical class 0.000 description 4
- 229950000688 phenothiazine Drugs 0.000 description 4
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 4
- GBROPGWFBFCKAG-UHFFFAOYSA-N picene Chemical compound C1=CC2=C3C=CC=CC3=CC=C2C2=C1C1=CC=CC=C1C=C2 GBROPGWFBFCKAG-UHFFFAOYSA-N 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 4
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical group N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000005932 reductive alkylation reaction Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 125000004665 trialkylsilyl group Chemical group 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 3
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 3
- APPNKFSCEWLFMU-UHFFFAOYSA-N 10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenoxazine-3-carboxylic acid Chemical compound C12=CC=CC=C2OC2=CC(C(O)=O)=CC=C2N1C(C1)CC2CCC1N2C APPNKFSCEWLFMU-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 3
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical group C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 3
- ZRMMSZDSUMNHJG-UHFFFAOYSA-N 3-hydroxy-4-[(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)amino]benzonitrile Chemical compound CN1C(C2)CCC1CC2NC1=CC=C(C#N)C=C1O ZRMMSZDSUMNHJG-UHFFFAOYSA-N 0.000 description 3
- LKOWKPGBAZVHOF-UHFFFAOYSA-N 4-fluoro-3-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC(C#N)=CC=C1F LKOWKPGBAZVHOF-UHFFFAOYSA-N 0.000 description 3
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 3
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Natural products C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 150000001448 anilines Chemical class 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 3
- AUAJATGQOPRBBD-UHFFFAOYSA-N methyl 10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenoxazine-3-carboxylate Chemical compound C12=CC=CC=C2OC2=CC(C(=O)OC)=CC=C2N1C1CC(N2C)CCC2C1 AUAJATGQOPRBBD-UHFFFAOYSA-N 0.000 description 3
- YEKUKKZIHGMINZ-UHFFFAOYSA-N methyl 6-methoxy-10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenoxazine-3-carboxylate Chemical compound C12=CC=CC(OC)=C2OC2=CC(C(=O)OC)=CC=C2N1C1CC(N2C)CCC2C1 YEKUKKZIHGMINZ-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- OVTRBEOXQDEIOR-UHFFFAOYSA-N n'-hydroxy-10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenoxazine-3-carboximidamide Chemical compound C12=CC=CC=C2OC2=CC(C(\N)=N\O)=CC=C2N1C(C1)CC2CCC1N2C OVTRBEOXQDEIOR-UHFFFAOYSA-N 0.000 description 3
- FTLANOKZIXLBML-UHFFFAOYSA-N n-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide Chemical group CC(=O)NC1=CC=CC=C1B1OC(C)(C)C(C)(C)O1 FTLANOKZIXLBML-UHFFFAOYSA-N 0.000 description 3
- SASNBVQSOZSTPD-UHFFFAOYSA-N n-methylphenethylamine Chemical compound CNCCC1=CC=CC=C1 SASNBVQSOZSTPD-UHFFFAOYSA-N 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- SBZOKPOSJNBRIT-UHFFFAOYSA-N tert-butyl 3-(2-hydroxyanilino)-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(C2)CCC1CC2NC1=CC=CC=C1O SBZOKPOSJNBRIT-UHFFFAOYSA-N 0.000 description 3
- MENILFUADYEXNU-UHFFFAOYSA-N tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound C1C(=O)CC2CCC1N2C(=O)OC(C)(C)C MENILFUADYEXNU-UHFFFAOYSA-N 0.000 description 3
- AQTSNKXEMWZOGA-UHFFFAOYSA-L (2-methanidylphenyl)-bis(2-methylphenyl)phosphane;palladium(2+);diacetate Chemical compound [Pd+2].[Pd+2].CC([O-])=O.CC([O-])=O.CC1=CC=CC=C1P(C=1C(=CC=CC=1)[CH2-])C1=CC=CC=C1C.CC1=CC=CC=C1P(C=1C(=CC=CC=1)[CH2-])C1=CC=CC=C1C AQTSNKXEMWZOGA-UHFFFAOYSA-L 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical group N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 2
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 2
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 2
- IFDLUCSRKDMIPS-UHFFFAOYSA-N 10-(8-azabicyclo[3.2.1]octan-3-yl)-3-bromophenothiazine Chemical group C12=CC=CC=C2SC2=CC(Br)=CC=C2N1C1CC(N2)CCC2C1 IFDLUCSRKDMIPS-UHFFFAOYSA-N 0.000 description 2
- AKSSZLKLGWZKCY-UHFFFAOYSA-N 10-(8-azabicyclo[3.2.1]octan-3-yl)-7-bromophenothiazin-4-ol Chemical compound C1C(N2)CCC2CC1N1C2=CC=C(Br)C=C2SC2=C1C=CC=C2O AKSSZLKLGWZKCY-UHFFFAOYSA-N 0.000 description 2
- AEEJSGGSTNTNRW-UHFFFAOYSA-N 10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenothiazine-3-carbonitrile Chemical compound C12=CC=CC=C2SC2=CC(C#N)=CC=C2N1C(C1)CC2CCC1N2C AEEJSGGSTNTNRW-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical group C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- ODMMNALOCMNQJZ-UHFFFAOYSA-N 1H-pyrrolizine Chemical group C1=CC=C2CC=CN21 ODMMNALOCMNQJZ-UHFFFAOYSA-N 0.000 description 2
- UGQSTTVJWUQQOQ-UHFFFAOYSA-N 2-[(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)amino]phenol Chemical compound CN1C(C2)CCC1CC2NC1=CC=CC=C1O UGQSTTVJWUQQOQ-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- VRVRGVPWCUEOGV-UHFFFAOYSA-N 2-aminothiophenol Chemical compound NC1=CC=CC=C1S VRVRGVPWCUEOGV-UHFFFAOYSA-N 0.000 description 2
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical class OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical group C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 2
- AABUSCIPSWFFNM-UHFFFAOYSA-N 3-bromo-6-methoxy-10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenothiazine Chemical class C1C(N2C)CCC2CC1N1C2=CC=C(Br)C=C2SC2=C1C=CC=C2OC AABUSCIPSWFFNM-UHFFFAOYSA-N 0.000 description 2
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 2
- CNNNDPJMKBJICD-UHFFFAOYSA-N 3-methoxy-4-[(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)amino]benzonitrile Chemical compound COC1=CC(C#N)=CC=C1NC1CC(N2C)CCC2C1 CNNNDPJMKBJICD-UHFFFAOYSA-N 0.000 description 2
- ZAKUXPKAPWYKQK-UHFFFAOYSA-N 3h-oxathiadiazole Chemical class N1SOC=N1 ZAKUXPKAPWYKQK-UHFFFAOYSA-N 0.000 description 2
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 2
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical group C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 2
- BAMAAZMJTSJZJG-UHFFFAOYSA-N 6-hydroxy-10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenoxazine-3-carbonitrile Chemical compound C12=CC=C(C#N)C=C2OC2=C(O)C=CC=C2N1C(C1)CC2CCC1N2C BAMAAZMJTSJZJG-UHFFFAOYSA-N 0.000 description 2
- 108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 108010065372 Dynorphins Proteins 0.000 description 2
- 108010049140 Endorphins Proteins 0.000 description 2
- 102000009025 Endorphins Human genes 0.000 description 2
- 108010092674 Enkephalins Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 2
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010093625 Opioid Peptides Proteins 0.000 description 2
- 102000001490 Opioid Peptides Human genes 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 238000003436 Schotten-Baumann reaction Methods 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- QVXFGVVYTKZLJN-KHPPLWFESA-N [(z)-hexadec-7-enyl] acetate Chemical compound CCCCCCCC\C=C/CCCCCCOC(C)=O QVXFGVVYTKZLJN-KHPPLWFESA-N 0.000 description 2
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 2
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 238000007083 alkoxycarbonylation reaction Methods 0.000 description 2
- 125000005012 alkyl thioether group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 125000005510 but-1-en-2-yl group Chemical group 0.000 description 2
- 125000005514 but-1-yn-3-yl group Chemical group 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000002327 cardiovascular agent Substances 0.000 description 2
- 229940125692 cardiovascular agent Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 208000018912 cluster headache syndrome Diseases 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- QSQIGGCOCHABAP-UHFFFAOYSA-N hexacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC=CC=C6C=C5C=C4C=C3C=C21 QSQIGGCOCHABAP-UHFFFAOYSA-N 0.000 description 2
- PKIFBGYEEVFWTJ-UHFFFAOYSA-N hexaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC6=CC=CC=C6C=C5C=C4C=CC3=CC2=C1 PKIFBGYEEVFWTJ-UHFFFAOYSA-N 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical group C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical group C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 2
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 102000051367 mu Opioid Receptors Human genes 0.000 description 2
- XHGSJPJETQTIGE-UHFFFAOYSA-N n-[2-(3-methoxy-2-nitrophenyl)sulfanylphenyl]-8-methyl-8-azabicyclo[3.2.1]octan-3-amine Chemical compound COC1=CC=CC(SC=2C(=CC=CC=2)NC2CC3CCC(N3C)C2)=C1[N+]([O-])=O XHGSJPJETQTIGE-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- PFTXKXWAXWAZBP-UHFFFAOYSA-N octacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC7=CC8=CC=CC=C8C=C7C=C6C=C5C=C4C=C3C=C21 PFTXKXWAXWAZBP-UHFFFAOYSA-N 0.000 description 2
- OVPVGJFDFSJUIG-UHFFFAOYSA-N octalene Chemical compound C1=CC=CC=C2C=CC=CC=CC2=C1 OVPVGJFDFSJUIG-UHFFFAOYSA-N 0.000 description 2
- WTFQBTLMPISHTA-UHFFFAOYSA-N octaphene Chemical compound C1=CC=C2C=C(C=C3C4=CC5=CC6=CC7=CC=CC=C7C=C6C=C5C=C4C=CC3=C3)C3=CC2=C1 WTFQBTLMPISHTA-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003399 opiate peptide Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 238000006053 organic reaction Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- LSQODMMMSXHVCN-UHFFFAOYSA-N ovalene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3C5=C6C(C=C3)=CC=C3C6=C6C(C=C3)=C3)C4=C5C6=C2C3=C1 LSQODMMMSXHVCN-UHFFFAOYSA-N 0.000 description 2
- ZVTQYRVARPYRRE-UHFFFAOYSA-N oxadiazol-4-one Chemical class O=C1CON=N1 ZVTQYRVARPYRRE-UHFFFAOYSA-N 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- JNGDFYLGDPAEBY-UHFFFAOYSA-N oxadiazole-4-thione Chemical class S=C1CON=N1 JNGDFYLGDPAEBY-UHFFFAOYSA-N 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- PMJHHCWVYXUKFD-UHFFFAOYSA-N penta-1,3-diene Chemical compound CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 2
- SLIUAWYAILUBJU-UHFFFAOYSA-N pentacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC=CC=C5C=C4C=C3C=C21 SLIUAWYAILUBJU-UHFFFAOYSA-N 0.000 description 2
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 2
- JQQSUOJIMKJQHS-UHFFFAOYSA-N pentaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC=CC=C5C=C4C=CC3=CC2=C1 JQQSUOJIMKJQHS-UHFFFAOYSA-N 0.000 description 2
- 238000005897 peptide coupling reaction Methods 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- DIJNSQQKNIVDPV-UHFFFAOYSA-N pleiadene Chemical compound C1=C2[CH]C=CC=C2C=C2C=CC=C3[C]2C1=CC=C3 DIJNSQQKNIVDPV-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000001749 primary amide group Chemical group 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 description 2
- LNKHTYQPVMAJSF-UHFFFAOYSA-N pyranthrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC3=C(C=CC=C4)C4=CC4=CC=C1C2=C34 LNKHTYQPVMAJSF-UHFFFAOYSA-N 0.000 description 2
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical group N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- FMKFBRKHHLWKDB-UHFFFAOYSA-N rubicene Chemical compound C12=CC=CC=C2C2=CC=CC3=C2C1=C1C=CC=C2C4=CC=CC=C4C3=C21 FMKFBRKHHLWKDB-UHFFFAOYSA-N 0.000 description 2
- WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000003334 secondary amides Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 2
- 150000003511 tertiary amides Chemical class 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 2
- 150000003536 tetrazoles Chemical group 0.000 description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical group C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 2
- 229930192474 thiophene Chemical group 0.000 description 2
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003852 triazoles Chemical group 0.000 description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 description 2
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- 125000005580 triphenylene group Chemical group 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 108020001612 μ-opioid receptors Proteins 0.000 description 2
- CMIBUZBMZCBCAT-HZPDHXFCSA-N (2r,3r)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HZPDHXFCSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- FZTLLUYFWAOGGB-UHFFFAOYSA-N 1,4-dioxane dioxane Chemical compound C1COCCO1.C1COCCO1 FZTLLUYFWAOGGB-UHFFFAOYSA-N 0.000 description 1
- SVYOXGBINYWSDQ-UHFFFAOYSA-N 1,4-dioxane;ethanol Chemical compound CCO.C1COCCO1 SVYOXGBINYWSDQ-UHFFFAOYSA-N 0.000 description 1
- XXBRUNLHYRNPHE-UHFFFAOYSA-N 10h-phenoxazine-3-carboximidamide Chemical compound C1=CC=C2OC3=CC(C(=N)N)=CC=C3NC2=C1 XXBRUNLHYRNPHE-UHFFFAOYSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical group O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- MWERVQXFJPXVOO-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine;oxolane Chemical compound C1CCOC1.C1CCCCN2CCCN=C21 MWERVQXFJPXVOO-UHFFFAOYSA-N 0.000 description 1
- LDGHLZFFKMEAOE-UHFFFAOYSA-N 2-amino-5-bromobenzenethiol Chemical compound NC1=CC=C(Br)C=C1S LDGHLZFFKMEAOE-UHFFFAOYSA-N 0.000 description 1
- FZCQMIRJCGWWCL-UHFFFAOYSA-N 2-amino-5-chlorophenol Chemical group NC1=CC=C(Cl)C=C1O FZCQMIRJCGWWCL-UHFFFAOYSA-N 0.000 description 1
- JKIFPWHZEZQCQA-UHFFFAOYSA-N 2-nitrobenzenethiol Chemical compound [O-][N+](=O)C1=CC=CC=C1S JKIFPWHZEZQCQA-UHFFFAOYSA-N 0.000 description 1
- KRTGJZMJJVEKRX-UHFFFAOYSA-N 2-phenylethan-1-yl Chemical group [CH2]CC1=CC=CC=C1 KRTGJZMJJVEKRX-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- ICNFHJVPAJKPHW-UHFFFAOYSA-N 4,4'-Thiodianiline Chemical compound C1=CC(N)=CC=C1SC1=CC=C(N)C=C1 ICNFHJVPAJKPHW-UHFFFAOYSA-N 0.000 description 1
- UQEANKGXXSENNF-UHFFFAOYSA-N 4-bromo-1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Br)=CC=C1F UQEANKGXXSENNF-UHFFFAOYSA-N 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- FPIWJQQRYHEICX-UHFFFAOYSA-N 6,11-dihydrobenzo[c][1]benzoxepine Chemical class C1OC2=CC=CC=C2CC2=CC=CC=C12 FPIWJQQRYHEICX-UHFFFAOYSA-N 0.000 description 1
- RQXFLYPAPJMSDK-UHFFFAOYSA-N 6-methoxy-10-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenoxazine-3-carboxylic acid Chemical group C1C(N2C)CCC2CC1N1C2=CC=C(C(O)=O)C=C2OC2=C1C=CC=C2OC RQXFLYPAPJMSDK-UHFFFAOYSA-N 0.000 description 1
- HJGMRAKQWLKWMH-UHFFFAOYSA-N 8-methyl-8-azabicyclo[3.2.1]octan-3-amine Chemical group C1C(N)CC2CCC1N2C HJGMRAKQWLKWMH-UHFFFAOYSA-N 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 201000006390 Brachial Plexus Neuritis Diseases 0.000 description 1
- 206010068065 Burning mouth syndrome Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 102100036873 Cyclin-I Human genes 0.000 description 1
- 102100035861 Cytosolic 5'-nucleotidase 1A Human genes 0.000 description 1
- MCMMCRYPQBNCPH-WMIMKTLMSA-N DPDPE Chemical compound C([C@H](N)C(=O)N[C@@H]1C(C)(C)SSC([C@@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)CNC1=O)C(O)=O)(C)C)C1=CC=C(O)C=C1 MCMMCRYPQBNCPH-WMIMKTLMSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- OIJXLIIMXHRJJH-KNLIIKEYSA-N Diprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)C(C)(C)O)OC)CN2CC1CC1 OIJXLIIMXHRJJH-KNLIIKEYSA-N 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 206010063491 Herpes zoster oticus Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000713124 Homo sapiens Cyclin-I Proteins 0.000 description 1
- 101000802744 Homo sapiens Cytosolic 5'-nucleotidase 1A Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 208000002472 Morton Neuroma Diseases 0.000 description 1
- 208000020059 Morton neuralgia Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- CKRZKMFTZCFYGB-UHFFFAOYSA-N N-phenylhydroxylamine Chemical compound ONC1=CC=CC=C1 CKRZKMFTZCFYGB-UHFFFAOYSA-N 0.000 description 1
- 229910017912 NH2OH Inorganic materials 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- WIYUZYBFCWCCQJ-IFKAHUTRSA-N Naltrindole Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C3=CC=CC=C3NC=25)O)CC1)O)CC1CC1 WIYUZYBFCWCCQJ-IFKAHUTRSA-N 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 206010068106 Occipital neuralgia Diseases 0.000 description 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 206010054048 Postoperative ileus Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 206010040744 Sinus headache Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000026137 Soft tissue injury Diseases 0.000 description 1
- 206010054874 Sphenopalatine neuralgia Diseases 0.000 description 1
- 208000003589 Spider Bites Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- JLFVIEQMRKMAIT-UHFFFAOYSA-N ac1l9mnz Chemical compound O.O.O JLFVIEQMRKMAIT-UHFFFAOYSA-N 0.000 description 1
- JDPAVWAQGBGGHD-UHFFFAOYSA-N aceanthrylene Chemical group C1=CC=C2C(C=CC3=CC=C4)=C3C4=CC2=C1 JDPAVWAQGBGGHD-UHFFFAOYSA-N 0.000 description 1
- SQFPKRNUGBRTAR-UHFFFAOYSA-N acephenanthrylene Chemical group C1=CC(C=C2)=C3C2=CC2=CC=CC=C2C3=C1 SQFPKRNUGBRTAR-UHFFFAOYSA-N 0.000 description 1
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000005910 aminocarbonylation reaction Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- BVUSIQTYUVWOSX-UHFFFAOYSA-N arsindole Chemical compound C1=CC=C2[As]C=CC2=C1 BVUSIQTYUVWOSX-UHFFFAOYSA-N 0.000 description 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- TWJVNKMWXNTSAP-UHFFFAOYSA-N azanium;hydroxide;hydrochloride Chemical compound [NH4+].O.[Cl-] TWJVNKMWXNTSAP-UHFFFAOYSA-N 0.000 description 1
- 125000005337 azoxy group Chemical group [N+]([O-])(=N*)* 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 239000012659 cardioprotective agent Substances 0.000 description 1
- 229940045200 cardioprotective agent Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000012790 cranial neuralgia Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 description 1
- 150000001987 diarylethers Chemical class 0.000 description 1
- 150000004833 diarylthioethers Chemical class 0.000 description 1
- JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 229950002494 diprenorphine Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 description 1
- 229950004155 etorphine Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000004967 femoral neuropathy Diseases 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 201000011349 geniculate herpes zoster Diseases 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 208000022119 inability to concentrate Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 1
- 208000037805 labour Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000032184 meralgia paresthetica Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- JHJGOVHOHUYCBQ-UHFFFAOYSA-N n,n-diethyl-10h-phenoxazine-3-carboxamide Chemical compound C1=CC=C2OC3=CC(C(=O)N(CC)CC)=CC=C3NC2=C1 JHJGOVHOHUYCBQ-UHFFFAOYSA-N 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 201000009985 neuronitis Diseases 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 210000001010 olfactory tubercle Anatomy 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- GQYRNQQEQNWITF-UHFFFAOYSA-N oxido-phenyl-sulfanylideneazanium Chemical class [O-][N+](=S)C1=CC=CC=C1 GQYRNQQEQNWITF-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000007771 sciatic neuropathy Diseases 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- HBLUGTCPWIYJKQ-UHFFFAOYSA-N tert-butyl 3-(3-pyridin-4-ylphenoxazin-10-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(C2)CCC1CC2N(C1=CC=2)C3=CC=CC=C3OC1=CC=2C1=CC=NC=C1 HBLUGTCPWIYJKQ-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000005075 thioxanthenes Chemical class 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 150000003732 xanthenes Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- 108020001588 κ-opioid receptors Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electroluminescent Light Sources (AREA)
- Lock And Its Accessories (AREA)
- Credit Cards Or The Like (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic ~-opioid modulators.
Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described. Formula (I).
Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described. Formula (I).
Description
TRICYCLIC S- OPIOID MODULATORS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims benefit to U.S. Provisional Application Serial Number 60/638,315, filed December 22, 2004, incorporated herein by reference in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT
The research and development of the invention described below was not federally sponsored.
BACKGROUND
The term "opiate" has been used to designate pharmacologically active alkaloids derived from opium, e.g., morphine, codeine, and many semi-synthetic congeners of morphine. After the isolation of peptide compounds with morphine-like actions, the term opioid was introduced to refer generically to all drugs with morphine-like actions. Included among opioids are various peptides that exhibit morphine-like activity, such as endorphins, enkephalins and dynorphins. However, some sources use the term "opiate" in a generic sense, and in such"contexts, opiate and opioid are interchangeable.
Additionally, the term opioid has been used to refer to antagonists of morphine-like drugs as well as to characterize receptors or binding sites that combine with such agents.
Opioids are generally employed as analgesics, but they may have many other pharmacological effects as well. Morphine and related opioids produce certain of their major effects on the central nervous and digestive systems.
The effects are diverse, including analgesia, drowsiness, mood changes, respiratory depression, dizziness, mental clouding, dysphoria, pruritus, increased pressure in the biliary tract, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous systems.
When therapeutic doses of morphine are given to patients with pain, they report that the pain is less intense, less discomforting, or entirely gone. In addition to experiencing relief of distress, some patients experience euphoria.
However, when morphine in a selected pain-relieving dose is given to a pain-free individual, the experience is not always pleasant; nausea is common, and vomiting may also occur. Drowsiness, inability to concentrate, difficulty in mentation, apathy, lessened physical activity, reduced visual acuity, and lethargy may ensue.
Two distinct classes of opioid molecules can bind opioid receptors: the opioid peptides (e.g., the enkephalins, dynorphins, and endorphins) and the alkaloid opiates (e.g., morphine, etorphine, diprenorphine and naloxone).
Subsequent to the initial demonstration of opiate binding sites (Pert, C. B.
and Snyder, S. H., Science (1973) 179:1011-1014), the differential pharmacological and physiological effects of both opioid peptide analogues and alkaloid opiates served to delineate multiple opioid receptors. Accordingly, three molecularly and pharmacologically distinct opioid receptor types have been described:
delta, kappa and mu. Furthermore, each type is believed to have sub-types (Wollemann, M., J Neurochem (1990) 54:1095-1101; Lord, J. A., et al., Nature (1977) 267:495-499).
All three of these opioid receptor types appear to share the same functional mechanisms at a cellular level. For example, the opioid receptors cause inhibition of adenylate cyclase, and inhibition of neurotransmitter release via both potassium channel activation and inhibition of Ca2+ channels (Evans, C. J., In: Biological Basis of Substance Abuse, S. G. Korenman & J. D.
Barchas,,eds.,.Oxford University Press (in press); North, A. R., et al., Proc Natl Acad Sci USA (1990) 87:7025-29; Gross, R. A., et al., Proc Natl Acad Sci USA
(1990) 87:7025-29; Sharma, S. K., et al., Proc Natl Acad Sci USA (1975) 72:3092-96). Although the functional mechanisms are the same, the behavioral manifestations of receptor-selective drugs differ greatly (Gilbert, P. E. &
Martin, W. R., J Pharmacol Exp Ther (1976) 198:66-82). Such differences may be attributable in part to the anatomical location of the different receptors.
Delta receptors have a more discrete distribution within the mammalian CNS than either mu or kappa receptors, with high concentrations in the amygdaloid complex, striatum, substantia nigra, olfactory bulb, olfactory tubercles, hippocampal formation, and the cerebral cortex (Mansour, A., et al., Trends in Neurosci (1988) 11:308-14). The rat cerebellum is remarkably devoid of opioid receptors including delta opioid receptors.
D. Delorme, E. Roberts and Z, Wei, World Patent WO/28275 (1998) discloses diaryl methylidenylpiperidines that are opioid analgesics, but does not disclose or suggest the compounds of the present invention.
C. Kaiser, and others (J. Med. Chem. 1974, Volume 17, pages 57-61) disclose some piperidylidene derivatives of thioxanthenes, xanthenes, dibenoxepins and acridans that are neuroleptic agents. These authors, however, do not disclose or suggest either the structure or the activity of the compounds of the present invention.
British Patent GB 1128734 (1966) discloses derivatives of 6,11-dihydrodibenzo[b,e]oxepine that are anticholinergic, anti-convulsive, muscle-relaxing, sedating, diuretic, and/or vasoactive agents. These, agents, however, differ significantly from the compounds of the present invention both structurally and pharmacologically.
There is a continuing need for new delta opioid receptor modulators as analgesics. There is a further need for delta opioid receptor selective agonists as analgesics having reduced side effects. There is also a need for delta opioid receptor antagonists as immunosuppressants, antiinflammatory agents;
agents for the treatment of neurological and psychiatric conditions, agents for the treatment of urological and reproductive conditions, medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases, having reduced side effects.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims benefit to U.S. Provisional Application Serial Number 60/638,315, filed December 22, 2004, incorporated herein by reference in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT
The research and development of the invention described below was not federally sponsored.
BACKGROUND
The term "opiate" has been used to designate pharmacologically active alkaloids derived from opium, e.g., morphine, codeine, and many semi-synthetic congeners of morphine. After the isolation of peptide compounds with morphine-like actions, the term opioid was introduced to refer generically to all drugs with morphine-like actions. Included among opioids are various peptides that exhibit morphine-like activity, such as endorphins, enkephalins and dynorphins. However, some sources use the term "opiate" in a generic sense, and in such"contexts, opiate and opioid are interchangeable.
Additionally, the term opioid has been used to refer to antagonists of morphine-like drugs as well as to characterize receptors or binding sites that combine with such agents.
Opioids are generally employed as analgesics, but they may have many other pharmacological effects as well. Morphine and related opioids produce certain of their major effects on the central nervous and digestive systems.
The effects are diverse, including analgesia, drowsiness, mood changes, respiratory depression, dizziness, mental clouding, dysphoria, pruritus, increased pressure in the biliary tract, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous systems.
When therapeutic doses of morphine are given to patients with pain, they report that the pain is less intense, less discomforting, or entirely gone. In addition to experiencing relief of distress, some patients experience euphoria.
However, when morphine in a selected pain-relieving dose is given to a pain-free individual, the experience is not always pleasant; nausea is common, and vomiting may also occur. Drowsiness, inability to concentrate, difficulty in mentation, apathy, lessened physical activity, reduced visual acuity, and lethargy may ensue.
Two distinct classes of opioid molecules can bind opioid receptors: the opioid peptides (e.g., the enkephalins, dynorphins, and endorphins) and the alkaloid opiates (e.g., morphine, etorphine, diprenorphine and naloxone).
Subsequent to the initial demonstration of opiate binding sites (Pert, C. B.
and Snyder, S. H., Science (1973) 179:1011-1014), the differential pharmacological and physiological effects of both opioid peptide analogues and alkaloid opiates served to delineate multiple opioid receptors. Accordingly, three molecularly and pharmacologically distinct opioid receptor types have been described:
delta, kappa and mu. Furthermore, each type is believed to have sub-types (Wollemann, M., J Neurochem (1990) 54:1095-1101; Lord, J. A., et al., Nature (1977) 267:495-499).
All three of these opioid receptor types appear to share the same functional mechanisms at a cellular level. For example, the opioid receptors cause inhibition of adenylate cyclase, and inhibition of neurotransmitter release via both potassium channel activation and inhibition of Ca2+ channels (Evans, C. J., In: Biological Basis of Substance Abuse, S. G. Korenman & J. D.
Barchas,,eds.,.Oxford University Press (in press); North, A. R., et al., Proc Natl Acad Sci USA (1990) 87:7025-29; Gross, R. A., et al., Proc Natl Acad Sci USA
(1990) 87:7025-29; Sharma, S. K., et al., Proc Natl Acad Sci USA (1975) 72:3092-96). Although the functional mechanisms are the same, the behavioral manifestations of receptor-selective drugs differ greatly (Gilbert, P. E. &
Martin, W. R., J Pharmacol Exp Ther (1976) 198:66-82). Such differences may be attributable in part to the anatomical location of the different receptors.
Delta receptors have a more discrete distribution within the mammalian CNS than either mu or kappa receptors, with high concentrations in the amygdaloid complex, striatum, substantia nigra, olfactory bulb, olfactory tubercles, hippocampal formation, and the cerebral cortex (Mansour, A., et al., Trends in Neurosci (1988) 11:308-14). The rat cerebellum is remarkably devoid of opioid receptors including delta opioid receptors.
D. Delorme, E. Roberts and Z, Wei, World Patent WO/28275 (1998) discloses diaryl methylidenylpiperidines that are opioid analgesics, but does not disclose or suggest the compounds of the present invention.
C. Kaiser, and others (J. Med. Chem. 1974, Volume 17, pages 57-61) disclose some piperidylidene derivatives of thioxanthenes, xanthenes, dibenoxepins and acridans that are neuroleptic agents. These authors, however, do not disclose or suggest either the structure or the activity of the compounds of the present invention.
British Patent GB 1128734 (1966) discloses derivatives of 6,11-dihydrodibenzo[b,e]oxepine that are anticholinergic, anti-convulsive, muscle-relaxing, sedating, diuretic, and/or vasoactive agents. These, agents, however, differ significantly from the compounds of the present invention both structurally and pharmacologically.
There is a continuing need for new delta opioid receptor modulators as analgesics. There is a further need for delta opioid receptor selective agonists as analgesics having reduced side effects. There is also a need for delta opioid receptor antagonists as immunosuppressants, antiinflammatory agents;
agents for the treatment of neurological and psychiatric conditions, agents for the treatment of urological and reproductive conditions, medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases, having reduced side effects.
SUMMARY
The present invention is directed, inter alia, to compounds of Formula (I) and compositions comprising a compound of Formula (I):
Y
G
i I
R4 , / \\
A
N
Formula (I) wherein:
G is -C(Z)N(Rl)R2, C6_loaryl, or a heterocycle selected from the group consisting of imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, tetrahydropyrimidinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, furyl, indazolyl, indolyl, indolinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, and pyridinyl; wherein aryl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1_8alkanyi, C2_$alkenyl, C2_$alkynyl-, Cl_$alkanyloxy, hydroxy(Cl_$)aikanyl, carboxy(Cl_$)alkanyi, Cl_$alkanylcarbonylamino, halogen, hydroxy, cyano, nitro, oxo, thioxo, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, Cl_$aikanylthio, Cl_$alkanylsulfonyl, Cl_$alkanylsulfonylamino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, Cl_8alkanylaminocarbonyl, di(Cl_$alkanyl)aminocarbonyl, and C1_6alkanyloxycarbonylamino;
R, is a substituent selected from the group consisting of hydrogen, CI_$alkanyl, C2_$alkenyl, and C2_$alkynyl;
R2 is a substituent selected from the group consisting of hydrogen;
Cl_$alkanyl; C2_$alkenyl; C2_$alkynyl; C6_1oaryl; and C1_$cycloalkanyl; wherein Cl_$alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, C1_6alkanyloxy, thioC,_6alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, CI_$alkanylaminocarbonyl, di(CI_$alkanyl)aminocarbonyl, C1_6alkanyloxycarbonyl, and aryloxy; and wherein any aryl-containing substituents and Cl_$cycloalkanyl substituents of R2 are optionally substituted with one to three substituents independently selected from the group consisting of Cl_$alkanyl, C2_8alkenyl, C2_$alkynyl, Cl_$alkanyloxy, trifluoromethyl, trifluoromethoxy, phenyl, halogen, cyano, hydroxy, CI_$alkanylthio, CI_$alkanylsulfonyl, and CI_$alkanylsulfonylamino;
or R, and R2 taken together with the nitrogen to which they are attached form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of CI_$alkanyl, hydroxy(Cl_$)alkanyl, hydroxy, amino, C1_6alkanylamino, di(Cl_6alkanyl)amino, and halogen;
R3 is a substituent selected from the group consisting of hydrogen, Cl_$alkanyl, halo1_3(C1 _8)alkanyl, C2_$alkenyl, C2_$alkynyl, C3_$cycloalkanyl, cycloalkanyl(CI_$)alkanyl, CI_$alkanyloxy(CI_$)alkanyl, C1_8alkanylthio(C1_8)alkanyl, hydroxyC,_$alkanyl, CI_$alkanyloxycarbonyl, halo1_3(C1_$)alkanylcarbonyl, formyl, thioformyl, carbamimidoyl, phenylimino(C1_8)alkanyl, phenyl(CI_8)alkanyl, phenyl(Cl_8)alkenyl, phenyl(C1_8)aikynyl, naphthyl(Cl_$)alkanyl and heteroaryl(C1_8)alkanyl wherein the heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indazolyl, indolyl, indolinyl, isoindolinyl,, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl, thiazolyl; wherein phenyl, naphthyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyl, C2-6alkenyl, C1_6alkanyloxy, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1_6alkanylcarbonyl, C1-6alkanylcarbonyloxy, Cl-6alkanylcarbonylamino, Cl-6alkanylthio, C1-6alkanylsulfonyl, halogen, hydroxy, cyano, fluoro(C1-6)alkanyl, thioureido, and fluoro(C1-6)aikanyloxy; alternatively, when phenyl and heteroaryl are optionally substituted with alkanyl or alkanyloxy substituents attached to adjacent carbon atoms, the two substituents can together form a fused cyclic alkanyl or cycloheteroalkanyl selected from the group consisting of -(CH2)3-5- ,-O(CH2)2-4- , -(CH2)2_40 -, and -O(CH2)1-30-;
R4 is one to three substituents independently selected from the group consisting of hydrogen; Cl-6alkanyl; C2-6alkenyl; C2-6alkynyl;
aryl(C2-6)alkynyl; C1-6alkanyloxy; amino; C1_6alkanylamino;
di(C1_6alkanyl)amino; C6-loarylamino wherein C6-loaryl is optionally substituted with one to three substitutents independently selected from the group consisting of CI-salkanyl, C1-6alkoxy, haiogen, and hydroxyl; formylamino; pyridinylamino; C1-6alkanylcarbonyl;
C1-6alkanylcarbonyloxy; C1-6alkanyloxycarbonyl; aminocarbonyl;
C1-6alkanylaminocarbonyl; di(C1-6alkanyl)aminocarbonyl;
C1-6alkanylcarbonylamino; C1-6alkanylthio; C1-6alkanylsulfonyl;
halogen; hydroxy; cyano; hydroxycarbonyl; C6-1oaryl; chromanyl;
chromenyl; furanyl; imidazolyl; indazolyl; indolyl; indolinyl;
isoindolinyl; isoquinolinyl; isothiazolyi; isoxazolyl; naphthyridinyl;
oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl; pyridinyl; pyrimidinyl;
pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl; quinoxalinyl;
tetrazolyl; thiazolyl; thienyl; fluoroalkanyl and fluoroalkanyloxy; or optionally, when R4 is two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the fused moiety is -(CH2)3_5-, -O(CH2)2_4- , -(CH2)2_40-, -O(CH2)1_30-, or -S-C(NH2)=N-;
R5 is one to two substituents independently selected from the group consisting of hydrogen, C1_6alkanyl, C2_6alkenyl, C1_6alkanyloxy, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, C1_6alkanylcarbonyl, Cl_6alkanylcarbonyloxy, C1_6alkanyloxycarbonyl, C1_6alkanylaminocarbonyl, C1_6alkanylcarbonylamino, C1_6alkanylthio, C1_6alkanylsulfonyl, halogen, hydroxy, cyano, fluoro(C1_6)alkanyl and fluoro(Cl_ 6)alkanyloxy;
A is -(CH2)m , wherein m is 2 or 3;
YisOorS;
Z is 0, S, NH, N(C1_6aikanyl), N(OH), N(OC1_6alkanyl), or N(phenyl);
and enantiomers, diastereomers, tautomers, solvates, or pharmaceutically acceptable salts thereof.
The present invention is also directed to, inter alia, veterinary and pharmaceutical compositions containing compounds of Formula (I) wherein the compositions are used to treat mild to severe pain in warm-blooded animals.
DETAILED DESCRIPTION
As used herein, the following underlined terms are intended to have the following meanings:
"Qa=6" (where a and b are integers) refers to a radical containing from a to b carbon atoms inclusive. For example, C1_3 denotes a radical containing 1, 2 or 3 carbon atoms "Alkyl:" refers to a saturated or unsaturated, branched, straight-chain or cyclic monovalent hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane, alkene or alkyne. Typical alkyl groups include, but are not limited to, methyl; ethyls such as ethanyl, ethenyl, ethynyl; propyls such as propan-1-yl, propan-2-yl , cyclopropan-1-yl, prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl, cycloprop-l-en-1-yl;
cycloprop-2-en-1-yl, prop-1-yn-1-yl, prop-2-yn-1-yl, etc.; butyls such as butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, cyclobutan-1 -yl, but-1 -en-1 -yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yi, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl, but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, etc.; and the like. Where specific levels of saturation are intended, the nomenclature "alkanyl", "alkenyl" and/or "alkynyl" is used, as defined below. In preferred embodiments, the alkyl groups are P-C6) alkyl, with P-C3) being particularly preferred.
"Alkanyl:" refers to a saturated branched, straight-chain or cyclic monovalent hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane. Typical alkanyl groups include, but are not limited to, methanyl; ethanyl; propanyis such as propan-1-yl, propan-2-yl, cyclopropan-1-yl, etc.; butyanyls such as butan-1-yl, butan-2-yl,.
2-methyl-propan-1-yl, 2-methyl-propan-2-yl, cyclobutan-1-yl, etc.; and the like.
In preferred embodiments, the alkanyl groups are (Cl_$) alkanyl, with (C1_3) being particularly preferred.
"Alkenyl" refers to an unsaturated branched, straight-chain or cyclic monovalent hydrocarbon radical having at least one carbon-carbon double bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkene. The radical may be in either the cis or trans conformation about the double bond(s). Typical alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop-1-en-1-yl, prop-1-en-2-yl; prop-2-en-1-yl, prop-2-en-2-yl, cycloprop-1-en-1-yi; cycloprop-2-en-1-yl; butenyis such as but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl, etc.; and the like.
"Alkynyl" refers to an unsaturated branched, straight-chain or cyclic monovalent hydrocarbon radical having at least one carbon-carbon triple bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkyne. Typical alkynyl groups include, but are not limited to, ethynyl;
propynyls such as prop-1-yn-1-yl, prop-2-yn-1-yl, etc.; butynyls such as but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, etc.; and the like.
"Heteroalkyl" and Heteroalkanyl" refer to alkyl or alkanyl radicals, respectively, in which one or more carbon atoms (and any necessary associated hydrogen atoms) are independently replaced with the same or different heteroatoms (including any necessary hydrogen or other atoms).
Typical heteroatoms to replace the carbon atom(s) include, but are not limited to, N, P, 0, S, Si, etc. Preferred heteroatoms are 0, N and S. Thus, heteroalkanyl radicals can contain one or more of the same or different heteroatomic groups, including, by way of example and not limitation, epoxy (-0-), epidioxy (-O-O-), thioether (-S-), epidithio (-SS-), epoxythio (-O-S-), epoxyimino (-O-NR'-), imino (-NR'-), biimino (-NR'-NR'-), azino (=N-N=), azo (-N=N-), azoxy (-N-0-N-), azimino (-NR'-N=N-), phosphano (-PH-), A4-sulfano (-SH2-), sulfonyl (-S(0)2-), and the like, where each R' is independently hydrogen or (CI-C6) alkyl.
"Parent Aromatic Ring System:" refers to an unsaturated cyclic or polycyclic ring system having a conjugated n electron system. Specifically included within the definition of "parent aromatic ring system" are fused ring systems in which one or more rings are aromatic and one or more rings are saturated or unsaturated, such as, for example, indane, indene, phenalene, etc.
Typical parent aromatic ring systems include, but are not limited to, aceanthryiene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, peryiene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene, and the like "6al:" refers to a monovalent aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. Typical aryl groups include, but are not limited to, radicals derived from aceanthrylene, acenaphthylene, acephenanthryiene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, peryiene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene, and the like. In preferred embodiments, the aryl group is (C5-20) aryl, with (C5-1o) being particularly preferred. Particularly preferred aryl groups are phenyl and naphthyl groups.
"Arylalkyl:" refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal carbon atom, is replaced with an aryl radical.. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethen-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl and the like. Where specific alkyl moieties are intended, the nomenclature arylalkanyl, aryiakenyl and/or arylalkynyl is used.
[In preferred embodiments, the arylalkyl group is (C6-26) arylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C1-6) and the aryl moiety is (C5-20). In particularly preferred embodiments the arylalkyl group is (C6-13), e.g., the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C1-3) and the aryl moiety is (C5_10). Even more preferred arylalkyl groups are phenylalkanyls.
"Alkan lroxy:" refers to a saturated branched, straight-chain or cyclic monovalent hydrocarbon alcohol radical derived by the removal of the hydrogen atom from the hydroxide oxygen of the alcohol. Typical alkanyloxy groups include, but are not limited to, methanyloxy; ethanyloxy; propanyloxy groups such as propan-1-yloxy (CH3CH2CH2O-), propan-2-yloxy ((CH3)2CHO-), cyclopropan-1-yloxy, etc.; butanyloxy groups such as butan-1-yloxy, butan-2-yloxy, 2-methyl-propan-1-yloxy, 2-methyl-propan-2-yloxy, cyclobutan-1-yloxy, etc.; and the like. In preferred embodiments, the alkanyloxy groups are (Cl_$) alkanyloxy groups, with (C1-3) being particularly preferred.
"Parent Heteroaromatic Ring System:" refers to a parent aromatic ring system in which one carbon atom is replaced with a heteroatom. Heteratoms to replace the carbon atoms include N, 0, and S. Specifically included within the definition of "parent heteroaromatic ring systems" are fused ring systems in which one or more rings are aromatic and one or more rings are saturated or unsaturated, such as, for example, arsindole, chromane, chromene, indole, indoline, xanthene, etc. Typical parent heteroaromatic ring systems include, but are not limited to, carbazole, imidazole, indazole, indole, indoline, indolizine, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like.
"Heteroary(:" refers to a monovalent heteroaromatic radical derived by the removal of one hydrogen atom from a single atom of a parent heteroaromatic ring system. Typical heteroaryl groups include, but are not limited to, radicals derived from carbazole, imidazole, indazole, indole, indoline, indolizine, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like. In preferred embodiments, the heteroaryl group is a 5-20 membered heteroaryl, with 5-10 membered heteroaryl being particularly preferred.
"Cycloheteroalkyl:" refers to a saturated or unsaturated monocyclic or bicyclic alkyl radical in which one carbon atom is replaced with N, 0 or S. In certain specified embodiments the cycloheteroalkyl may contain up to four heteroatoms independently selected from N, 0 or S. Typical cycloheteroalkyl moieties include, but are not limited to, radicals derived from imidazolidine, morpholine, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, and the like. In preferred embodiments, the cycloheteroalkyl is a 3-6 membered cycloheteroalkyl.
"Cycloheteroalkanyl:" refers to a saturated monocyclic or bicyclic alkanyl radical in which one carbon atom is replaced with N, 0 or S. In certain specified embodiments the cycloheteroalkanyl may contain up to four heteroatoms independently selected from N, 0 or S. Typical cycloheteroalkanyl moieties include, but are not limited to, radicals derived from imidazolidine, morpholine, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, and the like. In preferred embodiments, the cycloheteroalkanyl is a 3-6 membered cycloheteroalkanyl.
"Cycloheteroalkenyl:" refers to a saturated monocyclic or bicyclic alkenyl radical in which one carbon atom is replaced with N, 0 or S. In certain specified embodiments the cycloheteroalkenyl may contain up to. four' heteroatoms independently selected from N, 0 or S. Typical cycloheteroalkenyl moieties include, but are not limited to, radicals derived from imidazoline, pyrazoline, pyrroline, indoline, pyran, and the like. In preferred embodiments, the cycloheteroalkanyl is a 3-6 membered cycloheteroalkanyl.
"Substituted:" refers to a radical in which one or more hydrogen atoms are each independently replaced with the same or different substituent(s).
Typical substituents include, but are not limited to, -X, -R, -0-, =0, -OR, -0-OR, -SR, -S-, =S, -NRR, =NR, -CX3, -CN, -OCN, -SCN, -NCO, -NCS, -NO, -NO2, =N2, -N3, -NHOH, -S(0)20-, -S(0)20H, -S(O)aR, -P(O)(0)2, -P(O)(OH)2, -C(O)R, -C(O)X, -C(S)R, -C(S)X, -C(O)OR, -C(O)O-, -C(S)OR, -C(O)SR, -C(S)SR, -C(O)NRR, -C(S)NRR and -C(NR)NRR, where each X is independently a halogen (preferably -F, -Cl or -Br) and each R is independently -H, alkyl, alkanyl, alkenyl, alkynyl, alkylidene, alkylidyne, aryl, arylalkyl, arylheteroalkyl, heteroaryl, heteroarylalkyl or heteroaryl-heteroalkyl, as defined herein. Preferred substituents include hydroxy, halogen, CI_$alkyi, Cl_$alkanyloxy, fluorinated alkanyloxy, fluorinated alkyl, CI_$alkylthio, C3_$cycloalkyl, C3_8cycloalkanyloxy, nitro, amino, CI_$alkylamino, Cl_$dialkylamino, C3_$cycloalkylamino, cyano, carboxy, Cl_7alkanyloxycarbonyl, CI_7alkylcarbonyloxy, formyl, carbamoyl, phenyl, aroyl, carbamoyl, amidino, (C1_8alkylamino)carbonyl, (arylamino)carbonyl and aryl(C1_8alkyl)carbonyl.
With reference to substituents, the term "independentiy" means that when more than one of such substituent is possible, such substituents may be the same or different from each other.
Throughout this disclosure, the terminal portion of the designated side chain is described first, followed by the adjacent functionality toward the point of attachment. Thus, for example, a"phenylC1_6alkanylaminocarbonylC1_6alkyP' substituent refers to a group of the formula O
C1_6 alkanyl / \ .
- -Cl_6 alkanyl N/
The present invention is directed, inter alia, to compounds of Formula (I) and compositions comprising a compound of Formula (I):
Y
G
i Rq 1 , / \\
A
N
i Formula (I) wherein:
G is -C(Z)N(Rl)R2, C6_10ary1, or a heterocycle selected from the group consisting of imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, tetrahydropyrimidinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, furyl, indazolyl, indolyl, indolinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, and pyridinyl; wherein aryl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1_$alkanyl, C2_$alkenyl, C2_$alkynyl, C1_8alkanyloxy, hydroxy(C1_8)alkanyl, carboxy(Cl_8)alkanyl, Cl_$alkanylcarbonylamino, halogen, hydroxy, cyano, nitro, oxo, thioxo, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, Cl_$alkanylthio, Cl_$alkanylsulfonyl, Cl_$alkanylsulfonylamino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, C1_8alkanylaminocarbonyl, di(C1_8alkanyl)aminocarbonyl, and C1_6alkanyloxycarbonylamino;
R, is a substituent selected from the group consisting of hydrogen, Cl_$alkanyl, C2_$alkenyl, and C2_$alkynyl;
R2 is a substituent selected from the group consisting of hydrogen;
C1_8alkanyl; C2_$alkenyl; C2_$alkynyl; C6_10aryI; and Cl_$cycloalkanyl; wherein C1_$alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, C1_6alkanyloxy, thioC1_6alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, Cl_$alkanylaminocarbonyl, di(C1_8alkanyl)aminocarbonyl, Cl_6alkanyloxycarbonyl, and aryloxy; and wherein any aryl-containing substituents and Cl_$cycloalkanyl substituents of R2 are optionally substituted with one to three substituents independently selected from the group consisting of Cl_$alkanyl, CZ_$alkenyl, CZ_$alkynyl, C1_$alkanyloxy, trifluoromethyl, trifluoromethoxy, phenyl, halogen, cyano, hydroxy, C1_8alkanylthio, CI_$alkanylsulfonyl, and Cl_$alkanylsulfonylamino;
or R, and R2 taken together with the nitrogen to which they are attached form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of Cl_$alkanyl, hydroxy(CI_$)alkanyl, hydroxy, amino, C1_6alkanylamino, di(Cl_6alkanyl)amino, and halogen;
R3 is a substituent selected from the group consisting of hydrogen, CI_$alkanyl, halo1_3(Cl _$)alkanyl, C2_$alkenyl, C2_$alkynyl, C3_$cycloalkanyl, cycloalkanyl(Cl_$)alkanyl, CI_$alkanyloxy(Cl_$)alkanyl, Cl_$alkanylthio(CI_$)alkanyl, hydroxyC,_$alkanyl, Cl_$alkanyloxycarbonyl, halo1_3(Cl _$)alkanylcarbonyl, formyl, thioformyl, carbamimidoyl, phenylimino(Cl_$)alkanyl, phenyl(CI_$)aikanyl, phenyl(Cl_$)alkenyl, phenyl(Cl_$)alkynyl, naphthyl(CI_$)alkanyl and heteroaryl(Cl_$)alkanyl wherein the heteroaryl is selected from the -group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl, thiazolyl; wherein phenyl, naphthyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of Cl_oalkanyl, C2_6alkenyl, C1_6alkanyloxy, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, C1_6alkanylcarbonyl, C1_6alkanylcarbonyloxy, C1_6alkanylcarbonylamino, C1_6alkanylthio, C1_6alkanylsulfonyl, halogen, hydroxy, cyano, fluoro(C1_6)alkanyl, thioureido, and fluoro(C1_6)alkanyloxy; alternatively, when phenyl and heteroaryl are optionally substituted with alkanyl or alkanyloxy substituents attached to adjacent carbon atoms, the two substituents can together form a fused cyclic alkanyl or cycloheteroalkanyl selected from the group consisting of -(CH2)3_5- ,-O(CH2)2_4- ,-(CH2)2_40 -, and -O(CH2)1_30-;
R4 is one to three substituents independently selected from the group consisting of hydrogen; C1_6alkanyl; C2_6alkenyl; C2_6alkynyl;
aryl(C2_6)alkynyl; C1_6alkanyloxy; amino; C1_6alkanylamino;
di(C1_6alkanyl)amino; C6_10arylamino wherein C6_loaryl is optionally substituted with one to three substitutents independently selected from the group consisting of C1_6alkanyl, CI_6alkoxy, halogen, and hydroxyl; formylamino; pyridinylamino; C1_6alkanylcarbonyl;
C1_6alkanylcarbonyloxy; C1_6alkanyloxycarbonyl; aminocarbonyl;
C1_6alkanylaminocarbonyl; di(C1_6alkanyl)aminocarbonyl;
C1_6alkanylcarbonylamino; C1_6alkanylthio; C1_6alkanylsulfonyl;
halogen; hydroxy; cyano; hydroxycarbonyl; C6_1oaryl; chromanyl;
chromenyl; furanyl; imidazolyl; indazolyl; indolyl; indolinyl;
isoindolinyl; isoquinolinyl; isothiazolyl; isoxazolyl; naphthyridinyl;
oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl; pyridinyl; pyrimidinyl;
pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl; quinoxalinyl;
tetrazolyl; thiazolyl; thienyl; fluoroalkanyl and fluoroalkanyloxy; or optionally, when R4 is two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the fused moiety is -(CH2)3_5-, -O(CH2)2_4- , -(CH2)2_40-, -O(CH2)1_30-, or -S-C(NH2)=N-;
R5 is one to two substituents independently selected from the group consisting of hydrogen, C1_6alkanyl, C2_6alkenyl, C1_6alkanyloxy, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, C1_6alkanylcarbonyl, C1_6alkanylcarbonyloxy, Cl_6alkanyloxycarbonyl, C1_6alkanylaminocarbonyl, C1_6alkanylcarbonylamino, C1_6alkanylthio, C1_6alkanylsulfonyl, halogen, hydroxy, cyano, fluoro(C1_6)alkanyl and fluoro(Cl_ 6)alkanyloxy;
A is -(CH2)m , wherein m is 2 or 3;
YisOorS;
Z is 0, S, NH, N(C1_6alkanyl), N(OH), N(OC1_6alkanyl), or N(phenyl);
and enantiomers, diastereomers, tautomers, solvates, or pharmaceutically acceptable salts thereof.
An embodiment of the present invention is directed to a compound of Formula (I) wherein the structure is numbered as defined herein and the substituents are as defined herein.
a' y (3~ G
R al N R5 A
N
i Formula (I) The present invention is directed, inter alia, to analgesic and anti-pyretic uses of compositions comprising a compound of Formula (I):
Y
G
i R4 , \\
CA
N
Formula (I) wherein:
G is -C(Z)N(Rl)R2, C6_10aryl, or a heterocycle selected from the group consisting of: imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, tetrahydropyrimidinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, furyl, indazolyl, indolyl, indolinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, and pyridinyl; wherein aryl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of CI_$alkanyl, C2_$alkenyl, C2_$alkynyl, Cl_$alkanyloxy, hydroxy(CI_$)alkanyl, carboxy(CI_$)alkanyl, Cl_$alkanylcarbonylamino, halogen, hydroxy, cyano, nitro, oxo, thioxo, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, CI_$alkanylthio, Cl_$alkanylsulfonyl, CI_$alkanylsulfonylamino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, CI_$alkanylaminocarbonyl, di(CI_$alkanyl)aminocarbonyl, and Cl_6alkanyloxycarbonylamino;
R, is a substituent selected from the group consisting of hydrogen, CI_$alkanyl, C2_$alkenyl, and C2_8alkynyl;
R2 is a substituent selected from the group consisting of hydrogen;
CI_$alkanyl; C2_$alkenyl; C2_$aikynyl; C6_1oaryl; and C1_8cycloalkanyl; wherein Cl_$alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C1_6alkanylamino, di(CI_6alkanyl)amino, C1_6alkanyloxy, thioC1_6alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, CI_$alkanylaminocarbonyl, di(CI_$alkanyl)aminocarbonyl, C1_6alkanyloxycarbonyl, and aryloxy; and wherein any aryl-containing substituents and Cl_$cycloalkanyl substituents of R2 are optionally substituted with one to three substituents independently selected from the group consisting of Cl_$alkanyl, C2_$alkenyl, C2_$alkynyl, Cl_$alkanyloxy, trifluoromethyl, trifluoromethoxy, phenyl, halogen, cyano, hydroxy, C1_8alkanylthio, CI_$alkanylsulfonyl, and C1_8alkanylsulfonylamino;
or R, and R2 taken together with the nitrogen to which they are attached form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of CI_$alkanyl, hydroxy(CI_$)alkanyl, hydroxy, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, and halogen;
R3 is a substituent selected from the group consisting of hydrogen, Cl_$alkanyl, halo1_3(Cj_$)aikanyl, C2_8alkenyl, C2_$alkynyl, C3_$cycloalkanyl, cycloalkanyl(Cl_$)alkanyl, CI_$alkanyloxy(C~_$)alkanyl, CI_$alkanylthio(CI_$)alkanyl, hydroxyC,_$alkanyl, C1_8alkanyloxycarbonyl, halo1_3(CI_$)alkanylcarbonyl, formyl, thioformyl, carbamimidoyl, phenylimino(C1_8)alkanyl, phenyl(CI_8)alkanyl, phenyl(Cl_$)alkenyl, phenyl(Cl_$)alkynyl, naphthyl(CI_$)alkanyl and heteroaryl(Cl_$)alkanyl wherein the heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl, thiazoiyl; wherein phenyl, naphthyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyl, C2-6alkenyl, C1-6alkanyloxy, amino, Cl-6alkanylamino, di(Cl_6alkanyl)amino, C1-6alkanylcarbonyl, C1-6alkanylcarbonyloxy, C1-6alkanylcarbonylamino, C1-6alkanylthio, C1-6alkanylsulfonyl, halogen, hydroxy, cyano, fluoro(C1-6)alkanyl, thioureido, and fluoro(C1-6)alkanyloxy; alternatively, when phenyl and heteroaryl are optionally substituted with alkanyl or alkanioxy substituents attached to adjacent carbon atoms, the two substituents can together form a fused cyclic alkanyl or cycloheteroalkanyl selected from the group consisting of -(CH2)3-5- ,-O(CH2)2-4- ,-(CH2)2-40 -, and -O(CH2)1-30-;
R4 is one to three substituents independently selected from the group consisting of hydrogen; C1-6alkanyl; C2-6alkenyl; C2-6alkynyl;
aryl(C2-6)alkynyl; C1-6alkanyloxy; amino; C1-6alkanylamino;
di(C1-6alkanyl)amino; C6-loarylamino wherein C6-loaryl is optionally substituted with one to three substitutents independently selected from the group consisting of C1-6alkanyl, C1-6alkoxy, halogen, and hydroxy; formylamino; pyridinylamino; C1-6alkanylcarbonyl;
C1-6alkanylcarbonyloxy; C1-6alkanyloxycarbonyl; aminocarbonyl;
C1-6alkanylaminocarbonyl; di(C1-6alkanyl)aminocarbonyl;
C1-6alkanylcarbonylamino; C1-6alkanylthio; C1-6alkanylsulfonyl;
halogen; hydroxy; cyano; hydroxycarbonyl; C6-1oaryl; chromanyl;
chromenyl; furanyl; imidazolyl; indazolyl; indolyl; indolinyl;
isoindolinyl; isoquinolinyl; isothiazolyl; isoxazolyl; naphthyridinyl;
oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl; pyridinyl; pyrimidinyl;
pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl; quinoxalinyl;
tetrazolyl; thiazolyl; thienyl; fluoroalkanyl and fluoroalkanyloxy; or optionally; when R4 is two substituents attached to adjacent carbon atoms; the two substituents together form a single fused moiety; wherein the fused moiety is -(CH2)3_5- ,-O(CH2)2_4- , -(CH2)2_40-, -O(CH2)1_30-, or -S-C(NH2)=N-;
R5 is one to two substituents independently selected from the group consisting of hydrogen, C1_6alkanyl, C2_6alkenyl, C1_6alkanyloxy, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, C1_6alkanylcarbonyl, C1_6alkanylcarbonyloxy, C1_6alkanyloxycarbonyl, C1_6alkanylaminocarbonyl, C1_6alkanylcarbonylamino, C1_6alkanylthio, C1_6alkanylsulfonyl, halogen, hydroxy, cyano, fluoro(C1_6)alkanyl and fluoro(Cl_ 6)alkanyloxy;
A is -(CH2)m , wherein m is 2 or 3;
YisOorS;
Z is 0, S, NH, N(C1_6alkanyl), N(OH), N(OC1_6alkanyl), or N(phenyl);
and enantiomers, diastereomers, tautomers, solvates, or pharmaceutically acceptable salts thereof.
Embodiments of the present invention include compounds of Formula (I) wherein, preferably:
a) G is -C(Z)N(R,)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, tetrahydropyrimidinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, isothiazolyl, isoxazolyl, oxazolyi, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1_$alkanyl, C1_8alkanyloxy, hydroxy(CI_$)alkanyl, carboxy(Cl_$)alkanyl, Cl_$alkanylcarbonylamino, halogen, hydroxy, cyano, oxo, thioxo, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, Cl_$alkanylthio, aminocarbonyl, aminothiocarbonyl, CI_$alkanylaminocarbonyl, di(CI_$alkanyl)aminocarbonyl, and C1_6alkanyloxycarbonylamino;
b) G is -C(Z)N(Rj)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G (described herein) are optionally substituted with, one to three substituents independently selected from the group consisting of C1_4alkanyl, C1_4alkanyloxy, hydroxy(Cl_4)alkanyl, carboxy(C1_4)alkanyl, CI_4alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, Cl_$alkanylthio, aminocarbonyl, aminothiocarbonyl, CI_$alkanylaminocarbonyl, and di(C1_8alkanyl)aminocarbonyl;
c) G is -C(Z)N(Rj)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, thienyl, isothiazolyl, isoxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G (described herein) are optionally substituted with one to three substituents independently selected from the group consisting of C1_4alkanyl, C1_4alkanyloxy, hydroxy(C1_4)alkanyl, Cl_4alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, and aminocarbonyl;
d) R, is a substituent selected from the group consisting of hydrogen and C1_4alkanyl;
e) R, is selected from the group consisting of hydrogen, methyl, ethyl, and propyl;
f) R, is selected from the group consisting of hydrogen, methyl, or ethyl;
g) R2 is selected from the group consisting of hydrogen; C1_4alkanyl; phenyl;
and C1_6cycloalkanyl; wherein C1_4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, C1_4alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, CI_$alkanylaminocarbonyl, di(Cl_$alkanyl)aminocarbonyl, and phenoxy;
and wherein any phenyl-containing substituents and C1_6cycloalkanyl substituents of R2 are optionally substituted with one to three substituents independently selected from the group consisting of Cl_$alkanyl, CI_$alkanyloxy, trifluoromethyl, phenyl, fluoro, hydroxy, C1_8alkanylthio, Cl_$alkanylsulfonyl, and Cl_$alkanylsulfonylamino; or R, and R2 taken together with the nitrogen to which they are attached form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of Cl_ 4alkanyl, hydroxy(Cl_4)alkanyl, hydroxy, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, and fluoro;
h) R2 is selected from the group consisting of hydrogen, C1_4alkanyl, phenyl, and C1_6cycloalkanyl, wherein C1_4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1_4alkanyloxy, hydroxy, fluoro, aminocarbonyl, Cl_$alkanylaminocarbonyl, di(Cl_$alkanyl)aminocarbonyl, and phenoxy;
and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1_6alkanyl, C1_6alkanyloxy, fluoro, hydroxy, and C1_6alkanylthio; or R, and R2 taken together with the nitrogen to which they are attached form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of C14alkanyl and hydroxy;
i) R2 is selected from the group consisting of hydrogen, C1_4alkanyl and phenyl, wherein C1_4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1_4alkanyloxy, hydroxy, fluoro, and phenoxy; and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1_6alkanyl, C1_6alkanyloxy, fluoro, and hydroxy; or R, and R2taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from the group consisting of Cl-3alkanyl and hydroxy;
j) R3 is selected from the group consisting of hydrogen, Cl-$alkanyl, C2-$alkenyl, C2-$alkynyl, Cl-$alkanyloxy(Cl-$)alkanyl, Cl-$alkanylthio(CI-$)alkanyl, hydroxyC,-$alkanyl, thioformyl, phenylimino(C1-8)alkanyl, phenyl(Cl-$)alkanyl, and heteroaryl(CI-$)alkanyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indolyl, indolinyl, isoquinolinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein phenyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyloxy and hydroxy; or optionally, when phenyl and heteroaryl are optionally substituted with two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the moiety is selected from -O(CH2)1-30-;
k) R3 is selected from the group consisting of hydrogen, methyl, allyl, 2-methyl-allyl, propynyl, hydroxyethyl, methylthioethyl, methoxyethyl, thioformyl, phenyliminomethyl, phenethyl, and heteroaryl(Cl_8)alkanyl wherein the heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein the phenyl in any phenyl-containing substituent is optionally substituted with one hydroxyl group;
I) R3 is hydrogen, methyl, allyl, or heteroarylmethyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, and thienyl;
m) R4 is one to three substituents independently selected from the group consisting of hydrogen; CI-6alkanyl; CI-6alkanyloxy; C6_1oarylamino wherein C6-1oaryl is optionally substituted with one to three substitutents independently selected from the group consisting of C1-6alkanyl;
C1_6alkoxy, halogen, and hydroxy; formylamino; pyridinylamino;
aminocarbonyl; C1_6alkanylaminocarbonyl; C1_6alkanylcarbonylamino;
halogen; hydroxy; C6_1oaryl; chromanyl; chromenyl; furanyl; imidazolyl;
indazolyl; indolyl; indolinyl; isoindolinyl; isoquinolinyl; isothiazolyl;
isoxazolyl; naphthyridinyl; oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl;
pyridinyl; pyrimidinyl; pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl;
quinoxalinyl; tetrazolyl; thiazolyl; and thienyl;
n) R4 is one to two substituents independently selected from the group consisting of hydrogen, C1_4alkanyl, C1_4alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, and hyd roxy;
o) R4 is one to two substituents independently selected from the group consisting of hydrogen, methyl, methoxy, bromo, fluoro, a'- or (3'- phenyl, a'- or R'- pyridinyl, a'- or (3'- furanyl, and hydroxy;
p) R5 is one to two substituents independently selected from the group consisting of hydrogen and halogen;
q) R5 is hydrogen;
r) A is -(CH2)2_3-;
s) A is -(CH2)2-;
t) YisOorS;
u) Z is 0, NH, N(C1_6alkanyl), N(OH), N(OC1_6alkanyl), or N(phenyl);
v) Z is 0, NH, or N(OH);
w) ZisOorNH;
aa) G is -C(Z)N(R,)R2, phenyl, or a heterocycle selected from the group consisting of tetrazolyl, oxadizolyl, furyl, quinolinyl, thienyl, and pyridinyl;
wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of Cl_$alkanyl, CI_$alkanyloxy, hydroxy(Cl_$)alkanyl, carboxy(CI_$)alkanyl, Cl_$alkanylcarbonylamino, halogen, hydroxy, cyano, oxo, thioxo, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, C1_8alkanylthio, aminocarbonyl, aminothiocarbonyl, Cl_$alkanylaminocarbonyl, di(Cl_$alkanyl)aminocarbonyl, and C1_6alkanyloxycarbonylamino;
bb) G is -C(Z)N(R,)R2, phenyl, or a heterocycle selected from the group consisting of tetrazolyl, oxadizolyl, furyl, quinolinyl, thienyl, and pyridinyl;
wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1_4alkanyl, C1_4alkanyloxy, hydroxy(C1_4)alkanyl, Cl_4alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, and aminocarbonyl;
cc) G is -C(Z)N(R,)R2; tetrazolyl; pyridinyl; oxadiazolyl optionally substituted with oxo; or phenyl optionally substituted with (Cl_$)alkanylcarbonylamino;
dd) G is-C(Z)N(Rj)R2, 1 H-tetrazol-4-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 2-methylcarbonylaminophenyl, pyridin-3-yl or pyridin-4-yl;
dd) R2 is selected from the group consisting of hydrogen and C1_4alkanyl;
wherein C1_4alkanyl is optionally substituted with phenyl; or R, and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl wherein said pyrrolidinyl is optionally substituted with hydroxy;
ee) R2 is selected from the group consisting of hydrogen, methyl, ethyl, and phenethyl; or R, and R2 taken together with the nitrogen to which they are attached form pyrrolidin-1 -yl, 3-hydoxypyrrolidin-1 -yl or 3-(S)-hydoxypyrrolidin-1-yl;
ff) R3 is selected from the group consisting of hydrogen, Cl_$alkanyl, C2_$alkenyl, C2_$alkynyl, Cl_$alkanyloxy(Cl_$)alkanyl, C1_8alkanylthio(CI_$)alkanyl, hydroxyC,_$alkanyl, thioformyl, phenylimino(Cl_$)alkanyl, phenyl(CI_$)alkanyl, and heteroaryl(CI_$)alkanyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyi, furanyl, pyridinyl, thienyl, indolyl, indolinyl, isoquinolinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, thiazolyl, isoquinolinyl, tetrazolyl; wherein phenyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyloxy and hydroxy; or optionally, when phenyl and heteroaryl are optionally substituted with two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the moiety is selected from -O(CH2)1-30-;
gg) R3 is selected from the group consisting of hydrogen, methyl, methylbutenyl, propenyl, benzyl, phenethyl, and heteroaryl(C1-$)alkanyl wherein the heteroaryl is selected from the group consisting of imidazolyl, furanyl, pyridinyl, thienyl, and thiazolyl;
hh) R3 is selected from the group consisting of hydrogen, methyl, 3-methyl-2-butenyl, 2-propenyl, benzyl, 2-phenethyl, pyridin-2-ylmethyl, fur-3-ylmethyl, thiophene-2-ylmethyl, 1 H-imidazol-2-ylmethyl, and thiazol-2-ylmethyl;
ii) R4 is one to two substituents independently selected from the group consisting of hydrogen, methyl, phenyl, bromo, fluoro, aminocarbonyl, chloro and hydroxy;
jj) R4 is one to two substituents independently selected from the group consisting of hydrogen, a'-hydroxy and a'-methoxy;
kk) R4 is unsubstituted or substituted at the a' position;
II) R4 is hydrogen and Y is 0;
mm) R4 is a'-hydroxy and Y is 0;
nn) R4 is hydrogen and Y is S;
oo) R4 is a'-hydroxy and Y is S;
and combinations of a) through oo) above.
One embodiment of the present invention is a compound of Formula (I) wherein:
G is -C(Z)N(R1)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyi, oxathiadiazolyl, imidazolinyl, tetrahydropyrimidinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of CI_$alkanyl, CI_$alkanyloxy, hydroxy(CI_$)alkanyl, carboxy(C1_8)alkanyl, Cl_8alkanylcarbonylamino, halogen, hydroxy, cyano, oxo, thioxo, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, Cl_$alkanylthio, aminocarbonyl, aminothiocarbonyl, Cl_$alkanylaminocarbonyl, di(Cl_$alkanyl)aminocarbonyl, and C1_6alkanyloxycarbonylamino;
R, is hydrogen or C1_4alkanyl;
R2 is selected from the group consisting of hydrogen; C1_4alkanyl; phenyl;
and Cl_6cycloalkanyl; wherein C1_4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, C1_4alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, Cl_$alkanylaminocarbonyl, di(C1_8alkanyl)aminocarbonyl, and phenoxy;
and wherein the phenyl and C1_6cycloalkanyl substituents of R2 are optionally substituted with one to three substituents independently selected from the group consisting of Cl_$alkanyl, Cl_$alkanyloxy, trifluoromethyl, phenyl, fluoro, hydroxy, Cl_$alkanylthio, Cl_$alkanylsulfonyl, and Cl_$alkanylsulfonylamino; or R, and R2 taken together with the nitrogen to which they are attached form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of Cl_ 4alkanyl, hydroxy(C1_4)alkanyl, hydroxy, amino, Cl_6alkanylamino, di(C1_6alkanyl)amino, and fluoro;
R3 is selected from the group consisting of hydrogen, Cl_$alkanyl, C2_8alkenyl, C2_$alkynyl, C1_$alkanyloxy(Cj_$)alkanyl, CI_$alkanylthio(CI_$)alkanyl, hydroxyC,_$alkanyl, thioformyl, phenylimino(C1_8)alkanyl, phenyl(Cl_$)aikanyl, and heteroaryl(Cl_8)alkanyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indolyl, indolinyl, isoquinolinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein phenyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyloxy and hydroxy; or optionally, when phenyl and heteroaryl are optionally substituted with two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the moiety is selected from -O(CH2)1-30-1 R4 is one to three substituents independently selected from the group consisting of hydrogen; C1-6alkanyl; C1-6alkanyloxy; C6-1oarylamino wherein C6-1oaryl is optionally substituted with one to three substitutents independently selected from the group consisting of C1-6alkanyl;
C1-6alkoxy, halogen, and hydroxy; formylamino; pyridinylamino;
aminocarbonyl; C1_6alkanylaminocarbonyl; C1-6alkanylcarbonylamino;
halogen; hydroxy; C6-1oaryl; chromanyl; chromenyl; furanyl; imidazolyl;
indazolyl; indolyl; indolinyl; isoindolinyl; isoquinolinyl; isothiazolyl;
isoxazolyl; naphthyridinyl; oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl;
pyridinyl; pyrimidinyl; pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl;
quinoxalinyl; tetrazolyl; thiazolyl; and thienyl;
R5 is one to two substituents independently selected from the group consisting of hydrogen and halogen;
A is CH2CH2;
YisOorS;
Z is 0, NH, N(C1-6alkanyl), N(OH), N(OC1-6alkanyl), or N(phenyl); and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
Another embodiment of the present invention is a compound of Formula (I) wherein:
G is -C(Z)N(R1)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G (described herein) are optionally substituted with one to three substituents independently selected from the group consisting of C1_4alkanyl, C1_4alkanyloxy, hydroxy(C1_4)alkanyl, carboxy(C1_4)alkanyl, CI_4alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, Cl_galkanylthlo, aminocarbonyl, aminothiocarbonyl, Cl_$alkanylaminocarbonyl, and d i(Cl_$alkanyl)aminocarbonyl;
R, is selected from the group consisting of hydrogen, methyl, ethyl, and propyl;
R2 is selected from the group consisting of hydrogen, C1_4alkanyl, phenyl, and C1_6cycloalkanyl; wherein C1_4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1_4alkanyloxy, hydroxy, fluoro, aminocarbonyl, CI_8alkanylaminocarbonyl, di(C1_8alkanyl)aminocarbonyl, and phenoxy;
and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1_6alkanyl, C1_6afkanyloxy, fluoro, hydroxy, and C1_6alkanylthio; or R, and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrroiidinyl or piperidinyl is optionally substituted with a substituent selected from the group consisting of C1_3alkanyl and hydroxy;
R3 is selected from the group consisting of hydrogen, methyl, allyl, 2-methyl-allyl, propynyl, hydroxyethyl, methylthioethyl, methoxyethyl, thioformyl, phenyliminomethyl, phenethyl, and heteroaryl(Cl_8)alkanyl wherein the heteroaryl is seiected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl wherein the phenyl in any phenyl-containing substituent is optionally substituted with one hydroxyl group;
R4 is one to two substituents independently selected from the group consisting of hydrogen, C1_4alkanyl, C1_4alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, and hydroxy;
R5 is hydrogen;
A is CH2CH2;
YisOorS;
Z is 0, NH, or N(OH); and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
Another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein:
G is selected from -C(Z)N(R,)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, thienyl, isothiazolyl, isoxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1_4alkanyl, C1_4alkanyloxy, hydroxy(C1_4)alkanyl, C1_4alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, and aminocarbonyl;
R, is hydrogen, methyl, or ethyl;
R2 is independently selected from the group consisting of hydrogen, CI-4alkanyl and phenyl; wherein CI-4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1_4alkanyloxy, hydroxy, fluoro, and phenoxy; and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1_6alkanyl, C1_6alkanyloxy, fluoro, and hydroxy; or R, and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl are optionally substituted with a substituent selected from the group consisting of CI_3alkanyl and hydroxy;
R3 is hydrogen, methyl, allyl, or heteroarylmethyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxoiyl, imidazolyl, furanyl, pyridinyl, and thienyl;
R4 is one to two substituents independently selected from the group consisting of hydrogen, CI-4aikanyl, C1_4alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazoiyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyi, thienyl, and hyd roxy;
A is CH2CH2;
YisOorS;
Z is 0 or NH; and enantiomers, diasteromers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
Another embodiment of the present invention is directed to compounds of Formula (I) wherein:
G is -C(Z)N(R,)R2, phenyl, or a heterocycle selected from the group consisting of tetrazolyl, oxadiazolyl, furyl, quinolinyl, thienyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of Cl_$alkanyl, C1_8alkanyloxy, hydroxy(CI_$)aikanyl, carboxy(Cl_$)alkanyl, Cl_$alkanylcarbonylamino, halogen, hydroxy, cyano, oxo, thioxo, amino, Cl_6alkanylamino, di(C1_6alkanyl)amino, Cl_salkanylthio, aminocarbonyl, aminothiocarbonyl, CI_$alkanylaminocarbonyl, di(C1_8alkanyl)aminocarbonyl, and C1_6alkanyloxycarbonylamino;
R, is C1_4 alkanyl, or hydrogen;
R2 is hydrogen or C1_4 alkanyl optionally substituted with phenyl;
or R, and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl ring optionally substituted with hydroxy;
Z is NH or oxygen;
R3 is pyridinyl(Cl_$)aikanyl, furyl(CI_$)alkanyl, CI_$ alkanyl, hydrogen, C2_8 alkenyl, thienyl(CI_$)alkanyl, imidazolyl(Cl_$)alkanyl, phenyl(C1_8)alkanyl, or thiazolyl(Cl_$)aikanyl;
R4 is hydrogen, C1_6 alkanyl, C1_6 alkanyloxy, hydroxy, halogen, aminocarbonyl, or phenyl;
R5 is hydrogen;
A is CH2CH2;
YisOorS;
Z is 0 or NH; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
Another embodiment of the present invention is directed to compounds of Formula (I) wherein:
G is -C(Z)N(R,)R2; tetrazolyl, oxadiazolyl optionally substituted with oxo;
phenyl optionally substituted with (Cl_$)aikanylcarbonylamino; or pyridinyl;
R, is C1_4 alkanyl, or hydrogen;
R2 is hydrogen or C1_4 alkanyl optionally substituted with phenyl;
or R, and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl ring optionally substituted with hydroxy;
Z is NH or oxygen;
R3 is pyridinyl(CI_$)aikanyl, furyl(Cl_$)alkanyl, Cl_$ alkanyl, hydrogen, C2_$
alkenyl, thienyl(Cl_$)aikanyl, imidazolyl(C1_8)alkanyl, phenyl(Cl_$)alkanyl, or thiazolyl(CI_$)alkanyl;
R4 is hydrogen, a'-hydroxy, or a'-methoxy;
R5 is hydrogen;
A is CH2CH2;
YisOorS;
Z is 0 or NH; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
Another embodiment of the present invention is directed to compounds of Formula (I) wherein:
G is -C(Z)N(RI)R2, 1 H-tetrazol-4-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 2-methylcarbonylaminophenyl, 3-furyl, quinolin-3-yl, thiophen-3-yl, pyridin-3-yl or pyridin-4-yl, R, is hydrogen, ethyl, or methyl, R2 is methyl, ethyl, phenethyl, or hydrogen;
or R, and R2 taken together with the nitrogen to which they are attached form pyrrolidin-1-yl, 3-hydroxypyrrolidin-1-yl, or 3-(S)-hydroxypyrrolidin-1-yl;
Z is NH or oxygen, R3 is pyridin-2-ylmethyl, fur-3-ylmethyl, methyl, hydrogen, 3-methyl-2-butenyl, thiophene-2-ylmethyl, 2-propenyl, 1 H-imidazol-2-ylmethyl, 2-phenethyl, thiazol-2-ylmethyl, benzyl, or allyl;
R4 is hydrogen, a'-methyl, a'-phenyl, R"-bromo, [i"-fluoro, a'-aminocarbonyl, a'-chloro, a'-methoxy; or a'-hydroxy;
R5 is hydrogen;
A is CH2CH2;
Yis0orS;.
Z is 0 or NH; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof Another embodiment of the present invention is directed to compounds of Formula (I) wherein:
G is -C(Z)N(R,)R2, 1 H-tetrazol-4-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 2-methylcarbonylaminophenyl, pyridin-3-yl or pyridin-4-yl;
R, is hydrogen, ethyl, or methyl;
R2 is methyl, ethyl, phenethyl, or hydrogen;
or R, and R2 taken together with the nitrogen to which they are attached form pyrrolidin-1-yl, 3-hydroxypyrrolidin-1-yl, or 3-(S)-hydroxypyrrolidin-1-yl;
Z is NH or oxygen;
R3 is pyridin-2-ylmethyl, fur-3-ylmethyl, methyl, hydrogen, 3-methyl-2-butenyl, thiophene-2-ylmethyl, 2-propenyl, 1 H-imidazol-2-ylmethyl, 2-phenethyl, thiazol-2-ylmethyl, or benzyl;
R4 is hydrogen, a'-hydroxy, or a'-methoxy;
R5 is hydrogen;
A is CH2CH2;
YisOorS;
Z is 0 or NH; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
In certain embodiments of Formula (I) when R, and R2 are taken together with the nitrogen to which they are attached to form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of Cl_$alkanyl, hydroxy(Cl-$)alkanyl, hydroxy, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, and halogen;
Z is oxygen.
In certain embodiments of Formula (I) when R, and R2 are taken together with the nitrogen to which they are attached to form a pyrrolidinyl ring optionally substituted with hydroxy, Z is oxygen.
Another embodiment of the present invention is a compound of Formula~(I) wherein:
G is selected from -C(Z)N(R,)R2, 2-methyicarbonylaminophenyl, 2-aminocarbonyl-phenyl, 1 /--/-tetrazol-4-yl, 2-methyl-tetrazol-5-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 4H-[1,2,4]-oxadiazol-5-thioxo-3-yl, 4H-[1,2,4]thiadiazol-5-oxo-3-yl, [1,2,3,5]oxathiadiazol-2-oxo-4-yl, or pyridin-3-yl;
R, is hydrogen, methyl, or ethyl;
R2 is selected from the group consisting of hydrogen, C1_4alkanyl and phenyl; wherein C1_4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1_4alkanyloxy, hydroxy, fluoro, and phenoxy; and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1_6alkanyl, C1_6alkanyloxy, fluoro, and hydroxy;
or R, and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring;
R3 is selected from the group consisting of hydrogen, C1_8alkanyl, C2_$alkenyl, C2_$alkynyl, CI_$alkanyloxy(CI_$)alkanyl, CI_$alkanylthio(CI_$)alkanyl, hydroxyCi_$alkanyl, thioformyl, phenylimino(Cl_$)aikanyl, phenyl(C1_8)aikanyl, and heteroaryl(Cl_$)alkanyl wherein heteroaryl is selected from the group consisting of hydrogen, methyl, allyl, or heteroaryimethyl; wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxoiyl, imidazolyl, furanyl, pyridinyl, and thienyl; wherein phenyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C1_6alkanyloxy and hydroxy; or optionally, when phenyl and heteroaryl are optionally substituted with two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety;
wherein the moiety is selected from -O(CH2)1_30-;
R4 is one to three substituents independently selected from the group consisting of hydrogen, C1_4alkanyl, C1_4alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, and hydroxy;
R5 is hydrogen;
A is CH2CH2;
YisOorS;
Z is 0 or NH; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
Another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein G is independently selected from -C(Z)N(R,)R2, 2-methylcarbonylaminophenyl, 2-aminocarbonyl-phenyl, 1 H-tetrazol-4-yl, 2-methyl-tetrazol-5-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 4H-[1,2,4]-oxadiazol-5-thioxo-3-yl, 4H-[1,2,4]thiadiazol-5-oxo-3-yl, [1,2,3,5]oxathiadiazol-2-oxo-4-yl, and pyridin-3-yl; R, is hydrogen, methyl, or ethyl; R2 is a substituent selected from the group consisting of hydrogen, C1_4alkanyl and phenyl; wherein C1_4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, CI_4alkanyloxy, hydroxy, and 2,6-dimethyl-phenoxy; and wherein the any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1_6alkanyl, C1_6alkanyloxy, fluoro, and hydroxy; or R, and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from the group consisting of C1_3alkanyl and hydroxy; R3 is a substituent selected from the group consisting of benzo[1,3]dioxol-5-yimethyl, carbamimidoyl, 1-H-imidazol-4-ylmethyl, phenyliminomethyl, 1-prop-2-ynyl, thioformyl, 2-hydroxyphenyl-methyl, hydroxy-ethyl, methoxy-ethyl, 2-methyl-allyl, 2-methyl-but-2-enyl, allyl, furan-3-ylmethyl, H, Me, methylthioethyl, phenethyl, pyridin-2-yl methyl, and thiophen-2-ylmethyl; R4 is one to two substituents independently selected from the group consisting of hydrogen, C1_4alkanyl, C1_4alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, and hydroxy; R5 is H; A is CH2CH2;
Y is OorS;andZisOorNH.
Another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein G is selected from -C(Z)N(R,)R2, 2-methyicarbonylaminophenyl, 2-aminocarbonyl-phenyl, 1 H-tetrazol-4-yl, 2-methyl-tetrazol-5-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 4H-[1,2,4]-oxadiazol-5-thioxo-3-yl, 4H-[1,2,4]thiadiazol-5-oxo-3-yl, [1,2,3,5]oxathiadiazol-2-oxo-4-yl, or pyridin-3-yl; R, is hydrogen, methyl, or ethyl; R2 is a substituent seiected from the group consisting of hydrogen, C14alkanyl and phenyl; wherein C14alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, methoxy, hydroxy, and 2,6-dimethyl-phenoxy; and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1_6alkanyl, C1_6alkanyloxy, fluoro, and hydroxy; or R, and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl are optionally substituted with a substituent selected from the group consisting of C1_3alkanyl and hydroxy; R3 is a substituent selected from the group consisting of benzo[1,3]dioxol-5-yimethyl, carbamimidoyl, 1-H-imidazol-4-yl methyl, phenyliminomethyl, 1-prop-2-ynyl, thioformyl, 2-hydroxyphenyl-methyl, hydroxyethyl, methoxyethyl, allyl, furan-3-yl methyl, H, Me, methylthioethyl, and phenethyl; R4 is one to two substituents independently selected from the group consisting of hydrogen, methyl, methoxy, bromo, fluoro, a'- or [3'-phenyl, a'- or [i'-pyridinyl, a'- or (3'-furanyl, and hydroxy; R5 is H; A is CH2CH2; Y is 0 or S; and Z is 0 or NH.
Another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein G is selected from -C(Z)N(R,)R2, 2-methylcarbonylaminophenyl, 2-aminocarbonyi-phenyl, 1 H-tetrazol-4-yl, 2-methyl-tetrazol-5-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 4H-[1,2,4]-oxadiazol-5-thioxo-3-yl, 4H-[1,2,4]thiadiazol-5-oxo-3-yl, [1,2,3,5]oxathiadiazol-2-oxo-4-yl, or pyridin-3-yl; R, is hydrogen, methyl, or ethyl; R2 is a substituent selected from the group consisting of hydrogen, C1_4alkanyl and phenyl; wherein C1_4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, methoxy, hydroxy, and 2,6-dimethyl-phenoxy; and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1_6alkanyl, C1_6alkanyloxy, fluoro, and hydroxy; alternatively R, and R2 are taken together with the nitrogen to which they are attached to form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl are optionally substituted with a substituent selected from the group consisting of C1_3alkanyl and hydroxy; R3 is a substituent selected from the group consisting of H, benzo[1,3]dioxol-5-ylmethyl, 1-H-imidazol-4-yl methyl, furan-3-yimethyl, pyridin-2-ylmethyl, and phenyliminomethyl; R4 is a substituent independently selected from the group consisting of hydrogen, methyl, methoxy, bromo, fluoro a'- or [3'-phenyl, a'- or (3'-pyridinyl, a'- or (3'-furanyl, and hydroxy; R5 is H; A is CH2CH2; Y is 0 or S; and Z is 0 or NH.
Another embodiment of the present invention is directed to a compound of Formula (I) wherein R4 is preferably substituted at the a'- or (3'-position of Formula (I).
Another embodiment of the present invention is directed to compositions comprising a compound selected from the group consisting of:
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is 1 hl-imidazol-2-yl-methyl; R4 is a'-hydroxy; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is furan-3-yl-methyl; R4 is a'-hydroxy; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is a'-hydroxy; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is a'-methoxy; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is pyridin-2-yl-methyl; R4 is H; R5 is H; Y is 0; A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is furan-3-yl-methyl; R4 is H; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is thien-2-yl-methyl; R4 is H; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is benzyl; R4 is H; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is pyridin-3-yl; R3 is furan-3-yl methyl;
is H; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is furan-2-yl methyl; R4 is H; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is a'-methyl; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N=diethylaminocarbonyl; R3 is H; R4 is a'-phenyl; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is H; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is H; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is [i"-bromo; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is H; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is a'-chloro; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is [i"-fluoro; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is 2-methylcarbonylamino-phenyl; R3 is H; R4 is H; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is pyrrolidin-1-yl; R3 is H; R4 is H; R5 is H;
Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is furan-3-yl-methyl; R4 is H; R5 is H; Y is 0; and A is -CH2CH2-;
Another embodiment of the present invention is directed to compounds and compositions comprising a compound selected from the group consisting of:
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
(3-Hydroxy-pyrrolidin-1-yi)-[10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-methanone;
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid methyl-phenethyl-amide;
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine;
Endo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine;
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl )-10 H-phenoxazine;
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile;
Endo-1 0-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-N, N-d iethyl-10H-phenoxazine-3-carboxamidine;
Endo-N, N-Diethyl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxamid ine;
Endo-N, N-Diethyl-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxamidine;
Endo- 3-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one;
endo-1 0-(8-Aza-bicyclo[3.2. 1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid amide;
Endo-3-[10-(8-Pyrid in-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yI]-4H-[1,2,4]oxadiazol-5-one;
E ndo-3-[10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10 H-phenoxazi n-3-yl]-4H-[1,2,4]oxadiazol-5-one;
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-10H-phenoxazine-3-carboxylic acid diethylamide;
6-Methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10 H-phenoxazine-3-carboxylic acid diethylamide;
6-Hydroxy-l0-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
6-Methoxy-1 0-(8-methyl-8-aza-bicyclo[3.2. 1 ]oct-3-yl)-10 H-phenoxazi ne-3-carboxylic acid diethylamide;
10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine;
N, N-Diethyl-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxamidine;
3-[10-(8-M ethyl-8-aza-bicyclo [3.2.1 ]oct-3-yl )-10 H-phenoxazi n-3-yl]-4H-[1,2,4]oxad iazol-5-one;
10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyrid in-3-yi-10H-phenothiazine;
N-{2-[ 10-( 8- F u ra n-3-yl m eth yl-8-aza-b i cycl o[3.2.1 ]o ct-3-yi )-10 H-p h e n oth i azi n-3-yI]-phenyl}-acetamide;
10-[8-(3-Methyl-but-2-enyl )-8-aza-bicyclo[3.2.1 ]oct-3-yi]-3-pyrid in-3-yI-phenothiazine;
3-Pyridin-3-yI-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine;
10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-3-pyrid in-4-yI-10H-phenothiazine;
3-Pyridin-4-yI-10-(8-pyrid in-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine;
3-Pyrid in-4-yI-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenothiazine;
N-{2-[10-(8-AIIyi-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoth iazi n-3-yl]-phenyl}-acetamide;
N-{2-[10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide;
N-(2-{10-[8-(1 H-I m idazol-2-ylmethyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenothiazin-3-yl}-phenyl)-acetamide;
N-{2-[10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide;
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yI-10H-phenothiazine;
N-{2-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide;
10-(8-AIIyi-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yI-10H-phenothiazine;
Endo-1 0-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyrid in-3-yi-10 H-phenoxazine;
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-3-pyrid i n-3-yI-10H-phenoxazine;
Endo-3-Pyrid in-3-yI-10-(8-pyrid in-2-yl methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-phenoxazine;
Endo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyrid in-3-yI-10H-phenoxazine;
Endo-3-Pyridin-3-yI-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine;
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-chloro-10H-phenoxazine;
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyrid in-4-yI-10 H-phenoxazi ne;
E ndo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl )-3-pyrid i n-4-yI-10 H-phenoxazine;
Endo-3-Pyridin-4-yI-10-(8-pyrid in-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-phenoxazine;
Endo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-4-yI-10H-phenoxazine;
Endo-3-Pyridin-4-yI-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine;
Exo-3-(3-Pyridin-3-yl-phenoxazin-1 O-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester;
Exo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyrid in-3-yI-10H-phenoxazine;
Exo-3-Pyrid i n-3-yI-10-( 8-pyrid i n-2-yl methyl-8-aza-b icyclo [3.2.1 ]oct-3-yl)-10 H-phenoxazine;
Exo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyrid in-3-yI-10H-phenoxazine;
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-ch loro-10 H-phenoxazine;
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyrid in-4-yI-10 H-phenoxazine;
Exo-1 0-(8-Phenethyl-8-aza-bicyclo[3.2. 1 ]oct-3-yl)-3-pyrid in-4-yI-10H-phenoxazine;
Exo-3-Pyridin-4-yI-10-(8-pyrid in-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-phenoxazine;
Exo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-4-yI-10H-phenoxazine;
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine;
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile;
Exo-3-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yi]-4H-[1,2,4]oxadiazol-5-one;
6-Methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile;
6-Hyd roxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10 H-phenoxazine-3-carbonitrile;
[10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-pyrrolidin-1-yl-methanone;
[10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-pyrrolidin-1-yl-methanone;
{10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yi]-10 H-phenoth iazi n-3-yi}-pyrrolidin-1-yl-methanone;
[1 0-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2. 1 ]oct-3-yi)-10H-phenothiazin-3-yi]-(3-hydroxy-pyrrolidin-1-yl)-methanone;
(3-Hydroxy-pyrrolidin-1-yi)-[10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-phenothiazin-3-yl]-methanone;
{10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenothiazin-3-yl}-(3-methyl-pyrrolidin-l-yl)-methanone;
[1 0-(8-Methyl-8-aza-bicyclo[3.2. 1 ]oct-3-yl)-10H-phenothiazin-3-yl]-pyrrolidin-1 -yi-methanone;
(3-Hydroxy-pyrrolidin-1-yl)-[10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenothiazin-3-yl]-metha none;
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carboxylic acid ethylamide;
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
E nd o-10-(8-Pyrid i n-2-yl methyl-8-aza-b icyclo [3.2.1 ]oct-3-yi )-10 H-p henoxazi ne-3-carboxylic acid diethylamide;
Endo-10-(8-Thiazol-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-1 0-(8-Pyridin-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10 H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-[8-(1 H-I m idazol-2-yl methyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10 H-phenoxazine-3-carboxylic acid diethylamide;
Endo-1 0-(8-Benzyl-8-aza-bicyclo[3.2. 1 ]oct-3-yl )-10 H-phenoxazine-3-carboxyl ic acid diethylamide;
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-1 0-(8-Pyridi n-3-yl m ethyl-8-aza-b icyclo [3.2.1 ]o ct-3-yl )-10 H-p h e noxazi ne-3-carboxylic acid diethylamide;
Exo-10-(8-Th iophen-2-ylmethyl-8-aza-bicyclo[3.2.'1 ]oct-3-yl)-10H-phenoxazi ne-3-carboxylic acid diethylamide;
Exo-10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Benzyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10 H-phenoxazine-3-carboxyl ic acid diethylamide;
Exo-1 0-(8-Thiazol-2-ylmethyl-8-aza-bicyclo [3.2.1 ]oct-3-yl)-10 H-phenoxazine-carboxylic acid diethylamide;
Exo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi ne-3-carboxylic acid diethylamide;
Exo-10-[8-(1 H-Imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo- 1 0-(8-Aza-bicyclo [3.2.1 ]oct-3-yl)-7-pyrid in-3-yi-10H-phenoxazin-4-ol;
Endo-7-Pyridin-3-yI-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-phenoxazin-4-ol;
Endo-1 0-(8-Aza-bicyclo[3.2. 1 ]oct-3-yl)-3-ch lo ro-6-methoxy-10 H-phenoxazine;
Endo-1 0-(8-Aza-bicyclo[3.2. 1 ]oct-3-yl)-6-methoxy-3-pyrid in-3-yI-10H-phenoxazine;
Endo-6-Methoxy-3-pyridin-3-yI-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-10H-phenoxazine;
E n d o-10-( 8-Aza- b i cyc l o[3.2 .1 ]o ct-3-yl )-7-pyri d i n-4-yI-10 H-p h e n oxaz i n-4-o I;
Endo-7-Pyridin-4-yI-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-phenoxazin-4-ol;
E ndo-10-(8-Ph enethyl-8-aza-bicyclo [3.2.1 ]oct-3-yl )-7-pyrid i n-4-yI-10 H-phenoxazin- 4-ol;
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-3-pyrid in-4-yI-10H-phenoxazine;
Endo-6-Methoxy-3-pyridin-4-yI-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-10H-phenoxazine;
E ndo-6-Methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyrid in-4-yl-10H-phenoxazine;
Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10 H-phenoxazi n-3-yl]-phenyl}-acetamide;
Endo-N-{2-[10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10 H-phenoxazin-3-yl]-phenyl}-acetamide;
Endo-N-{2-[10-(8-Thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide;
Endo-N-{2-[10-(8-Pyrid in-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10 H-phenoxazin-3-yl]-phenyl}-acetamide;
Exo-N-{2-[10-(8-Aza-bicyclo [3.2.1 ]oct-3-yl)-10 H-phenoxazin-3-yl]-phenyl}-acetamide;
E ndo-N-{2-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-hyd roxy-10H-phenoxazi n-3-yl]-phenyl}-acetamide;
Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-lOH-phenoxazin-3-yl]-phenyl}-acetamide;
10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazo I-5-yl)-10 H-phenothiazine;
10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-phenothiazine;
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenothiazine;
N, N-Diethyl-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10 H-phenothiazi ne-3-carboxamidine;
N, N-Diethyl-1 0-(8-pyridi n-2-yl methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10 H-phenothiazine-3-carboxamidine;
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenothiazine;
N, N-Diethyl-1 0-(8-methyl-8-aza-bicyclo[3.2. 1 ]oct-3-yl)-10 H-p henoth iazine-3-carboxamidine;
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-3-pyrid in-3-y1-10 H-phenoth iazine;
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-7-pyridin-3-yl-10H-phenothiazin-4-ol;
6-Methoxy-1 0-(8-methyl-8-aza-bicyclo[3.2. 1 ]oct-3-yl)-10 H-phenothiazine-3-carboxylic acid diethylamide;
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-10H-phenoth iazi ne-3-carboxyl ic acid diethylamide;
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-hyd roxy-lOH-phenothiazi ne-3-carboxylic acid diethylamide; and enantiomers, diastereomers, tautomers, solvates, or pharmaceutically acceptable salts thereof.
Another embodiment of the present invention is a composition comprising the dextrorotatory enantiomer of a compound of formula (I), wherein said composition is substantially free from the levorotatory isomer of said compound. In the present context, substantially free means less than 25 %, preferably less than 10 %, more preferably less than 5 %, even more preferably less than 2 /a and even more preferably less than 1% of the levorotatory isomer calculated as.
% levorotatory -_ (mass levof otatory) x 100 (mass dextrof=otatoNy) + (mass levorotatory) Another embodiment of the present invention is a composition comprising the levorotatory enantiomer of a compound of formula (I) wherein said composition is substantially free from the dextrorotatory isomer of said compound. In the present context, substantially free from means less than 25 %, preferably less than 10 %, more preferably less than 5 %, even more preferably less than 2 % and even more preferably less than 1% of the dextrorotatory isomer calculated as %dextrorotatog = (mass dextrorotatory) X100 (mass dextj=oYOtator y) + (mass levorotatory) In certain embodiments, the present invention provides the endo isomer of a compound of formula (I) wherein said compound is substantially free from the exo isomer of said compound. In certain embodiments, the present invention provides compositions comprising the endo isomer of a compound of formula (I) wherein said composition is substantially free from the exo isomer of said compound. In the present context, substantially free means less than 25 %, preferably less than 10 %, more preferably less than 5 %, even more preferably less than 2 % and even more preferably less than 1% of the exo isomer.
In certain embodiments, the present invention provides the exo isomer of a compound of formula (I) wherein said compound is substantially free from the endo isomer of said compound. In certain embodiments, the present invention provides compositions comprising the exo isomer of a compound of formula (I) wherein said composition is substantially free from the endo isomer of said compound. In the present context, substantially free means less than 25 %, preferably less than 10 %, more preferably less than 5 %, even more preferably less than 2 % and even more preferably less than 1 /o of the endo isomer.
In other embodiments, compositions of the present invention comprise a mixture of the exo and endo isomers of a compound of formula (I).
The compounds of the present invention may also be present in the form of pharmaceutically acceptable salts. For use in medicine, the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts" (Ref. International J. Pharm., 1986, 33, 201-217; J. Pharm.Sci., 1997 (Jan), 66, 1, 1). Other salts well known to those in the art may, however, be useful in the preparation of compounds according to this invention or of their pharmaceutically acceptable salts. Representative organic or inorganic acids include, but are not limited to, hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic acid. Representative organic or inorganic bases include, but are not limited to, basic or cationic salts such as benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium and zinc.
The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds that are readily convertible in vivo into the required compound. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.
Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention.
In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.
Where the processes for the preparation of the compounds according to the invention give rise to mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography.
The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-I-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.
During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
Even though the compounds of the present invention (including their pharmaceutically, acceptable salts and pharmaceutically acceptable solvates) can be administered alone, they will generally be administered in admixture with a pharmaceutical carrier, excipient or diluent selected with regard to the intended route of administration and standard pharmaceutical or veterinary practice. Thus, the present invention is directed to pharmaceutical and veterinary compositions comprising compounds of Formula (I) and one or more pharmaceutically acceptable carriers, excipients or diluents.
By way of example, in the pharmaceutical and veterinary compositions of the present invention, the compounds of the present invention may be admixed with any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), and/or solubilising agent(s).
Tablets or capsules of the compounds may be administered singly or two or more at a time, as appropriate. It is also possible to administer the compounds in sustained release formulations.
Alternatively, the compounds of the general Formula (I) can be administered by inhalation or in the form of a suppository or pessary, or they may be applied, topically in the form of a lotion, solution, cream, ointment or dusting powder. An alternative means of transdermal administration is by use of a skin patch. For example, they can be incorporated into a cream consisting of an aqueous emulsion of polyethylene glycols or liquid paraffin. They can also be incorporated, at a concentration of between 1 and 10% by weight, into an ointment consisting of a white wax or white soft paraffin base together with such stabilizers and preservatives as may be required.
For some applications, preferably the compositions are administered orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavoring or coloring agents.
The compositions (as well as the compounds alone) can also be injected parenterally, for example intracavernosally, intravenously, intramuscularly or subcutaneously. In this case, the compositions will comprise a suitable carrier or diluent.
For parenteral administration, the compositions are best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood.
For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.
By way of further example, pharmaceutical and veterinary compositions containing one or more of the compounds of the invention described herein as the active ingredient can be prepared by intimately mixing the compound or compounds with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending upon the desired route of administration (e.g., oral, parenteral). Thus for liquid oral preparations such as suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, stabilizers,. coloring agents and the like;
for solid oral preparations, such as powders, capsules and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Solid oral preparations may also be coated with substances such as sugars or be enteric-coated so as to modulate the major site of absorption. For parenteral administration, the carrier will usually consist of sterile water and other ingredients may be added to increase solubility or preservation. Injectable suspensions or solutions may also be prepared utilizing aqueous carriers along with appropriate additives.
Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those skilled in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
It is also apparent to one skilled in the art that the therapeutically effective dose for active compounds of the invention or a pharmaceutical composition thereof will vary according to the desired effect. Therefore, optimal dosages to be administered may be readily determined and will vary with the particular compound used, the mode of administration, the strength of the preparation, and the advancement of the disease condition. In addition, factors associated with the particular subject being treated, including subject age, weight, diet and time of administration, will result in the need to adjust the dose to an appropriate therapeutic level. The above dosages are thus exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
Compounds of this invention may be administered in any of the foregoing compositions and dosage regimens or by means of those compositions and dosage regimens established in the art whenever use of the compounds of the invention as analgesics is required for a subject in need thereof.
The invention also provides a pharmaceutical or veterinary pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical and veterinary compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
The compounds of the present invention may be used to treat mild to severe pain in warm-blooded animals such as humans by administration of an analgesically effective dose. The dosage range would be from about 0.1 mg to about 15,000 mg, in particular from about 50 mg to about 3500 mg or, more particularly from about 100 mg to about 1000 mg of active ingredient in a regimen of about 1 to 4 times per day for an average (70 kg) human; although, it is apparent to one skilled in the art that the therapeutically effective amount for active compounds of the invention will vary as will the types of pain being treated.
For oral administration, a pharmaceutical composition is preferably provided in the form of tablets containing 0.01, 10.0, 50.0, 100, 150, 200, 250, and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated.
Examples of pain intended to be within the scope of the present invention include, but are not limited to, inflammatory pain, centrally mediated pain, peripherally mediated pain, visceral pain, structural or soft tissue injury related pain, progressive disease related pain, neuropathic pain and acute pain such as caused by acute injury, trauma or surgery and chronic pain such as headache and that caused by neuropathic conditions, post-stroke conditions, cancer, and migraine.
Compounds of the present invention are also useful as immunosuppressants, antiinflammatory agents, agents for the treatment and prevention of neurological and psychiatric conditions, for instance, depression and Parkinson's disease, agents for the treatment of urological and reproductive conditions, for instance, urinary incontinence and premature ejaculation, medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and cardioprotective agents and agents for the treatment of respiratory diseases.
The compounds of the present invention are also useful in treating pain caused by osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, mucositis, enteritis, cellulites, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, post-operative ileus, cholecystitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, post-herpetic neuralgia, trigeminal neuralgia, cluster headache, migraine headache, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, inflammatory bowel disease, irritable bowel syndrome, sinus headache, tension headache, labor, childbirth, menstrual cramps, and cancer.
In regard to the use of the present compounds in treatment of the disases or conditions such as those listed above, a therapeutically effective dose can be determined by persons skilled in the art by the use of established animal models. Such a dose would likely fall in the range of from about 0.01 mg to about 15,000 mg of active ingredient administered 1 to 4 times per day for an average (70 kg) human.
GENERAL SYNTHETIC METHODS
Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and are illustrated in the schemes that follow. Since the schemes are an illustration, the invention should not be construed as being limited by the chemical reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art.
Scheme 1 R.1Y I~ Q HY I~ Q
/ s R'YI~ Q Stage 1.1 HN Stage 1.2 HN
PN~NH2 + ~
Xl ~, ,~, 1.4 1.1 1.2 N 1.3 N
P P
Rq i\ ~~ )0lstage Ra ~1.4 R~ ~ N Stage 1.5 / N /
Stage 1.3 ~. ~. ,,4.
N 1.6 H 1 R 2 The preparation of compounds of this invention is illustrated in Schemes I through 11. The overall strategy in Scheme 1 is based on the synthesis of appropriately substituted compounds of formula 1.4 (Y =0, S) that are condensed with an appropriately substituted compound of formula 1.5. In compounds of formula 1.5, X2 and X3 can each be a halogen atom, trifluoromethanesulfonyloxy or a nitro group. In stage 1.1, a bridged N1-protected 4-aminopiperidine 1.1 is condensed with a properly substituted 0-protected phenol (Y=0) or thiophenol (Y=S) 1.2. The protective group on the N1 nitrogen of 1.1 (represented as P) may include an alkanyl, alkenyl or aralkanyl group in which case they are the therapeutically useful products of this invention. The group P may also be trifluoromethylcarbonyl, alkoxycarbonyl or aralkoxycarbonyl. Bridge A may include (CH2) 2 and (CH2) 3.
Useful phenol or thiophenol protective groups (R) include lower alkyl groups, benzyl, trialkylsilyl and the like. Appropriate substituents on the protected phenol or thiophenol in the 2-position (Xi) may include halogens and trifluoromethanesulfonyloxy. The Q group in the 5-position may be a substituent such as fluoro, chloro, bromo, cyano, iodo, carboxy, dialkylaminosulfonyl or trifluoromethanesulfonyloxy. Stage 1.2 includes deprotection of the phenol or thiophenol protective group. Such transformations may include the dealkylation of lower alkyl ethers to give their corresponding alcohols using reagents such as boron trihalides, or dealkylation of lower alkyl thioethers using reagents such as Na/NH3. A benzyl protective group may be removed under conditions of hydrogenation in the presence of a transition metal such as palladium. Trialkylsilyl protective groups may be removed by treatment with a source of fluoride anion such as tetrabutyl ammonium fluoride, or by exposure to an inorganic acid such as aqueous hydrogen chloride and the like.
In stage 1.3, hydroxyaniline (Y=0) or thioaniline (Y=S) 1.4 may be condensed with an appropriately substituted benzene moiety 1.5. Substituents X2 and X3 may include halogens, trifluoromethanesulfonyloxy, or a nitro group.
Useful coupling conditions of the anilino nitrogen with a compound of formula 1.5 include palladium.catalyzed condensations in the presence of a phosphine ligand such as Pd2(dba)3 and a base such as cesium carbonate. Coupling of the hydroxy or thio moiety with the remaining substituted phenyl group may proceed using Ullmann type coupling conditions. In addition, the two steps described in stage 1.3 may be reversed with biaryl ether or biaryl thioether formation preceding the formation of the biaryl amine. Alternatively, the condensation between compounds of formula 1.4 and compounds of formula 1.5 to yield compounds of formula 1.6 in one step may be affected by treatment with an inorganic base such as potassium carbonate in a suitable solvent such as dimethyl formamide.
The regiochemical outcome of the condensation between compounds of formula 1.4 and compounds of formula 1.5 depends on the position of the R4 substituent in compounds of formula 1.5 and on the reaction conditions used for the condensation. An extensive review on this topic is available in the literature (see, for eample: 'The Smiles and Related Rearrangements of aromatic Systems' by W. E. Truce, E. M. Kreider, and W. W. Brand in Organic Reactions, 1970, Vol. 18, pp.99-215).
The protective group P can be removed to obtain secondary amines I
as illustrated for Stage 1.4. These transformations may be carried out using certain acidic reagents such as hydrogen bromide or trimethylsilyl iodide.
Phenoxazines (Y=O) or phenothiazines (Y=S) of type 1.6 bearing readily cleavable groups such as methyl, allyl or benzyl may be transformed into the aforementioned alkoxycarbonyl derivatives by treatment with alkanylchloroformates such as ethyl chloroformate or 1-chloroethyl chloroformate and thus serve as sources of phenoxazines and phenothiazines 1. Phenoxazines or phenothiazines of type 1.6 bearing a trifluormethylcarbonyl group may be treated with potassium carbonate in an alcoholic solvent such as methanol to yield phenoxazines and phenothiazines 1.
Finally the secondary amines I may be converted to a compound of formula 2 as shown in Stage 1.5. These transformations may be carried out by reductive alkylation using a carbonyl compound and a reducing agent such as sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride, or tetramethylammonium triacetoxyborohydride. They may also be carried out by alkylation using an alkanyl, alkenyl or aralkyl halide and an organic or inorganic base.
The Q function in compounds 1 or 2 may be converted into group G, which may be -C(Z)NRIR2, an aryl substituent, or an appropriate heterocycle as defined herein, to give compounds of formula I. When the Q function is a halogen or trifluoromethanesulfonyloxy, it may be converted to an ester via alkoxycarbonylation using carbon monoxide, an aliphatic alcohol, a trialkanyl amine, and a palladium catalyst such as bis(triphenylphosphine) palladium(II)dichloride. Subsequently, when Q is an ester, the ester may be hydrolyzed to a carboxylic acid. The carboxylic acid may then be coupled with ammonia, a primary amine, or a secondary amine to form a primary, secondary or tertiary amide, respectively. Alternatively, the conversion of a carboxylic acid to an amide may be carried out via an acid chloride using thionyl chloride, oxalyl chloride, or the like, followed by a Schotten-Baumann reaction using ammonia or an amine in the presence of an alkali metal hydroxide.
Alternatively, the conversion of a carboxylic acid to an amide may be carried out via the use of peptide coupling agents such as 1,3-dicyclohexylcarbondiimide (DCC), O-(7-azabenzotriazol-1-yl)-N,N,N;N'-tetramethyluronium hexafluorophosphate (HATU), O-benzotriazol-1-yl-N,N,N;N'-tetramethyluronium hexafluorophosphate (HBTU), or the like.
Alternatively, the ester may be converted directly to the amide by the action of a dimethylaluminum amide.
Alternatively, when the Q function is a halogen or trifluoromethanesulfonyloxy, it may be converted directly to an amide via aminocarbonylation using a carbon monoxide source such as molybdenum hexacarbonyl, an appropriate amine, and a palladium catalyst such as Hermann's catalyst.
Alternatively, one may effect the transformation of the group Q to a substituent G (wherein G is an amidino or heterocycle) by way of a nitrile.
Synthesis of the nitrile may be accomplished by treatment of the compounds 1 or 2 (when Q is bromo or trifluoromethanesulfonyloxy) with Zn(CN)2 and a palladium cataiyst such as (Ph3P)4Pd or by treatment of the compounds 1 or 2 with CuCN at elevated temperatures. For the synthesis of amidino functional groups, the nitrile is treated with hydroxylamine under basic conditions to afford an oxime. Treatment of the oxime with a primary or secondary amine, CuCI, and an alkali metal carbonate under microwave irradiation in an aicoholic solvent provides the amidino compounds of the present invention. Microwave acceierated reactions may be performed using either a CEM Discover or a Personal Chemistry Smith Synthesizer microwave instrument. The oxime described above is instrumental in the preparation of compounds wherein G is a heterocycle. The oxime may be cyclized with a variety of electrophiies known to one versed in the art to give the heterocycles of the present invention.
For instance, reaction of an oxime with CDI provides oxadiazolones, and treatment of the oxime with TCDI provides the corresponding oxadiazolethiones.
Similarly, the treatment of the oxime with thionyl chloride in the presence of a tertiary amine gives oxathiadiazoles of the present invention.
Alternatively, compounds where Q is a halogen atom or a trifluoromethanesulfonyloxy group may participate in transition metal-mediated coupling reactions such as Suzuki, Stille or Negishi chemistry.
Desired end products of the present invention may include chemical modifications at R4. Such transformations may include the dealkylation of lower alkyl ethers to give the corresponding alcohols using reagents such as boron trihalides. Compounds where R4 is a halogen atorn may participate in transition metal-mediated coupling reactions such as Suzuki, Stille or Negishi chemistry.
Scheme 2 X, X, R ~ XZ HY \ Q Stage 2.1 Y Stage 2.2 R aE 4 I + /~ I R4 4 / NO2 X1 / NO2 NH2 2.1 2.2 2.3 Q 2.4 Y ~ Y Q
Xl' PN -I ~ R4 2 O .5 R 4NH / Stage 2.4 N
Stage 2.3 Q
6A~ ,~4.
2.6 N 1.6 P
Scheme 2 outlines an alternative approach to the synthesis of phenoxazines (Y=O) or phenothiazines (Y=S) 1.6. In this scheme, an appropriately substituted phenol (Y=O) or thiophenol (Y=S) of type 2.2 is reacted with an appropriately substituted benzene moiety 2.1 in the presence of a base, such as potassium carbonate or sodium hydroxide in an organic solvent, such as dimethyl formamide, dimethyl acetamide, dimethyl sulfoxide or the like as shown in stage 2.1. Appropriate substituents X, and X2 in this scheme may include halogens and trifluoromethanesulfonyloxy. In stage 2.2, the nitro functionality is reduced to the corresponding amine. This reduction can be accomplished via treatment with tin(II) chloride in an alcoholic solvent such as ethanol. Stage 2.3 depicts the conversion of primary aniline 2.4 to secondary aniline 2.6, which can be accomplished via reductive alkylation using a carbonyl compound 2.5 and a reducing agent such as sodium borohydride, sodium cyanoborohyd ride, sodium triacetoxyborohydride, or tetramethylammonium triacetoxyborohydride. Stage 2.4 depicts formation of compounds of formula 1.6, which can be accomplished by treatment of secondary aniline 2.6 with an appropriate base such as potassium carbonate.
Scheme 3 x2 Y
Ra5,,, YFi + X1 ~ Q Stage 3.1 Ra 3.1 3.2 2.3 Scheme 3 illustrates an alternative synthesis of compound 2.3. In this approach, an appropriately substituted 2-nitrophenol (Y=O) or 2-nitrothiophenol (Y=S) may be condensed with an appropriately substituted benzene moiety of type 3.2 under Ullmann type coupling conditions. Appropriate substituents X1 and X2 include halogens and trifluoromethanesulfonyloxy.
Scheme 4 X2 HY ~ Q aE Y PN~NH2 R4 + Stage 4.1 RX3 X1 ~ X3 Stage 4.2 Q
1.5 2.2 4.1 I ~ Y ~ Q
R4 I / ~ /
N
61.6 N
P
Scheme 4 illustrates an alternative approach to the synthesis of phenoxazines (Y=O) or phenothiazines (Y=S) 1.6. Condensation of appropriately substituted phenols (Y=O) or thiophenols (Y=S) 2.2 with substituted benzene moiety 1.5 under Ullmann type coupling conditions as shown in stage 4.1 may result in the formation of biaryl ethers (Y=O) or biaryl thioethers (Y=S) 4.1. Appropriate Xi, X2 and X3 substituents may include halogens and trifluoromethanesulfonyloxy. Palladium catalyzed condensation of biaryl ethers or biaryl thioethers 4.1 with bridged N1-protected 4-aminopiperidines 1.1 in the presence of a phosphine ligand such as Pd2(dba)3 and a base such as cesium carbonate is shown in stage 4.2 may result in the formation of phenoxazines or phenothiazines 1.6.
Scheme 5 ~
YH X Q
R4 iy +
3 x2 ~ \ Stage 5.1 Y
I ~ R4 i ~
x3 Q
5.1 3.2 4.1 An alternative approach to the synthesis of intermediate 4.1 is depicted in Scheme 5 and is based on the reaction of appropriately substituted phenois (Y=O) or thiophenois (Y=S) 5.1 with an appropriately substituted benzene moiety 3.2 under Ullmann type coupling conditions (stage 5.1). Substituents Xl, X2, and X3 may include halogens or trifluoromethanesulfonyloxy.
Scheme 6 X, NH X2 HY ~ Q
a,_ X 2 R4 N I/ R4 2 H X 2.2 X3 Stage 6.1 6-A Stage 6.2 Q
1.5 P 6.1 P 2.6 Scheme 6 illustrates an alternative approach to the synthesis of intermediates 2.6. An appropriately substituted compound of formula 1.5 may be reacted with bridged N1-protected 4-aminopiperidines 1.1 in the presence of a palladium catalyst such as Pd2(dba)3, a phosphine ligand and a base such as cesium carbonate as shown in stage 6.1. Appropriate X, and X2 substituents may include halogens and trifluoromethanesulfonyloxy. Compounds of formula 6.1 may then be reacted with appropriately substituted phenols (Y=O) or thiophenois (Y=S) 2.2 under Ullmann type coupling conditions to yield anilines 2.6 as shown in stage 6.2.
Scheme 7 X, ~ Q YH
X1 Q Stage 7.1 HN '/ Ra i/ x 3 Ra Y ~ Q
'~
PNaNH2 + HN ~ s X2 ,,4. Stage 7.2 1.1 3.2 N 7.1 P 6~
~ Y Q N 7.3 P
Stage 7.3 Ra ~/ N I/
1.6 P
Scheme 7 illustrates an alternative approach to the synthesis of phenoxazines (Y=O) or phenothiazines (Y=S) 1.6. Condensation of appropriately substituted compounds of formula 3.2 with bridged N1-protected 4-aminopiperidines 1.1 may result in formation of intermediate 7.1 as shown in stage 7.1. Appropriate Xl, X2, and X3 substituents may include halogens and trifluoromethanesulfonyloxy. Reaction of compounds 7.1 with appropriately substituted phenol (Y=O) or thiophenois (Y=S) 7.2 under Ullmann like coupling conditions may result in formation of compounds 7.3 as shown in stage 7.2.
Finally, ring closure of compounds 7.4 may be accomplished in the presence of a palladium catalyst such as Pd2(dba)3, a phosphine ligand such as 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (xant phos) and a base such as potassium tert-butoxide or cesium carbonate as shown in stage 7.3.
Scheme 8 R
PN -NHz R4 ~/ R4 N
Y YR ::x.:
R4 Stage 8.2 X, X3 Stage 8.1 ,A. 6 8.1 P 8.2 N 8.3 P
\
I\ N I YH \ Q R Y Q
Ra ~ Sta9e8.4 ~ a Stage 8.3 I/
/ _ N
XX, .ti4.
8.4 N 1.6 P P
Scheme 8 illustrates an alternative ternative synthesis of phenoxazines (Y=O) or phenothiazines (Y=S) 1.6 and is based on an Ullmann-like coupling of bridged N1-protected 4-aminopiperidines 1.1 with appropriately substituted and protected phenois (Y=O) or thiophenois (Y=S) 8.1 as shown in stage 8.1.
Useful phenoi or thiophenol protective groups for compounds 8.1 include lower alkyl groups, benzyl, trialkylsilyl and the like. Appropriate Xi, X2, and X3 substituents may include halogens and trifluoromethanesulfonyloxy. The resulting compounds 8.2 may be condensed with appropriately functionalized benzene compounds 3.2 to yield diarylanilines 8.3. Stage 8.3 includes deprotection of the phenol or thiophenol protective group. Such transformations may include the dealkylation of lower alkyl ethers to give their corresponding alcohols using reagents such as boron trihalides or the dealkylation of the alkyl thioethers using Na/NH3. A benzyl protective group may be removed under conditions of hydrogenation in the presence of a transition metal such as palladium. Trialkylsilyl protective groups may be removed by treatment with a source of fluoride anion such as tetrabutyl ammonium fluoride, or by exposure to an inorganic acid such as aqueous hydrogen chloride and the like. Finally, ring closure of compounds 8.3 to phenoxazines or phenothiazines 1.6 may be accomplished via an Ullmann type transformation as shown in stage 8.4.
Scheme 9 Y
YH I~
X ~ Q Stage 9.1 Q Stage 9.2 Ra + ~/ Ra I I Ra ~\%
X2 p2 N 2NH2N
9.1 9.2 9.3 9.4 ~
PNO Y Q
D75 Ra i/ HN I/
Stage 9.3 ,~.
N 7.4 P
Scheme 9 illustrates another synthetic approach to compounds 7.4.
Displacement of X7 in appropriately substituted compounds of formula 9.2 with appropriately substituted compounds of formula 9.1 as shown in stage 9.1 may lead to biaryl ethers (Y=O) and biarylthioethers (Y=S) 9.3. Appropriate X, and X2 substituents may include halogens and trifluoromethanesulfonyloxy.
Reduction of compounds 9.3 to amines 9.4 as shown in stage 9.2 may be accomplished using tin(II) chloride in an alcoholic solvent such as ethanol.
Stage 9.3 depicts the conversion of primary anilines 9.4 to secondary anilines 7.4 and can be accomplished via reductive alkylation using a carbonyl compounds 2.5 and a reducing agent such as sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride, or tetramethylammonium triacetoxyborohyd ride.
Scheme 10 HY Q
): Xz 2 02N 10.1 ~~ Y Q
R4 Ra i /
X3 Stage 10.1 02N
1.5 9.3 Scheme 10 illustrates another synthetic approach to compounds 9.3. For construction of diaryl ethers (Y=O) and diaryl thioethers (Y=S) 9.3, appropriately substituted 2-hydroxynitrobenzenes or 2-thionitrobenzenes 10.1 may be caused to react with appropriately substituted compounds of formula 1.5 under Ullmann type conditions as shown in stage 10.1. Appropriate X2 and X3 substituents may include halogens and trifluoromethanesulfonyloxy.
Scheme 11 YH PN~O Q
R4 i ~\ YH :'-2 R4 I / \ I/ ~ ~
R - N
4 i / NH
NH2 Stage 11.1 Stage 11.3 Y-O ,~R, C-A~ 11.1 N 11.2 1.6 P P
Stage 11.2 PN,Ia =O
'~~ 2.5 Y P
~ N
~
~
Stage 11.1 R N
11.3 Scheme 11 illustrates another synthetic approach to compounds 1.6. Stage 11.1 depicts the conversion of appropriately substituted 2-hydroxyanilines (Y=O) 11.1 to compounds 11.2 (Y=O), which can be accomplished via reductive alkylation using a carbonyl compound 2.5 and a reducing agent such as sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohyd ride, or tetramethylammonium triacetoxyborohyd ride.
Appropriately substituted 2-hydroxyanilines 11.2 may be caused to react with an appropriately substituted benzene 3.2 under Ullmann type conditions or under basic conditions such as potassium carbonate in DMF (when Xj= NO2) as shown in stage 11.3 to yield compounds of formula 1.6. Appropriate X, and X2 substituents may include halogens, trifluoromethanesulfonyloxy, and a nitro group.
The regiochemical outcome of the condensation of compounds of formula 11.2 with compounds of formula 3.2 depends on the position of the Q substituent in compounds of formula 3.2 and on the reaction conditions used for the condensation. An extensive review on this topic is available in the literature (see, for eample: 'The Smiles and Related Rearrangements of aromatic Systems' by W. E. Truce, E. M. Kreider, and W. W. Brand in Organic Reactions, 1970, Vol. 18, pp.99-215).
In compounds of formula 11.1 where Y is sulfur, an intermediate spiro compound of formula 11.3 may be formed. Compounds of formula 11.3 may be converted to compounds of formula 11.2 (Y = S) by treatment with a hydride reagent such as lithium aluminum hydride or sodium borohydride.
In the above Schemes 1 through 11, the Q function of compounds 2 may be converted into group G, which may be -C(Z)NRIR2, an aryl substituent, or an appropriate heterocycle as defined herein, to give compounds of formula 3.
When the Q function of compounds 2 is a halogen or trifluoromethanesulfonyloxy, it may be converted to an ester via alkoxycarbonylation using carbon monoxide, an aliphatic alcohol, a trialkanyl amine, and a palladium catalyst such as bis(triphenylphosphine) palladium(II)dichloride. Subsequently, when Q is an ester, the ester may be hydrolyzed to a carboxylic acid. The carboxylic acid may then be coupled with ammonia, a primary amine, or a secondary amine to form a primary, secondary or tertiary amide, respectively. Alternatively, the conversion of a carboxylic acid to an amide may be carried out via an acid chloride using thionyl chloride, oxalyl chloride, or the like, followed by a Schotten-Baumann reaction using ammonia or an amine in the presence of an alkali metal hydroxide.
Alternatively, the conversion of a carboxylic acid to an amide may be carried out via the use of peptide coupling agents such as 1,3-dicyclohexyicarbondiimide (DCC), 0-(7-azabenzotriazol-1-yl)-N,N,N;N'-tetramethyluronium hexafluorophosphate (HATU), O-benzotriazol-1-yl-N,N,N;N'tetramethyluronium hexafluorophosphate (HBTU), or the like.
Alternatively, the ester may be converted directly to the amide by the action of a dimethylaluminum amide.
Instead of proceeding to compounds 3 via an ester, one may effect the transformation of the group Q to a substituent G (wherein G is an amidino or heterocycle) by way of a nitrile. Synthesis of the nitrile may be accomplished by treatment of the compounds 2 (when Q is bromo or trifluoromethanesulfonyloxy) with Zn(CN)2 and a palladium catalyst such as (Ph3P)4Pd or by treatment of the compounds 2 with CuCN at elevated temperatures. For the synthesis of amidino functional groups, the nitrile is treated with hydroxylamine under basic conditions to afford an oxime.
Treatment of the oxime with a primary or secondary amine, CuCI, and an alkali metal carbonate under microwave irradiation in an alcoholic solvent provides the amidino compounds of the present invention. Microwave accelerated reactions may be performed using either a CEM Discover or a Personal Chemistry Smith Synthesizer microwave instrument. The oxime described above is instrumental in the preparation of compounds wherein G is a heterocycle. The oxime may be cyclized with a variety of electrophiles known to one versed in the art to give the heterocycles of the present invention.
For instance, reaction of an oxime with CDI provides oxadiazolones, and treatment of the oxime with TCDI provides the corresponding oxadiazolethiones.
Similarly, the treatment of the oxime with thionyl chloride in the presence of a tertiary amine gives oxathiadiazoles of the present invention.
An aryl substituent may be installed in place of the functional group Q by coupling compounds 2 (when Q is bromo or trifluoromethanesulfonyloxy) with a suitably substituted arylboronic acid in the presence of a palladium catalyst and an alkali metal carbonate.
Desired end products of the present invention may include chemical modifications at R4. Such transformations may include the dealkylation of lower alkyl ethers to give their corresponding alcohols, using reagents such as boron trihalides. Compounds where R4 is a halogen atom may participate in transition metal-mediated coupling reactions such as Suzuki, Stille or Negishi chemistry.
It is generally preferred that the respective product of each process step be separated from other components of the reaction mixture and subjected to purification before its use as a starting material in a subsequent step.
Separation techniques typically include evaporation, extraction, precipitation and filtration. Purification techniques typically include column chromatography (Still, W. C. et. al., J. Org. Chem. 1978, 43, 2921), thin-layer chromatography, crystallization and distillation. The structures of the final products, intermediates and starting materials are confirmed by spectroscopic, spectrometric and analytical methods including nuclear magnetic resonance (NMR), mass spectrometry (MS) and liquid chromatography (HPLC). In the descriptions for the preparation of compounds of this invention, ethyl ether, tetrahydrofuran and dioxane are common examples of an ethereal solvent;
benzene, toluene, hexanes and heptanes are typical hydrocarbon solvents and dichloromethane and dichloroethane are representative halogenated hydrocarbon solvents. In those cases where the product is isolated as the acid addition salt the free base may be obtained by techniques known to those skilled in the art. In those cases in which the product is isolated as an acid addition salt, the salt may contain one or more equivalents of the acid.
Enantiomers of the compounds of the present invention may be separated using chiral HPLC.
Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described above and are illustrated more particularly in the schemes that follow. Since the schemes are illustrations, the invention should not be construed as being limited by the chemical reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skili of persons versed in the art.
Abbreviations AcOH = acetic acid Boc = tert-butoxycarbonyl DIEA = N,N-diisopropyl-N-ethylamine DMF = N,N-dimethylformamide DMSO = dimethyl sulfoxide Et = ethyl h = hour(s) HBTU = O-benzotriazol-1-yI-N,N,N;N=tetramethyluronium hexafluorophosphate K2C03 = potassium carbonate Me = methyl min = minute(s) rt = room temperature xantphos = 4,5-bis(diphenylphosphino)-9,9-dimethyixanthene Although the foregoing invention has been described in detail by way of example for purposes of clarity of understanding, it will be apparent to the artisan that certain changes and modifications are comprehended by the disclosure and can be practiced without undue experimentation within the scope of the appended claims, which are presented by way of illustration not limitation.
All publications and patent documents cited above are hereby incorporated by reference in their entirety for all purposes to the same extent as if each were so individually denoted.
EXAMPLES
Example A
HO CO2Me -N O ~I U-N0 CO Me ~HO ~ 2 ~ HN 2 I / NaBH(OAc)3/HOAc K2CO3 N 1a O C02H HNNaOH cOXICO2Me --;
HBTU
THF
2a 3a Et3N
N DMF
O
N \
I/
N 4a I
Procedure 1 3-Hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-ylamino)-benzoic acid methyl ester, 1 a To a solution of 4-amino-3-hydroxybenzoic acid methyl ester (2.0g; 12 mmol) and 8-methyl-8-aza-bicyclo[3.2.1]octan-3-one (1.1g; 10.8 mmol) in dichloroethane (30 mL) was added sodium triacetoxyborohydride (3.2g; 15.1 mmol) and acetic acid (0.65 mL; 11.4 mmol). The mixture was stirred at rt for 16 h. The mixture was diluted with 1 N NaHCO3 solution and chloroform was added. The organic layer separated, and the aqueous phase was lyophilized.
The lyophilized residue was purified via reverse phase HPLC (eluent gradient:
to 50% acetonitrile in water containing 0.1 % TFA) to yield 1.61 g (36.9%) of a mixture of endo and exo isomers of 3-hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-ylamino)-benzoic acid methyl ester, 1a as a TFA salt. MS
m/z (MH+) 291.
Procedure 2 10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid methyl ester, 2a A mixture of the TFA salt of 3-hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-ylamino)-benzoic acid methyl ester, 1a (0.424g, 0.734 mmol), 2-fluoronitrobenzene (95 L, 0.9 mmol) and potassium carbonate (564 mg, 4 mmol) in DMF was heated to reflux for 70 min. The mixture was allowed to cool to rt, filtered, and purified via reverse phase HPLC to yield 440 mg (88%) of 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid methyl ester, 2a, as TFA salt. MS m/z (MH+) 365.1.
Procedure 3 10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenoxazine-3-carboxylic acid, 3a To a solution of 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenoxazine-3-carboxylic acid methyl ester, 2a (440 mg, 0.646 mmol) in THF (5 mL) was added I N NaOH (5 mL), and the mixture was stirred for 3 hr at rt. The solvent was removed, the residue was dissolved in DMF and acidified with a 2N TFA
solution, and purified via reverse phase HPLC to yield 295 mg (63%) of 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid, 3a, as a TFA salt. MS m/z (MH+) 351.1.
Procedure 4 10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 4a To a solution of the TFA salt of 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-phenoxazine-3-carboxylic acid 3a (65 mg, 0.14 mmol) and HBTU (64 mg; 0.17 mmol) in DMF (2 mL) was added triethylamine (69 L, 0.43 mmol). The mixture was stirred for 1 hr at rt, and purified without prior quenching via reverse phase HPLC (eluent gradient: acetonitrile in water containing 0.1 %
TFA) to yield 44.4 mg (61 %) of title compound 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 4a as a TFA salt. MS m/z (MH+) 406.2.
O
O NOH
A5a N
I
(3-Hydroxy-pyrrolidin-1-yi)-[10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-methanone, 5a Using an adaptation of Procedure 4, and substituting 3-hydroxypyrrolidine for diethylamine, the title compound (3-hydroxy-pyrrolidin-yl )-[10-(8-methyl-8-aza-b icyclo [3.2.1 ]oct-3-yl )-10H-p h enoxazi n-3-yl]-methanone, 5a was obtained as a TFA salt. MS m/z (MH+) 420.1.
O ~
~ I
aN O ~ N
~/ A6a N
I
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxyl ic acid methyl-phenethyl-amide, Using an adaptation of Procedure 4, and substituting N-methyl-N-phenethylamine for diethylamine, the title compound 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid methyl-phenethyl-amide, 6a was obtained as a TFA salt. MS m/z (MH+) 468.3.
Example B
/ OH OCNH
OH Boc-N O / ~ \ I NaBH(OAc)3/HOAc +
N lb N 2b i i Boc Boc N-N
,, F\ I aN:l O CN O I\ ~ H
1b 02N N
/
~ CNNaN3 C(N
KaC03 NH4CI
DMF DMF
N 3b N 4b Boc Boc N-N O N-N
N
'N
\ N CHO H
H
cXOXIIIIN
HCI ~
-~ _ dioxane NaBH(OAc)3 N 5b CICHZCH2CI N N 6b H I ~
/
Procedure 5 Endo-3-(2-Hydroxy-phenylamino)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1 b and Exo-3-(2-Hydroxy-phenylamino)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2b To a solution of 2-aminophenol (5.0g; 45.82 mmol) and 3-oxo-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (15.5 g; 68.8 mmol)-in dichloroethane (200 mL) was added acetic acid (2.62 mL; 45.77 mmol). The mixture was stirred at rt for 1 h and sodium triacetoxyborohydride (11.6g;
54.73 mmol) was added in small portions. The mixture was stirred at rt for 16 h and treated with H20 (200 mL). The organic layer was separated, dried over MgSO4, filtered, and evaporated. The residue was purified via column chromatography (eluent gradient: 10 to 30 % ethyl acetate in heptane) to yield 8g (55%) of endo-3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, lb and 1.5 g (10%) of exo-3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1b.
MS m/z (MH+) 318.9.
Procedure 6 Endo-3-(3-Cyano-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 3b To a solution of 4-fluoro-3-nitrobenzonitrile (0.29 g; 1.74 mmol) and endo-3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 b (0.55 g; 1.73 mmol) in DMF (6 mL) was added potassium carbonate (0.48 g; 3.47 mmol). The mixture was stirred at 170 C for 30 min. The mixture was allowed to cool to rt and poured into ice-water 910 mL). The solid was separated via filtration, washed with water, and dried to yield 0.63 g (86%) of endo-3-(3-cyano-phenoxazi n-10-yI)-8-aza-bicyclo[3.2.1 ]octane-8-carboxyl ic acid tert-butyl ester, 3b. MS m/z (MH+) 417.9.The material was used as such for the next reaction.
Procedure 7 Endo-3-[3-(l H-Tetrazol-5-yl)-phenoxazi n-10-yl]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 4b To a solution of endo-3-(3-cyano-phenoxazin-10-yi)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3b (1 g; 2.4 mmol) in DMF (20 mL) were added sodium azide (0.47 g, 7.23 mmol) and ammonium chloride (0.39 g; 7.29 mmol), and the mixture was heated at 120 C for 16h. The mixture was allowed to cool to rt, and filtered. The filtrate was acidified with 1 N
hydrochloric acid (10 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic layers were dried over MgSO4, filtered, and evaporated. The residue was used as such for the next reaction.
Procedure 8 Endo-10-(6-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b To a solution of endo-3-[3-(1 H-tetrazol-5-yl)-phenoxazin-10-yl]-8-aza-bicyclo[3.2.1]-octane-8-carboxylic acid tert-butyl ester, 4b (2.4 mmol) in dioxane (5 mL) was added a 4N hydrochloric acid solution (5 mL). The mixture was stirred at rt for 16 h. The mixture was filtered, and the filtrate was evaporated. The residue was purified via reverse phase chromatography (eluent gradient: acetonitrile in water containing 0.1 % TFA) to yield crudeendo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine, 5b as a TFA salt. MS m/z (MH+) 360.9. The material was used as such in the next reaction.
Procedure 9 Endo-1 0-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 6b To a suspension of the HCI salt of endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 W-tetrazol-5-yl)-10H-phenoxazine, 5b (0.2 g; 0.5 mmol) and 2-pyridylcarboxaldehyde (0.071 mL; 0.74 mmol) in dichloroethane (4 mL) was added sodium triacetoxyborohydride (0.13 g; 0.61 mmol). The mixture was stirred at rt for 15 h and a saturated NaHCO3 solution (3 mL). The organic layer was separated, and the aqueous phase was extracted with ethyl acetate (5 mL). The combined organic layers were dried over MgS 4, filtered, and evaporated. The residue was purified via reverse phase HPLC (eluent:
acetonitrile in water containing 0.1 % TFA) to yield 139.8 mg (quant.) of title compound endo-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 6b as a TFA salt. MS m/z (MH+) 452Ø
N_NN
~ N
~ xx H N
N 7b Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 7b Using an adaptation of Procedure 9, and substituting phenylacetaidehyde for 2-pyridyl carboxaldehyde, the title compound endo-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine, 7b was obtained as a TFA salt. MS m/z (MH+) 464.9.
O ~ /
xx1 8b N
H
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 8b Using an adaptation of Procedure 9, and substituting endo-3-(3-cyano-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 3b for endo-3-[3-(1 H-tetrazol-5-yl)-phenoxazin-10-yl]-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 4b, the title compound endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 8b was obtained as a TFA salt. MS m/z (MH+) 317.9.
Example C
0 ~ CN 0 NH NH
HN
N HCI
N _ --= N
MeMgBr dioxane N 3b Et2 Ic 2c Boc H
Boc N
NH
0 N~\
N C
HO
aN&
NaBH(OAc)3 CICH2CH2CI N 3c N
~ \
/
Procedure 10 Endo-3-[3-(N,N-Diethyl-carbamim idoyl)-phenoxazin-10-yI]-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 1 c To a solution of methylmagnesium bromide in diethyl ether (3.0 M, 2.4 mL, 7.2 mmol) under nitrogen was added dropwise a solution of diethylamine (0.749 mL, 7.19 mmol) in diethyl ether (2 mL). The mixture was heated to reflux for min, cooled to rt, and a suspension of endo-3-(3-cyano-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3b (1.0 g, 2.4 mmol) was added. The mixture was stirred at 40 C for 2 hr and water (10 mL) was added,. The organic layer was separated, and the aqueous layer was further extracted with chloroform (2 x 10 mL). The combined organic layers were dried over magnesium sulfate, filtered, and evaporated, yielding title compound endo-3-[3-(N,N-diethyl-carbamimidoyl)-phenoxazin-l0-yl]-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester Ic. MS m/z (MH+) 491ØThe residue was used as such for the next reaction.
Endo-1 0-(8-Aza-bicyclo[3.2.1]oct-3-yl)-N,N-d iethyl-10H-phenoxazine-3-carboxamidine, 2c Using an adaptation of Procedure 8, and substituting endo-3-[3-(N,N-Diethyl-carbamimidoyl)-phenoxazin-10-yl]-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 4b for endo-3-[3-(1 H-tetrazol-5-yl)-phenoxazin-10-yl]-8-aza-bicyclo[3.2.1]-octane-8-carboxylic acid tert-butyl ester, 4b, the title compound endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-N, N-diethyl-10H-phenoxazine-3-carboxamidine, 2c was obtained as a TFA salt. MS mlz (MH+) 390.9.
Endo-N,N-Diethyl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxamidine, 3c Using an adaptation of Procedure 8, and substituting endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-N,N-diethyl-10H-phenoxazine-3-carboxamidine, 2c for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, the title compound endo-N,N-diethyl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxamidine, 3c was obtained as a TFA salt. MS tn/z (MH+) 482Ø
NH
0 N--\
N 4c Endo-N, N-Diethyl-l0-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenoxazine-3-carboxamidine, 4c Using an adaptation of Procedure 9, substituting endo-N,IV diethyl-10-(8-pyrid i n-2-yl methyl-8-aza-bicyclo [3. 2.1 ]oct-3-yl )-10 H-phe noxazi ne-3-carboxamidine, 3c for endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yI)-10H-phenoxazine, 5b and phenyl acetaidehyde for 2-pyridyl carboxaldehyde, the title compound endo-N,N-diethyl-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxamidine, 4c was obtained as a TFA salt. MS m/z (MH+) 495Ø
Example D
NOH O
O CN
NH2 O I\ NH2 N NH2OH.HCI a /
N + N
EtOH
N 3b N 1d N 2d Boc 'Boc Boc O
a'4- O N NO
H HCI
CDI :110' - N + 2d dioxane dioxane 3d N
Boc N-O O
O ~
ccx0 + 4d 5d N N
H H
O
N CHO ~ O N~O
~ H
4d NaBH(OAc)3 6d N
~ \
/
Procedure 11 Endo-3-[3-(N-Hyd roxyca rbam i m i doyl )-phe noxazi n-10-y.i]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1d and endo-3-(3-Carbamoyl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2d To a solution of endo-3-(3-cyano-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3b (1 g; 2.40 mmol) in ethanol (20 mL) were added ammonium hydroxide hydrochloride (0.5 g; 7.19 mmol) and potassium carbonate (0.66 g; 4.78 mmol), and the mixture was heated to reflux for 16 h.
The mixture was allowed to cool to rt, water (20 mL) was added, and the mixture was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried over MgSO4, filtered, and evaporated, yielding a- 2:1 mixture of title compounds endo-3-[3-(N-hydroxycarbamimidoyl)-phenoxazin-10-yl]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1d and endo-3-(3-carbamoyl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2d. The crude mixture was used as such in the next reaction. 1d: MS m/z (MH+) 451.2., 2d: MS m/z (MH+) 458.3.
Procedure 12 Endo- 3-[3-(5-Oxo-4,5-dihydro-[1,2,41oxadiazol-3-yl)-phenoxazin-10-y11-8-aza-bicyclo[3.2.11octane-8-carboxylic acid tert-butyl ester, 3d To a solution of the 2:1 mixture of endo-3-[3-(N-hydroxycarbamimidoyl)-phenoxazin-10-yl]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 d and endo-3-(3-carbamoyl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2d (2.33 mmol) in dioxane (20 mL) was added 1,1'-carbonyidiimidazole (0.57 g; 3.52 mmol), and the mixture was stirred at 110 C for 4 h. The mixture was allowed to cool to rt, and the solution containing a crude mixture of endo- 3-[3-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-phenoxazin-10-yl]-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 3d (MS m/z (MH+) 477.1)and endo-3-(3-carbamoyl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2d was used as such in the next reaction.
Endo- 3-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2;4]oxadiazol-5-one, 4d and endo-l0-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid amide, 5d Using an adaptation of Procedure 8, and substituting a mixture of endo- 3-[3-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-phenoxazin-l0-yl]-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 3d and endo-3-(3-carbamoyl-phenoxazin-10-y1)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2d for endo-3-[3-(1 H-tetrazol-5-yl)-phenoxazin-10-yI]-8-aza-bicyclo[3.2.1]-octane-8-carboxylic acid tert-butyl ester, 4b, the title compounds endo- 3-[10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one, 4d and endo-1 0-(8-aza-bicyclo[3.2. 1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid amide, 5d were obtained as TFA salts. 4d: MS m/z (MH+) 377.0; 5d: MS
m/z (MH+) 335.9.
Endo-3-[10-(8-Pyridin-2-ylrnethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one, 6d Using an adaptation of Procedure 9, and substituting endo- 3-[10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one, 4d for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, the title compound endo-3-[10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yI)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one, 6d was obtained as a TFA salt. MS m/z (MH+) 467.9.
NO
~
O
\ zx N 7d Endo-3-[10-(8-Phenethyi-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi n-3-yI]-4H-[1,2,4]oxadiazoi-5-one, 7d Using an adaptation of Procedure 9, and substituting endo- 3-[10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one, 4d for endo-l0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, and phenyl acetaldehyde for 2-pyridyl carboxaldehyde, the title compound endo-3-[10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one, 7d was obtained as a TFA salt MS m/z (MH+) 480.9.
EXAMPLE E
Me HO C02Me OMe N O ~ CO2Me F F ~ ~
NO2 NO ~
/ MeOH 2 H 1a N
F KOH (OMe K2C03 DMF
1e N 2e OMe OMe 0 NaOH O CO2H H~ O &N'---dioxane N
HATU
3e DI EA 4e N DMF N
I I
O CI OMe 0 OMe 0 1. CI~ I\ O I\ N" OrCHO x~i CH2CI2 NaBH(OAc)3 2. MeOH HOAc N 5e CICH2CH2CI N 6e H
/
/ N
BBr3 CH2CI2 N 7e \
Procedure 13 1-Fluoro-3-methoxy-2-nitrobenzene, le To a solution of 2,,6-difluoronitrobenzene (5 g, 32 mmol) in methanol (50 mL) was added potassium hydroxide (1.8 g, 32.5 mmol), and the mixture was heated to reflux for 3 hr. Water was added, and the mixture was extracted with dichloromethane. The organic layer was separated, dried, filtered, and evaporated to yield 5.1 g (95%) of 1-fluoro-3-methoxy-2-nitrobenzene, le. MS
m/z (MH+) 172.
6-Methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi ne-3-carboxylic acid methyl ester, 2e Using an adaptation of Procedure 2, and substituting 1-fluoro-3-methoxy-2-nitrobenzene, le for 4-fluoro-3-nitrobenzonitrile, the title compound 6-methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid methyl ester, 2e was obtained as a TFA salt and as a mixture of endo and exo isomers. MS rn/z (MH+) 395.
Procedure 14 6-Methoxy-l0-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi ne-3-carboxylic acid, 3e To a solution of the TFA salt of 6-methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid methyl ester, 2e (270 mg, 0.7 mmol) in dioxane (15 mL) was added sodium hydroxide (31 mg, 0.77 mmol) for 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid methyl ester, 2a, the title compound 6-methoxy-l0-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid, 3e was obtained as a mixture of endo and exo isomers. MS m/z (MH+) 381.
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phe noxazi ne-3-carboxyl ic acid diethylamide, 4e Using an adaptation of Procedure 4, and substituting 6-methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid, 3e for 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid, 3a, N,N-diisopropyl-/V ethylamine for triethylamine and HATU for HBTU, the title compound 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 4e was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 436.
Procedure 15 10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-10H-phenoxazi ne-3-carboxyl ic acid diethylamide, 5e To a solution of the TFA salt of 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-phenoxazine-3-carboxylic acid diethylamide, 4e (110 mg, 0.25 mmol) in methylene chloride (10 mL) was added 1-chloroethyl chloroformate (0.58 mL, 0.75 mmol). The mixture was heated to reflux for 2h. The mixture was evaporated, dissolved in methanol (5 mL), and heated for 2h at reflux. Water was added, and the solution was extracted with methylene chloride. The organic phase was separated, evaporated, and purified via reverse phase HPLC to yield 69 mg (44.8%) of title compound 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-10H-phenoxazine-3-carboxylic acid diethylamide, 5e, as a TFA
salt. MS m/z= 422 (M+1).
6-Methoxy-l0-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi ne-3-carboxylic acid diethylamide, 6e Using an adaptation of Procedure 9, and substituting 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-lOH-phenoxazine-3-carboxylic acid diethylamide, 5e for endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine, 5b, and phenyl acetaldehyde for 2-pyridylcarboxaldehyde, the title compound 6-methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 6e was obtained as a TFA
salt and as a mixture of endo and exo isomers. MS m/z= 526 (M+1).
Procedure 16 6-Hydroxy-l0-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 7e To a solution of the TFA salt of 6-methoxy-l0-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 6e (55 mg, 0.086 mmol) in 1,2-dichloromethane (5 mL) at 0 C was added a 1 M
solution of BBr3 (0.43 mL, 0.43 mmol). The mixture was allowed to stir for 2 h at rt. A saturated NaHC 3 solution was added, and the organic phase was separated. The aqueous phase was extracted with methylene chloride, and the combined organic phases were dried, filtered, and evaporated. The residue was purified via reverse phase HPLC (eluent: CH3CN in water containing 0.1 %
TFA) to yield 23 mg (42.8%) of title compound 6-hydroxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 7e as a TFA salt and as a mixture of endo and exo isomers. MS m/z= 512 (M+1).
N
N9 8e I
6-Methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenoxazi ne-3-carboxylic acid diethylamide, 8e Using an adaptation of Procedure 16, and substituting the TFA salt of 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 4e for TFA salt of 6-methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 6e, the title compound 6-methoxy-l0-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 8e was obtained as a TFA salt and as a mixture of endo and exo isomers after reverse phase chromatography (eluent gradient: acetonitrile in water containing 0.1% TFA). MS m/z (MH+) 422.
Example F
/ OH F
-N\,)=O NH
OH
NaBH(OAc)3/HOAc KNHZ CICH CH CI 2C03 2 2 N 1f DMF
N_NN
(O1CN NaN cc /NH CI /
N --> N
DMF
2f 3f 2-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-ylamino)-phenol, 1f Using an adaptation of Procedure 5, and substituting 8-methyl-8-aza-bicyclo[3.2.1 ]-octan-3-one for 3-oxo-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, the title compound 2-(8-methyl-8-aza-bicyclo[3.2.1]oct-ylamino)-phenol, If was obtained as a TFA salt and as a mixture of endo and exo isomers after reverse phase chromatography (eluent gradient: acetonitrile in water containing 0.1% TFA). MS m/z (MH+) 232.9.
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi ne-3-carbon itri le, 2f Using an adaptation of Procedure 6, and substituting the TFA salt of 2-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-ylamino)-phenol, If for 3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 b, the title compound 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 2f was obtained as a mixture of endo and exo isomers. MS m/z (MH+) 332Ø
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 3f Using an adaptation of Procedure 7, and substituting 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 2f for 3-(3-cyano-phenoxazin-10-y1)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2b, the title compound 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yI)-10H-phenoxazine, 3f was obtained as a TFA salt and as a mixture of endo and exo isomers after reverse phase chromatography (eluent gradient:
acetonitrile in water containing 0.1% TFA). MS m/z (MH+) 375.1.
EXAMPLE G
NH
C(N O \ CN O \ N~\
I/ HN a I ~
- N
--~
2f MeMgBr lg Et20 I I
N,N-Diethyl-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxamidine, 1g Using an adaptation of Procedure 10, and substituting 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 2f for endo-3-(3-cyano-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 3b, the title compound N,N-diethyl-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yI)-10f / phenoxazine-3-carboxamidine, 1g was obtained as a TFA salt and as a mixture of endo and exo isomers after reverse phase chromatography (eluent gradient: acetonitrile in water containing 0.1 % TFA). MS m/z (MH') 405.3.
EXAMPLE H
O
IO NHCDI N
a /
dioxane K2CO3 1 h 2h 2f EtOH
N N N
I I I
N-Hydroxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ] oct-3-yl)-10H-phenoxazine-3-carboxamidine, 1 h Using an adaptation of Procedure 11, and substituting 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 2f for endo-3-(3-cyano-phenoxazin-10-y1)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 3b, the title compound N-Hydroxy-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxamidine, 1 h was obtained. MS m/z (MH+) 365Ø
Procedure 17 3-[10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi n-3-yl]-4H-[1,2,4]oxadiazol-5-one, 2h To a solution of N-Hydroxy-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxamidine, 1h (0.66 g; 1.81 mmol) in dioxane (20 mL) was added 1,1'-carbonyldiimidazole (0.44 g; 2.71 mmol), and the mixture was stirred at 110 C for 4 h. The mixture was allowed to cool to rt, and the solvent was evaporated. The residue was purified via reverse phase HPLC (eluent gradient: 20 to 45% CH3CN in H20 containing 0.1 % TFA) to yield 161 mg (17.6%) of title compound 3-[10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one, 2h as a TFA salt. MS mlz (MH+) 390.9.
EXAMPLE I
1. LiAIHq.
SH neat S (ON- THF
Br i CN 2. 02N
F Br 1i S Br S Br CI
~~ K2CO3 I~ D I o 0 NH N
DMF
S ~ Br HO
ccxiix__ S Br CHO I/ B-OH
O N
N --j N
5i NaBH(OAc)3 N Pd(PPh3)4 N 4i CH3COOH K2CO3 H CICH2CH2CI O c NMP
/I
S N
N
N
O c Procedure 18 Spiro compound, 11 A mixture of 2-aminothiophenol (4.3 mL, 39.9 mmol) and tropinone (5.6 g, 39.9 mmol) was allowed to stir and sit for 16 h at rt. The mixture was placed under vacuum (<0.3 mm Hg) for 6 h. HPLC-MS analysis revealed -60%
conversion to desired compound, 1 i. The material was used as such for the next reaction.
Procedure 19 [2-(4-Bromo-2-nitrophenylsulfanyl)-phenyl]-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amine, 2i To the mixture obtained from the previous reaction (Procedure 18) was added THF (20 mL), and the mixture was cooled to -78 C. A 1 M solution of lithium aluminum hydride in diethyl ether (60 mL, 60 mmol) was added in portions. The cooling bath was removed. More THF (60 mL) and 10 mL of the 1 M solution of lithium aluminum hydride were added. The mixture was stirred at rt for 90 min, cooled to -78 C, and treated with water (2.6 mL). The cooling bath was removed, and the mixture was allowed to warm to rt. A 1 N NaOH
solution (10.6 mL) was added, and the mixture was allowed to stir for 15 min.
MgSO4 (1 g) and THF (40 mL) were added, and the mixite was filtered. To the filtrate was added 2-fluoro-5-bromo-nitrobenzene (5.4 mL, 43.8 mmol), and the mixture was stirred for 15 min. The reaction mixture was filtered, and the solid was washed with THF (3 x 20 mL) and ethyl acetate (4 x 20 mL). The combined filtrates were evaporated, and the residue was purified via flash column chromatography (eluent gradient: 20% EtOAc containing 1% Et3N in heptane to 20% MeOH containing 1% Et3N in EtOAc), yielding 10 g (55.9%) of title compound [2-(4-bromo-2-nitrophenylsulfanyl)-phenyl]-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amine, 2i as a mixture of endo and exo isomers.
Procedure 20 3-Bromo-l0-(8-methyi-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 3i To a solution of [2-(4-bromo-2-nitrophenylsulfanyl)-phenyl]-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amine, 2i (9.7 g, 21.6 mmol) in DMSO (220 mL) was added potassium carbonate (3.3 g, 23.8 mmol). The mixture was heated under a N2 atmosphere to 170 C for 45 min. The mixture was allowed to cool to rt, diluted with H20 (250 mL), and extracted with EtOAc (4 x 100 mL). The organic phase was dried over Na2SO4, filtered, and evaporated. The residue was purified via flash column chromatography (eluent gradient: 1% Et3N in EtOAc to 30% MeOH in EtOAc containing 1% Et3N), yielding 1.9 g (21.9%) of title compound 3-bromo-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 3i as a mixture of endo and exo isomers. MS m/z (MH+) 401.1/403.1.
Procedure 21 10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-bromo-lOH-phenothiazine, 4i To a solution of 3-bromo-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine, 3i (1.0 g, 2.49 mmol) in 1,2-dichloroethane (15 mL) were added 1-chloroethyl chloroformate (807 L, 7.5 mmol) and N,N-diisopropyl-N-ethylamine (1.4 mL, 7.97 mmol). The mixture was heated to reflux for 2.5 h, allowed to cool to rt, and evaporated. The mixture was evaporated and the residue was dissolved dissolved in methanol (15 mL) and heated to reflux for 1 h. After work-up, the residue was purified via flash column chromatography (eluent gradient: 0 to 30% MeOH in EtOAc containing 1% triethylamine) to yield 150 mg of recovered starting material 3i and 382 mg (66%) of title compound 3-bromo-10-piperidin-4-yl-10H-phenothiazine, 4i as a mixture of endo and exo isomers. MS m/z (MH+) 387.1/389.1.
Procedure 22 3-Bromo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 5i To a solution of 3-bromo-10-piperidin-4-yl-10H-phenothiazine, 4i (11.2 mg; 0.029 mmol) and 3-furyl carboxaldehyde (8.4 mg; 0.087 mmol) in dichloroethane (120 L) was added acetic acid (5 L) and a solution of sodium triacetoxyborohydride (12 mg, 0.057 mmol) in DMF (100 ). The mixture was stirred at rt for 18 h, quenched with water (50 L), and lyophilized. The thus obtained crude 3-bromo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 5i as a mixture of endo and exo isomers was used as such for the next reaction.
Procedure 23 10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yl-10H-phenothiazine, 6i A mixture of 3-bromo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine, 5i (13.5 mg, 0.029 mmol), 3-pyridyl boronic acid (10.7 mg, 0.087 mmol), potassium carbonate (12 mg, 0.087 mmol) and Pd(PPh3)4 (3 mg, 2.5 mol) in NMP (300 L) and H20 (100 L) was heated to 160 C for 10 min in a microwave. The mixture was absorbed onto a 1 g SPE cartridge and eluted (eluent: 10% methanol in ethyl acetate containing 1% triethylamine).
The eluent (-15 mL) was collected and evaporated. The residue was purified via reverse phase HPLC (eluent: acetonitrile in water containing 0.1 % TFA) to yield title compound 10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yl-10H-phenothiazine, 6i as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 466.2.
s HN O
N ~
7i N
o C
N-{2-[10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide, 7i Using an adaptation of the method described in Procedure 23, substituting 2-acetylaminophenyl boronic acid for 3-pyridyl boronic acid, the title compound N-{2-[10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide, 7i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 522.2.
~ S
NI ~
/
8i N
10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-3-pyridi n-3-yI-10F/-phenothiazine, 8i Using an adaptation of the methods described in Procedures 22 and 23, substituting 3-methyl-but-2-enal for 3-furyl carboxaldehyde in Procedure 22, the title compound 10-[8-(3-methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-3-pyridin-3-yl-10H-phenothiazine, 8i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 454.3.
ol ~ S
NI ~
/
9i N
N
\
/
3-Pyridin-3-yI-10-(8-pyridin-2-ylmethyi-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 9i Using an adaptation of the methods described in Procedures 22 and 23, substituting 2-pyridyl carboxaldehyde for 3-furyl carboxaldehyde in Procedure 22, the title compound 3-pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 9i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 477.2.
N
CCNI::
10i N
10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-3-pyridin-4-yI-10H-phenothiazine, 101 Using an adaptation of the methods described in Procedures 22 and 23, substituting 3-methyl-but-2-enal for 3-furyl carboxaldehyde in Procedure 22, and 4-pyridyl boronic acid for 3-pyridyl boronic acid in Procedure 23, the title compound 10-[8-(3-methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-3-pyridin-yl-10H-phenothiazine, 10i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 454.3.
~
cc:x 11i N
N
~ \
/
3-Pyridin-4-yI-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 11 i Using an adaptation of the methods described in Procedures 22 and 23, substituting 2-pyridyl carboxaldehyde for 3-furyl carboxaldehyde in Procedure 22, and 4-pyridyl boronic acid for 3-pyridyl boronic acid in Procedure 23, the title compound 3-pyridin-4-yI-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 11 i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 477.3.
N
aN
12i N
&~S, 3-Pyridin-4-yl-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 121 Using an adaptation of the methods described in Procedures 22 and 23, substituting 2-thiophene carboxaldehyde for 3-furyl carboxaldehyde in Procedure 22, and 4-pyridyl boronic acid for 3-pyridyl boronic acid in Procedure 23, the title compound 3-pyridin-4-yl-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine, 12i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 482.2.
S \ ~ I
13i N
I
N-{2-[10-(8-AI IyI-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoth iazi n-3-yI]-phenyl}-acetamide, 13i Using an adaptation of the methods described in Procedures 22 and 23, substituting propenal for 3-furyl carboxaldehyde in Procedure 22, and 2-acetylaminophenyl boronic acid for 3-pyridyl boronic acid in Procedure 23, the title compound N-{2-[10-(8-allyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide, 13i was obtained as a TFA salt and as a mixture of endo and exo isomers.
I
s (::(N HN O
14i N
N-{2-[10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenothiazin-3-yl]-phenyl}-acetamide, 14i Using an adaptation of the methods described in Procedures 22 and 23, substituting phenyl acetaldehyde for 3-furyl carboxaldehyde in Procedure 22, and 2-acetylaminophenyl boronic acid for 3-pyridyl boronic acid in Procedure 23, the title compound N-{2-[10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-phenothiazin-3-yl]-phenyl}-acetamide, 14i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 546.3.
s / HN O
15i N
NJ
~NI
N-(2-{10-[8-(1 H-Im idazol-2-yl methyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenothiazin-3-yl}-phenyl)-acetamide, 15i Using an adaptation of the methods described in Procedures 22 and 23, substituting 1 H-imidazole-2-carboxaldehyde for 3-furyl carboxaldehyde in Procedure 22, and 2-acetylaminophenyl boronic acid for 3-pyridyl boronic acid in Procedure 23, the title compound N-(2-{10-[8-(1 H-Imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenothiazin-3-yl}-phenyl)-acetamide, 15i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 522.3.
i I
S
16i N
N-{2-[10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide, 16i Using an adaptation of the method described in Procedure 23, substituting 3-bromo-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenothiazine, 3i for 3-bromo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine, 51 and 2-acetylaminophenyl boronic acid for 3-pyridyl boronic acid, the title compound N-{2-[10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide, 16i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS mlz (MH+) 456.2.
I ~ S I N
a 17i N
H
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridi n-3-yl-10H-phenoth iazi ne, 17i Using an adaptation of the method described in Procedure 23, substituting 3-bromo-10-piperidin-4-yI-10H-phenothiazine, 4i for 3-bromo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine, 5i, the title compound 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yI-10H-phenothiazine, 17i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS
m/z (MH+) 386.2.
O
c(x9 18i N
H
N-{2-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phe noth iazi n-3-yl]-phenyl}-acetamide, 18i Using an adaptation of the method described in Procedure 23, substituting 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-bromo-10H-phenothiazine, 4i for 3-bromo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 5i and 2-acetylaminophenyl boronic acid for 3-pyridyl boronic acid, the title compound N-{2-[10-(8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide, 18i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 442.2.
S I ~ N
~
N
19i N
10-(8-AI Iyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridi n-3-yI-10H-phenothiazine, 19i Using an adaptation of the methods described in Procedures 22 and 23, substituting 2-propenal for 3-furyl carboxaldehyde in Procedure 22, the title compound 10-(8-allyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yl-10H-phenothiazine, 19i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (M+1 8+H) 444.2.
s HO CI HO I~ CI
CI OH Boc-N O ~j ~j HN HN
NaBH(OAc)3/HOAc +
NH2 CICH2CH2CI N 1j _2j i i Boc Boc F cc:xydI (fBOH
ON
j K2CO3 Cp2Fe(PtBu2)2PdCl2 DMF N 3j K2CO3 Boc 1,4-dioxane N 4j I
oc C
HO O N
O N Cr TFA %
N N
NaBH(OAc)3 H 5, N 6j Endo-3-(4-C h Ioro-2-hyd roxyphe nyl am i n o)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1j and exo-3-(4-chloro-2-hydroxyphenyl-amino)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2j Using an adaptation of the method described in Procedure 1, substituting 2-amino-5-chlorophenol for 4-amino-3-hydroxybenzoic acid methyl ester and 3-oxo-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester for 8-methyl-8-aza-bicyclo[3.2.1]octan-3-one, a 3:1 mixture of title compounds endo-3-(4-chloro-2-hydroxyphenylamino)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, Ij and exo-3-(4-chloro-2-hydroxyphenyl-amino)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2j was obtained.
Compounds Ij and 2j were separated via flash column chromatography (eluent gradient: 3% to 65% EtOAc in hexane), yielding 70% of endo isomer 1j (first eluting isomer; and 19% of exo isomer 2j (second eluting isomer) Endo-3-(3-Chlorophe noxazi n-10-y1)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 3j Using an adaptation of the method described in Procedure 2, substituting endo-3-(4-chloro-2-hydroxyphenylamino)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 j for the TFA salt of 3-hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-ylamino)-benzoic acid methyl ester, 1a, the title compound endo-3-(3-chlorophenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3j was obtained.
Procedure 24 Endo-3-(3-Pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 4j To a mixture of 3-pyridyl boronic acid (70.1 mg, 0.57 mmol), Cp2Fe(P-tBu2) 2PdCI2 (62 mg, 0.095 mmol), potassium carbonate (88 mg, 0.63 mmol) was added a solution of endo-3-(3-chlorophenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3j (135 mg, 0.317 mmol) in dioxane (3 mL, degassed with argon for 5 min prior to use). The mixture was heated to 120 C for 30 min in a microwave (300 W). The mixture was allowed to cool to rt, water and ethyl acetate were added. The organic layer was separated, dried over MgS04, filtered, and evaporated to yield 195 mg of crude title compound endo-3-(3-pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 4j. The material was used as such for the next reaction.
Procedure 25 Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyri di n-3-yl-10H-phenoxazine, 5j The crude endo-3-(3-pyridin-3-yl-phenoxazin-10-y1)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 4j, obtained from the previous reaction, was treated with TFA (3 mL), and the mixture was stirred for 30 min at rt. The TFA was removed under a nitrogen stream, and the residue was purified via reverse phase HPLC (eluent gradient: 10% to 30% CH3CN in water containing 0.1 % TFA). The desired fractions were combined, lyophilized, and dissolved in diethyl ether. The solution was washed with a saturated NaHCO3 solution. The aqueous phase was washed with diethyl ether, and the combined organic phases were dried over MgSO4, filtered, and evaporated to yield 58 mg (43% for 2 steps) of title compound endo-1 0-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine,5j. MS m/z (MH+) 370.2.
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl )-3-pyridi n-3-yI-10H-phenoxazine, 6j Using an adaptation of the method described in Procedure 9, substituting endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine, 5j for the HCI salt of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b and phenyl acetaldehyde for 2-pyridylcarboxaldehyde, the title compound endo-10-(8-phenethyl-8-aza-bicycio[3.2.1]oct-3-yl)-3-pyridin-3-y1-10H-phenoxazine, 6j was obtained as a TFA salt. MS m/z (MH+) 474.2.
I \ O I ~ \ N
a~
N
N 7j N
~ \
s Endo-3-Pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-10H-phenoxazine, 7j Using an adaptation of the method described in Procedure 9, substituting endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine, 5j for the HCI salt of 10-(8-aza-bicyclo[3.2. 1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b and 2-pyridyl carboxaldehyde for 2-pyridylcarboxaldehyde, the title compound endo-3-pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine, 7j was obtained as a TFA salt. MS m/z (MH+) 461.2.
0 \ N
!~
N
N 8i Endo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yI-10H-phenoxazine, 8j Using an adaptation of the method described in Procedure 9, substituting endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yi)-3-pyridin-3-yl-10H-phenoxazine, 5j for the HCI salt of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b and 3-furaldehyde for 2-pyridylcarboxaldehyde, the title compound endo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine, 8j was obtained as a TFA salt. MS m/z (MH+) 450.2.
O I ~ N
/
N
Endo-3-Pyridi n-3-yI-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine, 9j Using an adaptation of the method described in Procedure 9, substituting endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine, 5j for the HCI salt of (8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine, 4b and 2-thiophene carboxaldehyde for 2-pyridylcarboxaldehyde, the title compound endo-3-pyrid i n-3-y1-10-(8-th io ph e n-2-yl m ethyl-8-aza-b icyclo [3.2.1 ]oct-3-yl )-10H-phenoxazine, 9j was obtained as a TFA salt. MS m/z (MH+) 466.2.
cc:xd10j N
H
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-ch loro-10H-phenoxazine, 10j Using an adaptation of the method described in Procedure 25, substituting endo-3-(3-chloro-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 3j for endo-3-(3-pyridin-3-yl-phenoxazin-1 0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 4j, the title compound endo-l0-(8-aza-bicyclo[3.2.1 ]-oct-3-yl)-3-chloro-10H-phenoxazine, 10j was obtained as a TFA salt after reverse phase HPLC purification (eluent:
CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 327.1.
EXAMPLE K
B,OH IO N/ ~
TFA
e(PtBu2)2PdCl2 Cp2F
N 3j K2CO3 Boc 1,4-dioxane N 1 k Boc e N
N
O
I\ CHO
~I\ aN ~%\ / N
NaBH(OAc)3 3k N 2k CICH2CH2CI N
H
Endo- 3-(3-Pyridin-4-yl-phenoxazin-1O-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1k Using an adaptation of the method described in Procedure 24, substituting 4-pyridyl boronic acid for 3-pyridyl boronic acid, the title compound endo-3-(3-pyrid in-4-yl-phenoxazin-10-y1)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 k was obtained.
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-4-yI-10H-phenoxazine, 2k Using an adaptation of the method described in Procedure 25, substituting endo-3-(3-pyridin-4-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1 k for endo-3-(3-pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 4j, the title compound endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-yl-10H-phenoxazine, 2k was obtained as a TFA salt after reverse phase HPLC
purification (eluent gradient: 10% to 30% CH3CN in water containing 0.1 %
TFA). MS m/z (MH+) 370.2.
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyrid i n-4-yl-10H-phenoxazine, 3k Using an adaptation of the method described in Procedure 9, substituting the TFA salt of endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 2k for the HCI salt of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b and phenyl acetaidehyde for 2-pyridyl carboxaldehyde, the title compound endo-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 3k was obtained as a TFA salt. MS m/z (MH+) 474.3.
N
cc:xe N 4k N
~ \
/
Endo-3-Pyridin-4-y1-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine, 4k Using an adaptation of the method described in Procedure 9, substituting the TFA salt of endo-l0-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 2k for the HCI salt of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b, the title compound endo-3-pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine, 4k was obtained as a TFA salt. MS m/z (MH+) 461.3.
N
c(xN 5k O &-,:, Endo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-3-pyridi n-4-yl-10H-phenoxazine, 5k Using an adaptation of the method described in Procedure 9, substituting the TFA salt of endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 2k for the HCI salt of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b and 3-furaldehyde for 2-pyridylcarboxaldehyde, the title compound endo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yi)-3-pyridin-4-yl-10H-phenoxazine, 5k was obtained as a TFA salt. MS m/z (MH+) 450.3.
N
cXr< ~
N 6k Endo-3-Pyridin-4-y1-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine, 6k Using an adaptation of the method described in Procedure 9, substituting the TFA salt of endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 2k for the HCI salt of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yi)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b and 2-thiophene carboxaldehyde for 2-pyridylcarboxaldehyde, the title compound endo-3-pyridin-4-yl-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine, 6k was obtained as a TFA salt. MS m/z (MH+) 466.2.
EXAMPLE L
F o/
\/ I xyc flfBOH
N N
aj K2CO3 Cp2Fe(PtBua)2PdCI2 N 11 KaCOa I Boc 1,4-dioxane N 21 H20 Boc O N O N
CHO
TFA N I / N
C31 NaBH(OAc)3 41 N CICH2CH2CI (N
H
Exo-3-(3-Chlorophenoxazin-10-yi)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 11 Using an adaptation of the method described in Procedure 2, substituting exo-3-(4-chloro-2-hydroxyphenylamino)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2j for the TFA salt of 3-hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-ylamino)-benzoic acid methyl ester, 1a, the title compound exo-3-(3-chlorophenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 11 was obtained.
Endo- 3-(3-Pyridin-4-yl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 21 Using an adaptation of the method described in Procedure 24, substituting exo-3-(3-chlorophenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 11 for endo-3-(3-chlorophenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3j, the title compound 3-(3-pyridin-4-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 21 was obtained.
Exo-3-(3-Pyrid i n-3-yl-phenoxazi n-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 31 Using an adaptation of the method described in Procedure 25, substituting exo-3-(3-pyridin-3-yl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 21 for endo-3-(3-pyridin-3-yl-phenoxazin-10-y1)-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 4j, the title compound exo-3-(3-pyridin-3-yl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 31 was obtained as a TFA salt after reverse phase HPLC purification (eluent gradient: 10% to 30%
CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 370.2.
Exo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridi n-3-yI-10H-phenoxazine, 41 Using an adaptation of the method described in Procedure 9, substituting the TFA salt of exo-3-(3-pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 31 for the HCI salt of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b and phenyl acetaidehyde for 2-pyridyl carboxaldehyde, the title compound exo-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine, 41 was obtained as a TFA salt. MS m/z (MH+) 474.3.
c(X2N
e N
~ \
e Exo-3-Pyridi n-3-yI-10-(8-pyrid i n-2-ylmethyl-8-aza-bi cyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine, 51 Using an adaptation of the method described in Procedure 9, substituting the TFA salt of exo-3-(3-pyridin-3-yl-phenoxazin-1 0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 31 for the HCI salt of 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine, 4b, the title compound exo-3-pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-yl)-10H-phenoxazine, 51 was obtained as a TFA salt. MS m/z (MH+) 461.3.
I \ O
NI \
e CN
O
Exo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine, 61 Using an adaptation of the method described in Procedure 9, substituting the TFA salt of exo-3-(3-pyridin-3-yl-phenoxazin-1 0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 31 for the HCI salt of 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine, 4b and 3-furaldehyde for 2-pyridyl carboxaldehyde, the title compound exo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yI-10H-phenoxazine, 61 was obtained as a TFA salt. MS m/z (MH+) 450.2.
0 ci I~ le N
H
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-chloro-lOH-phenoxazine, 71 Using an adaptation of the method described in Procedure 25, substituting exo-3-(3-chloro-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 11 for endo-3-(3-pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 4j, the title compound exo-10-(8-aza-bicyclo[3.2.1 ]-oct-3-yl)-3-chloro-10H-phenoxazine, 71 was obtained as a TFA salt after reverse phase HPLC purification (eluent:
CH3CN in water containing 0.1% TFA). MS m/z (MH+) 327.1.
EXAMPLE M
O CI OH B,oH c:xi N
TFA
Cp2Fe(PtBua)2PdC12 CN , ll KzCO3 N 1m Boc 1,4-dioxane C
H2o I
Boc N N
N \
~
~
NaBH(OAc)3 a CICH2CH2CI N2m \N 3m H
/ I
\
Exo- 3-(3-Pyridin-4-yl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 m Using an adaptation of the method described in Procedure 24, substituting 4-pyridyl boronic acid for 3-pyridyl boronic acid, the title compound exo-3-(3-pyridin-4-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 m was obtained.
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridi n-4-y1-10H-phenoxazine, 2m Using an adaptation of the method described in Procedure 25, substituting exo-3-(3-pyridin-4-yl-phenoxazin-10-y1)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 11 for endo-3-(3-pyridin-3-yl-phenoxazin-yI)-8-aza-bicyclo[3.2.1 ]-octane-8-carboxyiic acid tert-butyl ester, 4j, the title compound exo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 2m was obtained as a TFA salt after reverse phase HPLC
purification (eluent gradient: 10% to 30% CH3CN in water containing 0.1 %
TFA). MS m/z (MH+) 370.2.
Exo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridi n-4-yl-10H-phenoxazine, 3m Using an adaptation of the method described in Procedure 9, substituting the TFA salt of ex -10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 2m for the HCI salt of 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b and phenyl acetaldehyde for 2-pyridyl carboxaldehyde, the title compound exo-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 3m was obtained as a TFA salt. MS m/z (MH+) 474.3.
N
N I \
aCN 0 ~
4m N
~ \
/
Exo-3-Pyri d i n-4-yI-10-(8-pyrid i n-2-yl m ethyl-8-aza-bi cyclo[3.2.1 ] oct-3-yl)-10H-phenoxazine, 4m Using an adaptation of the method described in Procedure 9, substituting the TFA salt of exo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 2m for the HCI salt of 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1 f-f-tetrazol-5-yl)-10f-f-phenoxazine, 4b, the title compound ex -3-pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine, 4m was obtained as a TFA salt. MS m/z (MH+) 461.2.
N
cc:c* CN 5m O c Exo-10-(8-Fu ran-3-yl methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridi n-4-yl-10H-phenoxazine, 5m Using an adaptation of the method described in Procedure 9, substituting the TFA salt of exo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 2m for the HCI salt of 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b and 3-furaldehyde for 2-pyridyl carboxaldehyde, the title compound exo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 5m was obtained as a TFA salt. MS m/z (MH+) 450.2.
EXAMPLE N
CH F CN
NaN3.
~
NH 2N CN N --~
(N 2b DMF CN In i i Boc Boc C N_NN C N_NN
1-55 I~ ~ H
N H HCI N
2n dioxane 3n N N
Boc H
Exo- 3-(3-Cyano-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 n Using an adaptation of the method described in Procedure 6, substituting exo-3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2b for endo-3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1b, the title compound exo- 3-(3-cyano-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 n was obtained. MS m/z (MH+) 439.9.
Exo-3-[3-(1 H-Tetrazol-5-yl)-phenoxazin-10-y1]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2n Using an adaptation of the method described in Procedure 7, substituting exo-3-(3-cyano-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 n for endo-3-(3-cyano-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 3b, the title compound exo-3-[3-(1 H-tetrazol-5-yl)-phenoxazin-l0-yl]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2n was obtained. MS
m/z (MH+) 460.9.
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-(I H-tetrazol-5-yl)-10H-phenoxazine, 3n Using an adaptation of the method described in Procedure 8, substituting exo-3-[3-(1 H-tetrazol-5-yl)-phenoxazin-10-yI]-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 2n for endo-3-[3-(1H-tetrazol-5-yl)-phenoxazin-10-yI]-8-aza-bicyclo[3.2.1]-octane-8-carboxylic acid tert-butyl ester, 4b, the title compound exo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yI)-10H-phenoxazine, 3n was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1% TFA). MS m/z (MH+) 360.9.
QZXYCN
4n N
H
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi ne-3-carbonitrile, 4n Using an adaptation of the method described in Procedure 25, substituting exo- 3-(3-cyano-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 n for endo-3-(3-pyridin-3-yl-phenoxazin-1 0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 4j, and using a 1:1 solution of TFA;CH2CI2 instead of neat TFA, the title compound exo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 4n was obtained as a TFA salt after reverse phase HPLC purification (eluent gradient: 20% to 45%
CH3CN in water containing 0.1% TFA). MS m/z (MH+) 317.9.
NOH N-O
0N)OINH2OH.HCI O CN I~ O I~ NH2 CDI
N aN
K2C03 dioxane EtOH -N 1n 'N lo CN 2o Boc Boc Boc O
HCI ~ O N- ~ / H
dioxane N
3o N
H
Exo-3-[3-(N-Hyd roxycarbam i m idoyl )-phe noxazi n-10-y1]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1o Using an adaptation of the method described in Procedure 11, substituting exo-3-(3-cyano-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, In for endo-3-(3-cyano-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3b, the title compound exo-3-[3-(N-hydroxycarbamimidoyl)-phenoxazin-10-yI]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, lo was obtained. MS
m/z (MH+) 450.9.
Exo-3-[3-(5-Oxo-4, 5-d i hyd ro-[1, 2,4] oxad i azol-3-yl )-phe n oxazi n-10-yI]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2o Using an adaptation of the method described in Procedure 12, substituting exo-3-[3-(N-hydroxycarbamimidoyl)-phenoxazin-10-y1]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1o for the mixture of endo-3-[3-(N-hydroxycarbamimidoyl)-phenoxazin-1 0-yl]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 d and endo-3-(3-carbamoyl-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2d, the title compound exo-3-[3-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-phenoxazin-l0-yl]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2o was obtained.
Exo-3-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenoxazi n-3-yl]-4H-[1,2,4]oxadiazol-5-one, 3o Using an adaptation of Procedure 8, and substituting exo-3-[3-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-phenoxazin-l0-yi]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2o for endo-3-[3-(1 f-/-tetrazol-5-yl)-phenoxazin-10-y1]-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 4b, the title compound exo-3-[10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one, 3o was obtained as TFA salt after purification via reverse phase HPLC (eluent gradient: 20% to 45% CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 376.8.
EXAMPLE P
MeO I~ CN HO I~ CN
~
Me0 CN
+ ~\% ~
Cs2CO3 HN BBr3 HN
~
Me DMF CH2CI2 N lp i 2p F OMe OH
~
~ Me cOCN
BBr3 -.~ N ]
DMF
N 3p 4p I ~
3-M eth oxy-4-(8-m eth yl-8-aza-b i cyc l o[3.2.1 ] oct-3-yl a m i n o)-benzonitrile, 1 p Using an adaptation of Procedure 2, substituting 8-methyl-8-aza-bicyclo[3.2.1]oct-3-ylamine for the TFA salt of 3-hydroxy-4-(8-methyl-8-aza-bicyclo[3.2. 1 ]oct-3-ylamino)-benzoic acid methyl ester, 1a, 1-fluoro-3-methoxy-2-nitrobenzene, 1e for 2-fluoronitrobenzene, and cesium carbonate for potassium carbonate, the title compound 3-methoxy-4-(8-methyl-8-aza-bicyclo[3.2. 1 ]oct-3-ylamino)-benzonitrile, 1p was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC
(eluent gradient: 20% to 45% CH3CN in water containing 0.1 % TFA). MS m/z=
272 (M+1).
3-Hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-ylam ino)-benzonitrile, 2p Using an adaptation of Procedure 13, substituting the TFA salt of 3-methoxy-4-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-ylamino)-benzonitrile, 1 p for the TFA salt of 6-methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 6e, the title compound 3-hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-ylamino)-benzonitrile, 2p was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC (eluent gradient: 20% to 45% CH3CN in water containing 0.1 %
TFA). MS m/z= 258 (M+1).
6-Methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 3p Using an adaptation of Procedure 2, substituting the TFA salt of 3-hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-ylamino)-benzonitrile, 2p for the TFA salt of 3-hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-ylamino)-benzoic acid methyl ester, 1a, and 1-fluoro-3-methoxy-2-nitrobenzene, 1e for 2-fluoronitrobenzene, the title compound 6-methoxy-1 0-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 3p was obtained as TFA
salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC (eluent gradient: 20% to 45% CH3CN in water containing 0.1 %
TFA). MS m/z= 362 (M+1).
6-Hyd roxy-l0-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 4p Using an adaptation of Procedure 13, substituting the TFA salt of 6-methoxy-1 0-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl )-10H-phenoxazi ne-3-carbonitrile, 3p for the TFA salt of 6-methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 6e, the title compound 6-hydroxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 4p was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC (eluent gradient: 20% to 45% CH3CN in water containing 0.1% TFA). MS m/z= 348 (M+1)=
EXAMPLE Q
1. OaCHO
~ S ~ Br NaBH(OAc)3 ~
~ \ S ~ \ N
~ N CICH2CH2CI
1q HN
~= N
N
H 4i Herrmann's O ~
catalyst -Mo(CO)6 DBU
THF
Procedure 26 [10-(8-Furan-3-yi methyl-8-aza-bicyclo[3.2.1 ] oct-3-yl)-10H-phenothiazin-3-yl]-pyrrolidin-1-yl-methanone, 1 q To a solution of a mixture of endo and exo isomers of 3-bromo-10-piperidin-4-yl-10H-phenothiazine, 4i (15 mg, 0.04 mmol) in dichloroethane (0.4 mL) were added 3-furaldehyde (10 L, 0.12 mmol), acetic acid (5 L) and sodium triacetoxy-borohyd ride (17 mg, 0.08 mmol). The mixture was allowed to stir at rt for 16 h, and quenched with a 2N NaOH solution (200 L). The mixture was absorbed onto a 1 g SPE cartridge and eluted (eluent: 10%
methanol in ethyl acetate containing 1% triethylamine). The eluent (-15 mL) was collected and evaporated. The residue was dissolved in THF (0.4 mL), and pyrrolidine (19 L, 0.15 mmol), Mo(CO)6 (16 mg, 0.06 mmol), Herrmann's catalyst (6 mg, 0.006 mmol), and DBU (27 L, 0.18 mmol) were added. The mixture was irradiated in a microwave oven at 150 C for 15 min. The mixture was evaporated, and the residue was purified via reverse phase HPLC (eluent gradient: CH3CN in water containing 0.1 % TFA) to yield [10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-pyrrolidin-1-yl-methanone, 1 q as a TFA salt and as a mixture of endo and exo isomers. MS
m/z (MH+) 486.2.
C S
N
2q N
[10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoth iazi n-3-yl]-pyrrolidin-1-yl-methanone, 2q Using an adaptation of Procedure 26, substituting phenyl acetaldehyde for 3-furaldehyde, the title compound [1 0-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-10H-phenothiazin-3-yl]-pyrrolidin-1-yl-methanone, 2q was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC (eluent gradient: 20% to 45% CH3CN in water containing 0.1 %
TFA). MS m/z= 510.3 (M+1).
alo~ S e N~/
N 3q {10-[8-(3-Methyi-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenothiazin-3-yl}-pyrrolidin-1-yl-methanone, 3q Using an adaptation of Procedure 26, substituting 3-methyl-but-2-enal for 3-furaldehyde, the title compound {1 0-[8-(3-methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenothiazin-3-yl}-pyrrolidin-1-yl-methanone, 3q was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC (eluent gradient: 20% to 45% CH3CN in water containing 0.1% TFA). MS m/z= 474.2 (M+1).
O
S N
OH
4q N
O
[10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenothiazin-3-yl]-(3-hydroxy-pyrrolidin-1-yl)-methanone, 4q Using an adaptation of Procedure 26, substituting 3-hydroxypyrrolidine for pyrrolidine, the title compound [1 0-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-(3-hydroxy-pyrrolidin-1-yl)-methanone, 4q was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC (eluent gradient: 20% to 45%
CH3CN in water containing 0.1 % TFA). MS m/z= 502.2 (M+1).
O
S N
OH
5q N
(3-Hydroxy-pyrrolidin-1-yi)-[10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yi]-methanone, 5q Using an adaptation of Procedure 26, substituting phenyl acetaidehyde for 3-furaidehyde and 3-hydroxypyrrolidine for pyrrolidine, the title' compound (3-hydroxy-pyrrolidin-l-yl)-[10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-phenothiazin-3-yl]-methanone, 5q was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC (eluent gradient: 20% to 45% CH3CN in water containing 0.1 % TFA). MS m/z= 526.2 (M+1).
O
S N
I
OH
N
6q N
{10-[8-(3-Methyl-but-2-enyl )-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenothiazin-3-yl}-(3-methyl-pyrrolidin-1-yl)-methanone, 6q Using an adaptation of Procedure 26, substituting 3-methyl-but-2-enal for 3-furaldehyde and 3-hydroxypyrrolidine for pyrrolidine, the title compound {10-[8-(3-methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenoth iazi n-yl}-(3-methyl-pyrrolidin-1-yl)-methanone, 6q was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC
(eluent gradient: 20% to 45% CH3CN in water containing 0.1% TFA). MS m/z=
490.2 (M+1).
EXAMPLE R
O
C S ~\ Br HN S &NC) N Herrmann's N
A 3i catalyst 1 r Mo(CO)6 N DBU N
~ THF ~
Procedure 27 [10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazi n-3-yl]-pyrrolidin-l-yl-methanone, 1 r To a solution of 3-bromo-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 3i (15 mg, 0.04 mmol) in THF (0.3 mL) was added pyrrolidine (12 L, 0.15 mmol), Mo(CO)s (16 mg, 0.06 mmol), Herrmann's catalyst (6 mg, 0.006 mmol), and DBU (27 L, 0.18 mmol), and the mixture was irradiated in a microwave oven at 150 C for 15 min. The mixture was evaporated, and the residue was purified via reverse phase HPLC (eluent gradient: CH3CN in water containing 0.1% TFA) to yield [10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-pyrrolidin-l-yl-methanone, I r as a TFA salt and a mixture of endo and exo isomers. MS m/z (MH+) 420.2.
S N~OH
N
IA2r N
I
(3-Hydroxy-pyrrolidin-l-yI)-[10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-10H-phenothiazin-3-yl]-methanone, 2r Using an adaptation of Procedure 27, substituting 3-hydroxypyrrolidine for pyrrolidine, the title compound (3-hydroxy-pyrrolidin-1-yl)-[10-(8-methyl-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-methanone, 2r was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC (eluent gradient: 20% to 45% CH3CN in water containing 0.1 % TFA). MS m/z= 436.2 (M+1).
S
N )eHA3r N
I
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoth iazi ne-3-carboxylic acid ethylamide, 3r Using an adaptation of Procedure 27, substituting ethylamine for pyrrolidine, the title compound 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carboxylic acid ethylamide, 3r was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC
(eluent gradient: 20% to 45% CH3CN in water containing 0.1% TFA). MS m/z=
394.2 (M+1).
EXAMPLE T
O
01( OH O 02N N/~ I ~\ N/\
NH
~~ N /
F/ TFA
N DMF N 1t lb goc Boc p e O 0 cc I/ N ~ ~
I/ ~ S CHO N
I
NaBH(OAc)3 N
N
2t CICH2CH2CI 3t K'iI:i Endo-3-(3-Diethylcarbamoyl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1t Using an adaptation of Procedure 6, and substituting endo-3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1b for 3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1b, the title compound endo-3-(3-diethylcarbamoyl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1t was obtained. The crude material was used as such in the next reaction.
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-1 H-phenoxazine-3-carboxylic acid diethylamide, 2t Using an adaptation of Procedure 25, substituting endo-3-(3-d iethylcarbamoyl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, It for endo-3-(3-pyridin-3-yi-phenoxazin-1 0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 4j, and using a 25%
solution of TFA in methylene chloride instead of neat TFA, the title compound endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2t was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 392.1.
Endo-10-(8-Thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenoxazine-3-carboxylic acid diethylamide, 3t Using an adaptation of Procedure 9, and substituting endo-10-(8-aza-bicyclo-[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2t for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yi)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, thiophene-2-carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohyd ride for sodium triacetoxybo ro hyd ride, and tetrahydrofuran for dichloroethane, the title compound endo-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 3t was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 488.1.
I / I / \
N
N 4t ~ \
/
Endo-1 0-(8-Pyridi n-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 4t Using an adaptation of Procedure 9, and substituting endo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2t for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazi ne, 5b, tetrabutylammonium triacetoxyborohydride for sodium triacetoxyborohydride, and tetrahydrofuran for dichloroethane, the title compound endo-1 0-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2. 1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 4t was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 483.1.
N ~ N~
~~
N
5t N
Endo-10-(8-Thiazol-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenoxazine-3-carboxylic acid diethylamide, 5t Using an adaptation of Procedure 9, and substituting endo-10-(8-aza-bicyclo-[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2t for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, thiazol-2-ylmethyl carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohydride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloroethane, the title compound endo-1 0-(8-thiazol-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 5t was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1% TFA). MS m/z (MH+) 489.1.
N
N
N
6t Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 6t Using an adaptation of Procedure 9, and substituting endo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2t for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, phenyl acetaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxy-bo rohyd ride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloro-ethane, the title compound endo-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 6t was obtained as a TFA salt after purification via reverse phase HPLC (eluent:
CH3CN in water containing 0.1 % TFA).
p N ~ N~\
~/
N
7t N
I , Endo-10-(8-Pyridin-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 7t Using an adaptation of Procedure 9, and substituting endo-10-(8-aza-bicyclo-[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2t for endo-l0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, 3-pyridyl carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxy-borohydride for sodium triacetoxyborohydride, and tetrahydrofuran for dichloro-ethane, the title compound endo-10-(8-pyridin-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 7t was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1% TFA). MS m/z (MH+) 483.1.
0 ~ N
~/
N
N
j8t Endo-10-[8-(3-Methyl-but-2-enyl)-8-aza-bicycio[3.2.1 ]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide Using an adaptation of Procedure 9, and substituting endo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2t for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, 3-methyl-but-2-enyl carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohyd ride for sodium triacetoxyborohydride, and tetrahydrofuran for dichloroethane, the title compound endo-10-[8-(3-methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide, 8t was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 460.1.
C ~ ~ N~\
~~
N
N
N ~ 9t N
Endo-10-[8-(1 H-Im idazol-2-yl methyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide, 9t Using an adaptation of Procedure 9, and substituting endo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2t for endo-1 0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, 1 H-imidazol-2-ylmethyl carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohyd ride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloroethane, the title compound endo-10-[8-(1 H-imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1 ]ocfi-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide, 9t was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 472.1.
~ 0 N
~
N
N
10t ~ \
/
Endo-10-(8-Benzyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi ne-3-carboxylic acid diethylamide, 10t Using an adaptation of Procedure 9, and substituting endo-10-(8-aza-bicyclo-[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2t for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, benzaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohyd ride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloroethane, the title compound endo-10-(8-benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 10t was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 482.1.
EXAMPLE U
/ OH O O
02N / N~ I\ I\ N
NH
F N /
TFA
- _ -~
i DMF CN lu 1 b Boc Boc 0 O \ N~
O N/\ I /
S CHO N
N \ ~
NaBH(OAc)3 N
H 2u CICH2CH2CI 3u Exo-3-(3-Diethylcarbamoyl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1u Using an adaptation of Procedure 6, and substituting exo-3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2b for 3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1b, the title compound exo-3-(3-diethylcarbamoyl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 u was obtained. The crude material was used as such in the next reaction.
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxyl ic acid diethylamide, 2u Using an adaptation of Procedure 25, substituting exo-3-(3-d iethylcarbamoyl-phenoxazin-10-y1)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1u for endo-3-(3-pyridin-3-yl-phenoxazin-1 0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 4j, and using a 25%
solution of TFA in methylene chloride instead of neat TFA, the title compound exo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2u was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 392.1.
Exo-10-(8-Phe nethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phe noxazi ne-3-carboxylic acid diethylamide, 3u Using an adaptation of Procedure 9, and substituting exo-10-(8-aza-bicyclo-[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2u for endo-1 0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, phenyl acetaidehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxy-borohydride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloro-ethane, the title compound exo-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 3u was obtained as a TFA salt after purification via reverse phase HPLC (eluent:
CH3CN in water containing 0.1 % TFA). MS m/z (MH+) ~ N~\
~
N~~
N
4u N ~
Exo-10-(8-Pyridin-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 4u Using an adaptation of Procedure 9, and substituting exo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2u for endo-1 0-(8-aza-bicyclo[3.2. 1 ]oct-3-yl)-3-(1 f-/-tetrazol-5-yl)-10H-phenoxazi ne, 5b, 3-pyridyl carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxy-borohyd ride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloro-ethane, the title compound exo-10-(8-pyridin-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 4u was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 483.1.
NI ~ N~
CN
S 5u ~ ~
Exo-10-(8-Th iophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 5u Using an adaptation of Procedure 9, and substituting exo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2u for endo-1 0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, thiophene-2-carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohydride for sodium triacetoxyborohydride, and tetrahydrofuran for dichloroethane, the title compound exo-1 0-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 5u was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 488.1.
0 ~ N~
~/
N
CN
6u Exo-10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yi]-10H-phenoxazine-3-carboxylic acid diethylamide, 6u Using an adaptation of Procedure 9, and substituting exo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2u for endo-1 0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, 3-methyl-but-2-enyl carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohyd ride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloroethane, the title compound exo-10-[8-(3-methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide, 6u was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 460.1.
O N
C-N
N 7u ~ \
/
Exo-1 0-(8-Pyridi n-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 7u Using an adaptation of Procedure 9, and substituting exo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2u for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, tetrabutylammonium triacetoxyborohydride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloroethane, the title compound exo-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 7u was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 483.1.
O ~ N
~/
N
N
~ 8u ~ /
Exo-10-(8-Be nzyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 8u Using an adaptation of Procedure 9, and substituting exo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10F/ phenoxazine-3-carboxylic acid diethylamide, 2u for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 I I tetrazol-5-yl)-10H-phenoxazine, 5b, benzaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohyd ride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloroethane, the title compound exo-10-(8-benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 8u was obtained as a TFA
salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 482.1.
N~ \ NI/\
s CN
S~ 9u -N
Exo-10-(8-Thiazol-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 9u Using an adaptation of Procedure 9, and substituting exo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2u for endo-l0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, thiazol-2-ylmethyl carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohydride for sodium triacetoxyborohydride, and tetrahydrofuran for dichioroethane, the title compound exo-10-(8-thiazol-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 9u was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1% TFA). MS m/z (MH+) 489.1.
O ~ N
~~
N
N
10u o Exo-10-(8-Furan-3-yl methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 10u Using an adaptation of Procedure 9, and substituting exo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2u for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, thiazol-2-ylmethyl carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohyd ride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloroethane, the title compound exo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]-oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 10u was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 472.1.
H N
N- 11u N
Exo-10-[8-(1 H-Imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1]oct-3-yi]-10H-phenoxazine-3-carboxylic acid diethylamide, 11 u Using an adaptation of Procedure 9, and substituting exo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2u for endo-1 0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, 1 H-imidazol-2-ylmethyl carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohyd ride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloroethane, the title compound xxo-10-[8-(1 H-imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide, 11u was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 /o TFA). MS
m/z (MH+) 472.1.
EXAMPLE V
HO \ CI F OMe OH
(/ I o \ O CI B-OH
HN N02 / I~
OMe N N
1j K2C03 Cp2Fe(PtBu2)2PdCI2 Boc N Iv 1,4-dioxane Boc OMe o i OH / i O N
~/ N\ CHO
O N BBr3 XNX) /
N 3v NaBH(OAc)3 N 2v N NaOAc OH
x O I ~ N
N ~
A4v N
N
~ \
/
Endo-3-(3-Chloro-6-methoxy-phenoxazi n-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1v Using an adaptation of Procedure 2, and substituting 6-fluoro-2-methoxy-nitrobenzene, 1e for 4-fluoro-3-nitrobenzonitrile and endo-3-(4-chloro-2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 j for the TFA salt of 3-hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-ylamino)-benzoic acid methyl ester, 1 a, the title compound endo-3-(3-chloro-6-methoxy-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1v was obtained. MS m/z (MH+) 457.2.
Endo-3-(6-Methoxy-3-pyridin-3-yl-phenoxazi n-10-y1)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2v Using an adaptation of the method described in Procedure 24, substituting endo-3-(3-chloro-6-methoxy-phenoxazin-10-y1)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1v for endo-3-(3-chlorophenoxazin-10-yI)-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 3j, the title compound endo-3-(6-methoxy-3-pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2v was obtained. MS m/z (MH+) 500.3.
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-7-pyridin-3-yl-10H-phenoxazin-4-ol, 3v Using an adaptation of the method described in Procedure 16, substituting endo-3-(6-methoxy-3-pyridin-3-yl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2v for the TFA salt of 6-methoxy-l0-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl )-10H-phenoxazi ne-3-carboxylic acid diethylamide, 6e, the title compound endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-3-yl-10H-phenoxazin-4-ol, 3v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1% TFA). MS m/z (MH+) 386.1.
Endo-7-Pyridi n-3-yI-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-10H-phenoxazin-4-ol, 4v Using an adaptation of the method described in Procedure 1, substituting the TFA salt of endo-l0-(8-aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-3-yl-10H-phenoxazin-4-ol, 3v for 4-amino-3-hydroxybenzoic acid methyl ester, and 2-pyridyl carboxaldehyde for 8-methyl-8-aza-bicyclo[3.2.1 ]octan-3-one, the title compound endo-7-pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-4-ol, 4v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA).
MS m/z (MH+) 477.2.
OMe 0 (N:1::rCl I N 5v H
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-ch loro-6-methoxy-10H-phenoxazine, 5v Using an adaptation of the method described in Procedure 25, substituting the TFA salt of endo-7-pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-4-ol, 4v for endo-3-(3-pyridin-3-yl-phenoxazin-1 0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 4j, the title compound endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-chloro-6-methoxy-10H-phenoxazine, 5v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA).
MS m/z (MH+) 357.1.
OMe / I
O N
N
N 6v H
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-3-pyridi n-3-yl-10H-phenoxazine, 6v Using an adaptation of the method described in Procedure 25, substituting endo-3-(6-methoxy-3-pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2v for endo-3-(3-pyridin-3-yl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 4j, the title compound endo-l0-(8-aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-3-pyridin-3-yl-10H-phenoxazine, 6v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 /o TFA). MS m/z (MH+) 400.2.
OMe ~ I
O ~ N
N ~ i N 7v N
\
/
Endo-6-M ethoxy-3-pyri d i n-3-y1-10-(8-pyri d i n-2-yl m ethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine, 7v Using an adaptation of the method described in Procedure 1, substituting endo-3-(6-methoxy-3-pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2v for 4-amino-3-hydroxybenzoic acid methyl ester, and 2-pyridyl carboxaldehyde for 8-methyl-8-aza-bicyclo[3.2.1]octan-3-one, the title compound endo-6-methoxy-3-pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine, 7v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 491.2.
OH N
O
NO
N 8v H
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-7-pyridi n-4-yi-10H-phenoxazin-4-ol, 8v Using an adaptation of the methods described in Procedures 24 and 16, substituting endo-3-(3-chloro-6-methoxy-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, lv for endo-3-(3-chlorophenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 3j, and 4-pyridylboronic acid for 3-pyridylboronic acid in Procedure 24, the title compound endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-4-yl-10H-phenoxazin-4-ol, 8v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 386.2.
OH N
O
NO
N 9v N
\
Endo-7-Pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-4-ol, 9v Using an adaptation of the method described in Procedure 1, substituting the TFA salt of endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-4-yl-10H-phenoxazin-4-ol, 8v for 4-amino-3-hydroxybenzoic acid methyl ester, and 2-pyridyl carboxaldehyde for 8-methyl-8-aza-bicyclo[3.2.1 ]octan-3-one, the title compound endo-7-pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-4-ol, 9v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA).
MS m/z (MH+) 477.3.
OH N
O \ ~ I
N
N 10v Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-7-pyrid i n-4-yl-10H-phenoxazi n-4-ol, 10v Using an adaptation of the method described in Procedure 1, substituting the TFA salt of endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-4-yl-10H-phenoxazin-4-ol, 8v for 4-amino-3-hydroxybenzoic acid methyl ester, and phenyl acetaidehyde for 8-methyl-8-aza-bicyclo[3.2.1]octan-3-one, the title compound endo-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-7-pyridin-4-yl-10H-phenoxazin-4-ol, 10v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA).
MS m/z (MH+) 490.3.
OMe \ ~ I
NI
N 11v H
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-3-pyrid i n-4-yl-10H-phenoxazine, 11v Using an adaptation of the methods described in Procedures 24 and 25, substituting endo-3-(3-chloro-6-methoxy-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1v for endo-3-(3-chlorophenoxazin-10-yI)-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 3j, and 4-pyridylboronic acid for 3-pyridylboronic acid in Procedure 24, the title compound endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-3-pyridin-4-yl-10H-phenoxazine, 11v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA).
MS m/z (MH+) 400.2.
OMe / N
\ O I \ ~ I
N
N 12v N
\
/
Endo-6-Methoxy-3-pyridin-4-y1-10-(8-pyridi n-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi ne, 12v Using an adaptation of the method described in Procedure 1, substituting the TFA salt of endo-l0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-pyridin-4-yl-10H-phenoxazine, 11v for 4-amino-3-hydroxybenzoic acid methyl ester, and 2-pyridyl carboxaldehyde for 8-methyl-8-aza-bicyclo[3.2.1]octan-3-one, the title compound endo-6-methoxy-3-pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine, 12v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 491.2.
OMe / N
~
N
N 13v Endo-6-Methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-4-y1-10H-phenoxazine, 13v Using an adaptation of the method described in Procedure 1, substituting the TFA salt of endo-1 0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-3-pyridin-4-y1-10H-phenoxazine, 11v for 4-amino-3-hydroxybenzoic acid methyl ester, and phenyl acetaldehyde for 8-methyl-8-aza-bicyclo[3.2.1 ]octan-3-one, the title compound endo-6-methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 13v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 504.3.
EXAMPLE X
O
B'O
NH O
eI:_,H ci ~\
O \
aN ~
~ Is O
N r TFA
Cp2Fe(PtBu2)aPdCIa N 3,j K2CO3 Boc 1,4-dioxane N lx H2O Boc ~ \ I
aN \ CHO O HN O /HN
N -rO
NaBH(OAc)3 N 2x N 3x H
Endo-3-[3-(2-Acetylaminophenyl)-phenoxazin-10-yI]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1x Using an adaptation of the method described in Procedure 24, substituting N-[2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide for 3-pyridyl boronic acid, the title compound endo-3-[3-(2-acetylaminophenyl)-phenoxazin-1 0-yl]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1x was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA).
Endo-N-{2-[10-(8-Aza-bi cyclo[3.2.1 ]oct-3-y1l)-10H-phenoxazi n-3-yl]-phenyl}-acetamide, 2x Using an adaptation of Procedure 25, substituting the TFA salt of endo-3-[3-(2-acetylaminophenyl)-phenoxazin-10-yI]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1x for endo-3-(3-pyridin-3-yl-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 4j, the title compound endo-N-{2-[10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide, 2x was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 426.2.
Endo-N-{2-[10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide, 3x Using an adaptation of the method described in Procedure 1, substituting the TFA salt of endo-N-{2-[10-(8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide, 2x for 4-amino-3-hydroxybenzoic acid methyl ester, and phenyl acetaidehyde for 8-methyl-8-aza-bicyclo[3.2.1 ]octan-3-one, the title compound endo-N-{2-[10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide, 3x was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 530.3.
i I
C O N HN O
N 4x Endo-N-{2-[10-(8-Th i ophe n-2-yl m ethyl-8-aza-bi cyclo[3.2.1 ] oct-3-yl )-10H-phenoxazin-3-yl]-phenyl}-acetamide, 4x Using an adaptation of the method described in Procedure 1, substituting the TFA salt of endo-N-{2-[10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-1 H-phenoxazin-3-yl]-phenyl}-acetamide, 2x for 4-amino-3-hydroxybenzoic acid methyl ester, and 2-thiophene carboxaldehyde for 8-methyl-8-aza-bicyclo[3.2.1]octan-3-one, the title compound endo-N-{2-[10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide, 4x was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 522.2.
i I
C N HN T O
N 5x N
~ \
/
Endo-N-{2-[10-(8-Pyri d i n-2-yl m ethyl-8-aza-bi cyc lo[3.2.1 ] oct-3-yl )-10H-phenoxazin-3-yl]-phenyl}-acetamide, 5x Using an adaptation of the method described in Procedure 1, substituting the TFA salt of endo-N-{2-[10-(8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide, 2x for 4-amino-3-hydroxybenzoic acid methyl ester, and 2-pyridyl carboxaldehyde for 8-methyl-8-aza-bicyclo[3.2.1]octan-3-one, the.title compound endo-N-{2-[10-(8-pyridin-2-yl methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi n-3-yl]-phenyl}-acetam ide, 5x was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 517.2.
EXAMPLE Y
1. 0 B-O coo G(NX121O
Cp2Fe(PtBu2)2PdCI2 CN K2CO3 1 Boo 1,4-dioxane N Cy 2.TFA
Exo-N-{2-[10-(3-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi n-3-yl]-phenyl}-acetamide, ly Using an adaptation of the methods described in Procedures 24 and 25, and substituting exo-3-(3-chlorophenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1I for endo-3-(3-chlorophenoxazin-10-yI)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3j, and N-[2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide for 3-pyridyl boronic acid in Procedure 24, the title compound exo-N-{2-[10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide, ly was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 426.2.
EXAMPLE Z
O
OMe ~ B,O OMe O ~ / NH
N O ( N O ~ ~ / / HN
~
1v CpaFe(PtBu2)2PdCi2 N K2CO3 N 1z Boc 1,4-dioxane Boc OH /
\ ~ I
BBr3 HN 0 N ~ /
2z N
H
Endo-3-[3-(2-Acetyl am i n ophe nyl )-6-methoxy-phe n oxazi n-10-y1]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1z Using an adaptation of the method described in Procedure 24, substituting N-[2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide for 3-pyridyl boronic acid, the title compound endo-3-[3-(2-acetylaminophenyl)-6-methoxy-phenoxazin-1 0-yl]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, lz was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 %
TFA).
Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl )-6-hydroxy-10H-phenoxazin-3-yi]-phenyl}-acetamide, 2z Using an adaptation of the method described in Procedure 16, substituting the TFA salt of endo-3-[3-(2-acetylaminophenyl)-6-methoxy-phenoxazin-10-yl]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1z for the TFA salt of 6-methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 6e, the title compound endo-N-{2-[10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-6-hydroxy-10H-phenoxazin-3-yl]-phenyl}-acetamide, 2z was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 442.2.
OMe /
O
I o N I i HN O
3z N
H
Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-10H-phenoxazin-3-yl]-phenyl}-acetamide, 3z Using an adaptation of the method described in Procedure 25, substituting the TFA salt of endo-3-[3-(2-acetylaminophenyl)-6-methoxy-phenoxazin-10-yI]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1z for endo-3-(3-pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 4j, the title compound endo-N-{2-[10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-10H-phenoxazin-3-yl]-phenyl}-acetamide, 3z was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 456.2.
EXAMPLE AA
c S Br S CN CHO
Zn(CN)2 N
Pd(PPh3)4 NaBH(OAc)3 4i DMF laa CH3COOH
H H
N_NN
~\ S ~\ CN S
aN~ TMSN3 (::~)Cr4 N
Bu20 2aa DME 3aa N N
Procedure 28 10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazi ne-3-carbonitri le, 1aa To a solution of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-bromo-10H-phenothiazine, 4i (50 mg, 0.13 mmol) in DMF (750 L) was added zinc cyanide (15 mg, 0.13 mmol) and tetrakistriphenylphosphine palladium (4 mg), the solution was purged with nitrogen, and the mixture was heated in the microwave for 5 min at 160 C. The mixture was allowed to cool to rt, and purified via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA) to yield title compound 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carbonitrile, 1 aa as a TFA salt and as a mixture of endo and exo isomers. MS
m/z (MH+) 334.1.
10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carbonitrile, 2aa Using an adaptation of the method described in Procedure 22, substituting the TFA salt of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carbonitrile, I aa for 3-bromo-10-piperidin-4-yl-10H-phenothiazine, 4i, the title compound 10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-yl)-10H-phenothiazine-3-carbonitrile, 2aa was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA) and as a mixture of endo and exo isomers.
Procedure 29 10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenothiazine, 3aa To a solution of 10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carbonitrile, 2aa (10 mg, 29 mol) in dimethoxyethane was added trimethylsilyl azide (15 L, 115 mol) and dibutyltin oxide (1.5 mg), and the mixture was heated in a microwave for 15 min at 150 C. The mixture was allowed to cool to rt, and purified via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA) to yield title compound 10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenothiazine, 3aa as a TFA
salt and as a mixture of endo and exo isomers. MS m/z (MH+) 481.2.
N'NN
I \ S I \ N
H
N
4aa N
N
~ \
/
10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yI)-10H-phenothiazine, 4aa Using an adaptation of the methods described in Procedures 22 and 29, substituting the TFA salt of 1 0-(8-aza-bicyclo[3.2. 1 ]oct-3-yl)-10H-phenothiazine-3-carbonitrile, 1aa for 3-bromo-10-piperidin-4-yl-10H-phenothiazine, 4i and 2-pyridyl carboxaldehyde for 3-furyl carboxaldehyde in Procedure 22, the title compound 10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenothiazine, 4aa was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA) and as a mixture of endo and exo isomers. MS m/z (MH+) 468.2.
N-NN
\ S ~ Ho N
5aa N
H
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yI)-3-(I H-tetrazol-5-yl)-10H-phenothiazine, 5aa Using an adaptation of the method described in Procedure 29, substituting the TFA salt of 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carbonitrile, 1 aa for 10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carbonitrile, 2aa, the title compound 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenothiazine, 5aa was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA) and as a mixture of endo and exo isomers.
MS m/z (MH+) 377.2.
NH
S N --\
N
6aa N
N,N-Diethyl-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10F/-phenothiazine-3-carboxamidine, 6aa Using an adaptation of the method described in Procedure 10, substituting the TFA salt of 10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-phenothiazine-3-carbonitriie, 2aa for endo-3-(3-cyano-phenoxazin-1 0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3b, the title compound N, N-diethyl-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-10H-phenothiazine-carboxamidine, 6aa was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA) and as a mixture of endo and exo isomers. MS m/z (MH+) 511.3.
NH
S ~ N ~\
~/
N
A 7aa N
N
~ \
/
N,N-Diethyl-10-(8-pyridi n-2-yl methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carboxamidine, 7aa Using an adaptation of the methods described in Procedures 22 and 10, substituting the TFA salt of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carbonitrile, 1aa for endo-3-(3-cyano-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3b, and 2-pyridyl carboxaldehyde for 3-furyl carboxaldehyde, the title compound N,N-diethyl-10-( 8-pyrid i n-2-yl m ethyl-8-aza-b i cyclo [3.2.1 ]oct-3-yl )-10H-p he noth i azi ne-3-carboxamidine, 7aa was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA) and as a mixture of endo and exo isomers.
MS m/z (MH+) 498.3.
EXAMPLE BB
N-N
, I
:ZnCN2 _ a N .
Pd(PPh3)4 DME
1bb 2bb 3i DMF
i i N
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoth iazi ne-3-carbonitrile, 1 bb Using an adaptation of the method described in Procedure 28, substituting 3-bromo-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 3i for endo-3-(3-cyano-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 3b, the title compound 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carbon itri le, 1 bb was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA) and as a mixture of endo and exo isomers. MS m/z (MH+) 348.1.
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-3-(1 H-tetrazol-5-yl)-10H-phenothiazine, 2bb Using an adaptation of the method described in Procedure 29, substituting the TFA salt of 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carbonitrile, I bb for 10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carbonitrile, 2aa, the title compound 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenothiazine, 2bb was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA) and as a mixture of endo and exo isomers.
MS m/z (MH+) 391.1.
NH
I ~ S I ~ N~
N
3bb N
I
N,N-Diethyl-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carboxamidine, 3bb Using an adaptation of the method described in Procedure 10, substituting the TFA salt of 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carbonitrile, 1 bb for endo-3-(3-cyano-phenoxazin-1 0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3b, the title compound N, N-d iethyl-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoth iazi ne-carboxamidine, 3bb was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA) and as a mixture of endo and exo isomers. MS m/z (MH+) 421.2.
EXAMPLE CC
Br SH 1. LiAIH4 ~ + neat Br, ~ S THF NH2 i H 2. 02N OMe 1cc F
02N OMe THF
OMe S Br O CI
K2CO 3 I j I j \/U
aNH ~ II
3cc DIEA
2cc CICH2CH2CI
HO
OMe OH I ~ B-OH
S B
Br N
cIIuIIIlBr 3 4cc + c ~ o N Pd(PPh3)4 N 4cc 5cc NMP
H H
OMe OH
S N S N
(N)O + I/ N I/
6cc 7cc Spiro compound, 1cc Using an adaptation of the method described in Procedure 18, substituting for 2-amino-5-bromothiophenol for 2-aminothiophenol, the title compound 1cc was obtained.
[2-(3-Methoxy-2-nitro-phenylsulfanyl)-phenyl]-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amine, 2cc Using an adaptation of the method described in Procedure 19, substituting spiro compound, 1cc for spiro compound 1i, the title compound [2-(3-methoxy-2-nitro-phenylsulfanyl)-phenyl]-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-yl)-amine, 2cc was obtained a mixture of endo and exo isomers.
3-Bromo-6-methoxy-1 0-(8-methyl-8-aza-bicycIo[3.2.1 ]oct-3-yi)-10H-phenothiazine, 3cc Using an adaptation of the method described in Procedure 20, substituting [2-(3-methoxy-2-nitro-phenylsulfanyl)-phenyl]-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amine, 2cc for [2-(4-bromo-2-nitrophenylsulfanyl)-phenyl]-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-amine, 2i, the titie compound bromo-6-methoxy-10-(8-methyl-8-aza-bicycio[3.2.1 ]oct-3-yl)-10H-phenothiazine, 3cc was obtained a mixture of endo and exo isomers.
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-bromo-6-methoxy-lOH-phenothiazine, 4cc Using an adaptation of the method described in Procedure 21, substituting 3-bromo-6-methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenothiazine, 3cc for 3-bromo-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine, 3i, the title compound 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-bromo-6-methoxy-10H-phenothiazine, 4cc was obtained a mixture of endo and exo isomers.
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yi)-7-bromo-10H-phenoth iazi n-4-ol, 5cc Using an adaptation of the method described in Procedure 16, substituting 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-bromo-6-methoxy-10H-phenothiazine, 4cc for 6-methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yi)-10H-phenoxazine-3-carboxylic acid diethylamide, 6e, a mixture of title compound 10-(8-aza-bicyclo-[3.2.1 ]oct-3-yl)-7-bromo-10H-phenothiazin-4-ol, 5cc and starting material 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-bromo-6-methoxy-10H-phenothiazine, 4cc was obtained a mixture of endo and exo isomers.
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-3-pyridi n-3-yl-10H-phenothiazine, 6cc and 10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-3-yl-10H-phenothiazin-4-ol, 7cc Using an adaptation of the method described in Procedure 23, substituting a mixture of 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-bromo-6-methoxy-10H-phenothiazine, 4cc and 10-(8-aza-bicyclo-[3.2.1 ]oct-3-yl)-7-bromo-10H-phenothiazin-4-ol, 5cc for 3-bromo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 5i, a mixture of title compounds (8-aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-3-pyridin-3-yI-10H-phenothiazine, 6cc and 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-7-pyridin-3-yI-10H-phenothiazin-4-ol, 7cc was obtained. The compounds were separated via reverse phase HPLC
(eluent: CH3CN in water containing 0.1 % TFA) to yield 6cc [MS m/z (MH+) 416.2] and 7cc [MS m/z (MH+) 402.2], bothy as TFA salts and mixtures of endo and exo isomers.) EXAMPLE DD
OMe HN OMe O
1. CI
5SXBr CHCIN Herrmann's N 2.
MeOH
catalyst 1 dd 3cc Mo(CO)6 DBU N
N THF ~
I
OMe 0 OH 0 S S
BBr3 ~ N
2dd 3dd H H
6-Methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carboxylic acid diethylamide, 1dd Using an adaptation of the method described in Procedure 26, substituting a mixture of endo and exo isomers of 3-bromo-6-methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 3cc for 3-bromo-l0-piperidin-4-yl-10H-phenothiazine, 4i, title compound 6-methoxy-l0-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carboxylic acid diethylamide, ldd was obtained as a mixture of endo and exo isomers.
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-10H-phenothiazi ne-3-carboxylic acid diethylamide, 2dd Using an adaptation of the method described in Procedure 21, substituting 3-bromo-6-methoxy-1 0-(8-methyl-8-aza-bicyclo[3.2. 1 ]oct-3-yl)-phenothiazine, 3cc for 3-bromo-l0-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine, 3i, title compound 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-10H-phenothiazine-3-carboxylic acid diethylamide, 2dd was obtained as a TFA
salt and as a mixture of endo and exo isomers.
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-hydroxy-101'%phenothiazi ne-3-carboxylic acid diethylamide, 3dd Using an adaptation of the method described in Procedure 16, substituting 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-10H-phenothiazine-3-carboxylic acid diethylamide, 2dd for 6-methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 6e, a mixture of title compound 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-6-hydroxy-lOH-phenothiazine-3-carboxylic acid diethylamide, 3dd was obtained. MS m/z (MH+) 424.2.
Biological Examples Rat Brain Delta Opioid Receptor Binding Assay Procedure: Male, Wistar rats (150-250 g, VAF, Charles River, Kingston, NY) were killed by C02, and their brains were removed and placed immediately in ice cold Tris HCI buffer (50 mM, pH 7.4). The forebrains were separated from the remainder of the brain by a coronal transection, beginning dorsally at the colliculi and passing ventrally through the midbrain-pontine junction.
After dissection, the forebrains were homogenized in Tris buffer in a Teflon -glass homogenizer. The homogenate was diluted to a concentration of 1 g of forebrain tissue per 80 mL Tris and centrifuged at 39,000 x g for 10 min. The pellet was resuspended in the same volume of Tris buffer containing 5 mM
MgCI2 with several brief pulses from a Polytron homogenizer. This particulate preparation was used for the delta opioid binding assays. Following incubation with the delta selective peptide ligand -4 nM [3H]DPDPE or 0.15 nM
[3H]naltrindole at 25 C for 2.5 h in a 96-well plate with total volume of I
mL, the plate contents were filtered through Wallac filtermat B sheets on a Tomtec 96-well harvester. The filters were rinsed three times with 2 mL of 10 mM
HEPES (pH 7.4), and dried in a 650 W microwave oven for 1.75 min twice. To each sample area 2 X 50 pL of Betaplate Scint scintillation fluid (LKB) was added and the radioactivity quantified on a LKB (Wallac) 1205 BetaPlate liquid scintillation counter.
Analysis: The data from the scintillation counter were used to calculate either the % inhibition compared to control binding (when only a single concentration of test compound was evaluated) or a K; value (when a range of concentrations was tested). Percent inhibition was calculated as: [(total dpm-test compound dpm)/(total dpm-nonspecific dpm)]*100. Kd and Ki values were calculated using GraphPad PRISM data analysis program.
Rat Brain Mu Opioid Receptor Binding Assay Procedure: Male, Wistar rats (150-250 g, VAF, Charles River, Kingston, NY) were killed by C02, and their brains were removed and placed immediately in ice cold Tris HCI buffer (50 mM, pH 7.4). The forebrains were separated from the remainder of the brain by a coronal transection, beginning dorsally at the colliculi and passing ventrally through the midbrain-pontine junction.
After dissection, the forebrains were homogenized in Tris buffer in a Teflon -glass homogenizer. The homogenate was diluted to a concentration of I g of forebrain tissue per 80 mL Tris and centrifuged at 39,000 x g for 10 min. The pellet was resuspended in the same volume of Tris buffer containing 5 mM
MgCl2 with several brief pulses from a Polytron homogenizer. This particulate preparation was used for the delta opioid binding assays. Following incubation with the mu selective peptide ligand, ~0.8 nM [3H]DAMGO, at 25 C for 2.5 h in a 96-well plate with total assay volume of 1 mL, the plate contents were filtered through Wallac fiitermat B sheets on a Tomtec 96-well harvester. The filters were rinsed three times with 2 mL of 10 mM HEPES (pH 7.4), and dried in a 650 W microwave oven for 1.75 min twice. To each sample area 2 X 40 pL of Betaplate Scint scintillation fluid (LKB) was added and the radioactivity quantifed on a LKB (Wallac) 1205 BetaPlate liquid scintillation counter.
Analysis: The data from the scintillation counter were used to calculate either the % inhibition compared to control binding (when only a single concentration of test compound was evaluated) or a K; value (when a range of concentrations tested). Percent inhibition was calculated as: [(total dpm-test compound dpm)/(total dpm-nonspecific dpm)]*100. Kd and Ki values were calculated using GraphPad PRISM data analysis program.
[35S1GTPrS Binding Assay in NG108-15 Cell Membranes (delta opioid) Methods: NG108-15 cell membranes can be purchased from Applied Cell Sciences (Rockville, MD). 8 mg/mL of membrane protein suspended in 10 mM TRIS-HCI pH 7.2, 2 mM EDTA, 10% sucrose. Membranes can be maintained at 4-8 C. A 1 mL volume of membranes can be added into 10 mL
coid binding assay buffer. The assay buffer contained 50 mM Tris, pH 7.6, 5 mM MgCi2, 100 mM NaCl, 1 mM DTT and 1 mM EGTA. The membrane suspension can be homogenized twice with a Polytron, and centrifuged at 3000 rpm for 10 min. The supernatant can be then centrifuged at 18,000 rpm for 20 min. Ten mL assay buffer can be added into the pellet containing tube. The pellet and buffer can be mixed with a Polytron.
Incubation procedure: The pellet membranes (75 pg/mL) can be preincubated with SPA (10 mg/mL) at 25 C for 45 min in the assay buffer. The SPA (5 mg/mL) coupled with membranes (37.5 pg/mL) can then be incubated with 0.1 nM [35S] GTPyS in the same Tris buffer containing 100 pM GDP in total volume of 200 pL. Increasing concentrations of receptor agonists can be used to stimulate [35S]- GTP~S binding. The basal binding can be tested in the absence of agonists and non-specific binding can be tested in the presence of pM unlabeled GTPyS. The data can be analyzed on a Packard Top Count.
DATA
% of Basal = (stimulated - non specific)*1 00/(basal - non specific).
EC50 value values can be calculated using GraphPad Prism.
[35S1GTPyS Binding Assays in CHO-hMOR Cell Membranes Methods: CHO-hMOR cell membranes can be purchased from Receptor Biology, Inc. (Baltimore, MD). About 10 mg/mL of membrane protein can be suspended in 10 mM TRIS-HCI pH 7.2, 2 mM EDTA, 10% sucrose, and the suspension kept on ice. A 1 mL volume of membranes can be added to 15 mL cold binding assay buffer containing 50 mM HEPES, pH 7.6, 5 mM MgCI2, 100 mM NaCI, 1 mM DTT and 1 mM EDTA. The membrane suspension can be homogenized with a Polytron and centrifuged at 3,000 rpm for 10 min. The supernatant can then be centrifuged at 18,000 rpm for 20 min. The pellet can be resuspended in 10 mL assay buffer with a Polytron. The membranes can be preincubated with wheat germ agglutinin coated SPA beads (Amersham) at 25 C for 45 min in the assay buffer. The SPA bead (5 mg/mL) coupled membranes (10 pg/mL) can be then incubated with 0.5 nM [35S]GTPyS in the assay buffer. The basal binding can be that taking place in the absence of added test compound; this unmodulated binding can be considered as 100%, with agonist stimulated binding rising to levels significantly above this value. A
range of concentrations of receptor agonist can be used to stimulate [35S]GTPyS binding. Both basal and non-specific binding can be tested in the absence of agonist; non-specific binding determination included 10 pM
unlabeled GTPyS.
Compounds can be tested for function as antagonists by evaluating their potential to inhibit agonist-stimulated GTP7S binding. Radioactivity can be quantified on a Packard TopCount. The following parameters can be calculated:
% stimulation = (test compound cpm - non-specific cpm) x 100 (basal cpm - non-specific cpm).
% inhibition =(% stimulation by 1 M DAMGO - % stimulation by test compound) x 100 (% stimulation by 1 M DAMGO -100) EC50 values can be calculated using GraphPad Prism.
Biological Data Compound Number delta (Ki, nM) mu (Ki, nM) 4t 0.1 4aa 0.1 6b 0.1 168.45 6d 0.1 336 9t 0.10 8t 0.18 4v 0.3 2z 0.62 10t 1.14 7e 2.2 7t 2.43 7u 3.27 8v 5.2 3v 8.3 8j 18.8 8u 20.70 3t 25.1 3z 27.63 12v 36.3 6u 44.49 3c 48.1 525 7v 56.6 5t 56.7 5x 81.82 2t 86.6 6e 99.5 7j 103.6 7i 122.84 554.3 9v 136.3 4x 161.3 2u 196.5 6t 231.0 5k 246.7 6v 263.2 6i 282.35 1055.7 4e 320.9 5aa 321.1 11 i 366.9 170.985 4a 373 6761 Compound Number delta (Ki, nM) mu (Ki, nM) 3r 396.8 682.2 11 v 399.5 5b 406 6849 5j 409.4 2x 414.6 41 424.6 8i 443.5 889.4 4k 444.8 5u 477.80 3m 480.1 12 i 491.45 1450 2c 492 9448 51 539.2 4u 542.55 13i 551.6 3740 6a 575 819 2h 598 2889 17i 629 1533.5 15i 629.55 168.9 2m 634.2 9i 649.35 538.4 1 r 651.95 2758 2k 695.5 2a 697 5152 31 729.1 2r 863.65 4340 4p 864.5 4m 868.9 4i 881 6613 laa 930.9 18i 940.75 8073 10i 949.05 317.3 61 1269.1 5m 1278.5 3u 1356.30 16i 1453 2654 3x 1585.0 ly 1601.8 14i 1603.5 598.75 3f 1752 1435 8b 1896 >10000 1g 2041 4285 5a 2116 6091 5v 2260.0 3i 2532 3185 7d 2633 123 Compound Number delta (Ki, nM) mu (Ki, nM) 2f 2644.5 2752 4c 3106 89.0 6j 3261.5 3k 3388.0 3p 5123.0 19i 5191 254 7b 5475 288 71 6211.5 9j 11865.0 10j 13321.5 6k 14223.5 10v >10000 13v >10000
The present invention is directed, inter alia, to compounds of Formula (I) and compositions comprising a compound of Formula (I):
Y
G
i I
R4 , / \\
A
N
Formula (I) wherein:
G is -C(Z)N(Rl)R2, C6_loaryl, or a heterocycle selected from the group consisting of imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, tetrahydropyrimidinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, furyl, indazolyl, indolyl, indolinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, and pyridinyl; wherein aryl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1_8alkanyi, C2_$alkenyl, C2_$alkynyl-, Cl_$alkanyloxy, hydroxy(Cl_$)aikanyl, carboxy(Cl_$)alkanyi, Cl_$alkanylcarbonylamino, halogen, hydroxy, cyano, nitro, oxo, thioxo, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, Cl_$aikanylthio, Cl_$alkanylsulfonyl, Cl_$alkanylsulfonylamino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, Cl_8alkanylaminocarbonyl, di(Cl_$alkanyl)aminocarbonyl, and C1_6alkanyloxycarbonylamino;
R, is a substituent selected from the group consisting of hydrogen, CI_$alkanyl, C2_$alkenyl, and C2_$alkynyl;
R2 is a substituent selected from the group consisting of hydrogen;
Cl_$alkanyl; C2_$alkenyl; C2_$alkynyl; C6_1oaryl; and C1_$cycloalkanyl; wherein Cl_$alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, C1_6alkanyloxy, thioC,_6alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, CI_$alkanylaminocarbonyl, di(CI_$alkanyl)aminocarbonyl, C1_6alkanyloxycarbonyl, and aryloxy; and wherein any aryl-containing substituents and Cl_$cycloalkanyl substituents of R2 are optionally substituted with one to three substituents independently selected from the group consisting of Cl_$alkanyl, C2_8alkenyl, C2_$alkynyl, Cl_$alkanyloxy, trifluoromethyl, trifluoromethoxy, phenyl, halogen, cyano, hydroxy, CI_$alkanylthio, CI_$alkanylsulfonyl, and CI_$alkanylsulfonylamino;
or R, and R2 taken together with the nitrogen to which they are attached form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of CI_$alkanyl, hydroxy(Cl_$)alkanyl, hydroxy, amino, C1_6alkanylamino, di(Cl_6alkanyl)amino, and halogen;
R3 is a substituent selected from the group consisting of hydrogen, Cl_$alkanyl, halo1_3(C1 _8)alkanyl, C2_$alkenyl, C2_$alkynyl, C3_$cycloalkanyl, cycloalkanyl(CI_$)alkanyl, CI_$alkanyloxy(CI_$)alkanyl, C1_8alkanylthio(C1_8)alkanyl, hydroxyC,_$alkanyl, CI_$alkanyloxycarbonyl, halo1_3(C1_$)alkanylcarbonyl, formyl, thioformyl, carbamimidoyl, phenylimino(C1_8)alkanyl, phenyl(CI_8)alkanyl, phenyl(Cl_8)alkenyl, phenyl(C1_8)aikynyl, naphthyl(Cl_$)alkanyl and heteroaryl(C1_8)alkanyl wherein the heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indazolyl, indolyl, indolinyl, isoindolinyl,, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl, thiazolyl; wherein phenyl, naphthyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyl, C2-6alkenyl, C1_6alkanyloxy, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1_6alkanylcarbonyl, C1-6alkanylcarbonyloxy, Cl-6alkanylcarbonylamino, Cl-6alkanylthio, C1-6alkanylsulfonyl, halogen, hydroxy, cyano, fluoro(C1-6)alkanyl, thioureido, and fluoro(C1-6)aikanyloxy; alternatively, when phenyl and heteroaryl are optionally substituted with alkanyl or alkanyloxy substituents attached to adjacent carbon atoms, the two substituents can together form a fused cyclic alkanyl or cycloheteroalkanyl selected from the group consisting of -(CH2)3-5- ,-O(CH2)2-4- , -(CH2)2_40 -, and -O(CH2)1-30-;
R4 is one to three substituents independently selected from the group consisting of hydrogen; Cl-6alkanyl; C2-6alkenyl; C2-6alkynyl;
aryl(C2-6)alkynyl; C1-6alkanyloxy; amino; C1_6alkanylamino;
di(C1_6alkanyl)amino; C6-loarylamino wherein C6-loaryl is optionally substituted with one to three substitutents independently selected from the group consisting of CI-salkanyl, C1-6alkoxy, haiogen, and hydroxyl; formylamino; pyridinylamino; C1-6alkanylcarbonyl;
C1-6alkanylcarbonyloxy; C1-6alkanyloxycarbonyl; aminocarbonyl;
C1-6alkanylaminocarbonyl; di(C1-6alkanyl)aminocarbonyl;
C1-6alkanylcarbonylamino; C1-6alkanylthio; C1-6alkanylsulfonyl;
halogen; hydroxy; cyano; hydroxycarbonyl; C6-1oaryl; chromanyl;
chromenyl; furanyl; imidazolyl; indazolyl; indolyl; indolinyl;
isoindolinyl; isoquinolinyl; isothiazolyi; isoxazolyl; naphthyridinyl;
oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl; pyridinyl; pyrimidinyl;
pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl; quinoxalinyl;
tetrazolyl; thiazolyl; thienyl; fluoroalkanyl and fluoroalkanyloxy; or optionally, when R4 is two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the fused moiety is -(CH2)3_5-, -O(CH2)2_4- , -(CH2)2_40-, -O(CH2)1_30-, or -S-C(NH2)=N-;
R5 is one to two substituents independently selected from the group consisting of hydrogen, C1_6alkanyl, C2_6alkenyl, C1_6alkanyloxy, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, C1_6alkanylcarbonyl, Cl_6alkanylcarbonyloxy, C1_6alkanyloxycarbonyl, C1_6alkanylaminocarbonyl, C1_6alkanylcarbonylamino, C1_6alkanylthio, C1_6alkanylsulfonyl, halogen, hydroxy, cyano, fluoro(C1_6)alkanyl and fluoro(Cl_ 6)alkanyloxy;
A is -(CH2)m , wherein m is 2 or 3;
YisOorS;
Z is 0, S, NH, N(C1_6aikanyl), N(OH), N(OC1_6alkanyl), or N(phenyl);
and enantiomers, diastereomers, tautomers, solvates, or pharmaceutically acceptable salts thereof.
The present invention is also directed to, inter alia, veterinary and pharmaceutical compositions containing compounds of Formula (I) wherein the compositions are used to treat mild to severe pain in warm-blooded animals.
DETAILED DESCRIPTION
As used herein, the following underlined terms are intended to have the following meanings:
"Qa=6" (where a and b are integers) refers to a radical containing from a to b carbon atoms inclusive. For example, C1_3 denotes a radical containing 1, 2 or 3 carbon atoms "Alkyl:" refers to a saturated or unsaturated, branched, straight-chain or cyclic monovalent hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane, alkene or alkyne. Typical alkyl groups include, but are not limited to, methyl; ethyls such as ethanyl, ethenyl, ethynyl; propyls such as propan-1-yl, propan-2-yl , cyclopropan-1-yl, prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl, cycloprop-l-en-1-yl;
cycloprop-2-en-1-yl, prop-1-yn-1-yl, prop-2-yn-1-yl, etc.; butyls such as butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, cyclobutan-1 -yl, but-1 -en-1 -yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yi, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl, but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, etc.; and the like. Where specific levels of saturation are intended, the nomenclature "alkanyl", "alkenyl" and/or "alkynyl" is used, as defined below. In preferred embodiments, the alkyl groups are P-C6) alkyl, with P-C3) being particularly preferred.
"Alkanyl:" refers to a saturated branched, straight-chain or cyclic monovalent hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane. Typical alkanyl groups include, but are not limited to, methanyl; ethanyl; propanyis such as propan-1-yl, propan-2-yl, cyclopropan-1-yl, etc.; butyanyls such as butan-1-yl, butan-2-yl,.
2-methyl-propan-1-yl, 2-methyl-propan-2-yl, cyclobutan-1-yl, etc.; and the like.
In preferred embodiments, the alkanyl groups are (Cl_$) alkanyl, with (C1_3) being particularly preferred.
"Alkenyl" refers to an unsaturated branched, straight-chain or cyclic monovalent hydrocarbon radical having at least one carbon-carbon double bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkene. The radical may be in either the cis or trans conformation about the double bond(s). Typical alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop-1-en-1-yl, prop-1-en-2-yl; prop-2-en-1-yl, prop-2-en-2-yl, cycloprop-1-en-1-yi; cycloprop-2-en-1-yl; butenyis such as but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl, etc.; and the like.
"Alkynyl" refers to an unsaturated branched, straight-chain or cyclic monovalent hydrocarbon radical having at least one carbon-carbon triple bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkyne. Typical alkynyl groups include, but are not limited to, ethynyl;
propynyls such as prop-1-yn-1-yl, prop-2-yn-1-yl, etc.; butynyls such as but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, etc.; and the like.
"Heteroalkyl" and Heteroalkanyl" refer to alkyl or alkanyl radicals, respectively, in which one or more carbon atoms (and any necessary associated hydrogen atoms) are independently replaced with the same or different heteroatoms (including any necessary hydrogen or other atoms).
Typical heteroatoms to replace the carbon atom(s) include, but are not limited to, N, P, 0, S, Si, etc. Preferred heteroatoms are 0, N and S. Thus, heteroalkanyl radicals can contain one or more of the same or different heteroatomic groups, including, by way of example and not limitation, epoxy (-0-), epidioxy (-O-O-), thioether (-S-), epidithio (-SS-), epoxythio (-O-S-), epoxyimino (-O-NR'-), imino (-NR'-), biimino (-NR'-NR'-), azino (=N-N=), azo (-N=N-), azoxy (-N-0-N-), azimino (-NR'-N=N-), phosphano (-PH-), A4-sulfano (-SH2-), sulfonyl (-S(0)2-), and the like, where each R' is independently hydrogen or (CI-C6) alkyl.
"Parent Aromatic Ring System:" refers to an unsaturated cyclic or polycyclic ring system having a conjugated n electron system. Specifically included within the definition of "parent aromatic ring system" are fused ring systems in which one or more rings are aromatic and one or more rings are saturated or unsaturated, such as, for example, indane, indene, phenalene, etc.
Typical parent aromatic ring systems include, but are not limited to, aceanthryiene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, peryiene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene, and the like "6al:" refers to a monovalent aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. Typical aryl groups include, but are not limited to, radicals derived from aceanthrylene, acenaphthylene, acephenanthryiene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, peryiene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene, and the like. In preferred embodiments, the aryl group is (C5-20) aryl, with (C5-1o) being particularly preferred. Particularly preferred aryl groups are phenyl and naphthyl groups.
"Arylalkyl:" refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal carbon atom, is replaced with an aryl radical.. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethen-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl and the like. Where specific alkyl moieties are intended, the nomenclature arylalkanyl, aryiakenyl and/or arylalkynyl is used.
[In preferred embodiments, the arylalkyl group is (C6-26) arylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C1-6) and the aryl moiety is (C5-20). In particularly preferred embodiments the arylalkyl group is (C6-13), e.g., the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C1-3) and the aryl moiety is (C5_10). Even more preferred arylalkyl groups are phenylalkanyls.
"Alkan lroxy:" refers to a saturated branched, straight-chain or cyclic monovalent hydrocarbon alcohol radical derived by the removal of the hydrogen atom from the hydroxide oxygen of the alcohol. Typical alkanyloxy groups include, but are not limited to, methanyloxy; ethanyloxy; propanyloxy groups such as propan-1-yloxy (CH3CH2CH2O-), propan-2-yloxy ((CH3)2CHO-), cyclopropan-1-yloxy, etc.; butanyloxy groups such as butan-1-yloxy, butan-2-yloxy, 2-methyl-propan-1-yloxy, 2-methyl-propan-2-yloxy, cyclobutan-1-yloxy, etc.; and the like. In preferred embodiments, the alkanyloxy groups are (Cl_$) alkanyloxy groups, with (C1-3) being particularly preferred.
"Parent Heteroaromatic Ring System:" refers to a parent aromatic ring system in which one carbon atom is replaced with a heteroatom. Heteratoms to replace the carbon atoms include N, 0, and S. Specifically included within the definition of "parent heteroaromatic ring systems" are fused ring systems in which one or more rings are aromatic and one or more rings are saturated or unsaturated, such as, for example, arsindole, chromane, chromene, indole, indoline, xanthene, etc. Typical parent heteroaromatic ring systems include, but are not limited to, carbazole, imidazole, indazole, indole, indoline, indolizine, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like.
"Heteroary(:" refers to a monovalent heteroaromatic radical derived by the removal of one hydrogen atom from a single atom of a parent heteroaromatic ring system. Typical heteroaryl groups include, but are not limited to, radicals derived from carbazole, imidazole, indazole, indole, indoline, indolizine, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like. In preferred embodiments, the heteroaryl group is a 5-20 membered heteroaryl, with 5-10 membered heteroaryl being particularly preferred.
"Cycloheteroalkyl:" refers to a saturated or unsaturated monocyclic or bicyclic alkyl radical in which one carbon atom is replaced with N, 0 or S. In certain specified embodiments the cycloheteroalkyl may contain up to four heteroatoms independently selected from N, 0 or S. Typical cycloheteroalkyl moieties include, but are not limited to, radicals derived from imidazolidine, morpholine, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, and the like. In preferred embodiments, the cycloheteroalkyl is a 3-6 membered cycloheteroalkyl.
"Cycloheteroalkanyl:" refers to a saturated monocyclic or bicyclic alkanyl radical in which one carbon atom is replaced with N, 0 or S. In certain specified embodiments the cycloheteroalkanyl may contain up to four heteroatoms independently selected from N, 0 or S. Typical cycloheteroalkanyl moieties include, but are not limited to, radicals derived from imidazolidine, morpholine, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, and the like. In preferred embodiments, the cycloheteroalkanyl is a 3-6 membered cycloheteroalkanyl.
"Cycloheteroalkenyl:" refers to a saturated monocyclic or bicyclic alkenyl radical in which one carbon atom is replaced with N, 0 or S. In certain specified embodiments the cycloheteroalkenyl may contain up to. four' heteroatoms independently selected from N, 0 or S. Typical cycloheteroalkenyl moieties include, but are not limited to, radicals derived from imidazoline, pyrazoline, pyrroline, indoline, pyran, and the like. In preferred embodiments, the cycloheteroalkanyl is a 3-6 membered cycloheteroalkanyl.
"Substituted:" refers to a radical in which one or more hydrogen atoms are each independently replaced with the same or different substituent(s).
Typical substituents include, but are not limited to, -X, -R, -0-, =0, -OR, -0-OR, -SR, -S-, =S, -NRR, =NR, -CX3, -CN, -OCN, -SCN, -NCO, -NCS, -NO, -NO2, =N2, -N3, -NHOH, -S(0)20-, -S(0)20H, -S(O)aR, -P(O)(0)2, -P(O)(OH)2, -C(O)R, -C(O)X, -C(S)R, -C(S)X, -C(O)OR, -C(O)O-, -C(S)OR, -C(O)SR, -C(S)SR, -C(O)NRR, -C(S)NRR and -C(NR)NRR, where each X is independently a halogen (preferably -F, -Cl or -Br) and each R is independently -H, alkyl, alkanyl, alkenyl, alkynyl, alkylidene, alkylidyne, aryl, arylalkyl, arylheteroalkyl, heteroaryl, heteroarylalkyl or heteroaryl-heteroalkyl, as defined herein. Preferred substituents include hydroxy, halogen, CI_$alkyi, Cl_$alkanyloxy, fluorinated alkanyloxy, fluorinated alkyl, CI_$alkylthio, C3_$cycloalkyl, C3_8cycloalkanyloxy, nitro, amino, CI_$alkylamino, Cl_$dialkylamino, C3_$cycloalkylamino, cyano, carboxy, Cl_7alkanyloxycarbonyl, CI_7alkylcarbonyloxy, formyl, carbamoyl, phenyl, aroyl, carbamoyl, amidino, (C1_8alkylamino)carbonyl, (arylamino)carbonyl and aryl(C1_8alkyl)carbonyl.
With reference to substituents, the term "independentiy" means that when more than one of such substituent is possible, such substituents may be the same or different from each other.
Throughout this disclosure, the terminal portion of the designated side chain is described first, followed by the adjacent functionality toward the point of attachment. Thus, for example, a"phenylC1_6alkanylaminocarbonylC1_6alkyP' substituent refers to a group of the formula O
C1_6 alkanyl / \ .
- -Cl_6 alkanyl N/
The present invention is directed, inter alia, to compounds of Formula (I) and compositions comprising a compound of Formula (I):
Y
G
i Rq 1 , / \\
A
N
i Formula (I) wherein:
G is -C(Z)N(Rl)R2, C6_10ary1, or a heterocycle selected from the group consisting of imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, tetrahydropyrimidinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, furyl, indazolyl, indolyl, indolinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, and pyridinyl; wherein aryl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1_$alkanyl, C2_$alkenyl, C2_$alkynyl, C1_8alkanyloxy, hydroxy(C1_8)alkanyl, carboxy(Cl_8)alkanyl, Cl_$alkanylcarbonylamino, halogen, hydroxy, cyano, nitro, oxo, thioxo, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, Cl_$alkanylthio, Cl_$alkanylsulfonyl, Cl_$alkanylsulfonylamino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, C1_8alkanylaminocarbonyl, di(C1_8alkanyl)aminocarbonyl, and C1_6alkanyloxycarbonylamino;
R, is a substituent selected from the group consisting of hydrogen, Cl_$alkanyl, C2_$alkenyl, and C2_$alkynyl;
R2 is a substituent selected from the group consisting of hydrogen;
C1_8alkanyl; C2_$alkenyl; C2_$alkynyl; C6_10aryI; and Cl_$cycloalkanyl; wherein C1_$alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, C1_6alkanyloxy, thioC1_6alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, Cl_$alkanylaminocarbonyl, di(C1_8alkanyl)aminocarbonyl, Cl_6alkanyloxycarbonyl, and aryloxy; and wherein any aryl-containing substituents and Cl_$cycloalkanyl substituents of R2 are optionally substituted with one to three substituents independently selected from the group consisting of Cl_$alkanyl, CZ_$alkenyl, CZ_$alkynyl, C1_$alkanyloxy, trifluoromethyl, trifluoromethoxy, phenyl, halogen, cyano, hydroxy, C1_8alkanylthio, CI_$alkanylsulfonyl, and Cl_$alkanylsulfonylamino;
or R, and R2 taken together with the nitrogen to which they are attached form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of Cl_$alkanyl, hydroxy(CI_$)alkanyl, hydroxy, amino, C1_6alkanylamino, di(Cl_6alkanyl)amino, and halogen;
R3 is a substituent selected from the group consisting of hydrogen, CI_$alkanyl, halo1_3(Cl _$)alkanyl, C2_$alkenyl, C2_$alkynyl, C3_$cycloalkanyl, cycloalkanyl(Cl_$)alkanyl, CI_$alkanyloxy(Cl_$)alkanyl, Cl_$alkanylthio(CI_$)alkanyl, hydroxyC,_$alkanyl, Cl_$alkanyloxycarbonyl, halo1_3(Cl _$)alkanylcarbonyl, formyl, thioformyl, carbamimidoyl, phenylimino(Cl_$)alkanyl, phenyl(CI_$)aikanyl, phenyl(Cl_$)alkenyl, phenyl(Cl_$)alkynyl, naphthyl(CI_$)alkanyl and heteroaryl(Cl_$)alkanyl wherein the heteroaryl is selected from the -group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl, thiazolyl; wherein phenyl, naphthyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of Cl_oalkanyl, C2_6alkenyl, C1_6alkanyloxy, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, C1_6alkanylcarbonyl, C1_6alkanylcarbonyloxy, C1_6alkanylcarbonylamino, C1_6alkanylthio, C1_6alkanylsulfonyl, halogen, hydroxy, cyano, fluoro(C1_6)alkanyl, thioureido, and fluoro(C1_6)alkanyloxy; alternatively, when phenyl and heteroaryl are optionally substituted with alkanyl or alkanyloxy substituents attached to adjacent carbon atoms, the two substituents can together form a fused cyclic alkanyl or cycloheteroalkanyl selected from the group consisting of -(CH2)3_5- ,-O(CH2)2_4- ,-(CH2)2_40 -, and -O(CH2)1_30-;
R4 is one to three substituents independently selected from the group consisting of hydrogen; C1_6alkanyl; C2_6alkenyl; C2_6alkynyl;
aryl(C2_6)alkynyl; C1_6alkanyloxy; amino; C1_6alkanylamino;
di(C1_6alkanyl)amino; C6_10arylamino wherein C6_loaryl is optionally substituted with one to three substitutents independently selected from the group consisting of C1_6alkanyl, CI_6alkoxy, halogen, and hydroxyl; formylamino; pyridinylamino; C1_6alkanylcarbonyl;
C1_6alkanylcarbonyloxy; C1_6alkanyloxycarbonyl; aminocarbonyl;
C1_6alkanylaminocarbonyl; di(C1_6alkanyl)aminocarbonyl;
C1_6alkanylcarbonylamino; C1_6alkanylthio; C1_6alkanylsulfonyl;
halogen; hydroxy; cyano; hydroxycarbonyl; C6_1oaryl; chromanyl;
chromenyl; furanyl; imidazolyl; indazolyl; indolyl; indolinyl;
isoindolinyl; isoquinolinyl; isothiazolyl; isoxazolyl; naphthyridinyl;
oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl; pyridinyl; pyrimidinyl;
pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl; quinoxalinyl;
tetrazolyl; thiazolyl; thienyl; fluoroalkanyl and fluoroalkanyloxy; or optionally, when R4 is two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the fused moiety is -(CH2)3_5-, -O(CH2)2_4- , -(CH2)2_40-, -O(CH2)1_30-, or -S-C(NH2)=N-;
R5 is one to two substituents independently selected from the group consisting of hydrogen, C1_6alkanyl, C2_6alkenyl, C1_6alkanyloxy, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, C1_6alkanylcarbonyl, C1_6alkanylcarbonyloxy, Cl_6alkanyloxycarbonyl, C1_6alkanylaminocarbonyl, C1_6alkanylcarbonylamino, C1_6alkanylthio, C1_6alkanylsulfonyl, halogen, hydroxy, cyano, fluoro(C1_6)alkanyl and fluoro(Cl_ 6)alkanyloxy;
A is -(CH2)m , wherein m is 2 or 3;
YisOorS;
Z is 0, S, NH, N(C1_6alkanyl), N(OH), N(OC1_6alkanyl), or N(phenyl);
and enantiomers, diastereomers, tautomers, solvates, or pharmaceutically acceptable salts thereof.
An embodiment of the present invention is directed to a compound of Formula (I) wherein the structure is numbered as defined herein and the substituents are as defined herein.
a' y (3~ G
R al N R5 A
N
i Formula (I) The present invention is directed, inter alia, to analgesic and anti-pyretic uses of compositions comprising a compound of Formula (I):
Y
G
i R4 , \\
CA
N
Formula (I) wherein:
G is -C(Z)N(Rl)R2, C6_10aryl, or a heterocycle selected from the group consisting of: imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, tetrahydropyrimidinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, furyl, indazolyl, indolyl, indolinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, and pyridinyl; wherein aryl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of CI_$alkanyl, C2_$alkenyl, C2_$alkynyl, Cl_$alkanyloxy, hydroxy(CI_$)alkanyl, carboxy(CI_$)alkanyl, Cl_$alkanylcarbonylamino, halogen, hydroxy, cyano, nitro, oxo, thioxo, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, CI_$alkanylthio, Cl_$alkanylsulfonyl, CI_$alkanylsulfonylamino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, CI_$alkanylaminocarbonyl, di(CI_$alkanyl)aminocarbonyl, and Cl_6alkanyloxycarbonylamino;
R, is a substituent selected from the group consisting of hydrogen, CI_$alkanyl, C2_$alkenyl, and C2_8alkynyl;
R2 is a substituent selected from the group consisting of hydrogen;
CI_$alkanyl; C2_$alkenyl; C2_$aikynyl; C6_1oaryl; and C1_8cycloalkanyl; wherein Cl_$alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C1_6alkanylamino, di(CI_6alkanyl)amino, C1_6alkanyloxy, thioC1_6alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, CI_$alkanylaminocarbonyl, di(CI_$alkanyl)aminocarbonyl, C1_6alkanyloxycarbonyl, and aryloxy; and wherein any aryl-containing substituents and Cl_$cycloalkanyl substituents of R2 are optionally substituted with one to three substituents independently selected from the group consisting of Cl_$alkanyl, C2_$alkenyl, C2_$alkynyl, Cl_$alkanyloxy, trifluoromethyl, trifluoromethoxy, phenyl, halogen, cyano, hydroxy, C1_8alkanylthio, CI_$alkanylsulfonyl, and C1_8alkanylsulfonylamino;
or R, and R2 taken together with the nitrogen to which they are attached form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of CI_$alkanyl, hydroxy(CI_$)alkanyl, hydroxy, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, and halogen;
R3 is a substituent selected from the group consisting of hydrogen, Cl_$alkanyl, halo1_3(Cj_$)aikanyl, C2_8alkenyl, C2_$alkynyl, C3_$cycloalkanyl, cycloalkanyl(Cl_$)alkanyl, CI_$alkanyloxy(C~_$)alkanyl, CI_$alkanylthio(CI_$)alkanyl, hydroxyC,_$alkanyl, C1_8alkanyloxycarbonyl, halo1_3(CI_$)alkanylcarbonyl, formyl, thioformyl, carbamimidoyl, phenylimino(C1_8)alkanyl, phenyl(CI_8)alkanyl, phenyl(Cl_$)alkenyl, phenyl(Cl_$)alkynyl, naphthyl(CI_$)alkanyl and heteroaryl(Cl_$)alkanyl wherein the heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl, thiazoiyl; wherein phenyl, naphthyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyl, C2-6alkenyl, C1-6alkanyloxy, amino, Cl-6alkanylamino, di(Cl_6alkanyl)amino, C1-6alkanylcarbonyl, C1-6alkanylcarbonyloxy, C1-6alkanylcarbonylamino, C1-6alkanylthio, C1-6alkanylsulfonyl, halogen, hydroxy, cyano, fluoro(C1-6)alkanyl, thioureido, and fluoro(C1-6)alkanyloxy; alternatively, when phenyl and heteroaryl are optionally substituted with alkanyl or alkanioxy substituents attached to adjacent carbon atoms, the two substituents can together form a fused cyclic alkanyl or cycloheteroalkanyl selected from the group consisting of -(CH2)3-5- ,-O(CH2)2-4- ,-(CH2)2-40 -, and -O(CH2)1-30-;
R4 is one to three substituents independently selected from the group consisting of hydrogen; C1-6alkanyl; C2-6alkenyl; C2-6alkynyl;
aryl(C2-6)alkynyl; C1-6alkanyloxy; amino; C1-6alkanylamino;
di(C1-6alkanyl)amino; C6-loarylamino wherein C6-loaryl is optionally substituted with one to three substitutents independently selected from the group consisting of C1-6alkanyl, C1-6alkoxy, halogen, and hydroxy; formylamino; pyridinylamino; C1-6alkanylcarbonyl;
C1-6alkanylcarbonyloxy; C1-6alkanyloxycarbonyl; aminocarbonyl;
C1-6alkanylaminocarbonyl; di(C1-6alkanyl)aminocarbonyl;
C1-6alkanylcarbonylamino; C1-6alkanylthio; C1-6alkanylsulfonyl;
halogen; hydroxy; cyano; hydroxycarbonyl; C6-1oaryl; chromanyl;
chromenyl; furanyl; imidazolyl; indazolyl; indolyl; indolinyl;
isoindolinyl; isoquinolinyl; isothiazolyl; isoxazolyl; naphthyridinyl;
oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl; pyridinyl; pyrimidinyl;
pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl; quinoxalinyl;
tetrazolyl; thiazolyl; thienyl; fluoroalkanyl and fluoroalkanyloxy; or optionally; when R4 is two substituents attached to adjacent carbon atoms; the two substituents together form a single fused moiety; wherein the fused moiety is -(CH2)3_5- ,-O(CH2)2_4- , -(CH2)2_40-, -O(CH2)1_30-, or -S-C(NH2)=N-;
R5 is one to two substituents independently selected from the group consisting of hydrogen, C1_6alkanyl, C2_6alkenyl, C1_6alkanyloxy, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, C1_6alkanylcarbonyl, C1_6alkanylcarbonyloxy, C1_6alkanyloxycarbonyl, C1_6alkanylaminocarbonyl, C1_6alkanylcarbonylamino, C1_6alkanylthio, C1_6alkanylsulfonyl, halogen, hydroxy, cyano, fluoro(C1_6)alkanyl and fluoro(Cl_ 6)alkanyloxy;
A is -(CH2)m , wherein m is 2 or 3;
YisOorS;
Z is 0, S, NH, N(C1_6alkanyl), N(OH), N(OC1_6alkanyl), or N(phenyl);
and enantiomers, diastereomers, tautomers, solvates, or pharmaceutically acceptable salts thereof.
Embodiments of the present invention include compounds of Formula (I) wherein, preferably:
a) G is -C(Z)N(R,)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, tetrahydropyrimidinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, isothiazolyl, isoxazolyl, oxazolyi, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1_$alkanyl, C1_8alkanyloxy, hydroxy(CI_$)alkanyl, carboxy(Cl_$)alkanyl, Cl_$alkanylcarbonylamino, halogen, hydroxy, cyano, oxo, thioxo, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, Cl_$alkanylthio, aminocarbonyl, aminothiocarbonyl, CI_$alkanylaminocarbonyl, di(CI_$alkanyl)aminocarbonyl, and C1_6alkanyloxycarbonylamino;
b) G is -C(Z)N(Rj)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G (described herein) are optionally substituted with, one to three substituents independently selected from the group consisting of C1_4alkanyl, C1_4alkanyloxy, hydroxy(Cl_4)alkanyl, carboxy(C1_4)alkanyl, CI_4alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, Cl_$alkanylthio, aminocarbonyl, aminothiocarbonyl, CI_$alkanylaminocarbonyl, and di(C1_8alkanyl)aminocarbonyl;
c) G is -C(Z)N(Rj)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, thienyl, isothiazolyl, isoxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G (described herein) are optionally substituted with one to three substituents independently selected from the group consisting of C1_4alkanyl, C1_4alkanyloxy, hydroxy(C1_4)alkanyl, Cl_4alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, and aminocarbonyl;
d) R, is a substituent selected from the group consisting of hydrogen and C1_4alkanyl;
e) R, is selected from the group consisting of hydrogen, methyl, ethyl, and propyl;
f) R, is selected from the group consisting of hydrogen, methyl, or ethyl;
g) R2 is selected from the group consisting of hydrogen; C1_4alkanyl; phenyl;
and C1_6cycloalkanyl; wherein C1_4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, C1_4alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, CI_$alkanylaminocarbonyl, di(Cl_$alkanyl)aminocarbonyl, and phenoxy;
and wherein any phenyl-containing substituents and C1_6cycloalkanyl substituents of R2 are optionally substituted with one to three substituents independently selected from the group consisting of Cl_$alkanyl, CI_$alkanyloxy, trifluoromethyl, phenyl, fluoro, hydroxy, C1_8alkanylthio, Cl_$alkanylsulfonyl, and Cl_$alkanylsulfonylamino; or R, and R2 taken together with the nitrogen to which they are attached form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of Cl_ 4alkanyl, hydroxy(Cl_4)alkanyl, hydroxy, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, and fluoro;
h) R2 is selected from the group consisting of hydrogen, C1_4alkanyl, phenyl, and C1_6cycloalkanyl, wherein C1_4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1_4alkanyloxy, hydroxy, fluoro, aminocarbonyl, Cl_$alkanylaminocarbonyl, di(Cl_$alkanyl)aminocarbonyl, and phenoxy;
and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1_6alkanyl, C1_6alkanyloxy, fluoro, hydroxy, and C1_6alkanylthio; or R, and R2 taken together with the nitrogen to which they are attached form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of C14alkanyl and hydroxy;
i) R2 is selected from the group consisting of hydrogen, C1_4alkanyl and phenyl, wherein C1_4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1_4alkanyloxy, hydroxy, fluoro, and phenoxy; and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1_6alkanyl, C1_6alkanyloxy, fluoro, and hydroxy; or R, and R2taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from the group consisting of Cl-3alkanyl and hydroxy;
j) R3 is selected from the group consisting of hydrogen, Cl-$alkanyl, C2-$alkenyl, C2-$alkynyl, Cl-$alkanyloxy(Cl-$)alkanyl, Cl-$alkanylthio(CI-$)alkanyl, hydroxyC,-$alkanyl, thioformyl, phenylimino(C1-8)alkanyl, phenyl(Cl-$)alkanyl, and heteroaryl(CI-$)alkanyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indolyl, indolinyl, isoquinolinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein phenyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyloxy and hydroxy; or optionally, when phenyl and heteroaryl are optionally substituted with two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the moiety is selected from -O(CH2)1-30-;
k) R3 is selected from the group consisting of hydrogen, methyl, allyl, 2-methyl-allyl, propynyl, hydroxyethyl, methylthioethyl, methoxyethyl, thioformyl, phenyliminomethyl, phenethyl, and heteroaryl(Cl_8)alkanyl wherein the heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein the phenyl in any phenyl-containing substituent is optionally substituted with one hydroxyl group;
I) R3 is hydrogen, methyl, allyl, or heteroarylmethyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, and thienyl;
m) R4 is one to three substituents independently selected from the group consisting of hydrogen; CI-6alkanyl; CI-6alkanyloxy; C6_1oarylamino wherein C6-1oaryl is optionally substituted with one to three substitutents independently selected from the group consisting of C1-6alkanyl;
C1_6alkoxy, halogen, and hydroxy; formylamino; pyridinylamino;
aminocarbonyl; C1_6alkanylaminocarbonyl; C1_6alkanylcarbonylamino;
halogen; hydroxy; C6_1oaryl; chromanyl; chromenyl; furanyl; imidazolyl;
indazolyl; indolyl; indolinyl; isoindolinyl; isoquinolinyl; isothiazolyl;
isoxazolyl; naphthyridinyl; oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl;
pyridinyl; pyrimidinyl; pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl;
quinoxalinyl; tetrazolyl; thiazolyl; and thienyl;
n) R4 is one to two substituents independently selected from the group consisting of hydrogen, C1_4alkanyl, C1_4alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, and hyd roxy;
o) R4 is one to two substituents independently selected from the group consisting of hydrogen, methyl, methoxy, bromo, fluoro, a'- or (3'- phenyl, a'- or R'- pyridinyl, a'- or (3'- furanyl, and hydroxy;
p) R5 is one to two substituents independently selected from the group consisting of hydrogen and halogen;
q) R5 is hydrogen;
r) A is -(CH2)2_3-;
s) A is -(CH2)2-;
t) YisOorS;
u) Z is 0, NH, N(C1_6alkanyl), N(OH), N(OC1_6alkanyl), or N(phenyl);
v) Z is 0, NH, or N(OH);
w) ZisOorNH;
aa) G is -C(Z)N(R,)R2, phenyl, or a heterocycle selected from the group consisting of tetrazolyl, oxadizolyl, furyl, quinolinyl, thienyl, and pyridinyl;
wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of Cl_$alkanyl, CI_$alkanyloxy, hydroxy(Cl_$)alkanyl, carboxy(CI_$)alkanyl, Cl_$alkanylcarbonylamino, halogen, hydroxy, cyano, oxo, thioxo, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, C1_8alkanylthio, aminocarbonyl, aminothiocarbonyl, Cl_$alkanylaminocarbonyl, di(Cl_$alkanyl)aminocarbonyl, and C1_6alkanyloxycarbonylamino;
bb) G is -C(Z)N(R,)R2, phenyl, or a heterocycle selected from the group consisting of tetrazolyl, oxadizolyl, furyl, quinolinyl, thienyl, and pyridinyl;
wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1_4alkanyl, C1_4alkanyloxy, hydroxy(C1_4)alkanyl, Cl_4alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, and aminocarbonyl;
cc) G is -C(Z)N(R,)R2; tetrazolyl; pyridinyl; oxadiazolyl optionally substituted with oxo; or phenyl optionally substituted with (Cl_$)alkanylcarbonylamino;
dd) G is-C(Z)N(Rj)R2, 1 H-tetrazol-4-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 2-methylcarbonylaminophenyl, pyridin-3-yl or pyridin-4-yl;
dd) R2 is selected from the group consisting of hydrogen and C1_4alkanyl;
wherein C1_4alkanyl is optionally substituted with phenyl; or R, and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl wherein said pyrrolidinyl is optionally substituted with hydroxy;
ee) R2 is selected from the group consisting of hydrogen, methyl, ethyl, and phenethyl; or R, and R2 taken together with the nitrogen to which they are attached form pyrrolidin-1 -yl, 3-hydoxypyrrolidin-1 -yl or 3-(S)-hydoxypyrrolidin-1-yl;
ff) R3 is selected from the group consisting of hydrogen, Cl_$alkanyl, C2_$alkenyl, C2_$alkynyl, Cl_$alkanyloxy(Cl_$)alkanyl, C1_8alkanylthio(CI_$)alkanyl, hydroxyC,_$alkanyl, thioformyl, phenylimino(Cl_$)alkanyl, phenyl(CI_$)alkanyl, and heteroaryl(CI_$)alkanyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyi, furanyl, pyridinyl, thienyl, indolyl, indolinyl, isoquinolinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, thiazolyl, isoquinolinyl, tetrazolyl; wherein phenyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyloxy and hydroxy; or optionally, when phenyl and heteroaryl are optionally substituted with two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the moiety is selected from -O(CH2)1-30-;
gg) R3 is selected from the group consisting of hydrogen, methyl, methylbutenyl, propenyl, benzyl, phenethyl, and heteroaryl(C1-$)alkanyl wherein the heteroaryl is selected from the group consisting of imidazolyl, furanyl, pyridinyl, thienyl, and thiazolyl;
hh) R3 is selected from the group consisting of hydrogen, methyl, 3-methyl-2-butenyl, 2-propenyl, benzyl, 2-phenethyl, pyridin-2-ylmethyl, fur-3-ylmethyl, thiophene-2-ylmethyl, 1 H-imidazol-2-ylmethyl, and thiazol-2-ylmethyl;
ii) R4 is one to two substituents independently selected from the group consisting of hydrogen, methyl, phenyl, bromo, fluoro, aminocarbonyl, chloro and hydroxy;
jj) R4 is one to two substituents independently selected from the group consisting of hydrogen, a'-hydroxy and a'-methoxy;
kk) R4 is unsubstituted or substituted at the a' position;
II) R4 is hydrogen and Y is 0;
mm) R4 is a'-hydroxy and Y is 0;
nn) R4 is hydrogen and Y is S;
oo) R4 is a'-hydroxy and Y is S;
and combinations of a) through oo) above.
One embodiment of the present invention is a compound of Formula (I) wherein:
G is -C(Z)N(R1)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyi, oxathiadiazolyl, imidazolinyl, tetrahydropyrimidinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of CI_$alkanyl, CI_$alkanyloxy, hydroxy(CI_$)alkanyl, carboxy(C1_8)alkanyl, Cl_8alkanylcarbonylamino, halogen, hydroxy, cyano, oxo, thioxo, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, Cl_$alkanylthio, aminocarbonyl, aminothiocarbonyl, Cl_$alkanylaminocarbonyl, di(Cl_$alkanyl)aminocarbonyl, and C1_6alkanyloxycarbonylamino;
R, is hydrogen or C1_4alkanyl;
R2 is selected from the group consisting of hydrogen; C1_4alkanyl; phenyl;
and Cl_6cycloalkanyl; wherein C1_4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, C1_4alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, Cl_$alkanylaminocarbonyl, di(C1_8alkanyl)aminocarbonyl, and phenoxy;
and wherein the phenyl and C1_6cycloalkanyl substituents of R2 are optionally substituted with one to three substituents independently selected from the group consisting of Cl_$alkanyl, Cl_$alkanyloxy, trifluoromethyl, phenyl, fluoro, hydroxy, Cl_$alkanylthio, Cl_$alkanylsulfonyl, and Cl_$alkanylsulfonylamino; or R, and R2 taken together with the nitrogen to which they are attached form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of Cl_ 4alkanyl, hydroxy(C1_4)alkanyl, hydroxy, amino, Cl_6alkanylamino, di(C1_6alkanyl)amino, and fluoro;
R3 is selected from the group consisting of hydrogen, Cl_$alkanyl, C2_8alkenyl, C2_$alkynyl, C1_$alkanyloxy(Cj_$)alkanyl, CI_$alkanylthio(CI_$)alkanyl, hydroxyC,_$alkanyl, thioformyl, phenylimino(C1_8)alkanyl, phenyl(Cl_$)aikanyl, and heteroaryl(Cl_8)alkanyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indolyl, indolinyl, isoquinolinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein phenyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyloxy and hydroxy; or optionally, when phenyl and heteroaryl are optionally substituted with two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the moiety is selected from -O(CH2)1-30-1 R4 is one to three substituents independently selected from the group consisting of hydrogen; C1-6alkanyl; C1-6alkanyloxy; C6-1oarylamino wherein C6-1oaryl is optionally substituted with one to three substitutents independently selected from the group consisting of C1-6alkanyl;
C1-6alkoxy, halogen, and hydroxy; formylamino; pyridinylamino;
aminocarbonyl; C1_6alkanylaminocarbonyl; C1-6alkanylcarbonylamino;
halogen; hydroxy; C6-1oaryl; chromanyl; chromenyl; furanyl; imidazolyl;
indazolyl; indolyl; indolinyl; isoindolinyl; isoquinolinyl; isothiazolyl;
isoxazolyl; naphthyridinyl; oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl;
pyridinyl; pyrimidinyl; pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl;
quinoxalinyl; tetrazolyl; thiazolyl; and thienyl;
R5 is one to two substituents independently selected from the group consisting of hydrogen and halogen;
A is CH2CH2;
YisOorS;
Z is 0, NH, N(C1-6alkanyl), N(OH), N(OC1-6alkanyl), or N(phenyl); and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
Another embodiment of the present invention is a compound of Formula (I) wherein:
G is -C(Z)N(R1)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G (described herein) are optionally substituted with one to three substituents independently selected from the group consisting of C1_4alkanyl, C1_4alkanyloxy, hydroxy(C1_4)alkanyl, carboxy(C1_4)alkanyl, CI_4alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, Cl_galkanylthlo, aminocarbonyl, aminothiocarbonyl, Cl_$alkanylaminocarbonyl, and d i(Cl_$alkanyl)aminocarbonyl;
R, is selected from the group consisting of hydrogen, methyl, ethyl, and propyl;
R2 is selected from the group consisting of hydrogen, C1_4alkanyl, phenyl, and C1_6cycloalkanyl; wherein C1_4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1_4alkanyloxy, hydroxy, fluoro, aminocarbonyl, CI_8alkanylaminocarbonyl, di(C1_8alkanyl)aminocarbonyl, and phenoxy;
and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1_6alkanyl, C1_6afkanyloxy, fluoro, hydroxy, and C1_6alkanylthio; or R, and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrroiidinyl or piperidinyl is optionally substituted with a substituent selected from the group consisting of C1_3alkanyl and hydroxy;
R3 is selected from the group consisting of hydrogen, methyl, allyl, 2-methyl-allyl, propynyl, hydroxyethyl, methylthioethyl, methoxyethyl, thioformyl, phenyliminomethyl, phenethyl, and heteroaryl(Cl_8)alkanyl wherein the heteroaryl is seiected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl wherein the phenyl in any phenyl-containing substituent is optionally substituted with one hydroxyl group;
R4 is one to two substituents independently selected from the group consisting of hydrogen, C1_4alkanyl, C1_4alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, and hydroxy;
R5 is hydrogen;
A is CH2CH2;
YisOorS;
Z is 0, NH, or N(OH); and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
Another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein:
G is selected from -C(Z)N(R,)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, thienyl, isothiazolyl, isoxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1_4alkanyl, C1_4alkanyloxy, hydroxy(C1_4)alkanyl, C1_4alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, and aminocarbonyl;
R, is hydrogen, methyl, or ethyl;
R2 is independently selected from the group consisting of hydrogen, CI-4alkanyl and phenyl; wherein CI-4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1_4alkanyloxy, hydroxy, fluoro, and phenoxy; and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1_6alkanyl, C1_6alkanyloxy, fluoro, and hydroxy; or R, and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl are optionally substituted with a substituent selected from the group consisting of CI_3alkanyl and hydroxy;
R3 is hydrogen, methyl, allyl, or heteroarylmethyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxoiyl, imidazolyl, furanyl, pyridinyl, and thienyl;
R4 is one to two substituents independently selected from the group consisting of hydrogen, CI-4aikanyl, C1_4alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazoiyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyi, thienyl, and hyd roxy;
A is CH2CH2;
YisOorS;
Z is 0 or NH; and enantiomers, diasteromers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
Another embodiment of the present invention is directed to compounds of Formula (I) wherein:
G is -C(Z)N(R,)R2, phenyl, or a heterocycle selected from the group consisting of tetrazolyl, oxadiazolyl, furyl, quinolinyl, thienyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of Cl_$alkanyl, C1_8alkanyloxy, hydroxy(CI_$)aikanyl, carboxy(Cl_$)alkanyl, Cl_$alkanylcarbonylamino, halogen, hydroxy, cyano, oxo, thioxo, amino, Cl_6alkanylamino, di(C1_6alkanyl)amino, Cl_salkanylthio, aminocarbonyl, aminothiocarbonyl, CI_$alkanylaminocarbonyl, di(C1_8alkanyl)aminocarbonyl, and C1_6alkanyloxycarbonylamino;
R, is C1_4 alkanyl, or hydrogen;
R2 is hydrogen or C1_4 alkanyl optionally substituted with phenyl;
or R, and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl ring optionally substituted with hydroxy;
Z is NH or oxygen;
R3 is pyridinyl(Cl_$)aikanyl, furyl(CI_$)alkanyl, CI_$ alkanyl, hydrogen, C2_8 alkenyl, thienyl(CI_$)alkanyl, imidazolyl(Cl_$)alkanyl, phenyl(C1_8)alkanyl, or thiazolyl(Cl_$)aikanyl;
R4 is hydrogen, C1_6 alkanyl, C1_6 alkanyloxy, hydroxy, halogen, aminocarbonyl, or phenyl;
R5 is hydrogen;
A is CH2CH2;
YisOorS;
Z is 0 or NH; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
Another embodiment of the present invention is directed to compounds of Formula (I) wherein:
G is -C(Z)N(R,)R2; tetrazolyl, oxadiazolyl optionally substituted with oxo;
phenyl optionally substituted with (Cl_$)aikanylcarbonylamino; or pyridinyl;
R, is C1_4 alkanyl, or hydrogen;
R2 is hydrogen or C1_4 alkanyl optionally substituted with phenyl;
or R, and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl ring optionally substituted with hydroxy;
Z is NH or oxygen;
R3 is pyridinyl(CI_$)aikanyl, furyl(Cl_$)alkanyl, Cl_$ alkanyl, hydrogen, C2_$
alkenyl, thienyl(Cl_$)aikanyl, imidazolyl(C1_8)alkanyl, phenyl(Cl_$)alkanyl, or thiazolyl(CI_$)alkanyl;
R4 is hydrogen, a'-hydroxy, or a'-methoxy;
R5 is hydrogen;
A is CH2CH2;
YisOorS;
Z is 0 or NH; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
Another embodiment of the present invention is directed to compounds of Formula (I) wherein:
G is -C(Z)N(RI)R2, 1 H-tetrazol-4-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 2-methylcarbonylaminophenyl, 3-furyl, quinolin-3-yl, thiophen-3-yl, pyridin-3-yl or pyridin-4-yl, R, is hydrogen, ethyl, or methyl, R2 is methyl, ethyl, phenethyl, or hydrogen;
or R, and R2 taken together with the nitrogen to which they are attached form pyrrolidin-1-yl, 3-hydroxypyrrolidin-1-yl, or 3-(S)-hydroxypyrrolidin-1-yl;
Z is NH or oxygen, R3 is pyridin-2-ylmethyl, fur-3-ylmethyl, methyl, hydrogen, 3-methyl-2-butenyl, thiophene-2-ylmethyl, 2-propenyl, 1 H-imidazol-2-ylmethyl, 2-phenethyl, thiazol-2-ylmethyl, benzyl, or allyl;
R4 is hydrogen, a'-methyl, a'-phenyl, R"-bromo, [i"-fluoro, a'-aminocarbonyl, a'-chloro, a'-methoxy; or a'-hydroxy;
R5 is hydrogen;
A is CH2CH2;
Yis0orS;.
Z is 0 or NH; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof Another embodiment of the present invention is directed to compounds of Formula (I) wherein:
G is -C(Z)N(R,)R2, 1 H-tetrazol-4-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 2-methylcarbonylaminophenyl, pyridin-3-yl or pyridin-4-yl;
R, is hydrogen, ethyl, or methyl;
R2 is methyl, ethyl, phenethyl, or hydrogen;
or R, and R2 taken together with the nitrogen to which they are attached form pyrrolidin-1-yl, 3-hydroxypyrrolidin-1-yl, or 3-(S)-hydroxypyrrolidin-1-yl;
Z is NH or oxygen;
R3 is pyridin-2-ylmethyl, fur-3-ylmethyl, methyl, hydrogen, 3-methyl-2-butenyl, thiophene-2-ylmethyl, 2-propenyl, 1 H-imidazol-2-ylmethyl, 2-phenethyl, thiazol-2-ylmethyl, or benzyl;
R4 is hydrogen, a'-hydroxy, or a'-methoxy;
R5 is hydrogen;
A is CH2CH2;
YisOorS;
Z is 0 or NH; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
In certain embodiments of Formula (I) when R, and R2 are taken together with the nitrogen to which they are attached to form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of Cl_$alkanyl, hydroxy(Cl-$)alkanyl, hydroxy, amino, C1_6alkanylamino, di(C1_6alkanyl)amino, and halogen;
Z is oxygen.
In certain embodiments of Formula (I) when R, and R2 are taken together with the nitrogen to which they are attached to form a pyrrolidinyl ring optionally substituted with hydroxy, Z is oxygen.
Another embodiment of the present invention is a compound of Formula~(I) wherein:
G is selected from -C(Z)N(R,)R2, 2-methyicarbonylaminophenyl, 2-aminocarbonyl-phenyl, 1 /--/-tetrazol-4-yl, 2-methyl-tetrazol-5-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 4H-[1,2,4]-oxadiazol-5-thioxo-3-yl, 4H-[1,2,4]thiadiazol-5-oxo-3-yl, [1,2,3,5]oxathiadiazol-2-oxo-4-yl, or pyridin-3-yl;
R, is hydrogen, methyl, or ethyl;
R2 is selected from the group consisting of hydrogen, C1_4alkanyl and phenyl; wherein C1_4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1_4alkanyloxy, hydroxy, fluoro, and phenoxy; and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1_6alkanyl, C1_6alkanyloxy, fluoro, and hydroxy;
or R, and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring;
R3 is selected from the group consisting of hydrogen, C1_8alkanyl, C2_$alkenyl, C2_$alkynyl, CI_$alkanyloxy(CI_$)alkanyl, CI_$alkanylthio(CI_$)alkanyl, hydroxyCi_$alkanyl, thioformyl, phenylimino(Cl_$)aikanyl, phenyl(C1_8)aikanyl, and heteroaryl(Cl_$)alkanyl wherein heteroaryl is selected from the group consisting of hydrogen, methyl, allyl, or heteroaryimethyl; wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxoiyl, imidazolyl, furanyl, pyridinyl, and thienyl; wherein phenyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C1_6alkanyloxy and hydroxy; or optionally, when phenyl and heteroaryl are optionally substituted with two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety;
wherein the moiety is selected from -O(CH2)1_30-;
R4 is one to three substituents independently selected from the group consisting of hydrogen, C1_4alkanyl, C1_4alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, and hydroxy;
R5 is hydrogen;
A is CH2CH2;
YisOorS;
Z is 0 or NH; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
Another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein G is independently selected from -C(Z)N(R,)R2, 2-methylcarbonylaminophenyl, 2-aminocarbonyl-phenyl, 1 H-tetrazol-4-yl, 2-methyl-tetrazol-5-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 4H-[1,2,4]-oxadiazol-5-thioxo-3-yl, 4H-[1,2,4]thiadiazol-5-oxo-3-yl, [1,2,3,5]oxathiadiazol-2-oxo-4-yl, and pyridin-3-yl; R, is hydrogen, methyl, or ethyl; R2 is a substituent selected from the group consisting of hydrogen, C1_4alkanyl and phenyl; wherein C1_4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, CI_4alkanyloxy, hydroxy, and 2,6-dimethyl-phenoxy; and wherein the any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1_6alkanyl, C1_6alkanyloxy, fluoro, and hydroxy; or R, and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from the group consisting of C1_3alkanyl and hydroxy; R3 is a substituent selected from the group consisting of benzo[1,3]dioxol-5-yimethyl, carbamimidoyl, 1-H-imidazol-4-ylmethyl, phenyliminomethyl, 1-prop-2-ynyl, thioformyl, 2-hydroxyphenyl-methyl, hydroxy-ethyl, methoxy-ethyl, 2-methyl-allyl, 2-methyl-but-2-enyl, allyl, furan-3-ylmethyl, H, Me, methylthioethyl, phenethyl, pyridin-2-yl methyl, and thiophen-2-ylmethyl; R4 is one to two substituents independently selected from the group consisting of hydrogen, C1_4alkanyl, C1_4alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, and hydroxy; R5 is H; A is CH2CH2;
Y is OorS;andZisOorNH.
Another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein G is selected from -C(Z)N(R,)R2, 2-methyicarbonylaminophenyl, 2-aminocarbonyl-phenyl, 1 H-tetrazol-4-yl, 2-methyl-tetrazol-5-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 4H-[1,2,4]-oxadiazol-5-thioxo-3-yl, 4H-[1,2,4]thiadiazol-5-oxo-3-yl, [1,2,3,5]oxathiadiazol-2-oxo-4-yl, or pyridin-3-yl; R, is hydrogen, methyl, or ethyl; R2 is a substituent seiected from the group consisting of hydrogen, C14alkanyl and phenyl; wherein C14alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, methoxy, hydroxy, and 2,6-dimethyl-phenoxy; and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1_6alkanyl, C1_6alkanyloxy, fluoro, and hydroxy; or R, and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl are optionally substituted with a substituent selected from the group consisting of C1_3alkanyl and hydroxy; R3 is a substituent selected from the group consisting of benzo[1,3]dioxol-5-yimethyl, carbamimidoyl, 1-H-imidazol-4-yl methyl, phenyliminomethyl, 1-prop-2-ynyl, thioformyl, 2-hydroxyphenyl-methyl, hydroxyethyl, methoxyethyl, allyl, furan-3-yl methyl, H, Me, methylthioethyl, and phenethyl; R4 is one to two substituents independently selected from the group consisting of hydrogen, methyl, methoxy, bromo, fluoro, a'- or [3'-phenyl, a'- or [i'-pyridinyl, a'- or (3'-furanyl, and hydroxy; R5 is H; A is CH2CH2; Y is 0 or S; and Z is 0 or NH.
Another embodiment of the present invention is directed to compositions comprising a compound of Formula (I) wherein G is selected from -C(Z)N(R,)R2, 2-methylcarbonylaminophenyl, 2-aminocarbonyi-phenyl, 1 H-tetrazol-4-yl, 2-methyl-tetrazol-5-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 4H-[1,2,4]-oxadiazol-5-thioxo-3-yl, 4H-[1,2,4]thiadiazol-5-oxo-3-yl, [1,2,3,5]oxathiadiazol-2-oxo-4-yl, or pyridin-3-yl; R, is hydrogen, methyl, or ethyl; R2 is a substituent selected from the group consisting of hydrogen, C1_4alkanyl and phenyl; wherein C1_4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, methoxy, hydroxy, and 2,6-dimethyl-phenoxy; and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1_6alkanyl, C1_6alkanyloxy, fluoro, and hydroxy; alternatively R, and R2 are taken together with the nitrogen to which they are attached to form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl are optionally substituted with a substituent selected from the group consisting of C1_3alkanyl and hydroxy; R3 is a substituent selected from the group consisting of H, benzo[1,3]dioxol-5-ylmethyl, 1-H-imidazol-4-yl methyl, furan-3-yimethyl, pyridin-2-ylmethyl, and phenyliminomethyl; R4 is a substituent independently selected from the group consisting of hydrogen, methyl, methoxy, bromo, fluoro a'- or [3'-phenyl, a'- or (3'-pyridinyl, a'- or (3'-furanyl, and hydroxy; R5 is H; A is CH2CH2; Y is 0 or S; and Z is 0 or NH.
Another embodiment of the present invention is directed to a compound of Formula (I) wherein R4 is preferably substituted at the a'- or (3'-position of Formula (I).
Another embodiment of the present invention is directed to compositions comprising a compound selected from the group consisting of:
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is 1 hl-imidazol-2-yl-methyl; R4 is a'-hydroxy; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is furan-3-yl-methyl; R4 is a'-hydroxy; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is a'-hydroxy; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is a'-methoxy; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is pyridin-2-yl-methyl; R4 is H; R5 is H; Y is 0; A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is furan-3-yl-methyl; R4 is H; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is thien-2-yl-methyl; R4 is H; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is benzyl; R4 is H; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is pyridin-3-yl; R3 is furan-3-yl methyl;
is H; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is furan-2-yl methyl; R4 is H; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is a'-methyl; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N=diethylaminocarbonyl; R3 is H; R4 is a'-phenyl; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is H; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is H; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is [i"-bromo; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is H; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is a'-chloro; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is [i"-fluoro; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is 2-methylcarbonylamino-phenyl; R3 is H; R4 is H; R5 is H; Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is pyrrolidin-1-yl; R3 is H; R4 is H; R5 is H;
Y is 0; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is furan-3-yl-methyl; R4 is H; R5 is H; Y is 0; and A is -CH2CH2-;
Another embodiment of the present invention is directed to compounds and compositions comprising a compound selected from the group consisting of:
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
(3-Hydroxy-pyrrolidin-1-yi)-[10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-methanone;
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid methyl-phenethyl-amide;
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine;
Endo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine;
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl )-10 H-phenoxazine;
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile;
Endo-1 0-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-N, N-d iethyl-10H-phenoxazine-3-carboxamidine;
Endo-N, N-Diethyl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxamid ine;
Endo-N, N-Diethyl-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxamidine;
Endo- 3-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one;
endo-1 0-(8-Aza-bicyclo[3.2. 1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid amide;
Endo-3-[10-(8-Pyrid in-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yI]-4H-[1,2,4]oxadiazol-5-one;
E ndo-3-[10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10 H-phenoxazi n-3-yl]-4H-[1,2,4]oxadiazol-5-one;
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-10H-phenoxazine-3-carboxylic acid diethylamide;
6-Methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10 H-phenoxazine-3-carboxylic acid diethylamide;
6-Hydroxy-l0-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
6-Methoxy-1 0-(8-methyl-8-aza-bicyclo[3.2. 1 ]oct-3-yl)-10 H-phenoxazi ne-3-carboxylic acid diethylamide;
10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine;
N, N-Diethyl-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxamidine;
3-[10-(8-M ethyl-8-aza-bicyclo [3.2.1 ]oct-3-yl )-10 H-phenoxazi n-3-yl]-4H-[1,2,4]oxad iazol-5-one;
10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyrid in-3-yi-10H-phenothiazine;
N-{2-[ 10-( 8- F u ra n-3-yl m eth yl-8-aza-b i cycl o[3.2.1 ]o ct-3-yi )-10 H-p h e n oth i azi n-3-yI]-phenyl}-acetamide;
10-[8-(3-Methyl-but-2-enyl )-8-aza-bicyclo[3.2.1 ]oct-3-yi]-3-pyrid in-3-yI-phenothiazine;
3-Pyridin-3-yI-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine;
10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-3-pyrid in-4-yI-10H-phenothiazine;
3-Pyridin-4-yI-10-(8-pyrid in-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine;
3-Pyrid in-4-yI-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenothiazine;
N-{2-[10-(8-AIIyi-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoth iazi n-3-yl]-phenyl}-acetamide;
N-{2-[10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide;
N-(2-{10-[8-(1 H-I m idazol-2-ylmethyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenothiazin-3-yl}-phenyl)-acetamide;
N-{2-[10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide;
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yI-10H-phenothiazine;
N-{2-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide;
10-(8-AIIyi-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yI-10H-phenothiazine;
Endo-1 0-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyrid in-3-yi-10 H-phenoxazine;
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-3-pyrid i n-3-yI-10H-phenoxazine;
Endo-3-Pyrid in-3-yI-10-(8-pyrid in-2-yl methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-phenoxazine;
Endo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyrid in-3-yI-10H-phenoxazine;
Endo-3-Pyridin-3-yI-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine;
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-chloro-10H-phenoxazine;
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyrid in-4-yI-10 H-phenoxazi ne;
E ndo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl )-3-pyrid i n-4-yI-10 H-phenoxazine;
Endo-3-Pyridin-4-yI-10-(8-pyrid in-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-phenoxazine;
Endo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-4-yI-10H-phenoxazine;
Endo-3-Pyridin-4-yI-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine;
Exo-3-(3-Pyridin-3-yl-phenoxazin-1 O-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester;
Exo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyrid in-3-yI-10H-phenoxazine;
Exo-3-Pyrid i n-3-yI-10-( 8-pyrid i n-2-yl methyl-8-aza-b icyclo [3.2.1 ]oct-3-yl)-10 H-phenoxazine;
Exo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyrid in-3-yI-10H-phenoxazine;
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-ch loro-10 H-phenoxazine;
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyrid in-4-yI-10 H-phenoxazine;
Exo-1 0-(8-Phenethyl-8-aza-bicyclo[3.2. 1 ]oct-3-yl)-3-pyrid in-4-yI-10H-phenoxazine;
Exo-3-Pyridin-4-yI-10-(8-pyrid in-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-phenoxazine;
Exo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-4-yI-10H-phenoxazine;
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine;
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile;
Exo-3-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yi]-4H-[1,2,4]oxadiazol-5-one;
6-Methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile;
6-Hyd roxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10 H-phenoxazine-3-carbonitrile;
[10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-pyrrolidin-1-yl-methanone;
[10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-pyrrolidin-1-yl-methanone;
{10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yi]-10 H-phenoth iazi n-3-yi}-pyrrolidin-1-yl-methanone;
[1 0-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2. 1 ]oct-3-yi)-10H-phenothiazin-3-yi]-(3-hydroxy-pyrrolidin-1-yl)-methanone;
(3-Hydroxy-pyrrolidin-1-yi)-[10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-phenothiazin-3-yl]-methanone;
{10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenothiazin-3-yl}-(3-methyl-pyrrolidin-l-yl)-methanone;
[1 0-(8-Methyl-8-aza-bicyclo[3.2. 1 ]oct-3-yl)-10H-phenothiazin-3-yl]-pyrrolidin-1 -yi-methanone;
(3-Hydroxy-pyrrolidin-1-yl)-[10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenothiazin-3-yl]-metha none;
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carboxylic acid ethylamide;
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
E nd o-10-(8-Pyrid i n-2-yl methyl-8-aza-b icyclo [3.2.1 ]oct-3-yi )-10 H-p henoxazi ne-3-carboxylic acid diethylamide;
Endo-10-(8-Thiazol-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-1 0-(8-Pyridin-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10 H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-[8-(1 H-I m idazol-2-yl methyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10 H-phenoxazine-3-carboxylic acid diethylamide;
Endo-1 0-(8-Benzyl-8-aza-bicyclo[3.2. 1 ]oct-3-yl )-10 H-phenoxazine-3-carboxyl ic acid diethylamide;
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-1 0-(8-Pyridi n-3-yl m ethyl-8-aza-b icyclo [3.2.1 ]o ct-3-yl )-10 H-p h e noxazi ne-3-carboxylic acid diethylamide;
Exo-10-(8-Th iophen-2-ylmethyl-8-aza-bicyclo[3.2.'1 ]oct-3-yl)-10H-phenoxazi ne-3-carboxylic acid diethylamide;
Exo-10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Benzyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10 H-phenoxazine-3-carboxyl ic acid diethylamide;
Exo-1 0-(8-Thiazol-2-ylmethyl-8-aza-bicyclo [3.2.1 ]oct-3-yl)-10 H-phenoxazine-carboxylic acid diethylamide;
Exo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi ne-3-carboxylic acid diethylamide;
Exo-10-[8-(1 H-Imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo- 1 0-(8-Aza-bicyclo [3.2.1 ]oct-3-yl)-7-pyrid in-3-yi-10H-phenoxazin-4-ol;
Endo-7-Pyridin-3-yI-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-phenoxazin-4-ol;
Endo-1 0-(8-Aza-bicyclo[3.2. 1 ]oct-3-yl)-3-ch lo ro-6-methoxy-10 H-phenoxazine;
Endo-1 0-(8-Aza-bicyclo[3.2. 1 ]oct-3-yl)-6-methoxy-3-pyrid in-3-yI-10H-phenoxazine;
Endo-6-Methoxy-3-pyridin-3-yI-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-10H-phenoxazine;
E n d o-10-( 8-Aza- b i cyc l o[3.2 .1 ]o ct-3-yl )-7-pyri d i n-4-yI-10 H-p h e n oxaz i n-4-o I;
Endo-7-Pyridin-4-yI-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-phenoxazin-4-ol;
E ndo-10-(8-Ph enethyl-8-aza-bicyclo [3.2.1 ]oct-3-yl )-7-pyrid i n-4-yI-10 H-phenoxazin- 4-ol;
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-3-pyrid in-4-yI-10H-phenoxazine;
Endo-6-Methoxy-3-pyridin-4-yI-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-10H-phenoxazine;
E ndo-6-Methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyrid in-4-yl-10H-phenoxazine;
Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10 H-phenoxazi n-3-yl]-phenyl}-acetamide;
Endo-N-{2-[10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10 H-phenoxazin-3-yl]-phenyl}-acetamide;
Endo-N-{2-[10-(8-Thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide;
Endo-N-{2-[10-(8-Pyrid in-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10 H-phenoxazin-3-yl]-phenyl}-acetamide;
Exo-N-{2-[10-(8-Aza-bicyclo [3.2.1 ]oct-3-yl)-10 H-phenoxazin-3-yl]-phenyl}-acetamide;
E ndo-N-{2-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-hyd roxy-10H-phenoxazi n-3-yl]-phenyl}-acetamide;
Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-lOH-phenoxazin-3-yl]-phenyl}-acetamide;
10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazo I-5-yl)-10 H-phenothiazine;
10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-phenothiazine;
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenothiazine;
N, N-Diethyl-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10 H-phenothiazi ne-3-carboxamidine;
N, N-Diethyl-1 0-(8-pyridi n-2-yl methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10 H-phenothiazine-3-carboxamidine;
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenothiazine;
N, N-Diethyl-1 0-(8-methyl-8-aza-bicyclo[3.2. 1 ]oct-3-yl)-10 H-p henoth iazine-3-carboxamidine;
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-3-pyrid in-3-y1-10 H-phenoth iazine;
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-7-pyridin-3-yl-10H-phenothiazin-4-ol;
6-Methoxy-1 0-(8-methyl-8-aza-bicyclo[3.2. 1 ]oct-3-yl)-10 H-phenothiazine-3-carboxylic acid diethylamide;
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-10H-phenoth iazi ne-3-carboxyl ic acid diethylamide;
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-hyd roxy-lOH-phenothiazi ne-3-carboxylic acid diethylamide; and enantiomers, diastereomers, tautomers, solvates, or pharmaceutically acceptable salts thereof.
Another embodiment of the present invention is a composition comprising the dextrorotatory enantiomer of a compound of formula (I), wherein said composition is substantially free from the levorotatory isomer of said compound. In the present context, substantially free means less than 25 %, preferably less than 10 %, more preferably less than 5 %, even more preferably less than 2 /a and even more preferably less than 1% of the levorotatory isomer calculated as.
% levorotatory -_ (mass levof otatory) x 100 (mass dextrof=otatoNy) + (mass levorotatory) Another embodiment of the present invention is a composition comprising the levorotatory enantiomer of a compound of formula (I) wherein said composition is substantially free from the dextrorotatory isomer of said compound. In the present context, substantially free from means less than 25 %, preferably less than 10 %, more preferably less than 5 %, even more preferably less than 2 % and even more preferably less than 1% of the dextrorotatory isomer calculated as %dextrorotatog = (mass dextrorotatory) X100 (mass dextj=oYOtator y) + (mass levorotatory) In certain embodiments, the present invention provides the endo isomer of a compound of formula (I) wherein said compound is substantially free from the exo isomer of said compound. In certain embodiments, the present invention provides compositions comprising the endo isomer of a compound of formula (I) wherein said composition is substantially free from the exo isomer of said compound. In the present context, substantially free means less than 25 %, preferably less than 10 %, more preferably less than 5 %, even more preferably less than 2 % and even more preferably less than 1% of the exo isomer.
In certain embodiments, the present invention provides the exo isomer of a compound of formula (I) wherein said compound is substantially free from the endo isomer of said compound. In certain embodiments, the present invention provides compositions comprising the exo isomer of a compound of formula (I) wherein said composition is substantially free from the endo isomer of said compound. In the present context, substantially free means less than 25 %, preferably less than 10 %, more preferably less than 5 %, even more preferably less than 2 % and even more preferably less than 1 /o of the endo isomer.
In other embodiments, compositions of the present invention comprise a mixture of the exo and endo isomers of a compound of formula (I).
The compounds of the present invention may also be present in the form of pharmaceutically acceptable salts. For use in medicine, the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts" (Ref. International J. Pharm., 1986, 33, 201-217; J. Pharm.Sci., 1997 (Jan), 66, 1, 1). Other salts well known to those in the art may, however, be useful in the preparation of compounds according to this invention or of their pharmaceutically acceptable salts. Representative organic or inorganic acids include, but are not limited to, hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic acid. Representative organic or inorganic bases include, but are not limited to, basic or cationic salts such as benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium and zinc.
The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds that are readily convertible in vivo into the required compound. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.
Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention.
In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.
Where the processes for the preparation of the compounds according to the invention give rise to mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography.
The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-I-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.
During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
Even though the compounds of the present invention (including their pharmaceutically, acceptable salts and pharmaceutically acceptable solvates) can be administered alone, they will generally be administered in admixture with a pharmaceutical carrier, excipient or diluent selected with regard to the intended route of administration and standard pharmaceutical or veterinary practice. Thus, the present invention is directed to pharmaceutical and veterinary compositions comprising compounds of Formula (I) and one or more pharmaceutically acceptable carriers, excipients or diluents.
By way of example, in the pharmaceutical and veterinary compositions of the present invention, the compounds of the present invention may be admixed with any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), and/or solubilising agent(s).
Tablets or capsules of the compounds may be administered singly or two or more at a time, as appropriate. It is also possible to administer the compounds in sustained release formulations.
Alternatively, the compounds of the general Formula (I) can be administered by inhalation or in the form of a suppository or pessary, or they may be applied, topically in the form of a lotion, solution, cream, ointment or dusting powder. An alternative means of transdermal administration is by use of a skin patch. For example, they can be incorporated into a cream consisting of an aqueous emulsion of polyethylene glycols or liquid paraffin. They can also be incorporated, at a concentration of between 1 and 10% by weight, into an ointment consisting of a white wax or white soft paraffin base together with such stabilizers and preservatives as may be required.
For some applications, preferably the compositions are administered orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavoring or coloring agents.
The compositions (as well as the compounds alone) can also be injected parenterally, for example intracavernosally, intravenously, intramuscularly or subcutaneously. In this case, the compositions will comprise a suitable carrier or diluent.
For parenteral administration, the compositions are best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood.
For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.
By way of further example, pharmaceutical and veterinary compositions containing one or more of the compounds of the invention described herein as the active ingredient can be prepared by intimately mixing the compound or compounds with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending upon the desired route of administration (e.g., oral, parenteral). Thus for liquid oral preparations such as suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, stabilizers,. coloring agents and the like;
for solid oral preparations, such as powders, capsules and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Solid oral preparations may also be coated with substances such as sugars or be enteric-coated so as to modulate the major site of absorption. For parenteral administration, the carrier will usually consist of sterile water and other ingredients may be added to increase solubility or preservation. Injectable suspensions or solutions may also be prepared utilizing aqueous carriers along with appropriate additives.
Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those skilled in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
It is also apparent to one skilled in the art that the therapeutically effective dose for active compounds of the invention or a pharmaceutical composition thereof will vary according to the desired effect. Therefore, optimal dosages to be administered may be readily determined and will vary with the particular compound used, the mode of administration, the strength of the preparation, and the advancement of the disease condition. In addition, factors associated with the particular subject being treated, including subject age, weight, diet and time of administration, will result in the need to adjust the dose to an appropriate therapeutic level. The above dosages are thus exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
Compounds of this invention may be administered in any of the foregoing compositions and dosage regimens or by means of those compositions and dosage regimens established in the art whenever use of the compounds of the invention as analgesics is required for a subject in need thereof.
The invention also provides a pharmaceutical or veterinary pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical and veterinary compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
The compounds of the present invention may be used to treat mild to severe pain in warm-blooded animals such as humans by administration of an analgesically effective dose. The dosage range would be from about 0.1 mg to about 15,000 mg, in particular from about 50 mg to about 3500 mg or, more particularly from about 100 mg to about 1000 mg of active ingredient in a regimen of about 1 to 4 times per day for an average (70 kg) human; although, it is apparent to one skilled in the art that the therapeutically effective amount for active compounds of the invention will vary as will the types of pain being treated.
For oral administration, a pharmaceutical composition is preferably provided in the form of tablets containing 0.01, 10.0, 50.0, 100, 150, 200, 250, and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated.
Examples of pain intended to be within the scope of the present invention include, but are not limited to, inflammatory pain, centrally mediated pain, peripherally mediated pain, visceral pain, structural or soft tissue injury related pain, progressive disease related pain, neuropathic pain and acute pain such as caused by acute injury, trauma or surgery and chronic pain such as headache and that caused by neuropathic conditions, post-stroke conditions, cancer, and migraine.
Compounds of the present invention are also useful as immunosuppressants, antiinflammatory agents, agents for the treatment and prevention of neurological and psychiatric conditions, for instance, depression and Parkinson's disease, agents for the treatment of urological and reproductive conditions, for instance, urinary incontinence and premature ejaculation, medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and cardioprotective agents and agents for the treatment of respiratory diseases.
The compounds of the present invention are also useful in treating pain caused by osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, mucositis, enteritis, cellulites, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, post-operative ileus, cholecystitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, post-herpetic neuralgia, trigeminal neuralgia, cluster headache, migraine headache, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, inflammatory bowel disease, irritable bowel syndrome, sinus headache, tension headache, labor, childbirth, menstrual cramps, and cancer.
In regard to the use of the present compounds in treatment of the disases or conditions such as those listed above, a therapeutically effective dose can be determined by persons skilled in the art by the use of established animal models. Such a dose would likely fall in the range of from about 0.01 mg to about 15,000 mg of active ingredient administered 1 to 4 times per day for an average (70 kg) human.
GENERAL SYNTHETIC METHODS
Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and are illustrated in the schemes that follow. Since the schemes are an illustration, the invention should not be construed as being limited by the chemical reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art.
Scheme 1 R.1Y I~ Q HY I~ Q
/ s R'YI~ Q Stage 1.1 HN Stage 1.2 HN
PN~NH2 + ~
Xl ~, ,~, 1.4 1.1 1.2 N 1.3 N
P P
Rq i\ ~~ )0lstage Ra ~1.4 R~ ~ N Stage 1.5 / N /
Stage 1.3 ~. ~. ,,4.
N 1.6 H 1 R 2 The preparation of compounds of this invention is illustrated in Schemes I through 11. The overall strategy in Scheme 1 is based on the synthesis of appropriately substituted compounds of formula 1.4 (Y =0, S) that are condensed with an appropriately substituted compound of formula 1.5. In compounds of formula 1.5, X2 and X3 can each be a halogen atom, trifluoromethanesulfonyloxy or a nitro group. In stage 1.1, a bridged N1-protected 4-aminopiperidine 1.1 is condensed with a properly substituted 0-protected phenol (Y=0) or thiophenol (Y=S) 1.2. The protective group on the N1 nitrogen of 1.1 (represented as P) may include an alkanyl, alkenyl or aralkanyl group in which case they are the therapeutically useful products of this invention. The group P may also be trifluoromethylcarbonyl, alkoxycarbonyl or aralkoxycarbonyl. Bridge A may include (CH2) 2 and (CH2) 3.
Useful phenol or thiophenol protective groups (R) include lower alkyl groups, benzyl, trialkylsilyl and the like. Appropriate substituents on the protected phenol or thiophenol in the 2-position (Xi) may include halogens and trifluoromethanesulfonyloxy. The Q group in the 5-position may be a substituent such as fluoro, chloro, bromo, cyano, iodo, carboxy, dialkylaminosulfonyl or trifluoromethanesulfonyloxy. Stage 1.2 includes deprotection of the phenol or thiophenol protective group. Such transformations may include the dealkylation of lower alkyl ethers to give their corresponding alcohols using reagents such as boron trihalides, or dealkylation of lower alkyl thioethers using reagents such as Na/NH3. A benzyl protective group may be removed under conditions of hydrogenation in the presence of a transition metal such as palladium. Trialkylsilyl protective groups may be removed by treatment with a source of fluoride anion such as tetrabutyl ammonium fluoride, or by exposure to an inorganic acid such as aqueous hydrogen chloride and the like.
In stage 1.3, hydroxyaniline (Y=0) or thioaniline (Y=S) 1.4 may be condensed with an appropriately substituted benzene moiety 1.5. Substituents X2 and X3 may include halogens, trifluoromethanesulfonyloxy, or a nitro group.
Useful coupling conditions of the anilino nitrogen with a compound of formula 1.5 include palladium.catalyzed condensations in the presence of a phosphine ligand such as Pd2(dba)3 and a base such as cesium carbonate. Coupling of the hydroxy or thio moiety with the remaining substituted phenyl group may proceed using Ullmann type coupling conditions. In addition, the two steps described in stage 1.3 may be reversed with biaryl ether or biaryl thioether formation preceding the formation of the biaryl amine. Alternatively, the condensation between compounds of formula 1.4 and compounds of formula 1.5 to yield compounds of formula 1.6 in one step may be affected by treatment with an inorganic base such as potassium carbonate in a suitable solvent such as dimethyl formamide.
The regiochemical outcome of the condensation between compounds of formula 1.4 and compounds of formula 1.5 depends on the position of the R4 substituent in compounds of formula 1.5 and on the reaction conditions used for the condensation. An extensive review on this topic is available in the literature (see, for eample: 'The Smiles and Related Rearrangements of aromatic Systems' by W. E. Truce, E. M. Kreider, and W. W. Brand in Organic Reactions, 1970, Vol. 18, pp.99-215).
The protective group P can be removed to obtain secondary amines I
as illustrated for Stage 1.4. These transformations may be carried out using certain acidic reagents such as hydrogen bromide or trimethylsilyl iodide.
Phenoxazines (Y=O) or phenothiazines (Y=S) of type 1.6 bearing readily cleavable groups such as methyl, allyl or benzyl may be transformed into the aforementioned alkoxycarbonyl derivatives by treatment with alkanylchloroformates such as ethyl chloroformate or 1-chloroethyl chloroformate and thus serve as sources of phenoxazines and phenothiazines 1. Phenoxazines or phenothiazines of type 1.6 bearing a trifluormethylcarbonyl group may be treated with potassium carbonate in an alcoholic solvent such as methanol to yield phenoxazines and phenothiazines 1.
Finally the secondary amines I may be converted to a compound of formula 2 as shown in Stage 1.5. These transformations may be carried out by reductive alkylation using a carbonyl compound and a reducing agent such as sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride, or tetramethylammonium triacetoxyborohydride. They may also be carried out by alkylation using an alkanyl, alkenyl or aralkyl halide and an organic or inorganic base.
The Q function in compounds 1 or 2 may be converted into group G, which may be -C(Z)NRIR2, an aryl substituent, or an appropriate heterocycle as defined herein, to give compounds of formula I. When the Q function is a halogen or trifluoromethanesulfonyloxy, it may be converted to an ester via alkoxycarbonylation using carbon monoxide, an aliphatic alcohol, a trialkanyl amine, and a palladium catalyst such as bis(triphenylphosphine) palladium(II)dichloride. Subsequently, when Q is an ester, the ester may be hydrolyzed to a carboxylic acid. The carboxylic acid may then be coupled with ammonia, a primary amine, or a secondary amine to form a primary, secondary or tertiary amide, respectively. Alternatively, the conversion of a carboxylic acid to an amide may be carried out via an acid chloride using thionyl chloride, oxalyl chloride, or the like, followed by a Schotten-Baumann reaction using ammonia or an amine in the presence of an alkali metal hydroxide.
Alternatively, the conversion of a carboxylic acid to an amide may be carried out via the use of peptide coupling agents such as 1,3-dicyclohexylcarbondiimide (DCC), O-(7-azabenzotriazol-1-yl)-N,N,N;N'-tetramethyluronium hexafluorophosphate (HATU), O-benzotriazol-1-yl-N,N,N;N'-tetramethyluronium hexafluorophosphate (HBTU), or the like.
Alternatively, the ester may be converted directly to the amide by the action of a dimethylaluminum amide.
Alternatively, when the Q function is a halogen or trifluoromethanesulfonyloxy, it may be converted directly to an amide via aminocarbonylation using a carbon monoxide source such as molybdenum hexacarbonyl, an appropriate amine, and a palladium catalyst such as Hermann's catalyst.
Alternatively, one may effect the transformation of the group Q to a substituent G (wherein G is an amidino or heterocycle) by way of a nitrile.
Synthesis of the nitrile may be accomplished by treatment of the compounds 1 or 2 (when Q is bromo or trifluoromethanesulfonyloxy) with Zn(CN)2 and a palladium cataiyst such as (Ph3P)4Pd or by treatment of the compounds 1 or 2 with CuCN at elevated temperatures. For the synthesis of amidino functional groups, the nitrile is treated with hydroxylamine under basic conditions to afford an oxime. Treatment of the oxime with a primary or secondary amine, CuCI, and an alkali metal carbonate under microwave irradiation in an aicoholic solvent provides the amidino compounds of the present invention. Microwave acceierated reactions may be performed using either a CEM Discover or a Personal Chemistry Smith Synthesizer microwave instrument. The oxime described above is instrumental in the preparation of compounds wherein G is a heterocycle. The oxime may be cyclized with a variety of electrophiies known to one versed in the art to give the heterocycles of the present invention.
For instance, reaction of an oxime with CDI provides oxadiazolones, and treatment of the oxime with TCDI provides the corresponding oxadiazolethiones.
Similarly, the treatment of the oxime with thionyl chloride in the presence of a tertiary amine gives oxathiadiazoles of the present invention.
Alternatively, compounds where Q is a halogen atom or a trifluoromethanesulfonyloxy group may participate in transition metal-mediated coupling reactions such as Suzuki, Stille or Negishi chemistry.
Desired end products of the present invention may include chemical modifications at R4. Such transformations may include the dealkylation of lower alkyl ethers to give the corresponding alcohols using reagents such as boron trihalides. Compounds where R4 is a halogen atorn may participate in transition metal-mediated coupling reactions such as Suzuki, Stille or Negishi chemistry.
Scheme 2 X, X, R ~ XZ HY \ Q Stage 2.1 Y Stage 2.2 R aE 4 I + /~ I R4 4 / NO2 X1 / NO2 NH2 2.1 2.2 2.3 Q 2.4 Y ~ Y Q
Xl' PN -I ~ R4 2 O .5 R 4NH / Stage 2.4 N
Stage 2.3 Q
6A~ ,~4.
2.6 N 1.6 P
Scheme 2 outlines an alternative approach to the synthesis of phenoxazines (Y=O) or phenothiazines (Y=S) 1.6. In this scheme, an appropriately substituted phenol (Y=O) or thiophenol (Y=S) of type 2.2 is reacted with an appropriately substituted benzene moiety 2.1 in the presence of a base, such as potassium carbonate or sodium hydroxide in an organic solvent, such as dimethyl formamide, dimethyl acetamide, dimethyl sulfoxide or the like as shown in stage 2.1. Appropriate substituents X, and X2 in this scheme may include halogens and trifluoromethanesulfonyloxy. In stage 2.2, the nitro functionality is reduced to the corresponding amine. This reduction can be accomplished via treatment with tin(II) chloride in an alcoholic solvent such as ethanol. Stage 2.3 depicts the conversion of primary aniline 2.4 to secondary aniline 2.6, which can be accomplished via reductive alkylation using a carbonyl compound 2.5 and a reducing agent such as sodium borohydride, sodium cyanoborohyd ride, sodium triacetoxyborohydride, or tetramethylammonium triacetoxyborohydride. Stage 2.4 depicts formation of compounds of formula 1.6, which can be accomplished by treatment of secondary aniline 2.6 with an appropriate base such as potassium carbonate.
Scheme 3 x2 Y
Ra5,,, YFi + X1 ~ Q Stage 3.1 Ra 3.1 3.2 2.3 Scheme 3 illustrates an alternative synthesis of compound 2.3. In this approach, an appropriately substituted 2-nitrophenol (Y=O) or 2-nitrothiophenol (Y=S) may be condensed with an appropriately substituted benzene moiety of type 3.2 under Ullmann type coupling conditions. Appropriate substituents X1 and X2 include halogens and trifluoromethanesulfonyloxy.
Scheme 4 X2 HY ~ Q aE Y PN~NH2 R4 + Stage 4.1 RX3 X1 ~ X3 Stage 4.2 Q
1.5 2.2 4.1 I ~ Y ~ Q
R4 I / ~ /
N
61.6 N
P
Scheme 4 illustrates an alternative approach to the synthesis of phenoxazines (Y=O) or phenothiazines (Y=S) 1.6. Condensation of appropriately substituted phenols (Y=O) or thiophenols (Y=S) 2.2 with substituted benzene moiety 1.5 under Ullmann type coupling conditions as shown in stage 4.1 may result in the formation of biaryl ethers (Y=O) or biaryl thioethers (Y=S) 4.1. Appropriate Xi, X2 and X3 substituents may include halogens and trifluoromethanesulfonyloxy. Palladium catalyzed condensation of biaryl ethers or biaryl thioethers 4.1 with bridged N1-protected 4-aminopiperidines 1.1 in the presence of a phosphine ligand such as Pd2(dba)3 and a base such as cesium carbonate is shown in stage 4.2 may result in the formation of phenoxazines or phenothiazines 1.6.
Scheme 5 ~
YH X Q
R4 iy +
3 x2 ~ \ Stage 5.1 Y
I ~ R4 i ~
x3 Q
5.1 3.2 4.1 An alternative approach to the synthesis of intermediate 4.1 is depicted in Scheme 5 and is based on the reaction of appropriately substituted phenois (Y=O) or thiophenois (Y=S) 5.1 with an appropriately substituted benzene moiety 3.2 under Ullmann type coupling conditions (stage 5.1). Substituents Xl, X2, and X3 may include halogens or trifluoromethanesulfonyloxy.
Scheme 6 X, NH X2 HY ~ Q
a,_ X 2 R4 N I/ R4 2 H X 2.2 X3 Stage 6.1 6-A Stage 6.2 Q
1.5 P 6.1 P 2.6 Scheme 6 illustrates an alternative approach to the synthesis of intermediates 2.6. An appropriately substituted compound of formula 1.5 may be reacted with bridged N1-protected 4-aminopiperidines 1.1 in the presence of a palladium catalyst such as Pd2(dba)3, a phosphine ligand and a base such as cesium carbonate as shown in stage 6.1. Appropriate X, and X2 substituents may include halogens and trifluoromethanesulfonyloxy. Compounds of formula 6.1 may then be reacted with appropriately substituted phenols (Y=O) or thiophenois (Y=S) 2.2 under Ullmann type coupling conditions to yield anilines 2.6 as shown in stage 6.2.
Scheme 7 X, ~ Q YH
X1 Q Stage 7.1 HN '/ Ra i/ x 3 Ra Y ~ Q
'~
PNaNH2 + HN ~ s X2 ,,4. Stage 7.2 1.1 3.2 N 7.1 P 6~
~ Y Q N 7.3 P
Stage 7.3 Ra ~/ N I/
1.6 P
Scheme 7 illustrates an alternative approach to the synthesis of phenoxazines (Y=O) or phenothiazines (Y=S) 1.6. Condensation of appropriately substituted compounds of formula 3.2 with bridged N1-protected 4-aminopiperidines 1.1 may result in formation of intermediate 7.1 as shown in stage 7.1. Appropriate Xl, X2, and X3 substituents may include halogens and trifluoromethanesulfonyloxy. Reaction of compounds 7.1 with appropriately substituted phenol (Y=O) or thiophenois (Y=S) 7.2 under Ullmann like coupling conditions may result in formation of compounds 7.3 as shown in stage 7.2.
Finally, ring closure of compounds 7.4 may be accomplished in the presence of a palladium catalyst such as Pd2(dba)3, a phosphine ligand such as 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (xant phos) and a base such as potassium tert-butoxide or cesium carbonate as shown in stage 7.3.
Scheme 8 R
PN -NHz R4 ~/ R4 N
Y YR ::x.:
R4 Stage 8.2 X, X3 Stage 8.1 ,A. 6 8.1 P 8.2 N 8.3 P
\
I\ N I YH \ Q R Y Q
Ra ~ Sta9e8.4 ~ a Stage 8.3 I/
/ _ N
XX, .ti4.
8.4 N 1.6 P P
Scheme 8 illustrates an alternative ternative synthesis of phenoxazines (Y=O) or phenothiazines (Y=S) 1.6 and is based on an Ullmann-like coupling of bridged N1-protected 4-aminopiperidines 1.1 with appropriately substituted and protected phenois (Y=O) or thiophenois (Y=S) 8.1 as shown in stage 8.1.
Useful phenoi or thiophenol protective groups for compounds 8.1 include lower alkyl groups, benzyl, trialkylsilyl and the like. Appropriate Xi, X2, and X3 substituents may include halogens and trifluoromethanesulfonyloxy. The resulting compounds 8.2 may be condensed with appropriately functionalized benzene compounds 3.2 to yield diarylanilines 8.3. Stage 8.3 includes deprotection of the phenol or thiophenol protective group. Such transformations may include the dealkylation of lower alkyl ethers to give their corresponding alcohols using reagents such as boron trihalides or the dealkylation of the alkyl thioethers using Na/NH3. A benzyl protective group may be removed under conditions of hydrogenation in the presence of a transition metal such as palladium. Trialkylsilyl protective groups may be removed by treatment with a source of fluoride anion such as tetrabutyl ammonium fluoride, or by exposure to an inorganic acid such as aqueous hydrogen chloride and the like. Finally, ring closure of compounds 8.3 to phenoxazines or phenothiazines 1.6 may be accomplished via an Ullmann type transformation as shown in stage 8.4.
Scheme 9 Y
YH I~
X ~ Q Stage 9.1 Q Stage 9.2 Ra + ~/ Ra I I Ra ~\%
X2 p2 N 2NH2N
9.1 9.2 9.3 9.4 ~
PNO Y Q
D75 Ra i/ HN I/
Stage 9.3 ,~.
N 7.4 P
Scheme 9 illustrates another synthetic approach to compounds 7.4.
Displacement of X7 in appropriately substituted compounds of formula 9.2 with appropriately substituted compounds of formula 9.1 as shown in stage 9.1 may lead to biaryl ethers (Y=O) and biarylthioethers (Y=S) 9.3. Appropriate X, and X2 substituents may include halogens and trifluoromethanesulfonyloxy.
Reduction of compounds 9.3 to amines 9.4 as shown in stage 9.2 may be accomplished using tin(II) chloride in an alcoholic solvent such as ethanol.
Stage 9.3 depicts the conversion of primary anilines 9.4 to secondary anilines 7.4 and can be accomplished via reductive alkylation using a carbonyl compounds 2.5 and a reducing agent such as sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride, or tetramethylammonium triacetoxyborohyd ride.
Scheme 10 HY Q
): Xz 2 02N 10.1 ~~ Y Q
R4 Ra i /
X3 Stage 10.1 02N
1.5 9.3 Scheme 10 illustrates another synthetic approach to compounds 9.3. For construction of diaryl ethers (Y=O) and diaryl thioethers (Y=S) 9.3, appropriately substituted 2-hydroxynitrobenzenes or 2-thionitrobenzenes 10.1 may be caused to react with appropriately substituted compounds of formula 1.5 under Ullmann type conditions as shown in stage 10.1. Appropriate X2 and X3 substituents may include halogens and trifluoromethanesulfonyloxy.
Scheme 11 YH PN~O Q
R4 i ~\ YH :'-2 R4 I / \ I/ ~ ~
R - N
4 i / NH
NH2 Stage 11.1 Stage 11.3 Y-O ,~R, C-A~ 11.1 N 11.2 1.6 P P
Stage 11.2 PN,Ia =O
'~~ 2.5 Y P
~ N
~
~
Stage 11.1 R N
11.3 Scheme 11 illustrates another synthetic approach to compounds 1.6. Stage 11.1 depicts the conversion of appropriately substituted 2-hydroxyanilines (Y=O) 11.1 to compounds 11.2 (Y=O), which can be accomplished via reductive alkylation using a carbonyl compound 2.5 and a reducing agent such as sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohyd ride, or tetramethylammonium triacetoxyborohyd ride.
Appropriately substituted 2-hydroxyanilines 11.2 may be caused to react with an appropriately substituted benzene 3.2 under Ullmann type conditions or under basic conditions such as potassium carbonate in DMF (when Xj= NO2) as shown in stage 11.3 to yield compounds of formula 1.6. Appropriate X, and X2 substituents may include halogens, trifluoromethanesulfonyloxy, and a nitro group.
The regiochemical outcome of the condensation of compounds of formula 11.2 with compounds of formula 3.2 depends on the position of the Q substituent in compounds of formula 3.2 and on the reaction conditions used for the condensation. An extensive review on this topic is available in the literature (see, for eample: 'The Smiles and Related Rearrangements of aromatic Systems' by W. E. Truce, E. M. Kreider, and W. W. Brand in Organic Reactions, 1970, Vol. 18, pp.99-215).
In compounds of formula 11.1 where Y is sulfur, an intermediate spiro compound of formula 11.3 may be formed. Compounds of formula 11.3 may be converted to compounds of formula 11.2 (Y = S) by treatment with a hydride reagent such as lithium aluminum hydride or sodium borohydride.
In the above Schemes 1 through 11, the Q function of compounds 2 may be converted into group G, which may be -C(Z)NRIR2, an aryl substituent, or an appropriate heterocycle as defined herein, to give compounds of formula 3.
When the Q function of compounds 2 is a halogen or trifluoromethanesulfonyloxy, it may be converted to an ester via alkoxycarbonylation using carbon monoxide, an aliphatic alcohol, a trialkanyl amine, and a palladium catalyst such as bis(triphenylphosphine) palladium(II)dichloride. Subsequently, when Q is an ester, the ester may be hydrolyzed to a carboxylic acid. The carboxylic acid may then be coupled with ammonia, a primary amine, or a secondary amine to form a primary, secondary or tertiary amide, respectively. Alternatively, the conversion of a carboxylic acid to an amide may be carried out via an acid chloride using thionyl chloride, oxalyl chloride, or the like, followed by a Schotten-Baumann reaction using ammonia or an amine in the presence of an alkali metal hydroxide.
Alternatively, the conversion of a carboxylic acid to an amide may be carried out via the use of peptide coupling agents such as 1,3-dicyclohexyicarbondiimide (DCC), 0-(7-azabenzotriazol-1-yl)-N,N,N;N'-tetramethyluronium hexafluorophosphate (HATU), O-benzotriazol-1-yl-N,N,N;N'tetramethyluronium hexafluorophosphate (HBTU), or the like.
Alternatively, the ester may be converted directly to the amide by the action of a dimethylaluminum amide.
Instead of proceeding to compounds 3 via an ester, one may effect the transformation of the group Q to a substituent G (wherein G is an amidino or heterocycle) by way of a nitrile. Synthesis of the nitrile may be accomplished by treatment of the compounds 2 (when Q is bromo or trifluoromethanesulfonyloxy) with Zn(CN)2 and a palladium catalyst such as (Ph3P)4Pd or by treatment of the compounds 2 with CuCN at elevated temperatures. For the synthesis of amidino functional groups, the nitrile is treated with hydroxylamine under basic conditions to afford an oxime.
Treatment of the oxime with a primary or secondary amine, CuCI, and an alkali metal carbonate under microwave irradiation in an alcoholic solvent provides the amidino compounds of the present invention. Microwave accelerated reactions may be performed using either a CEM Discover or a Personal Chemistry Smith Synthesizer microwave instrument. The oxime described above is instrumental in the preparation of compounds wherein G is a heterocycle. The oxime may be cyclized with a variety of electrophiles known to one versed in the art to give the heterocycles of the present invention.
For instance, reaction of an oxime with CDI provides oxadiazolones, and treatment of the oxime with TCDI provides the corresponding oxadiazolethiones.
Similarly, the treatment of the oxime with thionyl chloride in the presence of a tertiary amine gives oxathiadiazoles of the present invention.
An aryl substituent may be installed in place of the functional group Q by coupling compounds 2 (when Q is bromo or trifluoromethanesulfonyloxy) with a suitably substituted arylboronic acid in the presence of a palladium catalyst and an alkali metal carbonate.
Desired end products of the present invention may include chemical modifications at R4. Such transformations may include the dealkylation of lower alkyl ethers to give their corresponding alcohols, using reagents such as boron trihalides. Compounds where R4 is a halogen atom may participate in transition metal-mediated coupling reactions such as Suzuki, Stille or Negishi chemistry.
It is generally preferred that the respective product of each process step be separated from other components of the reaction mixture and subjected to purification before its use as a starting material in a subsequent step.
Separation techniques typically include evaporation, extraction, precipitation and filtration. Purification techniques typically include column chromatography (Still, W. C. et. al., J. Org. Chem. 1978, 43, 2921), thin-layer chromatography, crystallization and distillation. The structures of the final products, intermediates and starting materials are confirmed by spectroscopic, spectrometric and analytical methods including nuclear magnetic resonance (NMR), mass spectrometry (MS) and liquid chromatography (HPLC). In the descriptions for the preparation of compounds of this invention, ethyl ether, tetrahydrofuran and dioxane are common examples of an ethereal solvent;
benzene, toluene, hexanes and heptanes are typical hydrocarbon solvents and dichloromethane and dichloroethane are representative halogenated hydrocarbon solvents. In those cases where the product is isolated as the acid addition salt the free base may be obtained by techniques known to those skilled in the art. In those cases in which the product is isolated as an acid addition salt, the salt may contain one or more equivalents of the acid.
Enantiomers of the compounds of the present invention may be separated using chiral HPLC.
Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described above and are illustrated more particularly in the schemes that follow. Since the schemes are illustrations, the invention should not be construed as being limited by the chemical reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skili of persons versed in the art.
Abbreviations AcOH = acetic acid Boc = tert-butoxycarbonyl DIEA = N,N-diisopropyl-N-ethylamine DMF = N,N-dimethylformamide DMSO = dimethyl sulfoxide Et = ethyl h = hour(s) HBTU = O-benzotriazol-1-yI-N,N,N;N=tetramethyluronium hexafluorophosphate K2C03 = potassium carbonate Me = methyl min = minute(s) rt = room temperature xantphos = 4,5-bis(diphenylphosphino)-9,9-dimethyixanthene Although the foregoing invention has been described in detail by way of example for purposes of clarity of understanding, it will be apparent to the artisan that certain changes and modifications are comprehended by the disclosure and can be practiced without undue experimentation within the scope of the appended claims, which are presented by way of illustration not limitation.
All publications and patent documents cited above are hereby incorporated by reference in their entirety for all purposes to the same extent as if each were so individually denoted.
EXAMPLES
Example A
HO CO2Me -N O ~I U-N0 CO Me ~HO ~ 2 ~ HN 2 I / NaBH(OAc)3/HOAc K2CO3 N 1a O C02H HNNaOH cOXICO2Me --;
HBTU
THF
2a 3a Et3N
N DMF
O
N \
I/
N 4a I
Procedure 1 3-Hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-ylamino)-benzoic acid methyl ester, 1 a To a solution of 4-amino-3-hydroxybenzoic acid methyl ester (2.0g; 12 mmol) and 8-methyl-8-aza-bicyclo[3.2.1]octan-3-one (1.1g; 10.8 mmol) in dichloroethane (30 mL) was added sodium triacetoxyborohydride (3.2g; 15.1 mmol) and acetic acid (0.65 mL; 11.4 mmol). The mixture was stirred at rt for 16 h. The mixture was diluted with 1 N NaHCO3 solution and chloroform was added. The organic layer separated, and the aqueous phase was lyophilized.
The lyophilized residue was purified via reverse phase HPLC (eluent gradient:
to 50% acetonitrile in water containing 0.1 % TFA) to yield 1.61 g (36.9%) of a mixture of endo and exo isomers of 3-hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-ylamino)-benzoic acid methyl ester, 1a as a TFA salt. MS
m/z (MH+) 291.
Procedure 2 10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid methyl ester, 2a A mixture of the TFA salt of 3-hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-ylamino)-benzoic acid methyl ester, 1a (0.424g, 0.734 mmol), 2-fluoronitrobenzene (95 L, 0.9 mmol) and potassium carbonate (564 mg, 4 mmol) in DMF was heated to reflux for 70 min. The mixture was allowed to cool to rt, filtered, and purified via reverse phase HPLC to yield 440 mg (88%) of 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid methyl ester, 2a, as TFA salt. MS m/z (MH+) 365.1.
Procedure 3 10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenoxazine-3-carboxylic acid, 3a To a solution of 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenoxazine-3-carboxylic acid methyl ester, 2a (440 mg, 0.646 mmol) in THF (5 mL) was added I N NaOH (5 mL), and the mixture was stirred for 3 hr at rt. The solvent was removed, the residue was dissolved in DMF and acidified with a 2N TFA
solution, and purified via reverse phase HPLC to yield 295 mg (63%) of 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid, 3a, as a TFA salt. MS m/z (MH+) 351.1.
Procedure 4 10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 4a To a solution of the TFA salt of 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-phenoxazine-3-carboxylic acid 3a (65 mg, 0.14 mmol) and HBTU (64 mg; 0.17 mmol) in DMF (2 mL) was added triethylamine (69 L, 0.43 mmol). The mixture was stirred for 1 hr at rt, and purified without prior quenching via reverse phase HPLC (eluent gradient: acetonitrile in water containing 0.1 %
TFA) to yield 44.4 mg (61 %) of title compound 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 4a as a TFA salt. MS m/z (MH+) 406.2.
O
O NOH
A5a N
I
(3-Hydroxy-pyrrolidin-1-yi)-[10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-methanone, 5a Using an adaptation of Procedure 4, and substituting 3-hydroxypyrrolidine for diethylamine, the title compound (3-hydroxy-pyrrolidin-yl )-[10-(8-methyl-8-aza-b icyclo [3.2.1 ]oct-3-yl )-10H-p h enoxazi n-3-yl]-methanone, 5a was obtained as a TFA salt. MS m/z (MH+) 420.1.
O ~
~ I
aN O ~ N
~/ A6a N
I
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxyl ic acid methyl-phenethyl-amide, Using an adaptation of Procedure 4, and substituting N-methyl-N-phenethylamine for diethylamine, the title compound 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid methyl-phenethyl-amide, 6a was obtained as a TFA salt. MS m/z (MH+) 468.3.
Example B
/ OH OCNH
OH Boc-N O / ~ \ I NaBH(OAc)3/HOAc +
N lb N 2b i i Boc Boc N-N
,, F\ I aN:l O CN O I\ ~ H
1b 02N N
/
~ CNNaN3 C(N
KaC03 NH4CI
DMF DMF
N 3b N 4b Boc Boc N-N O N-N
N
'N
\ N CHO H
H
cXOXIIIIN
HCI ~
-~ _ dioxane NaBH(OAc)3 N 5b CICHZCH2CI N N 6b H I ~
/
Procedure 5 Endo-3-(2-Hydroxy-phenylamino)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1 b and Exo-3-(2-Hydroxy-phenylamino)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2b To a solution of 2-aminophenol (5.0g; 45.82 mmol) and 3-oxo-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (15.5 g; 68.8 mmol)-in dichloroethane (200 mL) was added acetic acid (2.62 mL; 45.77 mmol). The mixture was stirred at rt for 1 h and sodium triacetoxyborohydride (11.6g;
54.73 mmol) was added in small portions. The mixture was stirred at rt for 16 h and treated with H20 (200 mL). The organic layer was separated, dried over MgSO4, filtered, and evaporated. The residue was purified via column chromatography (eluent gradient: 10 to 30 % ethyl acetate in heptane) to yield 8g (55%) of endo-3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, lb and 1.5 g (10%) of exo-3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1b.
MS m/z (MH+) 318.9.
Procedure 6 Endo-3-(3-Cyano-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 3b To a solution of 4-fluoro-3-nitrobenzonitrile (0.29 g; 1.74 mmol) and endo-3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 b (0.55 g; 1.73 mmol) in DMF (6 mL) was added potassium carbonate (0.48 g; 3.47 mmol). The mixture was stirred at 170 C for 30 min. The mixture was allowed to cool to rt and poured into ice-water 910 mL). The solid was separated via filtration, washed with water, and dried to yield 0.63 g (86%) of endo-3-(3-cyano-phenoxazi n-10-yI)-8-aza-bicyclo[3.2.1 ]octane-8-carboxyl ic acid tert-butyl ester, 3b. MS m/z (MH+) 417.9.The material was used as such for the next reaction.
Procedure 7 Endo-3-[3-(l H-Tetrazol-5-yl)-phenoxazi n-10-yl]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 4b To a solution of endo-3-(3-cyano-phenoxazin-10-yi)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3b (1 g; 2.4 mmol) in DMF (20 mL) were added sodium azide (0.47 g, 7.23 mmol) and ammonium chloride (0.39 g; 7.29 mmol), and the mixture was heated at 120 C for 16h. The mixture was allowed to cool to rt, and filtered. The filtrate was acidified with 1 N
hydrochloric acid (10 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic layers were dried over MgSO4, filtered, and evaporated. The residue was used as such for the next reaction.
Procedure 8 Endo-10-(6-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b To a solution of endo-3-[3-(1 H-tetrazol-5-yl)-phenoxazin-10-yl]-8-aza-bicyclo[3.2.1]-octane-8-carboxylic acid tert-butyl ester, 4b (2.4 mmol) in dioxane (5 mL) was added a 4N hydrochloric acid solution (5 mL). The mixture was stirred at rt for 16 h. The mixture was filtered, and the filtrate was evaporated. The residue was purified via reverse phase chromatography (eluent gradient: acetonitrile in water containing 0.1 % TFA) to yield crudeendo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine, 5b as a TFA salt. MS m/z (MH+) 360.9. The material was used as such in the next reaction.
Procedure 9 Endo-1 0-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 6b To a suspension of the HCI salt of endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 W-tetrazol-5-yl)-10H-phenoxazine, 5b (0.2 g; 0.5 mmol) and 2-pyridylcarboxaldehyde (0.071 mL; 0.74 mmol) in dichloroethane (4 mL) was added sodium triacetoxyborohydride (0.13 g; 0.61 mmol). The mixture was stirred at rt for 15 h and a saturated NaHCO3 solution (3 mL). The organic layer was separated, and the aqueous phase was extracted with ethyl acetate (5 mL). The combined organic layers were dried over MgS 4, filtered, and evaporated. The residue was purified via reverse phase HPLC (eluent:
acetonitrile in water containing 0.1 % TFA) to yield 139.8 mg (quant.) of title compound endo-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 6b as a TFA salt. MS m/z (MH+) 452Ø
N_NN
~ N
~ xx H N
N 7b Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 7b Using an adaptation of Procedure 9, and substituting phenylacetaidehyde for 2-pyridyl carboxaldehyde, the title compound endo-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine, 7b was obtained as a TFA salt. MS m/z (MH+) 464.9.
O ~ /
xx1 8b N
H
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 8b Using an adaptation of Procedure 9, and substituting endo-3-(3-cyano-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 3b for endo-3-[3-(1 H-tetrazol-5-yl)-phenoxazin-10-yl]-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 4b, the title compound endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 8b was obtained as a TFA salt. MS m/z (MH+) 317.9.
Example C
0 ~ CN 0 NH NH
HN
N HCI
N _ --= N
MeMgBr dioxane N 3b Et2 Ic 2c Boc H
Boc N
NH
0 N~\
N C
HO
aN&
NaBH(OAc)3 CICH2CH2CI N 3c N
~ \
/
Procedure 10 Endo-3-[3-(N,N-Diethyl-carbamim idoyl)-phenoxazin-10-yI]-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 1 c To a solution of methylmagnesium bromide in diethyl ether (3.0 M, 2.4 mL, 7.2 mmol) under nitrogen was added dropwise a solution of diethylamine (0.749 mL, 7.19 mmol) in diethyl ether (2 mL). The mixture was heated to reflux for min, cooled to rt, and a suspension of endo-3-(3-cyano-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3b (1.0 g, 2.4 mmol) was added. The mixture was stirred at 40 C for 2 hr and water (10 mL) was added,. The organic layer was separated, and the aqueous layer was further extracted with chloroform (2 x 10 mL). The combined organic layers were dried over magnesium sulfate, filtered, and evaporated, yielding title compound endo-3-[3-(N,N-diethyl-carbamimidoyl)-phenoxazin-l0-yl]-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester Ic. MS m/z (MH+) 491ØThe residue was used as such for the next reaction.
Endo-1 0-(8-Aza-bicyclo[3.2.1]oct-3-yl)-N,N-d iethyl-10H-phenoxazine-3-carboxamidine, 2c Using an adaptation of Procedure 8, and substituting endo-3-[3-(N,N-Diethyl-carbamimidoyl)-phenoxazin-10-yl]-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 4b for endo-3-[3-(1 H-tetrazol-5-yl)-phenoxazin-10-yl]-8-aza-bicyclo[3.2.1]-octane-8-carboxylic acid tert-butyl ester, 4b, the title compound endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-N, N-diethyl-10H-phenoxazine-3-carboxamidine, 2c was obtained as a TFA salt. MS mlz (MH+) 390.9.
Endo-N,N-Diethyl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxamidine, 3c Using an adaptation of Procedure 8, and substituting endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-N,N-diethyl-10H-phenoxazine-3-carboxamidine, 2c for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, the title compound endo-N,N-diethyl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxamidine, 3c was obtained as a TFA salt. MS tn/z (MH+) 482Ø
NH
0 N--\
N 4c Endo-N, N-Diethyl-l0-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenoxazine-3-carboxamidine, 4c Using an adaptation of Procedure 9, substituting endo-N,IV diethyl-10-(8-pyrid i n-2-yl methyl-8-aza-bicyclo [3. 2.1 ]oct-3-yl )-10 H-phe noxazi ne-3-carboxamidine, 3c for endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yI)-10H-phenoxazine, 5b and phenyl acetaidehyde for 2-pyridyl carboxaldehyde, the title compound endo-N,N-diethyl-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxamidine, 4c was obtained as a TFA salt. MS m/z (MH+) 495Ø
Example D
NOH O
O CN
NH2 O I\ NH2 N NH2OH.HCI a /
N + N
EtOH
N 3b N 1d N 2d Boc 'Boc Boc O
a'4- O N NO
H HCI
CDI :110' - N + 2d dioxane dioxane 3d N
Boc N-O O
O ~
ccx0 + 4d 5d N N
H H
O
N CHO ~ O N~O
~ H
4d NaBH(OAc)3 6d N
~ \
/
Procedure 11 Endo-3-[3-(N-Hyd roxyca rbam i m i doyl )-phe noxazi n-10-y.i]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1d and endo-3-(3-Carbamoyl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2d To a solution of endo-3-(3-cyano-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3b (1 g; 2.40 mmol) in ethanol (20 mL) were added ammonium hydroxide hydrochloride (0.5 g; 7.19 mmol) and potassium carbonate (0.66 g; 4.78 mmol), and the mixture was heated to reflux for 16 h.
The mixture was allowed to cool to rt, water (20 mL) was added, and the mixture was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried over MgSO4, filtered, and evaporated, yielding a- 2:1 mixture of title compounds endo-3-[3-(N-hydroxycarbamimidoyl)-phenoxazin-10-yl]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1d and endo-3-(3-carbamoyl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2d. The crude mixture was used as such in the next reaction. 1d: MS m/z (MH+) 451.2., 2d: MS m/z (MH+) 458.3.
Procedure 12 Endo- 3-[3-(5-Oxo-4,5-dihydro-[1,2,41oxadiazol-3-yl)-phenoxazin-10-y11-8-aza-bicyclo[3.2.11octane-8-carboxylic acid tert-butyl ester, 3d To a solution of the 2:1 mixture of endo-3-[3-(N-hydroxycarbamimidoyl)-phenoxazin-10-yl]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 d and endo-3-(3-carbamoyl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2d (2.33 mmol) in dioxane (20 mL) was added 1,1'-carbonyidiimidazole (0.57 g; 3.52 mmol), and the mixture was stirred at 110 C for 4 h. The mixture was allowed to cool to rt, and the solution containing a crude mixture of endo- 3-[3-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-phenoxazin-10-yl]-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 3d (MS m/z (MH+) 477.1)and endo-3-(3-carbamoyl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2d was used as such in the next reaction.
Endo- 3-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2;4]oxadiazol-5-one, 4d and endo-l0-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid amide, 5d Using an adaptation of Procedure 8, and substituting a mixture of endo- 3-[3-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-phenoxazin-l0-yl]-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 3d and endo-3-(3-carbamoyl-phenoxazin-10-y1)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2d for endo-3-[3-(1 H-tetrazol-5-yl)-phenoxazin-10-yI]-8-aza-bicyclo[3.2.1]-octane-8-carboxylic acid tert-butyl ester, 4b, the title compounds endo- 3-[10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one, 4d and endo-1 0-(8-aza-bicyclo[3.2. 1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid amide, 5d were obtained as TFA salts. 4d: MS m/z (MH+) 377.0; 5d: MS
m/z (MH+) 335.9.
Endo-3-[10-(8-Pyridin-2-ylrnethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one, 6d Using an adaptation of Procedure 9, and substituting endo- 3-[10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one, 4d for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, the title compound endo-3-[10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yI)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one, 6d was obtained as a TFA salt. MS m/z (MH+) 467.9.
NO
~
O
\ zx N 7d Endo-3-[10-(8-Phenethyi-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi n-3-yI]-4H-[1,2,4]oxadiazoi-5-one, 7d Using an adaptation of Procedure 9, and substituting endo- 3-[10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one, 4d for endo-l0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, and phenyl acetaldehyde for 2-pyridyl carboxaldehyde, the title compound endo-3-[10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one, 7d was obtained as a TFA salt MS m/z (MH+) 480.9.
EXAMPLE E
Me HO C02Me OMe N O ~ CO2Me F F ~ ~
NO2 NO ~
/ MeOH 2 H 1a N
F KOH (OMe K2C03 DMF
1e N 2e OMe OMe 0 NaOH O CO2H H~ O &N'---dioxane N
HATU
3e DI EA 4e N DMF N
I I
O CI OMe 0 OMe 0 1. CI~ I\ O I\ N" OrCHO x~i CH2CI2 NaBH(OAc)3 2. MeOH HOAc N 5e CICH2CH2CI N 6e H
/
/ N
BBr3 CH2CI2 N 7e \
Procedure 13 1-Fluoro-3-methoxy-2-nitrobenzene, le To a solution of 2,,6-difluoronitrobenzene (5 g, 32 mmol) in methanol (50 mL) was added potassium hydroxide (1.8 g, 32.5 mmol), and the mixture was heated to reflux for 3 hr. Water was added, and the mixture was extracted with dichloromethane. The organic layer was separated, dried, filtered, and evaporated to yield 5.1 g (95%) of 1-fluoro-3-methoxy-2-nitrobenzene, le. MS
m/z (MH+) 172.
6-Methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi ne-3-carboxylic acid methyl ester, 2e Using an adaptation of Procedure 2, and substituting 1-fluoro-3-methoxy-2-nitrobenzene, le for 4-fluoro-3-nitrobenzonitrile, the title compound 6-methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid methyl ester, 2e was obtained as a TFA salt and as a mixture of endo and exo isomers. MS rn/z (MH+) 395.
Procedure 14 6-Methoxy-l0-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi ne-3-carboxylic acid, 3e To a solution of the TFA salt of 6-methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid methyl ester, 2e (270 mg, 0.7 mmol) in dioxane (15 mL) was added sodium hydroxide (31 mg, 0.77 mmol) for 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid methyl ester, 2a, the title compound 6-methoxy-l0-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid, 3e was obtained as a mixture of endo and exo isomers. MS m/z (MH+) 381.
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phe noxazi ne-3-carboxyl ic acid diethylamide, 4e Using an adaptation of Procedure 4, and substituting 6-methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid, 3e for 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid, 3a, N,N-diisopropyl-/V ethylamine for triethylamine and HATU for HBTU, the title compound 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 4e was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 436.
Procedure 15 10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-10H-phenoxazi ne-3-carboxyl ic acid diethylamide, 5e To a solution of the TFA salt of 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-phenoxazine-3-carboxylic acid diethylamide, 4e (110 mg, 0.25 mmol) in methylene chloride (10 mL) was added 1-chloroethyl chloroformate (0.58 mL, 0.75 mmol). The mixture was heated to reflux for 2h. The mixture was evaporated, dissolved in methanol (5 mL), and heated for 2h at reflux. Water was added, and the solution was extracted with methylene chloride. The organic phase was separated, evaporated, and purified via reverse phase HPLC to yield 69 mg (44.8%) of title compound 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-10H-phenoxazine-3-carboxylic acid diethylamide, 5e, as a TFA
salt. MS m/z= 422 (M+1).
6-Methoxy-l0-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi ne-3-carboxylic acid diethylamide, 6e Using an adaptation of Procedure 9, and substituting 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-lOH-phenoxazine-3-carboxylic acid diethylamide, 5e for endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine, 5b, and phenyl acetaldehyde for 2-pyridylcarboxaldehyde, the title compound 6-methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 6e was obtained as a TFA
salt and as a mixture of endo and exo isomers. MS m/z= 526 (M+1).
Procedure 16 6-Hydroxy-l0-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 7e To a solution of the TFA salt of 6-methoxy-l0-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 6e (55 mg, 0.086 mmol) in 1,2-dichloromethane (5 mL) at 0 C was added a 1 M
solution of BBr3 (0.43 mL, 0.43 mmol). The mixture was allowed to stir for 2 h at rt. A saturated NaHC 3 solution was added, and the organic phase was separated. The aqueous phase was extracted with methylene chloride, and the combined organic phases were dried, filtered, and evaporated. The residue was purified via reverse phase HPLC (eluent: CH3CN in water containing 0.1 %
TFA) to yield 23 mg (42.8%) of title compound 6-hydroxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 7e as a TFA salt and as a mixture of endo and exo isomers. MS m/z= 512 (M+1).
N
N9 8e I
6-Methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenoxazi ne-3-carboxylic acid diethylamide, 8e Using an adaptation of Procedure 16, and substituting the TFA salt of 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 4e for TFA salt of 6-methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 6e, the title compound 6-methoxy-l0-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 8e was obtained as a TFA salt and as a mixture of endo and exo isomers after reverse phase chromatography (eluent gradient: acetonitrile in water containing 0.1% TFA). MS m/z (MH+) 422.
Example F
/ OH F
-N\,)=O NH
OH
NaBH(OAc)3/HOAc KNHZ CICH CH CI 2C03 2 2 N 1f DMF
N_NN
(O1CN NaN cc /NH CI /
N --> N
DMF
2f 3f 2-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-ylamino)-phenol, 1f Using an adaptation of Procedure 5, and substituting 8-methyl-8-aza-bicyclo[3.2.1 ]-octan-3-one for 3-oxo-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, the title compound 2-(8-methyl-8-aza-bicyclo[3.2.1]oct-ylamino)-phenol, If was obtained as a TFA salt and as a mixture of endo and exo isomers after reverse phase chromatography (eluent gradient: acetonitrile in water containing 0.1% TFA). MS m/z (MH+) 232.9.
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi ne-3-carbon itri le, 2f Using an adaptation of Procedure 6, and substituting the TFA salt of 2-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-ylamino)-phenol, If for 3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 b, the title compound 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 2f was obtained as a mixture of endo and exo isomers. MS m/z (MH+) 332Ø
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 3f Using an adaptation of Procedure 7, and substituting 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 2f for 3-(3-cyano-phenoxazin-10-y1)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2b, the title compound 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yI)-10H-phenoxazine, 3f was obtained as a TFA salt and as a mixture of endo and exo isomers after reverse phase chromatography (eluent gradient:
acetonitrile in water containing 0.1% TFA). MS m/z (MH+) 375.1.
EXAMPLE G
NH
C(N O \ CN O \ N~\
I/ HN a I ~
- N
--~
2f MeMgBr lg Et20 I I
N,N-Diethyl-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxamidine, 1g Using an adaptation of Procedure 10, and substituting 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 2f for endo-3-(3-cyano-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 3b, the title compound N,N-diethyl-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yI)-10f / phenoxazine-3-carboxamidine, 1g was obtained as a TFA salt and as a mixture of endo and exo isomers after reverse phase chromatography (eluent gradient: acetonitrile in water containing 0.1 % TFA). MS m/z (MH') 405.3.
EXAMPLE H
O
IO NHCDI N
a /
dioxane K2CO3 1 h 2h 2f EtOH
N N N
I I I
N-Hydroxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ] oct-3-yl)-10H-phenoxazine-3-carboxamidine, 1 h Using an adaptation of Procedure 11, and substituting 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 2f for endo-3-(3-cyano-phenoxazin-10-y1)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 3b, the title compound N-Hydroxy-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxamidine, 1 h was obtained. MS m/z (MH+) 365Ø
Procedure 17 3-[10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi n-3-yl]-4H-[1,2,4]oxadiazol-5-one, 2h To a solution of N-Hydroxy-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxamidine, 1h (0.66 g; 1.81 mmol) in dioxane (20 mL) was added 1,1'-carbonyldiimidazole (0.44 g; 2.71 mmol), and the mixture was stirred at 110 C for 4 h. The mixture was allowed to cool to rt, and the solvent was evaporated. The residue was purified via reverse phase HPLC (eluent gradient: 20 to 45% CH3CN in H20 containing 0.1 % TFA) to yield 161 mg (17.6%) of title compound 3-[10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one, 2h as a TFA salt. MS mlz (MH+) 390.9.
EXAMPLE I
1. LiAIHq.
SH neat S (ON- THF
Br i CN 2. 02N
F Br 1i S Br S Br CI
~~ K2CO3 I~ D I o 0 NH N
DMF
S ~ Br HO
ccxiix__ S Br CHO I/ B-OH
O N
N --j N
5i NaBH(OAc)3 N Pd(PPh3)4 N 4i CH3COOH K2CO3 H CICH2CH2CI O c NMP
/I
S N
N
N
O c Procedure 18 Spiro compound, 11 A mixture of 2-aminothiophenol (4.3 mL, 39.9 mmol) and tropinone (5.6 g, 39.9 mmol) was allowed to stir and sit for 16 h at rt. The mixture was placed under vacuum (<0.3 mm Hg) for 6 h. HPLC-MS analysis revealed -60%
conversion to desired compound, 1 i. The material was used as such for the next reaction.
Procedure 19 [2-(4-Bromo-2-nitrophenylsulfanyl)-phenyl]-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amine, 2i To the mixture obtained from the previous reaction (Procedure 18) was added THF (20 mL), and the mixture was cooled to -78 C. A 1 M solution of lithium aluminum hydride in diethyl ether (60 mL, 60 mmol) was added in portions. The cooling bath was removed. More THF (60 mL) and 10 mL of the 1 M solution of lithium aluminum hydride were added. The mixture was stirred at rt for 90 min, cooled to -78 C, and treated with water (2.6 mL). The cooling bath was removed, and the mixture was allowed to warm to rt. A 1 N NaOH
solution (10.6 mL) was added, and the mixture was allowed to stir for 15 min.
MgSO4 (1 g) and THF (40 mL) were added, and the mixite was filtered. To the filtrate was added 2-fluoro-5-bromo-nitrobenzene (5.4 mL, 43.8 mmol), and the mixture was stirred for 15 min. The reaction mixture was filtered, and the solid was washed with THF (3 x 20 mL) and ethyl acetate (4 x 20 mL). The combined filtrates were evaporated, and the residue was purified via flash column chromatography (eluent gradient: 20% EtOAc containing 1% Et3N in heptane to 20% MeOH containing 1% Et3N in EtOAc), yielding 10 g (55.9%) of title compound [2-(4-bromo-2-nitrophenylsulfanyl)-phenyl]-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amine, 2i as a mixture of endo and exo isomers.
Procedure 20 3-Bromo-l0-(8-methyi-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 3i To a solution of [2-(4-bromo-2-nitrophenylsulfanyl)-phenyl]-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amine, 2i (9.7 g, 21.6 mmol) in DMSO (220 mL) was added potassium carbonate (3.3 g, 23.8 mmol). The mixture was heated under a N2 atmosphere to 170 C for 45 min. The mixture was allowed to cool to rt, diluted with H20 (250 mL), and extracted with EtOAc (4 x 100 mL). The organic phase was dried over Na2SO4, filtered, and evaporated. The residue was purified via flash column chromatography (eluent gradient: 1% Et3N in EtOAc to 30% MeOH in EtOAc containing 1% Et3N), yielding 1.9 g (21.9%) of title compound 3-bromo-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 3i as a mixture of endo and exo isomers. MS m/z (MH+) 401.1/403.1.
Procedure 21 10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-bromo-lOH-phenothiazine, 4i To a solution of 3-bromo-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine, 3i (1.0 g, 2.49 mmol) in 1,2-dichloroethane (15 mL) were added 1-chloroethyl chloroformate (807 L, 7.5 mmol) and N,N-diisopropyl-N-ethylamine (1.4 mL, 7.97 mmol). The mixture was heated to reflux for 2.5 h, allowed to cool to rt, and evaporated. The mixture was evaporated and the residue was dissolved dissolved in methanol (15 mL) and heated to reflux for 1 h. After work-up, the residue was purified via flash column chromatography (eluent gradient: 0 to 30% MeOH in EtOAc containing 1% triethylamine) to yield 150 mg of recovered starting material 3i and 382 mg (66%) of title compound 3-bromo-10-piperidin-4-yl-10H-phenothiazine, 4i as a mixture of endo and exo isomers. MS m/z (MH+) 387.1/389.1.
Procedure 22 3-Bromo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 5i To a solution of 3-bromo-10-piperidin-4-yl-10H-phenothiazine, 4i (11.2 mg; 0.029 mmol) and 3-furyl carboxaldehyde (8.4 mg; 0.087 mmol) in dichloroethane (120 L) was added acetic acid (5 L) and a solution of sodium triacetoxyborohydride (12 mg, 0.057 mmol) in DMF (100 ). The mixture was stirred at rt for 18 h, quenched with water (50 L), and lyophilized. The thus obtained crude 3-bromo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 5i as a mixture of endo and exo isomers was used as such for the next reaction.
Procedure 23 10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yl-10H-phenothiazine, 6i A mixture of 3-bromo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine, 5i (13.5 mg, 0.029 mmol), 3-pyridyl boronic acid (10.7 mg, 0.087 mmol), potassium carbonate (12 mg, 0.087 mmol) and Pd(PPh3)4 (3 mg, 2.5 mol) in NMP (300 L) and H20 (100 L) was heated to 160 C for 10 min in a microwave. The mixture was absorbed onto a 1 g SPE cartridge and eluted (eluent: 10% methanol in ethyl acetate containing 1% triethylamine).
The eluent (-15 mL) was collected and evaporated. The residue was purified via reverse phase HPLC (eluent: acetonitrile in water containing 0.1 % TFA) to yield title compound 10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yl-10H-phenothiazine, 6i as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 466.2.
s HN O
N ~
7i N
o C
N-{2-[10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide, 7i Using an adaptation of the method described in Procedure 23, substituting 2-acetylaminophenyl boronic acid for 3-pyridyl boronic acid, the title compound N-{2-[10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide, 7i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 522.2.
~ S
NI ~
/
8i N
10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-3-pyridi n-3-yI-10F/-phenothiazine, 8i Using an adaptation of the methods described in Procedures 22 and 23, substituting 3-methyl-but-2-enal for 3-furyl carboxaldehyde in Procedure 22, the title compound 10-[8-(3-methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-3-pyridin-3-yl-10H-phenothiazine, 8i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 454.3.
ol ~ S
NI ~
/
9i N
N
\
/
3-Pyridin-3-yI-10-(8-pyridin-2-ylmethyi-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 9i Using an adaptation of the methods described in Procedures 22 and 23, substituting 2-pyridyl carboxaldehyde for 3-furyl carboxaldehyde in Procedure 22, the title compound 3-pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 9i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 477.2.
N
CCNI::
10i N
10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-3-pyridin-4-yI-10H-phenothiazine, 101 Using an adaptation of the methods described in Procedures 22 and 23, substituting 3-methyl-but-2-enal for 3-furyl carboxaldehyde in Procedure 22, and 4-pyridyl boronic acid for 3-pyridyl boronic acid in Procedure 23, the title compound 10-[8-(3-methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-3-pyridin-yl-10H-phenothiazine, 10i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 454.3.
~
cc:x 11i N
N
~ \
/
3-Pyridin-4-yI-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 11 i Using an adaptation of the methods described in Procedures 22 and 23, substituting 2-pyridyl carboxaldehyde for 3-furyl carboxaldehyde in Procedure 22, and 4-pyridyl boronic acid for 3-pyridyl boronic acid in Procedure 23, the title compound 3-pyridin-4-yI-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 11 i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 477.3.
N
aN
12i N
&~S, 3-Pyridin-4-yl-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 121 Using an adaptation of the methods described in Procedures 22 and 23, substituting 2-thiophene carboxaldehyde for 3-furyl carboxaldehyde in Procedure 22, and 4-pyridyl boronic acid for 3-pyridyl boronic acid in Procedure 23, the title compound 3-pyridin-4-yl-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine, 12i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 482.2.
S \ ~ I
13i N
I
N-{2-[10-(8-AI IyI-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoth iazi n-3-yI]-phenyl}-acetamide, 13i Using an adaptation of the methods described in Procedures 22 and 23, substituting propenal for 3-furyl carboxaldehyde in Procedure 22, and 2-acetylaminophenyl boronic acid for 3-pyridyl boronic acid in Procedure 23, the title compound N-{2-[10-(8-allyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide, 13i was obtained as a TFA salt and as a mixture of endo and exo isomers.
I
s (::(N HN O
14i N
N-{2-[10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenothiazin-3-yl]-phenyl}-acetamide, 14i Using an adaptation of the methods described in Procedures 22 and 23, substituting phenyl acetaldehyde for 3-furyl carboxaldehyde in Procedure 22, and 2-acetylaminophenyl boronic acid for 3-pyridyl boronic acid in Procedure 23, the title compound N-{2-[10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-phenothiazin-3-yl]-phenyl}-acetamide, 14i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 546.3.
s / HN O
15i N
NJ
~NI
N-(2-{10-[8-(1 H-Im idazol-2-yl methyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenothiazin-3-yl}-phenyl)-acetamide, 15i Using an adaptation of the methods described in Procedures 22 and 23, substituting 1 H-imidazole-2-carboxaldehyde for 3-furyl carboxaldehyde in Procedure 22, and 2-acetylaminophenyl boronic acid for 3-pyridyl boronic acid in Procedure 23, the title compound N-(2-{10-[8-(1 H-Imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenothiazin-3-yl}-phenyl)-acetamide, 15i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 522.3.
i I
S
16i N
N-{2-[10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide, 16i Using an adaptation of the method described in Procedure 23, substituting 3-bromo-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenothiazine, 3i for 3-bromo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine, 51 and 2-acetylaminophenyl boronic acid for 3-pyridyl boronic acid, the title compound N-{2-[10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide, 16i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS mlz (MH+) 456.2.
I ~ S I N
a 17i N
H
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridi n-3-yl-10H-phenoth iazi ne, 17i Using an adaptation of the method described in Procedure 23, substituting 3-bromo-10-piperidin-4-yI-10H-phenothiazine, 4i for 3-bromo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine, 5i, the title compound 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yI-10H-phenothiazine, 17i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS
m/z (MH+) 386.2.
O
c(x9 18i N
H
N-{2-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phe noth iazi n-3-yl]-phenyl}-acetamide, 18i Using an adaptation of the method described in Procedure 23, substituting 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-bromo-10H-phenothiazine, 4i for 3-bromo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 5i and 2-acetylaminophenyl boronic acid for 3-pyridyl boronic acid, the title compound N-{2-[10-(8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide, 18i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (MH+) 442.2.
S I ~ N
~
N
19i N
10-(8-AI Iyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridi n-3-yI-10H-phenothiazine, 19i Using an adaptation of the methods described in Procedures 22 and 23, substituting 2-propenal for 3-furyl carboxaldehyde in Procedure 22, the title compound 10-(8-allyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yl-10H-phenothiazine, 19i was obtained as a TFA salt and as a mixture of endo and exo isomers. MS m/z (M+1 8+H) 444.2.
s HO CI HO I~ CI
CI OH Boc-N O ~j ~j HN HN
NaBH(OAc)3/HOAc +
NH2 CICH2CH2CI N 1j _2j i i Boc Boc F cc:xydI (fBOH
ON
j K2CO3 Cp2Fe(PtBu2)2PdCl2 DMF N 3j K2CO3 Boc 1,4-dioxane N 4j I
oc C
HO O N
O N Cr TFA %
N N
NaBH(OAc)3 H 5, N 6j Endo-3-(4-C h Ioro-2-hyd roxyphe nyl am i n o)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1j and exo-3-(4-chloro-2-hydroxyphenyl-amino)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2j Using an adaptation of the method described in Procedure 1, substituting 2-amino-5-chlorophenol for 4-amino-3-hydroxybenzoic acid methyl ester and 3-oxo-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester for 8-methyl-8-aza-bicyclo[3.2.1]octan-3-one, a 3:1 mixture of title compounds endo-3-(4-chloro-2-hydroxyphenylamino)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, Ij and exo-3-(4-chloro-2-hydroxyphenyl-amino)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2j was obtained.
Compounds Ij and 2j were separated via flash column chromatography (eluent gradient: 3% to 65% EtOAc in hexane), yielding 70% of endo isomer 1j (first eluting isomer; and 19% of exo isomer 2j (second eluting isomer) Endo-3-(3-Chlorophe noxazi n-10-y1)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 3j Using an adaptation of the method described in Procedure 2, substituting endo-3-(4-chloro-2-hydroxyphenylamino)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 j for the TFA salt of 3-hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-ylamino)-benzoic acid methyl ester, 1a, the title compound endo-3-(3-chlorophenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3j was obtained.
Procedure 24 Endo-3-(3-Pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 4j To a mixture of 3-pyridyl boronic acid (70.1 mg, 0.57 mmol), Cp2Fe(P-tBu2) 2PdCI2 (62 mg, 0.095 mmol), potassium carbonate (88 mg, 0.63 mmol) was added a solution of endo-3-(3-chlorophenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3j (135 mg, 0.317 mmol) in dioxane (3 mL, degassed with argon for 5 min prior to use). The mixture was heated to 120 C for 30 min in a microwave (300 W). The mixture was allowed to cool to rt, water and ethyl acetate were added. The organic layer was separated, dried over MgS04, filtered, and evaporated to yield 195 mg of crude title compound endo-3-(3-pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 4j. The material was used as such for the next reaction.
Procedure 25 Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyri di n-3-yl-10H-phenoxazine, 5j The crude endo-3-(3-pyridin-3-yl-phenoxazin-10-y1)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 4j, obtained from the previous reaction, was treated with TFA (3 mL), and the mixture was stirred for 30 min at rt. The TFA was removed under a nitrogen stream, and the residue was purified via reverse phase HPLC (eluent gradient: 10% to 30% CH3CN in water containing 0.1 % TFA). The desired fractions were combined, lyophilized, and dissolved in diethyl ether. The solution was washed with a saturated NaHCO3 solution. The aqueous phase was washed with diethyl ether, and the combined organic phases were dried over MgSO4, filtered, and evaporated to yield 58 mg (43% for 2 steps) of title compound endo-1 0-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine,5j. MS m/z (MH+) 370.2.
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl )-3-pyridi n-3-yI-10H-phenoxazine, 6j Using an adaptation of the method described in Procedure 9, substituting endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine, 5j for the HCI salt of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b and phenyl acetaldehyde for 2-pyridylcarboxaldehyde, the title compound endo-10-(8-phenethyl-8-aza-bicycio[3.2.1]oct-3-yl)-3-pyridin-3-y1-10H-phenoxazine, 6j was obtained as a TFA salt. MS m/z (MH+) 474.2.
I \ O I ~ \ N
a~
N
N 7j N
~ \
s Endo-3-Pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-10H-phenoxazine, 7j Using an adaptation of the method described in Procedure 9, substituting endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine, 5j for the HCI salt of 10-(8-aza-bicyclo[3.2. 1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b and 2-pyridyl carboxaldehyde for 2-pyridylcarboxaldehyde, the title compound endo-3-pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine, 7j was obtained as a TFA salt. MS m/z (MH+) 461.2.
0 \ N
!~
N
N 8i Endo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yI-10H-phenoxazine, 8j Using an adaptation of the method described in Procedure 9, substituting endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yi)-3-pyridin-3-yl-10H-phenoxazine, 5j for the HCI salt of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b and 3-furaldehyde for 2-pyridylcarboxaldehyde, the title compound endo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine, 8j was obtained as a TFA salt. MS m/z (MH+) 450.2.
O I ~ N
/
N
Endo-3-Pyridi n-3-yI-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine, 9j Using an adaptation of the method described in Procedure 9, substituting endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine, 5j for the HCI salt of (8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine, 4b and 2-thiophene carboxaldehyde for 2-pyridylcarboxaldehyde, the title compound endo-3-pyrid i n-3-y1-10-(8-th io ph e n-2-yl m ethyl-8-aza-b icyclo [3.2.1 ]oct-3-yl )-10H-phenoxazine, 9j was obtained as a TFA salt. MS m/z (MH+) 466.2.
cc:xd10j N
H
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-ch loro-10H-phenoxazine, 10j Using an adaptation of the method described in Procedure 25, substituting endo-3-(3-chloro-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 3j for endo-3-(3-pyridin-3-yl-phenoxazin-1 0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 4j, the title compound endo-l0-(8-aza-bicyclo[3.2.1 ]-oct-3-yl)-3-chloro-10H-phenoxazine, 10j was obtained as a TFA salt after reverse phase HPLC purification (eluent:
CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 327.1.
EXAMPLE K
B,OH IO N/ ~
TFA
e(PtBu2)2PdCl2 Cp2F
N 3j K2CO3 Boc 1,4-dioxane N 1 k Boc e N
N
O
I\ CHO
~I\ aN ~%\ / N
NaBH(OAc)3 3k N 2k CICH2CH2CI N
H
Endo- 3-(3-Pyridin-4-yl-phenoxazin-1O-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1k Using an adaptation of the method described in Procedure 24, substituting 4-pyridyl boronic acid for 3-pyridyl boronic acid, the title compound endo-3-(3-pyrid in-4-yl-phenoxazin-10-y1)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 k was obtained.
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-4-yI-10H-phenoxazine, 2k Using an adaptation of the method described in Procedure 25, substituting endo-3-(3-pyridin-4-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1 k for endo-3-(3-pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 4j, the title compound endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-yl-10H-phenoxazine, 2k was obtained as a TFA salt after reverse phase HPLC
purification (eluent gradient: 10% to 30% CH3CN in water containing 0.1 %
TFA). MS m/z (MH+) 370.2.
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyrid i n-4-yl-10H-phenoxazine, 3k Using an adaptation of the method described in Procedure 9, substituting the TFA salt of endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 2k for the HCI salt of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b and phenyl acetaidehyde for 2-pyridyl carboxaldehyde, the title compound endo-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 3k was obtained as a TFA salt. MS m/z (MH+) 474.3.
N
cc:xe N 4k N
~ \
/
Endo-3-Pyridin-4-y1-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine, 4k Using an adaptation of the method described in Procedure 9, substituting the TFA salt of endo-l0-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 2k for the HCI salt of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b, the title compound endo-3-pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine, 4k was obtained as a TFA salt. MS m/z (MH+) 461.3.
N
c(xN 5k O &-,:, Endo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-3-pyridi n-4-yl-10H-phenoxazine, 5k Using an adaptation of the method described in Procedure 9, substituting the TFA salt of endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 2k for the HCI salt of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b and 3-furaldehyde for 2-pyridylcarboxaldehyde, the title compound endo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yi)-3-pyridin-4-yl-10H-phenoxazine, 5k was obtained as a TFA salt. MS m/z (MH+) 450.3.
N
cXr< ~
N 6k Endo-3-Pyridin-4-y1-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine, 6k Using an adaptation of the method described in Procedure 9, substituting the TFA salt of endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 2k for the HCI salt of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yi)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b and 2-thiophene carboxaldehyde for 2-pyridylcarboxaldehyde, the title compound endo-3-pyridin-4-yl-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine, 6k was obtained as a TFA salt. MS m/z (MH+) 466.2.
EXAMPLE L
F o/
\/ I xyc flfBOH
N N
aj K2CO3 Cp2Fe(PtBua)2PdCI2 N 11 KaCOa I Boc 1,4-dioxane N 21 H20 Boc O N O N
CHO
TFA N I / N
C31 NaBH(OAc)3 41 N CICH2CH2CI (N
H
Exo-3-(3-Chlorophenoxazin-10-yi)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 11 Using an adaptation of the method described in Procedure 2, substituting exo-3-(4-chloro-2-hydroxyphenylamino)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2j for the TFA salt of 3-hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-ylamino)-benzoic acid methyl ester, 1a, the title compound exo-3-(3-chlorophenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 11 was obtained.
Endo- 3-(3-Pyridin-4-yl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 21 Using an adaptation of the method described in Procedure 24, substituting exo-3-(3-chlorophenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 11 for endo-3-(3-chlorophenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3j, the title compound 3-(3-pyridin-4-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 21 was obtained.
Exo-3-(3-Pyrid i n-3-yl-phenoxazi n-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 31 Using an adaptation of the method described in Procedure 25, substituting exo-3-(3-pyridin-3-yl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 21 for endo-3-(3-pyridin-3-yl-phenoxazin-10-y1)-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 4j, the title compound exo-3-(3-pyridin-3-yl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 31 was obtained as a TFA salt after reverse phase HPLC purification (eluent gradient: 10% to 30%
CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 370.2.
Exo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridi n-3-yI-10H-phenoxazine, 41 Using an adaptation of the method described in Procedure 9, substituting the TFA salt of exo-3-(3-pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 31 for the HCI salt of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b and phenyl acetaidehyde for 2-pyridyl carboxaldehyde, the title compound exo-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine, 41 was obtained as a TFA salt. MS m/z (MH+) 474.3.
c(X2N
e N
~ \
e Exo-3-Pyridi n-3-yI-10-(8-pyrid i n-2-ylmethyl-8-aza-bi cyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine, 51 Using an adaptation of the method described in Procedure 9, substituting the TFA salt of exo-3-(3-pyridin-3-yl-phenoxazin-1 0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 31 for the HCI salt of 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine, 4b, the title compound exo-3-pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-yl)-10H-phenoxazine, 51 was obtained as a TFA salt. MS m/z (MH+) 461.3.
I \ O
NI \
e CN
O
Exo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine, 61 Using an adaptation of the method described in Procedure 9, substituting the TFA salt of exo-3-(3-pyridin-3-yl-phenoxazin-1 0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 31 for the HCI salt of 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine, 4b and 3-furaldehyde for 2-pyridyl carboxaldehyde, the title compound exo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-3-yI-10H-phenoxazine, 61 was obtained as a TFA salt. MS m/z (MH+) 450.2.
0 ci I~ le N
H
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-chloro-lOH-phenoxazine, 71 Using an adaptation of the method described in Procedure 25, substituting exo-3-(3-chloro-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 11 for endo-3-(3-pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 4j, the title compound exo-10-(8-aza-bicyclo[3.2.1 ]-oct-3-yl)-3-chloro-10H-phenoxazine, 71 was obtained as a TFA salt after reverse phase HPLC purification (eluent:
CH3CN in water containing 0.1% TFA). MS m/z (MH+) 327.1.
EXAMPLE M
O CI OH B,oH c:xi N
TFA
Cp2Fe(PtBua)2PdC12 CN , ll KzCO3 N 1m Boc 1,4-dioxane C
H2o I
Boc N N
N \
~
~
NaBH(OAc)3 a CICH2CH2CI N2m \N 3m H
/ I
\
Exo- 3-(3-Pyridin-4-yl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 m Using an adaptation of the method described in Procedure 24, substituting 4-pyridyl boronic acid for 3-pyridyl boronic acid, the title compound exo-3-(3-pyridin-4-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 m was obtained.
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridi n-4-y1-10H-phenoxazine, 2m Using an adaptation of the method described in Procedure 25, substituting exo-3-(3-pyridin-4-yl-phenoxazin-10-y1)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 11 for endo-3-(3-pyridin-3-yl-phenoxazin-yI)-8-aza-bicyclo[3.2.1 ]-octane-8-carboxyiic acid tert-butyl ester, 4j, the title compound exo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 2m was obtained as a TFA salt after reverse phase HPLC
purification (eluent gradient: 10% to 30% CH3CN in water containing 0.1 %
TFA). MS m/z (MH+) 370.2.
Exo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridi n-4-yl-10H-phenoxazine, 3m Using an adaptation of the method described in Procedure 9, substituting the TFA salt of ex -10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 2m for the HCI salt of 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b and phenyl acetaldehyde for 2-pyridyl carboxaldehyde, the title compound exo-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 3m was obtained as a TFA salt. MS m/z (MH+) 474.3.
N
N I \
aCN 0 ~
4m N
~ \
/
Exo-3-Pyri d i n-4-yI-10-(8-pyrid i n-2-yl m ethyl-8-aza-bi cyclo[3.2.1 ] oct-3-yl)-10H-phenoxazine, 4m Using an adaptation of the method described in Procedure 9, substituting the TFA salt of exo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 2m for the HCI salt of 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1 f-f-tetrazol-5-yl)-10f-f-phenoxazine, 4b, the title compound ex -3-pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine, 4m was obtained as a TFA salt. MS m/z (MH+) 461.2.
N
cc:c* CN 5m O c Exo-10-(8-Fu ran-3-yl methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridi n-4-yl-10H-phenoxazine, 5m Using an adaptation of the method described in Procedure 9, substituting the TFA salt of exo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 2m for the HCI salt of 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 4b and 3-furaldehyde for 2-pyridyl carboxaldehyde, the title compound exo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 5m was obtained as a TFA salt. MS m/z (MH+) 450.2.
EXAMPLE N
CH F CN
NaN3.
~
NH 2N CN N --~
(N 2b DMF CN In i i Boc Boc C N_NN C N_NN
1-55 I~ ~ H
N H HCI N
2n dioxane 3n N N
Boc H
Exo- 3-(3-Cyano-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 n Using an adaptation of the method described in Procedure 6, substituting exo-3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2b for endo-3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1b, the title compound exo- 3-(3-cyano-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 n was obtained. MS m/z (MH+) 439.9.
Exo-3-[3-(1 H-Tetrazol-5-yl)-phenoxazin-10-y1]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2n Using an adaptation of the method described in Procedure 7, substituting exo-3-(3-cyano-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 n for endo-3-(3-cyano-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 3b, the title compound exo-3-[3-(1 H-tetrazol-5-yl)-phenoxazin-l0-yl]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2n was obtained. MS
m/z (MH+) 460.9.
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-(I H-tetrazol-5-yl)-10H-phenoxazine, 3n Using an adaptation of the method described in Procedure 8, substituting exo-3-[3-(1 H-tetrazol-5-yl)-phenoxazin-10-yI]-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 2n for endo-3-[3-(1H-tetrazol-5-yl)-phenoxazin-10-yI]-8-aza-bicyclo[3.2.1]-octane-8-carboxylic acid tert-butyl ester, 4b, the title compound exo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yI)-10H-phenoxazine, 3n was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1% TFA). MS m/z (MH+) 360.9.
QZXYCN
4n N
H
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi ne-3-carbonitrile, 4n Using an adaptation of the method described in Procedure 25, substituting exo- 3-(3-cyano-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 n for endo-3-(3-pyridin-3-yl-phenoxazin-1 0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 4j, and using a 1:1 solution of TFA;CH2CI2 instead of neat TFA, the title compound exo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 4n was obtained as a TFA salt after reverse phase HPLC purification (eluent gradient: 20% to 45%
CH3CN in water containing 0.1% TFA). MS m/z (MH+) 317.9.
NOH N-O
0N)OINH2OH.HCI O CN I~ O I~ NH2 CDI
N aN
K2C03 dioxane EtOH -N 1n 'N lo CN 2o Boc Boc Boc O
HCI ~ O N- ~ / H
dioxane N
3o N
H
Exo-3-[3-(N-Hyd roxycarbam i m idoyl )-phe noxazi n-10-y1]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1o Using an adaptation of the method described in Procedure 11, substituting exo-3-(3-cyano-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, In for endo-3-(3-cyano-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3b, the title compound exo-3-[3-(N-hydroxycarbamimidoyl)-phenoxazin-10-yI]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, lo was obtained. MS
m/z (MH+) 450.9.
Exo-3-[3-(5-Oxo-4, 5-d i hyd ro-[1, 2,4] oxad i azol-3-yl )-phe n oxazi n-10-yI]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2o Using an adaptation of the method described in Procedure 12, substituting exo-3-[3-(N-hydroxycarbamimidoyl)-phenoxazin-10-y1]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1o for the mixture of endo-3-[3-(N-hydroxycarbamimidoyl)-phenoxazin-1 0-yl]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 d and endo-3-(3-carbamoyl-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2d, the title compound exo-3-[3-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-phenoxazin-l0-yl]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2o was obtained.
Exo-3-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenoxazi n-3-yl]-4H-[1,2,4]oxadiazol-5-one, 3o Using an adaptation of Procedure 8, and substituting exo-3-[3-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-phenoxazin-l0-yi]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2o for endo-3-[3-(1 f-/-tetrazol-5-yl)-phenoxazin-10-y1]-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 4b, the title compound exo-3-[10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one, 3o was obtained as TFA salt after purification via reverse phase HPLC (eluent gradient: 20% to 45% CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 376.8.
EXAMPLE P
MeO I~ CN HO I~ CN
~
Me0 CN
+ ~\% ~
Cs2CO3 HN BBr3 HN
~
Me DMF CH2CI2 N lp i 2p F OMe OH
~
~ Me cOCN
BBr3 -.~ N ]
DMF
N 3p 4p I ~
3-M eth oxy-4-(8-m eth yl-8-aza-b i cyc l o[3.2.1 ] oct-3-yl a m i n o)-benzonitrile, 1 p Using an adaptation of Procedure 2, substituting 8-methyl-8-aza-bicyclo[3.2.1]oct-3-ylamine for the TFA salt of 3-hydroxy-4-(8-methyl-8-aza-bicyclo[3.2. 1 ]oct-3-ylamino)-benzoic acid methyl ester, 1a, 1-fluoro-3-methoxy-2-nitrobenzene, 1e for 2-fluoronitrobenzene, and cesium carbonate for potassium carbonate, the title compound 3-methoxy-4-(8-methyl-8-aza-bicyclo[3.2. 1 ]oct-3-ylamino)-benzonitrile, 1p was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC
(eluent gradient: 20% to 45% CH3CN in water containing 0.1 % TFA). MS m/z=
272 (M+1).
3-Hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-ylam ino)-benzonitrile, 2p Using an adaptation of Procedure 13, substituting the TFA salt of 3-methoxy-4-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-ylamino)-benzonitrile, 1 p for the TFA salt of 6-methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 6e, the title compound 3-hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-ylamino)-benzonitrile, 2p was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC (eluent gradient: 20% to 45% CH3CN in water containing 0.1 %
TFA). MS m/z= 258 (M+1).
6-Methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 3p Using an adaptation of Procedure 2, substituting the TFA salt of 3-hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-ylamino)-benzonitrile, 2p for the TFA salt of 3-hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-ylamino)-benzoic acid methyl ester, 1a, and 1-fluoro-3-methoxy-2-nitrobenzene, 1e for 2-fluoronitrobenzene, the title compound 6-methoxy-1 0-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 3p was obtained as TFA
salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC (eluent gradient: 20% to 45% CH3CN in water containing 0.1 %
TFA). MS m/z= 362 (M+1).
6-Hyd roxy-l0-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 4p Using an adaptation of Procedure 13, substituting the TFA salt of 6-methoxy-1 0-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl )-10H-phenoxazi ne-3-carbonitrile, 3p for the TFA salt of 6-methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 6e, the title compound 6-hydroxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carbonitrile, 4p was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC (eluent gradient: 20% to 45% CH3CN in water containing 0.1% TFA). MS m/z= 348 (M+1)=
EXAMPLE Q
1. OaCHO
~ S ~ Br NaBH(OAc)3 ~
~ \ S ~ \ N
~ N CICH2CH2CI
1q HN
~= N
N
H 4i Herrmann's O ~
catalyst -Mo(CO)6 DBU
THF
Procedure 26 [10-(8-Furan-3-yi methyl-8-aza-bicyclo[3.2.1 ] oct-3-yl)-10H-phenothiazin-3-yl]-pyrrolidin-1-yl-methanone, 1 q To a solution of a mixture of endo and exo isomers of 3-bromo-10-piperidin-4-yl-10H-phenothiazine, 4i (15 mg, 0.04 mmol) in dichloroethane (0.4 mL) were added 3-furaldehyde (10 L, 0.12 mmol), acetic acid (5 L) and sodium triacetoxy-borohyd ride (17 mg, 0.08 mmol). The mixture was allowed to stir at rt for 16 h, and quenched with a 2N NaOH solution (200 L). The mixture was absorbed onto a 1 g SPE cartridge and eluted (eluent: 10%
methanol in ethyl acetate containing 1% triethylamine). The eluent (-15 mL) was collected and evaporated. The residue was dissolved in THF (0.4 mL), and pyrrolidine (19 L, 0.15 mmol), Mo(CO)6 (16 mg, 0.06 mmol), Herrmann's catalyst (6 mg, 0.006 mmol), and DBU (27 L, 0.18 mmol) were added. The mixture was irradiated in a microwave oven at 150 C for 15 min. The mixture was evaporated, and the residue was purified via reverse phase HPLC (eluent gradient: CH3CN in water containing 0.1 % TFA) to yield [10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-pyrrolidin-1-yl-methanone, 1 q as a TFA salt and as a mixture of endo and exo isomers. MS
m/z (MH+) 486.2.
C S
N
2q N
[10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoth iazi n-3-yl]-pyrrolidin-1-yl-methanone, 2q Using an adaptation of Procedure 26, substituting phenyl acetaldehyde for 3-furaldehyde, the title compound [1 0-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-10H-phenothiazin-3-yl]-pyrrolidin-1-yl-methanone, 2q was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC (eluent gradient: 20% to 45% CH3CN in water containing 0.1 %
TFA). MS m/z= 510.3 (M+1).
alo~ S e N~/
N 3q {10-[8-(3-Methyi-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenothiazin-3-yl}-pyrrolidin-1-yl-methanone, 3q Using an adaptation of Procedure 26, substituting 3-methyl-but-2-enal for 3-furaldehyde, the title compound {1 0-[8-(3-methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenothiazin-3-yl}-pyrrolidin-1-yl-methanone, 3q was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC (eluent gradient: 20% to 45% CH3CN in water containing 0.1% TFA). MS m/z= 474.2 (M+1).
O
S N
OH
4q N
O
[10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenothiazin-3-yl]-(3-hydroxy-pyrrolidin-1-yl)-methanone, 4q Using an adaptation of Procedure 26, substituting 3-hydroxypyrrolidine for pyrrolidine, the title compound [1 0-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-(3-hydroxy-pyrrolidin-1-yl)-methanone, 4q was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC (eluent gradient: 20% to 45%
CH3CN in water containing 0.1 % TFA). MS m/z= 502.2 (M+1).
O
S N
OH
5q N
(3-Hydroxy-pyrrolidin-1-yi)-[10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yi]-methanone, 5q Using an adaptation of Procedure 26, substituting phenyl acetaidehyde for 3-furaidehyde and 3-hydroxypyrrolidine for pyrrolidine, the title' compound (3-hydroxy-pyrrolidin-l-yl)-[10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-phenothiazin-3-yl]-methanone, 5q was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC (eluent gradient: 20% to 45% CH3CN in water containing 0.1 % TFA). MS m/z= 526.2 (M+1).
O
S N
I
OH
N
6q N
{10-[8-(3-Methyl-but-2-enyl )-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenothiazin-3-yl}-(3-methyl-pyrrolidin-1-yl)-methanone, 6q Using an adaptation of Procedure 26, substituting 3-methyl-but-2-enal for 3-furaldehyde and 3-hydroxypyrrolidine for pyrrolidine, the title compound {10-[8-(3-methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenoth iazi n-yl}-(3-methyl-pyrrolidin-1-yl)-methanone, 6q was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC
(eluent gradient: 20% to 45% CH3CN in water containing 0.1% TFA). MS m/z=
490.2 (M+1).
EXAMPLE R
O
C S ~\ Br HN S &NC) N Herrmann's N
A 3i catalyst 1 r Mo(CO)6 N DBU N
~ THF ~
Procedure 27 [10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazi n-3-yl]-pyrrolidin-l-yl-methanone, 1 r To a solution of 3-bromo-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 3i (15 mg, 0.04 mmol) in THF (0.3 mL) was added pyrrolidine (12 L, 0.15 mmol), Mo(CO)s (16 mg, 0.06 mmol), Herrmann's catalyst (6 mg, 0.006 mmol), and DBU (27 L, 0.18 mmol), and the mixture was irradiated in a microwave oven at 150 C for 15 min. The mixture was evaporated, and the residue was purified via reverse phase HPLC (eluent gradient: CH3CN in water containing 0.1% TFA) to yield [10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-pyrrolidin-l-yl-methanone, I r as a TFA salt and a mixture of endo and exo isomers. MS m/z (MH+) 420.2.
S N~OH
N
IA2r N
I
(3-Hydroxy-pyrrolidin-l-yI)-[10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-10H-phenothiazin-3-yl]-methanone, 2r Using an adaptation of Procedure 27, substituting 3-hydroxypyrrolidine for pyrrolidine, the title compound (3-hydroxy-pyrrolidin-1-yl)-[10-(8-methyl-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazin-3-yl]-methanone, 2r was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC (eluent gradient: 20% to 45% CH3CN in water containing 0.1 % TFA). MS m/z= 436.2 (M+1).
S
N )eHA3r N
I
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoth iazi ne-3-carboxylic acid ethylamide, 3r Using an adaptation of Procedure 27, substituting ethylamine for pyrrolidine, the title compound 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carboxylic acid ethylamide, 3r was obtained as TFA salt and as a mixture of endo and exo isomers after purification via reverse phase HPLC
(eluent gradient: 20% to 45% CH3CN in water containing 0.1% TFA). MS m/z=
394.2 (M+1).
EXAMPLE T
O
01( OH O 02N N/~ I ~\ N/\
NH
~~ N /
F/ TFA
N DMF N 1t lb goc Boc p e O 0 cc I/ N ~ ~
I/ ~ S CHO N
I
NaBH(OAc)3 N
N
2t CICH2CH2CI 3t K'iI:i Endo-3-(3-Diethylcarbamoyl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1t Using an adaptation of Procedure 6, and substituting endo-3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1b for 3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1b, the title compound endo-3-(3-diethylcarbamoyl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1t was obtained. The crude material was used as such in the next reaction.
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-1 H-phenoxazine-3-carboxylic acid diethylamide, 2t Using an adaptation of Procedure 25, substituting endo-3-(3-d iethylcarbamoyl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, It for endo-3-(3-pyridin-3-yi-phenoxazin-1 0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 4j, and using a 25%
solution of TFA in methylene chloride instead of neat TFA, the title compound endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2t was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 392.1.
Endo-10-(8-Thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenoxazine-3-carboxylic acid diethylamide, 3t Using an adaptation of Procedure 9, and substituting endo-10-(8-aza-bicyclo-[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2t for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yi)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, thiophene-2-carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohyd ride for sodium triacetoxybo ro hyd ride, and tetrahydrofuran for dichloroethane, the title compound endo-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 3t was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 488.1.
I / I / \
N
N 4t ~ \
/
Endo-1 0-(8-Pyridi n-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 4t Using an adaptation of Procedure 9, and substituting endo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2t for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazi ne, 5b, tetrabutylammonium triacetoxyborohydride for sodium triacetoxyborohydride, and tetrahydrofuran for dichloroethane, the title compound endo-1 0-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2. 1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 4t was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 483.1.
N ~ N~
~~
N
5t N
Endo-10-(8-Thiazol-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenoxazine-3-carboxylic acid diethylamide, 5t Using an adaptation of Procedure 9, and substituting endo-10-(8-aza-bicyclo-[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2t for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, thiazol-2-ylmethyl carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohydride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloroethane, the title compound endo-1 0-(8-thiazol-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 5t was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1% TFA). MS m/z (MH+) 489.1.
N
N
N
6t Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 6t Using an adaptation of Procedure 9, and substituting endo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2t for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, phenyl acetaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxy-bo rohyd ride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloro-ethane, the title compound endo-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 6t was obtained as a TFA salt after purification via reverse phase HPLC (eluent:
CH3CN in water containing 0.1 % TFA).
p N ~ N~\
~/
N
7t N
I , Endo-10-(8-Pyridin-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 7t Using an adaptation of Procedure 9, and substituting endo-10-(8-aza-bicyclo-[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2t for endo-l0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, 3-pyridyl carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxy-borohydride for sodium triacetoxyborohydride, and tetrahydrofuran for dichloro-ethane, the title compound endo-10-(8-pyridin-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 7t was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1% TFA). MS m/z (MH+) 483.1.
0 ~ N
~/
N
N
j8t Endo-10-[8-(3-Methyl-but-2-enyl)-8-aza-bicycio[3.2.1 ]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide Using an adaptation of Procedure 9, and substituting endo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2t for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, 3-methyl-but-2-enyl carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohyd ride for sodium triacetoxyborohydride, and tetrahydrofuran for dichloroethane, the title compound endo-10-[8-(3-methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide, 8t was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 460.1.
C ~ ~ N~\
~~
N
N
N ~ 9t N
Endo-10-[8-(1 H-Im idazol-2-yl methyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide, 9t Using an adaptation of Procedure 9, and substituting endo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2t for endo-1 0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, 1 H-imidazol-2-ylmethyl carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohyd ride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloroethane, the title compound endo-10-[8-(1 H-imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1 ]ocfi-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide, 9t was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 472.1.
~ 0 N
~
N
N
10t ~ \
/
Endo-10-(8-Benzyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi ne-3-carboxylic acid diethylamide, 10t Using an adaptation of Procedure 9, and substituting endo-10-(8-aza-bicyclo-[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2t for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, benzaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohyd ride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloroethane, the title compound endo-10-(8-benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 10t was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 482.1.
EXAMPLE U
/ OH O O
02N / N~ I\ I\ N
NH
F N /
TFA
- _ -~
i DMF CN lu 1 b Boc Boc 0 O \ N~
O N/\ I /
S CHO N
N \ ~
NaBH(OAc)3 N
H 2u CICH2CH2CI 3u Exo-3-(3-Diethylcarbamoyl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1u Using an adaptation of Procedure 6, and substituting exo-3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2b for 3-(2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1b, the title compound exo-3-(3-diethylcarbamoyl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 u was obtained. The crude material was used as such in the next reaction.
Exo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxyl ic acid diethylamide, 2u Using an adaptation of Procedure 25, substituting exo-3-(3-d iethylcarbamoyl-phenoxazin-10-y1)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1u for endo-3-(3-pyridin-3-yl-phenoxazin-1 0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 4j, and using a 25%
solution of TFA in methylene chloride instead of neat TFA, the title compound exo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2u was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 392.1.
Exo-10-(8-Phe nethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phe noxazi ne-3-carboxylic acid diethylamide, 3u Using an adaptation of Procedure 9, and substituting exo-10-(8-aza-bicyclo-[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2u for endo-1 0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, phenyl acetaidehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxy-borohydride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloro-ethane, the title compound exo-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 3u was obtained as a TFA salt after purification via reverse phase HPLC (eluent:
CH3CN in water containing 0.1 % TFA). MS m/z (MH+) ~ N~\
~
N~~
N
4u N ~
Exo-10-(8-Pyridin-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 4u Using an adaptation of Procedure 9, and substituting exo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2u for endo-1 0-(8-aza-bicyclo[3.2. 1 ]oct-3-yl)-3-(1 f-/-tetrazol-5-yl)-10H-phenoxazi ne, 5b, 3-pyridyl carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxy-borohyd ride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloro-ethane, the title compound exo-10-(8-pyridin-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 4u was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 483.1.
NI ~ N~
CN
S 5u ~ ~
Exo-10-(8-Th iophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 5u Using an adaptation of Procedure 9, and substituting exo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2u for endo-1 0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, thiophene-2-carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohydride for sodium triacetoxyborohydride, and tetrahydrofuran for dichloroethane, the title compound exo-1 0-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 5u was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 488.1.
0 ~ N~
~/
N
CN
6u Exo-10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yi]-10H-phenoxazine-3-carboxylic acid diethylamide, 6u Using an adaptation of Procedure 9, and substituting exo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2u for endo-1 0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, 3-methyl-but-2-enyl carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohyd ride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloroethane, the title compound exo-10-[8-(3-methyl-but-2-enyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide, 6u was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 460.1.
O N
C-N
N 7u ~ \
/
Exo-1 0-(8-Pyridi n-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 7u Using an adaptation of Procedure 9, and substituting exo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2u for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, tetrabutylammonium triacetoxyborohydride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloroethane, the title compound exo-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 7u was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 483.1.
O ~ N
~/
N
N
~ 8u ~ /
Exo-10-(8-Be nzyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 8u Using an adaptation of Procedure 9, and substituting exo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10F/ phenoxazine-3-carboxylic acid diethylamide, 2u for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 I I tetrazol-5-yl)-10H-phenoxazine, 5b, benzaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohyd ride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloroethane, the title compound exo-10-(8-benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 8u was obtained as a TFA
salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 482.1.
N~ \ NI/\
s CN
S~ 9u -N
Exo-10-(8-Thiazol-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 9u Using an adaptation of Procedure 9, and substituting exo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2u for endo-l0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, thiazol-2-ylmethyl carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohydride for sodium triacetoxyborohydride, and tetrahydrofuran for dichioroethane, the title compound exo-10-(8-thiazol-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 9u was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1% TFA). MS m/z (MH+) 489.1.
O ~ N
~~
N
N
10u o Exo-10-(8-Furan-3-yl methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 10u Using an adaptation of Procedure 9, and substituting exo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2u for endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, thiazol-2-ylmethyl carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohyd ride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloroethane, the title compound exo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]-oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 10u was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 472.1.
H N
N- 11u N
Exo-10-[8-(1 H-Imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1]oct-3-yi]-10H-phenoxazine-3-carboxylic acid diethylamide, 11 u Using an adaptation of Procedure 9, and substituting exo-10-(8-aza-bicyclo-[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 2u for endo-1 0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenoxazine, 5b, 1 H-imidazol-2-ylmethyl carboxaldehyde for 2-pyridyl carboxaldehyde, tetrabutylammonium triacetoxyborohyd ride for sodium triacetoxyborohyd ride, and tetrahydrofuran for dichloroethane, the title compound xxo-10-[8-(1 H-imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1 ]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide, 11u was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 /o TFA). MS
m/z (MH+) 472.1.
EXAMPLE V
HO \ CI F OMe OH
(/ I o \ O CI B-OH
HN N02 / I~
OMe N N
1j K2C03 Cp2Fe(PtBu2)2PdCI2 Boc N Iv 1,4-dioxane Boc OMe o i OH / i O N
~/ N\ CHO
O N BBr3 XNX) /
N 3v NaBH(OAc)3 N 2v N NaOAc OH
x O I ~ N
N ~
A4v N
N
~ \
/
Endo-3-(3-Chloro-6-methoxy-phenoxazi n-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1v Using an adaptation of Procedure 2, and substituting 6-fluoro-2-methoxy-nitrobenzene, 1e for 4-fluoro-3-nitrobenzonitrile and endo-3-(4-chloro-2-hydroxy-phenylamino)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1 j for the TFA salt of 3-hydroxy-4-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-ylamino)-benzoic acid methyl ester, 1 a, the title compound endo-3-(3-chloro-6-methoxy-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1v was obtained. MS m/z (MH+) 457.2.
Endo-3-(6-Methoxy-3-pyridin-3-yl-phenoxazi n-10-y1)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2v Using an adaptation of the method described in Procedure 24, substituting endo-3-(3-chloro-6-methoxy-phenoxazin-10-y1)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1v for endo-3-(3-chlorophenoxazin-10-yI)-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 3j, the title compound endo-3-(6-methoxy-3-pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2v was obtained. MS m/z (MH+) 500.3.
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-7-pyridin-3-yl-10H-phenoxazin-4-ol, 3v Using an adaptation of the method described in Procedure 16, substituting endo-3-(6-methoxy-3-pyridin-3-yl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 2v for the TFA salt of 6-methoxy-l0-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl )-10H-phenoxazi ne-3-carboxylic acid diethylamide, 6e, the title compound endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-3-yl-10H-phenoxazin-4-ol, 3v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1% TFA). MS m/z (MH+) 386.1.
Endo-7-Pyridi n-3-yI-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-10H-phenoxazin-4-ol, 4v Using an adaptation of the method described in Procedure 1, substituting the TFA salt of endo-l0-(8-aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-3-yl-10H-phenoxazin-4-ol, 3v for 4-amino-3-hydroxybenzoic acid methyl ester, and 2-pyridyl carboxaldehyde for 8-methyl-8-aza-bicyclo[3.2.1 ]octan-3-one, the title compound endo-7-pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-4-ol, 4v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA).
MS m/z (MH+) 477.2.
OMe 0 (N:1::rCl I N 5v H
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-ch loro-6-methoxy-10H-phenoxazine, 5v Using an adaptation of the method described in Procedure 25, substituting the TFA salt of endo-7-pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-4-ol, 4v for endo-3-(3-pyridin-3-yl-phenoxazin-1 0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 4j, the title compound endo-10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-chloro-6-methoxy-10H-phenoxazine, 5v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA).
MS m/z (MH+) 357.1.
OMe / I
O N
N
N 6v H
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-3-pyridi n-3-yl-10H-phenoxazine, 6v Using an adaptation of the method described in Procedure 25, substituting endo-3-(6-methoxy-3-pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2v for endo-3-(3-pyridin-3-yl-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 4j, the title compound endo-l0-(8-aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-3-pyridin-3-yl-10H-phenoxazine, 6v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 /o TFA). MS m/z (MH+) 400.2.
OMe ~ I
O ~ N
N ~ i N 7v N
\
/
Endo-6-M ethoxy-3-pyri d i n-3-y1-10-(8-pyri d i n-2-yl m ethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine, 7v Using an adaptation of the method described in Procedure 1, substituting endo-3-(6-methoxy-3-pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 2v for 4-amino-3-hydroxybenzoic acid methyl ester, and 2-pyridyl carboxaldehyde for 8-methyl-8-aza-bicyclo[3.2.1]octan-3-one, the title compound endo-6-methoxy-3-pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine, 7v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 491.2.
OH N
O
NO
N 8v H
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-7-pyridi n-4-yi-10H-phenoxazin-4-ol, 8v Using an adaptation of the methods described in Procedures 24 and 16, substituting endo-3-(3-chloro-6-methoxy-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, lv for endo-3-(3-chlorophenoxazin-10-yl)-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 3j, and 4-pyridylboronic acid for 3-pyridylboronic acid in Procedure 24, the title compound endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-4-yl-10H-phenoxazin-4-ol, 8v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 386.2.
OH N
O
NO
N 9v N
\
Endo-7-Pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-4-ol, 9v Using an adaptation of the method described in Procedure 1, substituting the TFA salt of endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-4-yl-10H-phenoxazin-4-ol, 8v for 4-amino-3-hydroxybenzoic acid methyl ester, and 2-pyridyl carboxaldehyde for 8-methyl-8-aza-bicyclo[3.2.1 ]octan-3-one, the title compound endo-7-pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-4-ol, 9v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA).
MS m/z (MH+) 477.3.
OH N
O \ ~ I
N
N 10v Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-7-pyrid i n-4-yl-10H-phenoxazi n-4-ol, 10v Using an adaptation of the method described in Procedure 1, substituting the TFA salt of endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-4-yl-10H-phenoxazin-4-ol, 8v for 4-amino-3-hydroxybenzoic acid methyl ester, and phenyl acetaidehyde for 8-methyl-8-aza-bicyclo[3.2.1]octan-3-one, the title compound endo-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-7-pyridin-4-yl-10H-phenoxazin-4-ol, 10v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA).
MS m/z (MH+) 490.3.
OMe \ ~ I
NI
N 11v H
Endo-10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-3-pyrid i n-4-yl-10H-phenoxazine, 11v Using an adaptation of the methods described in Procedures 24 and 25, substituting endo-3-(3-chloro-6-methoxy-phenoxazin-l0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1v for endo-3-(3-chlorophenoxazin-10-yI)-8-aza-bicyclo[3.2.1 ]-octane-8-carboxylic acid tert-butyl ester, 3j, and 4-pyridylboronic acid for 3-pyridylboronic acid in Procedure 24, the title compound endo-10-(8-aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-3-pyridin-4-yl-10H-phenoxazine, 11v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA).
MS m/z (MH+) 400.2.
OMe / N
\ O I \ ~ I
N
N 12v N
\
/
Endo-6-Methoxy-3-pyridin-4-y1-10-(8-pyridi n-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi ne, 12v Using an adaptation of the method described in Procedure 1, substituting the TFA salt of endo-l0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-pyridin-4-yl-10H-phenoxazine, 11v for 4-amino-3-hydroxybenzoic acid methyl ester, and 2-pyridyl carboxaldehyde for 8-methyl-8-aza-bicyclo[3.2.1]octan-3-one, the title compound endo-6-methoxy-3-pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine, 12v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 491.2.
OMe / N
~
N
N 13v Endo-6-Methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-pyridin-4-y1-10H-phenoxazine, 13v Using an adaptation of the method described in Procedure 1, substituting the TFA salt of endo-1 0-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-3-pyridin-4-y1-10H-phenoxazine, 11v for 4-amino-3-hydroxybenzoic acid methyl ester, and phenyl acetaldehyde for 8-methyl-8-aza-bicyclo[3.2.1 ]octan-3-one, the title compound endo-6-methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine, 13v was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 504.3.
EXAMPLE X
O
B'O
NH O
eI:_,H ci ~\
O \
aN ~
~ Is O
N r TFA
Cp2Fe(PtBu2)aPdCIa N 3,j K2CO3 Boc 1,4-dioxane N lx H2O Boc ~ \ I
aN \ CHO O HN O /HN
N -rO
NaBH(OAc)3 N 2x N 3x H
Endo-3-[3-(2-Acetylaminophenyl)-phenoxazin-10-yI]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1x Using an adaptation of the method described in Procedure 24, substituting N-[2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide for 3-pyridyl boronic acid, the title compound endo-3-[3-(2-acetylaminophenyl)-phenoxazin-1 0-yl]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1x was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA).
Endo-N-{2-[10-(8-Aza-bi cyclo[3.2.1 ]oct-3-y1l)-10H-phenoxazi n-3-yl]-phenyl}-acetamide, 2x Using an adaptation of Procedure 25, substituting the TFA salt of endo-3-[3-(2-acetylaminophenyl)-phenoxazin-10-yI]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1x for endo-3-(3-pyridin-3-yl-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 4j, the title compound endo-N-{2-[10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide, 2x was obtained as a TFA salt after purification via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 426.2.
Endo-N-{2-[10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide, 3x Using an adaptation of the method described in Procedure 1, substituting the TFA salt of endo-N-{2-[10-(8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide, 2x for 4-amino-3-hydroxybenzoic acid methyl ester, and phenyl acetaidehyde for 8-methyl-8-aza-bicyclo[3.2.1 ]octan-3-one, the title compound endo-N-{2-[10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide, 3x was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 530.3.
i I
C O N HN O
N 4x Endo-N-{2-[10-(8-Th i ophe n-2-yl m ethyl-8-aza-bi cyclo[3.2.1 ] oct-3-yl )-10H-phenoxazin-3-yl]-phenyl}-acetamide, 4x Using an adaptation of the method described in Procedure 1, substituting the TFA salt of endo-N-{2-[10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-1 H-phenoxazin-3-yl]-phenyl}-acetamide, 2x for 4-amino-3-hydroxybenzoic acid methyl ester, and 2-thiophene carboxaldehyde for 8-methyl-8-aza-bicyclo[3.2.1]octan-3-one, the title compound endo-N-{2-[10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide, 4x was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 522.2.
i I
C N HN T O
N 5x N
~ \
/
Endo-N-{2-[10-(8-Pyri d i n-2-yl m ethyl-8-aza-bi cyc lo[3.2.1 ] oct-3-yl )-10H-phenoxazin-3-yl]-phenyl}-acetamide, 5x Using an adaptation of the method described in Procedure 1, substituting the TFA salt of endo-N-{2-[10-(8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide, 2x for 4-amino-3-hydroxybenzoic acid methyl ester, and 2-pyridyl carboxaldehyde for 8-methyl-8-aza-bicyclo[3.2.1]octan-3-one, the.title compound endo-N-{2-[10-(8-pyridin-2-yl methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi n-3-yl]-phenyl}-acetam ide, 5x was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 517.2.
EXAMPLE Y
1. 0 B-O coo G(NX121O
Cp2Fe(PtBu2)2PdCI2 CN K2CO3 1 Boo 1,4-dioxane N Cy 2.TFA
Exo-N-{2-[10-(3-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazi n-3-yl]-phenyl}-acetamide, ly Using an adaptation of the methods described in Procedures 24 and 25, and substituting exo-3-(3-chlorophenoxazin-l0-yl)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1I for endo-3-(3-chlorophenoxazin-10-yI)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3j, and N-[2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide for 3-pyridyl boronic acid in Procedure 24, the title compound exo-N-{2-[10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide, ly was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 426.2.
EXAMPLE Z
O
OMe ~ B,O OMe O ~ / NH
N O ( N O ~ ~ / / HN
~
1v CpaFe(PtBu2)2PdCi2 N K2CO3 N 1z Boc 1,4-dioxane Boc OH /
\ ~ I
BBr3 HN 0 N ~ /
2z N
H
Endo-3-[3-(2-Acetyl am i n ophe nyl )-6-methoxy-phe n oxazi n-10-y1]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 1z Using an adaptation of the method described in Procedure 24, substituting N-[2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide for 3-pyridyl boronic acid, the title compound endo-3-[3-(2-acetylaminophenyl)-6-methoxy-phenoxazin-1 0-yl]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, lz was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 %
TFA).
Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl )-6-hydroxy-10H-phenoxazin-3-yi]-phenyl}-acetamide, 2z Using an adaptation of the method described in Procedure 16, substituting the TFA salt of endo-3-[3-(2-acetylaminophenyl)-6-methoxy-phenoxazin-10-yl]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1z for the TFA salt of 6-methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 6e, the title compound endo-N-{2-[10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-6-hydroxy-10H-phenoxazin-3-yl]-phenyl}-acetamide, 2z was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 442.2.
OMe /
O
I o N I i HN O
3z N
H
Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-10H-phenoxazin-3-yl]-phenyl}-acetamide, 3z Using an adaptation of the method described in Procedure 25, substituting the TFA salt of endo-3-[3-(2-acetylaminophenyl)-6-methoxy-phenoxazin-10-yI]-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 1z for endo-3-(3-pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 4j, the title compound endo-N-{2-[10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-10H-phenoxazin-3-yl]-phenyl}-acetamide, 3z was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA). MS m/z (MH+) 456.2.
EXAMPLE AA
c S Br S CN CHO
Zn(CN)2 N
Pd(PPh3)4 NaBH(OAc)3 4i DMF laa CH3COOH
H H
N_NN
~\ S ~\ CN S
aN~ TMSN3 (::~)Cr4 N
Bu20 2aa DME 3aa N N
Procedure 28 10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazi ne-3-carbonitri le, 1aa To a solution of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-bromo-10H-phenothiazine, 4i (50 mg, 0.13 mmol) in DMF (750 L) was added zinc cyanide (15 mg, 0.13 mmol) and tetrakistriphenylphosphine palladium (4 mg), the solution was purged with nitrogen, and the mixture was heated in the microwave for 5 min at 160 C. The mixture was allowed to cool to rt, and purified via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA) to yield title compound 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carbonitrile, 1 aa as a TFA salt and as a mixture of endo and exo isomers. MS
m/z (MH+) 334.1.
10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carbonitrile, 2aa Using an adaptation of the method described in Procedure 22, substituting the TFA salt of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carbonitrile, I aa for 3-bromo-10-piperidin-4-yl-10H-phenothiazine, 4i, the title compound 10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-yl)-10H-phenothiazine-3-carbonitrile, 2aa was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA) and as a mixture of endo and exo isomers.
Procedure 29 10-(8-Phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenothiazine, 3aa To a solution of 10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carbonitrile, 2aa (10 mg, 29 mol) in dimethoxyethane was added trimethylsilyl azide (15 L, 115 mol) and dibutyltin oxide (1.5 mg), and the mixture was heated in a microwave for 15 min at 150 C. The mixture was allowed to cool to rt, and purified via reverse phase HPLC (eluent: CH3CN in water containing 0.1 % TFA) to yield title compound 10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenothiazine, 3aa as a TFA
salt and as a mixture of endo and exo isomers. MS m/z (MH+) 481.2.
N'NN
I \ S I \ N
H
N
4aa N
N
~ \
/
10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yI)-10H-phenothiazine, 4aa Using an adaptation of the methods described in Procedures 22 and 29, substituting the TFA salt of 1 0-(8-aza-bicyclo[3.2. 1 ]oct-3-yl)-10H-phenothiazine-3-carbonitrile, 1aa for 3-bromo-10-piperidin-4-yl-10H-phenothiazine, 4i and 2-pyridyl carboxaldehyde for 3-furyl carboxaldehyde in Procedure 22, the title compound 10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenothiazine, 4aa was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA) and as a mixture of endo and exo isomers. MS m/z (MH+) 468.2.
N-NN
\ S ~ Ho N
5aa N
H
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yI)-3-(I H-tetrazol-5-yl)-10H-phenothiazine, 5aa Using an adaptation of the method described in Procedure 29, substituting the TFA salt of 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carbonitrile, 1 aa for 10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carbonitrile, 2aa, the title compound 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenothiazine, 5aa was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA) and as a mixture of endo and exo isomers.
MS m/z (MH+) 377.2.
NH
S N --\
N
6aa N
N,N-Diethyl-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10F/-phenothiazine-3-carboxamidine, 6aa Using an adaptation of the method described in Procedure 10, substituting the TFA salt of 10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-phenothiazine-3-carbonitriie, 2aa for endo-3-(3-cyano-phenoxazin-1 0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3b, the title compound N, N-diethyl-10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-10H-phenothiazine-carboxamidine, 6aa was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA) and as a mixture of endo and exo isomers. MS m/z (MH+) 511.3.
NH
S ~ N ~\
~/
N
A 7aa N
N
~ \
/
N,N-Diethyl-10-(8-pyridi n-2-yl methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carboxamidine, 7aa Using an adaptation of the methods described in Procedures 22 and 10, substituting the TFA salt of 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carbonitrile, 1aa for endo-3-(3-cyano-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3b, and 2-pyridyl carboxaldehyde for 3-furyl carboxaldehyde, the title compound N,N-diethyl-10-( 8-pyrid i n-2-yl m ethyl-8-aza-b i cyclo [3.2.1 ]oct-3-yl )-10H-p he noth i azi ne-3-carboxamidine, 7aa was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA) and as a mixture of endo and exo isomers.
MS m/z (MH+) 498.3.
EXAMPLE BB
N-N
, I
:ZnCN2 _ a N .
Pd(PPh3)4 DME
1bb 2bb 3i DMF
i i N
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoth iazi ne-3-carbonitrile, 1 bb Using an adaptation of the method described in Procedure 28, substituting 3-bromo-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 3i for endo-3-(3-cyano-phenoxazin-10-yI)-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid tert-butyl ester, 3b, the title compound 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carbon itri le, 1 bb was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA) and as a mixture of endo and exo isomers. MS m/z (MH+) 348.1.
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yI)-3-(1 H-tetrazol-5-yl)-10H-phenothiazine, 2bb Using an adaptation of the method described in Procedure 29, substituting the TFA salt of 10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carbonitrile, I bb for 10-(8-phenethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carbonitrile, 2aa, the title compound 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-(1 H-tetrazol-5-yl)-10H-phenothiazine, 2bb was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA) and as a mixture of endo and exo isomers.
MS m/z (MH+) 391.1.
NH
I ~ S I ~ N~
N
3bb N
I
N,N-Diethyl-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carboxamidine, 3bb Using an adaptation of the method described in Procedure 10, substituting the TFA salt of 10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carbonitrile, 1 bb for endo-3-(3-cyano-phenoxazin-1 0-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 3b, the title compound N, N-d iethyl-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoth iazi ne-carboxamidine, 3bb was obtained as a TFA salt after purification via reverse phase chromatography (eluent: CH3CN in water containing 0.1 % TFA) and as a mixture of endo and exo isomers. MS m/z (MH+) 421.2.
EXAMPLE CC
Br SH 1. LiAIH4 ~ + neat Br, ~ S THF NH2 i H 2. 02N OMe 1cc F
02N OMe THF
OMe S Br O CI
K2CO 3 I j I j \/U
aNH ~ II
3cc DIEA
2cc CICH2CH2CI
HO
OMe OH I ~ B-OH
S B
Br N
cIIuIIIlBr 3 4cc + c ~ o N Pd(PPh3)4 N 4cc 5cc NMP
H H
OMe OH
S N S N
(N)O + I/ N I/
6cc 7cc Spiro compound, 1cc Using an adaptation of the method described in Procedure 18, substituting for 2-amino-5-bromothiophenol for 2-aminothiophenol, the title compound 1cc was obtained.
[2-(3-Methoxy-2-nitro-phenylsulfanyl)-phenyl]-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amine, 2cc Using an adaptation of the method described in Procedure 19, substituting spiro compound, 1cc for spiro compound 1i, the title compound [2-(3-methoxy-2-nitro-phenylsulfanyl)-phenyl]-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-yl)-amine, 2cc was obtained a mixture of endo and exo isomers.
3-Bromo-6-methoxy-1 0-(8-methyl-8-aza-bicycIo[3.2.1 ]oct-3-yi)-10H-phenothiazine, 3cc Using an adaptation of the method described in Procedure 20, substituting [2-(3-methoxy-2-nitro-phenylsulfanyl)-phenyl]-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amine, 2cc for [2-(4-bromo-2-nitrophenylsulfanyl)-phenyl]-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-amine, 2i, the titie compound bromo-6-methoxy-10-(8-methyl-8-aza-bicycio[3.2.1 ]oct-3-yl)-10H-phenothiazine, 3cc was obtained a mixture of endo and exo isomers.
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-3-bromo-6-methoxy-lOH-phenothiazine, 4cc Using an adaptation of the method described in Procedure 21, substituting 3-bromo-6-methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yi)-10H-phenothiazine, 3cc for 3-bromo-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine, 3i, the title compound 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-bromo-6-methoxy-10H-phenothiazine, 4cc was obtained a mixture of endo and exo isomers.
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yi)-7-bromo-10H-phenoth iazi n-4-ol, 5cc Using an adaptation of the method described in Procedure 16, substituting 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-3-bromo-6-methoxy-10H-phenothiazine, 4cc for 6-methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yi)-10H-phenoxazine-3-carboxylic acid diethylamide, 6e, a mixture of title compound 10-(8-aza-bicyclo-[3.2.1 ]oct-3-yl)-7-bromo-10H-phenothiazin-4-ol, 5cc and starting material 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-bromo-6-methoxy-10H-phenothiazine, 4cc was obtained a mixture of endo and exo isomers.
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-3-pyridi n-3-yl-10H-phenothiazine, 6cc and 10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-3-yl-10H-phenothiazin-4-ol, 7cc Using an adaptation of the method described in Procedure 23, substituting a mixture of 10-(8-aza-bicyclo[3.2.1]oct-3-yl)-3-bromo-6-methoxy-10H-phenothiazine, 4cc and 10-(8-aza-bicyclo-[3.2.1 ]oct-3-yl)-7-bromo-10H-phenothiazin-4-ol, 5cc for 3-bromo-10-(8-furan-3-ylmethyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 5i, a mixture of title compounds (8-aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-3-pyridin-3-yI-10H-phenothiazine, 6cc and 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-7-pyridin-3-yI-10H-phenothiazin-4-ol, 7cc was obtained. The compounds were separated via reverse phase HPLC
(eluent: CH3CN in water containing 0.1 % TFA) to yield 6cc [MS m/z (MH+) 416.2] and 7cc [MS m/z (MH+) 402.2], bothy as TFA salts and mixtures of endo and exo isomers.) EXAMPLE DD
OMe HN OMe O
1. CI
5SXBr CHCIN Herrmann's N 2.
MeOH
catalyst 1 dd 3cc Mo(CO)6 DBU N
N THF ~
I
OMe 0 OH 0 S S
BBr3 ~ N
2dd 3dd H H
6-Methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carboxylic acid diethylamide, 1dd Using an adaptation of the method described in Procedure 26, substituting a mixture of endo and exo isomers of 3-bromo-6-methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine, 3cc for 3-bromo-l0-piperidin-4-yl-10H-phenothiazine, 4i, title compound 6-methoxy-l0-(8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenothiazine-3-carboxylic acid diethylamide, ldd was obtained as a mixture of endo and exo isomers.
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-10H-phenothiazi ne-3-carboxylic acid diethylamide, 2dd Using an adaptation of the method described in Procedure 21, substituting 3-bromo-6-methoxy-1 0-(8-methyl-8-aza-bicyclo[3.2. 1 ]oct-3-yl)-phenothiazine, 3cc for 3-bromo-l0-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine, 3i, title compound 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-10H-phenothiazine-3-carboxylic acid diethylamide, 2dd was obtained as a TFA
salt and as a mixture of endo and exo isomers.
10-(8-Aza-bicyclo[3.2.1 ]oct-3-yl)-6-hydroxy-101'%phenothiazi ne-3-carboxylic acid diethylamide, 3dd Using an adaptation of the method described in Procedure 16, substituting 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-6-methoxy-10H-phenothiazine-3-carboxylic acid diethylamide, 2dd for 6-methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide, 6e, a mixture of title compound 10-(8-aza-bicyclo[3.2.1 ]oct-3-yl)-6-hydroxy-lOH-phenothiazine-3-carboxylic acid diethylamide, 3dd was obtained. MS m/z (MH+) 424.2.
Biological Examples Rat Brain Delta Opioid Receptor Binding Assay Procedure: Male, Wistar rats (150-250 g, VAF, Charles River, Kingston, NY) were killed by C02, and their brains were removed and placed immediately in ice cold Tris HCI buffer (50 mM, pH 7.4). The forebrains were separated from the remainder of the brain by a coronal transection, beginning dorsally at the colliculi and passing ventrally through the midbrain-pontine junction.
After dissection, the forebrains were homogenized in Tris buffer in a Teflon -glass homogenizer. The homogenate was diluted to a concentration of 1 g of forebrain tissue per 80 mL Tris and centrifuged at 39,000 x g for 10 min. The pellet was resuspended in the same volume of Tris buffer containing 5 mM
MgCI2 with several brief pulses from a Polytron homogenizer. This particulate preparation was used for the delta opioid binding assays. Following incubation with the delta selective peptide ligand -4 nM [3H]DPDPE or 0.15 nM
[3H]naltrindole at 25 C for 2.5 h in a 96-well plate with total volume of I
mL, the plate contents were filtered through Wallac filtermat B sheets on a Tomtec 96-well harvester. The filters were rinsed three times with 2 mL of 10 mM
HEPES (pH 7.4), and dried in a 650 W microwave oven for 1.75 min twice. To each sample area 2 X 50 pL of Betaplate Scint scintillation fluid (LKB) was added and the radioactivity quantified on a LKB (Wallac) 1205 BetaPlate liquid scintillation counter.
Analysis: The data from the scintillation counter were used to calculate either the % inhibition compared to control binding (when only a single concentration of test compound was evaluated) or a K; value (when a range of concentrations was tested). Percent inhibition was calculated as: [(total dpm-test compound dpm)/(total dpm-nonspecific dpm)]*100. Kd and Ki values were calculated using GraphPad PRISM data analysis program.
Rat Brain Mu Opioid Receptor Binding Assay Procedure: Male, Wistar rats (150-250 g, VAF, Charles River, Kingston, NY) were killed by C02, and their brains were removed and placed immediately in ice cold Tris HCI buffer (50 mM, pH 7.4). The forebrains were separated from the remainder of the brain by a coronal transection, beginning dorsally at the colliculi and passing ventrally through the midbrain-pontine junction.
After dissection, the forebrains were homogenized in Tris buffer in a Teflon -glass homogenizer. The homogenate was diluted to a concentration of I g of forebrain tissue per 80 mL Tris and centrifuged at 39,000 x g for 10 min. The pellet was resuspended in the same volume of Tris buffer containing 5 mM
MgCl2 with several brief pulses from a Polytron homogenizer. This particulate preparation was used for the delta opioid binding assays. Following incubation with the mu selective peptide ligand, ~0.8 nM [3H]DAMGO, at 25 C for 2.5 h in a 96-well plate with total assay volume of 1 mL, the plate contents were filtered through Wallac fiitermat B sheets on a Tomtec 96-well harvester. The filters were rinsed three times with 2 mL of 10 mM HEPES (pH 7.4), and dried in a 650 W microwave oven for 1.75 min twice. To each sample area 2 X 40 pL of Betaplate Scint scintillation fluid (LKB) was added and the radioactivity quantifed on a LKB (Wallac) 1205 BetaPlate liquid scintillation counter.
Analysis: The data from the scintillation counter were used to calculate either the % inhibition compared to control binding (when only a single concentration of test compound was evaluated) or a K; value (when a range of concentrations tested). Percent inhibition was calculated as: [(total dpm-test compound dpm)/(total dpm-nonspecific dpm)]*100. Kd and Ki values were calculated using GraphPad PRISM data analysis program.
[35S1GTPrS Binding Assay in NG108-15 Cell Membranes (delta opioid) Methods: NG108-15 cell membranes can be purchased from Applied Cell Sciences (Rockville, MD). 8 mg/mL of membrane protein suspended in 10 mM TRIS-HCI pH 7.2, 2 mM EDTA, 10% sucrose. Membranes can be maintained at 4-8 C. A 1 mL volume of membranes can be added into 10 mL
coid binding assay buffer. The assay buffer contained 50 mM Tris, pH 7.6, 5 mM MgCi2, 100 mM NaCl, 1 mM DTT and 1 mM EGTA. The membrane suspension can be homogenized twice with a Polytron, and centrifuged at 3000 rpm for 10 min. The supernatant can be then centrifuged at 18,000 rpm for 20 min. Ten mL assay buffer can be added into the pellet containing tube. The pellet and buffer can be mixed with a Polytron.
Incubation procedure: The pellet membranes (75 pg/mL) can be preincubated with SPA (10 mg/mL) at 25 C for 45 min in the assay buffer. The SPA (5 mg/mL) coupled with membranes (37.5 pg/mL) can then be incubated with 0.1 nM [35S] GTPyS in the same Tris buffer containing 100 pM GDP in total volume of 200 pL. Increasing concentrations of receptor agonists can be used to stimulate [35S]- GTP~S binding. The basal binding can be tested in the absence of agonists and non-specific binding can be tested in the presence of pM unlabeled GTPyS. The data can be analyzed on a Packard Top Count.
DATA
% of Basal = (stimulated - non specific)*1 00/(basal - non specific).
EC50 value values can be calculated using GraphPad Prism.
[35S1GTPyS Binding Assays in CHO-hMOR Cell Membranes Methods: CHO-hMOR cell membranes can be purchased from Receptor Biology, Inc. (Baltimore, MD). About 10 mg/mL of membrane protein can be suspended in 10 mM TRIS-HCI pH 7.2, 2 mM EDTA, 10% sucrose, and the suspension kept on ice. A 1 mL volume of membranes can be added to 15 mL cold binding assay buffer containing 50 mM HEPES, pH 7.6, 5 mM MgCI2, 100 mM NaCI, 1 mM DTT and 1 mM EDTA. The membrane suspension can be homogenized with a Polytron and centrifuged at 3,000 rpm for 10 min. The supernatant can then be centrifuged at 18,000 rpm for 20 min. The pellet can be resuspended in 10 mL assay buffer with a Polytron. The membranes can be preincubated with wheat germ agglutinin coated SPA beads (Amersham) at 25 C for 45 min in the assay buffer. The SPA bead (5 mg/mL) coupled membranes (10 pg/mL) can be then incubated with 0.5 nM [35S]GTPyS in the assay buffer. The basal binding can be that taking place in the absence of added test compound; this unmodulated binding can be considered as 100%, with agonist stimulated binding rising to levels significantly above this value. A
range of concentrations of receptor agonist can be used to stimulate [35S]GTPyS binding. Both basal and non-specific binding can be tested in the absence of agonist; non-specific binding determination included 10 pM
unlabeled GTPyS.
Compounds can be tested for function as antagonists by evaluating their potential to inhibit agonist-stimulated GTP7S binding. Radioactivity can be quantified on a Packard TopCount. The following parameters can be calculated:
% stimulation = (test compound cpm - non-specific cpm) x 100 (basal cpm - non-specific cpm).
% inhibition =(% stimulation by 1 M DAMGO - % stimulation by test compound) x 100 (% stimulation by 1 M DAMGO -100) EC50 values can be calculated using GraphPad Prism.
Biological Data Compound Number delta (Ki, nM) mu (Ki, nM) 4t 0.1 4aa 0.1 6b 0.1 168.45 6d 0.1 336 9t 0.10 8t 0.18 4v 0.3 2z 0.62 10t 1.14 7e 2.2 7t 2.43 7u 3.27 8v 5.2 3v 8.3 8j 18.8 8u 20.70 3t 25.1 3z 27.63 12v 36.3 6u 44.49 3c 48.1 525 7v 56.6 5t 56.7 5x 81.82 2t 86.6 6e 99.5 7j 103.6 7i 122.84 554.3 9v 136.3 4x 161.3 2u 196.5 6t 231.0 5k 246.7 6v 263.2 6i 282.35 1055.7 4e 320.9 5aa 321.1 11 i 366.9 170.985 4a 373 6761 Compound Number delta (Ki, nM) mu (Ki, nM) 3r 396.8 682.2 11 v 399.5 5b 406 6849 5j 409.4 2x 414.6 41 424.6 8i 443.5 889.4 4k 444.8 5u 477.80 3m 480.1 12 i 491.45 1450 2c 492 9448 51 539.2 4u 542.55 13i 551.6 3740 6a 575 819 2h 598 2889 17i 629 1533.5 15i 629.55 168.9 2m 634.2 9i 649.35 538.4 1 r 651.95 2758 2k 695.5 2a 697 5152 31 729.1 2r 863.65 4340 4p 864.5 4m 868.9 4i 881 6613 laa 930.9 18i 940.75 8073 10i 949.05 317.3 61 1269.1 5m 1278.5 3u 1356.30 16i 1453 2654 3x 1585.0 ly 1601.8 14i 1603.5 598.75 3f 1752 1435 8b 1896 >10000 1g 2041 4285 5a 2116 6091 5v 2260.0 3i 2532 3185 7d 2633 123 Compound Number delta (Ki, nM) mu (Ki, nM) 2f 2644.5 2752 4c 3106 89.0 6j 3261.5 3k 3388.0 3p 5123.0 19i 5191 254 7b 5475 288 71 6211.5 9j 11865.0 10j 13321.5 6k 14223.5 10v >10000 13v >10000
Claims (95)
1. A compound of Formula (I):
wherein:
G is -C(Z)N(R1)R2, C6-10aryl, or a heterocycle selected from the group consisting of imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, tetrahydropyrimidinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, furyl, indazolyl, indolyl, indolinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, and pyridinyl; wherein aryl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1-8alkanyl, C2-8alkenyl, C2-8alkynyl, C1-8alkanyloxy, hydroxy(C1-8)alkanyl, carboxy(C1-8)alkanyl, C1-8alkanylcarbonylamino, halogen, hydroxy, cyano, nitro, oxo, thioxo, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-8alkanylthio, C1-8alkanylsulfonyl, C1-8alkanylsulfonylamino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, C1-8alkanylaminocarbonyl, di(C1-8alkanyl)aminocarbonyl, and C1-6alkanyloxycarbonylamino;
R1 is a substituent selected from the group consisting of hydrogen, C1-8alkanyl, C2-8alkenyl, and C2-8alkynyl;
R2 is a substituent selected from the group consisting of hydrogen;
C1-8alkanyl; C2-8alkenyl; C2-8alkynyl; C6-10aryl; and C1-8cycloalkanyl;
wherein C1-8alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-6alkanyloxy, thioC1-6alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, C1-8alkanylaminocarbonyl, di(C1-8alkanyl)aminocarbonyl, C1-6alkanyloxycarbonyl, and aryloxy; and wherein any aryl-containing substituents and C1-8cycloalkanyl substituents of R2 are optionally substituted with one to three substituents independently selected from the group consisting of C1-8alkanyl, C2-8alkenyl, C2-8alkynyl, C1-8alkanyloxy, trifluoromethyl, trifluoromethoxy, phenyl, halogen, cyano, hydroxy, C1-8alkanylthio, C1-8alkanylsulfonyl, and C1-8alkanylsulfonylamino;
or R1 and R2 taken together with the nitrogen to which they are attached form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of C1-8alkanyl, hydroxy(C1-8)alkanyl, hydroxy, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, and halogen;
R3 is a substituent selected from the group consisting of hydrogen, C1-8alkanyl, halo1-3(C1-8)alkanyl, C2-8alkenyl, C2-8alkynyl, C3-8cycloalkanyl, cycloalkanyl(C1-8)alkanyl, C1-8alkanyloxy(C1-8)alkanyl, C1-8alkanylthio(C1-8)alkanyl, hydroxyC1-8alkanyl, C1-8alkanyloxycarbonyl, halo1-3(C1-8)alkanylcarbonyl, formyl, thioformyl, carbamimidoyl, phenylimino(C1-8)alkanyl, phenyl(C1-8)alkanyl, phenyl(C1-8)alkenyl, phenyl(C1-8)alkynyl, naphthyl(C1-8)alkanyl and heteroaryl(C1-8)alkanyl wherein the heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl, thiazolyl; wherein phenyl, naphthyl, and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyl, C2-6alkenyl, C1-6alkanyloxy, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-6alkanylcarbonyl, C1-6alkanylcarbonyloxy, C1-6alkanylcarbonylamino, C1-6alkanylthio, C1-6alkanylsulfonyl, halogen, hydroxy, cyano, fluoro(C1-6)alkanyl, thioureido, and fluoro(C1-6)alkanyloxy; alternatively, when phenyl and heteroaryl are optionally substituted with alkanyl or alkanyloxy substituents attached to adjacent carbon atoms, the two substituents can together form a fused cyclic alkanyl or cycloheteroalkanyl selected from the group consisting of -(CH2)3-5- ,-O(CH2)2-4- , -(CH2)2-4O-, and -O(CH2)1-3O-;
R4 is one to three substituents independently selected from the group consisting of hydrogen; C1-6alkanyl; C2-6alkenyl; C2-6alkynyl;
aryl(C2-6)alkynyl; C1-6alkanyloxy; amino; C1-6alkanylamino;
di(C1-6alkanyl)amino; C6-10arylamino wherein C6-10aryl is optionally substituted with one to three substitutents independently selected from the group consisting of C1-6alkanyl, C1-6alkoxy, halogen, and hydroxy; formylamino; pyridinylamino; C1-6alkanylcarbonyl;
C1-6alkanylcarbonyloxy; C1-6alkanyloxycarbonyl; aminocarbonyl;
C1-6alkanylaminocarbonyl; di(C1-6alkanyl)aminocarbonyl;
C1-6alkanylcarbonylamino; C1-6alkanylthio; C1-6alkanylsulfonyl;
halogen; hydroxy; cyano; hydroxycarbonyl; C6-10aryl; chromanyl;
chromenyl; furanyl; imidazolyl; indazolyl; indolyl; indolinyl;
isoindolinyl; isoquinolinyl; isothiazolyl; isoxazolyl; naphthyridinyl;
oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl; pyridinyl; pyrimidinyl;
pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl; quinoxalinyl;
tetrazolyl; thiazolyl; thienyl; fluoroalkanyl and fluoroalkanyloxy; or optionally; when R4 is two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the fused moiety is -(CH2)3-5- ,-O(CH2)2-4- , -(CH2)2-4O-, -O(CH2)1-3O-, or -S-C(NH2)=N-;
R5 is one to two substituents independently selected from the group consisting of hydrogen, C1-6alkanyl, C2-6alkenyl, C1-6alkanyloxy, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-6alkanylcarbonyl, C1-6alkanylcarbonyloxy, C1-6alkanyloxycarbonyl, C1-6alkanylaminocarbonyl, C1-6alkanylcarbonylamino, C1-6alkanylthio, C1-6alkanylsulfonyl, halogen, hydroxy, cyano, fluoro(C1-6)alkanyl and fluoro(C1-6)alkanyloxy;
A is -(CH2)m-, wherein m is 2 or 3;
Y is O or S;
Z is O, S, NH, N(C1-6alkanyl), N(OH), N(OC1-6alkanyl), or N(phenyl);
and enantiomers, diastereomers, tautomers, solvates, or pharmaceutically acceptable salts thereof.
wherein:
G is -C(Z)N(R1)R2, C6-10aryl, or a heterocycle selected from the group consisting of imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, tetrahydropyrimidinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, furyl, indazolyl, indolyl, indolinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, and pyridinyl; wherein aryl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1-8alkanyl, C2-8alkenyl, C2-8alkynyl, C1-8alkanyloxy, hydroxy(C1-8)alkanyl, carboxy(C1-8)alkanyl, C1-8alkanylcarbonylamino, halogen, hydroxy, cyano, nitro, oxo, thioxo, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-8alkanylthio, C1-8alkanylsulfonyl, C1-8alkanylsulfonylamino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, C1-8alkanylaminocarbonyl, di(C1-8alkanyl)aminocarbonyl, and C1-6alkanyloxycarbonylamino;
R1 is a substituent selected from the group consisting of hydrogen, C1-8alkanyl, C2-8alkenyl, and C2-8alkynyl;
R2 is a substituent selected from the group consisting of hydrogen;
C1-8alkanyl; C2-8alkenyl; C2-8alkynyl; C6-10aryl; and C1-8cycloalkanyl;
wherein C1-8alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-6alkanyloxy, thioC1-6alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, C1-8alkanylaminocarbonyl, di(C1-8alkanyl)aminocarbonyl, C1-6alkanyloxycarbonyl, and aryloxy; and wherein any aryl-containing substituents and C1-8cycloalkanyl substituents of R2 are optionally substituted with one to three substituents independently selected from the group consisting of C1-8alkanyl, C2-8alkenyl, C2-8alkynyl, C1-8alkanyloxy, trifluoromethyl, trifluoromethoxy, phenyl, halogen, cyano, hydroxy, C1-8alkanylthio, C1-8alkanylsulfonyl, and C1-8alkanylsulfonylamino;
or R1 and R2 taken together with the nitrogen to which they are attached form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of C1-8alkanyl, hydroxy(C1-8)alkanyl, hydroxy, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, and halogen;
R3 is a substituent selected from the group consisting of hydrogen, C1-8alkanyl, halo1-3(C1-8)alkanyl, C2-8alkenyl, C2-8alkynyl, C3-8cycloalkanyl, cycloalkanyl(C1-8)alkanyl, C1-8alkanyloxy(C1-8)alkanyl, C1-8alkanylthio(C1-8)alkanyl, hydroxyC1-8alkanyl, C1-8alkanyloxycarbonyl, halo1-3(C1-8)alkanylcarbonyl, formyl, thioformyl, carbamimidoyl, phenylimino(C1-8)alkanyl, phenyl(C1-8)alkanyl, phenyl(C1-8)alkenyl, phenyl(C1-8)alkynyl, naphthyl(C1-8)alkanyl and heteroaryl(C1-8)alkanyl wherein the heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl, thiazolyl; wherein phenyl, naphthyl, and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyl, C2-6alkenyl, C1-6alkanyloxy, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-6alkanylcarbonyl, C1-6alkanylcarbonyloxy, C1-6alkanylcarbonylamino, C1-6alkanylthio, C1-6alkanylsulfonyl, halogen, hydroxy, cyano, fluoro(C1-6)alkanyl, thioureido, and fluoro(C1-6)alkanyloxy; alternatively, when phenyl and heteroaryl are optionally substituted with alkanyl or alkanyloxy substituents attached to adjacent carbon atoms, the two substituents can together form a fused cyclic alkanyl or cycloheteroalkanyl selected from the group consisting of -(CH2)3-5- ,-O(CH2)2-4- , -(CH2)2-4O-, and -O(CH2)1-3O-;
R4 is one to three substituents independently selected from the group consisting of hydrogen; C1-6alkanyl; C2-6alkenyl; C2-6alkynyl;
aryl(C2-6)alkynyl; C1-6alkanyloxy; amino; C1-6alkanylamino;
di(C1-6alkanyl)amino; C6-10arylamino wherein C6-10aryl is optionally substituted with one to three substitutents independently selected from the group consisting of C1-6alkanyl, C1-6alkoxy, halogen, and hydroxy; formylamino; pyridinylamino; C1-6alkanylcarbonyl;
C1-6alkanylcarbonyloxy; C1-6alkanyloxycarbonyl; aminocarbonyl;
C1-6alkanylaminocarbonyl; di(C1-6alkanyl)aminocarbonyl;
C1-6alkanylcarbonylamino; C1-6alkanylthio; C1-6alkanylsulfonyl;
halogen; hydroxy; cyano; hydroxycarbonyl; C6-10aryl; chromanyl;
chromenyl; furanyl; imidazolyl; indazolyl; indolyl; indolinyl;
isoindolinyl; isoquinolinyl; isothiazolyl; isoxazolyl; naphthyridinyl;
oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl; pyridinyl; pyrimidinyl;
pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl; quinoxalinyl;
tetrazolyl; thiazolyl; thienyl; fluoroalkanyl and fluoroalkanyloxy; or optionally; when R4 is two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the fused moiety is -(CH2)3-5- ,-O(CH2)2-4- , -(CH2)2-4O-, -O(CH2)1-3O-, or -S-C(NH2)=N-;
R5 is one to two substituents independently selected from the group consisting of hydrogen, C1-6alkanyl, C2-6alkenyl, C1-6alkanyloxy, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-6alkanylcarbonyl, C1-6alkanylcarbonyloxy, C1-6alkanyloxycarbonyl, C1-6alkanylaminocarbonyl, C1-6alkanylcarbonylamino, C1-6alkanylthio, C1-6alkanylsulfonyl, halogen, hydroxy, cyano, fluoro(C1-6)alkanyl and fluoro(C1-6)alkanyloxy;
A is -(CH2)m-, wherein m is 2 or 3;
Y is O or S;
Z is O, S, NH, N(C1-6alkanyl), N(OH), N(OC1-6alkanyl), or N(phenyl);
and enantiomers, diastereomers, tautomers, solvates, or pharmaceutically acceptable salts thereof.
2. The compound according to claim 1 wherein G is -C(Z)N(R1)R2, phenyl, or a heterocycle selected from the group consisting of tetrazolyl, oxadizolyl, furyl, quinolinyl, thienyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1-8alkanyl, C1-8alkanyloxy, hydroxy(C1-8)alkanyl, carboxy(C1-8)alkanyl, C1-8alkanylcarbonylamino, halogen, hydroxy, cyano, oxo, thioxo, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-8alkanylthio, aminocarbonyl, aminothiocarbonyl, C1-8alkanylaminocarbonyl, di(C1-8alkanyl)aminocarbonyl, and C1-6alkanyloxycarbonylamino.
3. The compound according to claim 1 wherein G is -C(Z)N(R1)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, tetrahydropyrimidinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1-8alkanyl, C1-8alkanyloxy, hydroxy(C1-8)alkanyl, carboxy(C1-8)alkanyl, C1-8alkanylcarbonylamino, halogen, hydroxy, cyano, oxo, thioxo, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-8alkanylthio, aminocarbonyl, aminothiocarbonyl, C1-8alkanylaminocarbonyl, di(C1-8alkanyl)aminocarbonyl, and C1-6alkanyloxycarbonylamino.
4. The compound according to claim 1 wherein G is -C(Z)N(R1)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G
are optionally substituted with one to three substituents independently selected from the group consisting of C1-4alkanyl, C1-4alkanyloxy, hydroxy(C1-4)alkanyl, carboxy(C1-4)alkanyl, C1-4alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-8alkanylthio, aminocarbonyl, aminothiocarbonyl, C1-8alkanylaminocarbonyl, and di(C1-8alkanyl)aminocarbonyl.
are optionally substituted with one to three substituents independently selected from the group consisting of C1-4alkanyl, C1-4alkanyloxy, hydroxy(C1-4)alkanyl, carboxy(C1-4)alkanyl, C1-4alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-8alkanylthio, aminocarbonyl, aminothiocarbonyl, C1-8alkanylaminocarbonyl, and di(C1-8alkanyl)aminocarbonyl.
5. The compound according to claim 1 wherein G is -C(Z)N(R1)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, thienyl, isothiazolyl, isoxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1-4alkanyl, C1-4alkanyloxy, hydroxy(C1-4)alkanyl, C1-4alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, and aminocarbonyl.
6. The compound according to claim 1 wherein G is -C(Z)N(R1)R2, phenyl, or a heterocycle selected from the group consisting of tetrazolyl, oxadizolyl, furyl, quinolinyl, thienyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1-4alkanyl, C1-4alkanyloxy, hydroxy(C1-4)alkanyl, C1-4alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, and aminocarbonyl.
7. The compound according to claim 1 wherein G is -C(Z)N(R1)R2, tetrazolyl, pyridinyl, oxadiazolyl optionally substituted with oxo, or phenyl optionally substituted with (C1-8)alkanylcarbonylamino.
8. The compound according to claim 1 wherein G is-C(Z)N(R1)R2, 1H-tetrazol-4-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 2-methylcarbonylaminophenyl, pyridin-3-yl or pyridin-4-yl.
9. The compound according to claim 1 wherein R1 is a substituent selected from the group consisting of hydrogen and C1-4alkanyl.
10. The compound according to claim 1 wherein R1 is selected from the group consisting of hydrogen, methyl, ethyl, and propyl.
11. The compound according to claim 1 wherein R1 is selected from the group consisting of hydrogen, methyl, and ethyl.
12. The compound according to claim 1 wherein R2 is selected from the group consisting of hydrogen; C1-4alkanyl; phenyl; and C1-6cycloalkanyl;
wherein C1-4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-4alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, C1-8alkanylaminocarbonyl, di(C1-8alkanyl)aminocarbonyl, and phenoxy; and wherein any phenyl-containing substituents and C1-6cycloalkanyl substituents of R2 are optionally substituted with one to three substituents independently selected from the group consisting of C1-8alkanyl, C1-8alkanyloxy, trifluoromethyl, phenyl, fluoro, hydroxy, C1-8alkanylthio, C1-8alkanylsulfonyl, and C1-8alkanylsulfonylamino; or R1 and R2 taken together with the nitrogen to which they are attached form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of C1-4alkanyl, hydroxy(C1-4)alkanyl, hydroxy, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, and fluoro.
wherein C1-4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-4alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, C1-8alkanylaminocarbonyl, di(C1-8alkanyl)aminocarbonyl, and phenoxy; and wherein any phenyl-containing substituents and C1-6cycloalkanyl substituents of R2 are optionally substituted with one to three substituents independently selected from the group consisting of C1-8alkanyl, C1-8alkanyloxy, trifluoromethyl, phenyl, fluoro, hydroxy, C1-8alkanylthio, C1-8alkanylsulfonyl, and C1-8alkanylsulfonylamino; or R1 and R2 taken together with the nitrogen to which they are attached form a 5-7 membered cycloheteroalkyl optionally substituted with one to three substituents independently selected from the group consisting of C1-4alkanyl, hydroxy(C1-4)alkanyl, hydroxy, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, and fluoro.
13. The compound according to claim 1 wherein R2 is selected from the group consisting of hydrogen, C1-4alkanyl, phenyl, and C1-6cycloalkanyl;
wherein C1-4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1-4alkanyloxy, hydroxy, fluoro, aminocarbonyl, C1-8alkanylaminocarbonyl, di(C1-8alkanyl)aminocarbonyl, and phenoxy;
and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyl, C1-6alkanyloxy, fluoro, hydroxy, and C1-6alkanylthio; or R1 and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from the group consisting of C1-4alkanyl and hydroxy.
wherein C1-4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1-4alkanyloxy, hydroxy, fluoro, aminocarbonyl, C1-8alkanylaminocarbonyl, di(C1-8alkanyl)aminocarbonyl, and phenoxy;
and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyl, C1-6alkanyloxy, fluoro, hydroxy, and C1-6alkanylthio; or R1 and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from the group consisting of C1-4alkanyl and hydroxy.
14. The compound according to claim 1 wherein R2 is selected from the group consisting of hydrogen, C1-4alkanyl and phenyl; wherein C1-4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1-4alkanyloxy, hydroxy, fluoro, and phenoxy; and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyl, C1-6alkanyloxy, fluoro, and hydroxy; or R1 and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from the group consisting of C1-3alkanyl and hydroxy.
15. The compound according to claim 1 wherein R2 is selected from the group consisting of hydrogen and C1-4alkanyl; wherein C1-4alkanyl is optionally substituted with phenyl; or R1 and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl wherein said pyrrolidinyl is optionally substituted with hydroxy.
16. The compound according to claim 1 wherein R2 is selected from the group consisting of hydrogen, methyl, ethyl, and phenethyl; or R1 and R2 taken together with the nitrogen to which they are attached form pyrrolidin-1-yl, 3-hydoxypyrrolidin-1-yl or 3-(S)-hydoxypyrrolidin-1-yl.
17. The compound according to claim 1 wherein R3 is selected from the group consisting of hydrogen, C1-8alkanyl, C2-8alkenyl, C2-8alkynyl, C1-8alkanyloxy(C1-8)alkanyl, C1-8alkanylthio(C1-8)alkanyl, hydroxyC1-8alkanyl, thioformyl, phenylimino(C1-8)alkanyl, phenyl(C1-8)alkanyl, and heteroaryl(C1-8)alkanyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indolyl, indolinyl, isoquinolinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein phenyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyloxy and hydroxy; or optionally, when phenyl and heteroaryl are optionally substituted with two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the moiety is selected from -O(CH2)1-3O-.
18. The compound according to claim 1 wherein R3 is selected from the group consisting of hydrogen, C1-8alkanyl, C2-8alkenyl, C2-8alkynyl, C1-8alkanyloxy(C1-8)alkanyl, C1-8alkanylthio(C1-8)alkanyl, hydroxyC1-8alkanyl, thioformyl, phenylimino(C1-8)alkanyl, phenyl(C1-8)alkanyl, and heteroaryl(C1-8)alkanyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indolyl, indolinyl, isoquinolinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, thiazolyl, isoquinolinyl, tetrazolyl; wherein phenyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyloxy and hydroxy; or optionally, when phenyl and heteroaryl are optionally substituted with two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the moiety is selected from -O(CH2)1-3O-.
19. The compound according to claim 1 wherein R3 is selected from the group consisting of hydrogen, methyl, allyl, 2-methyl-allyl, propynyl, hydroxyethyl, methylthioethyl, methoxyethyl, thioformyl, phenyliminomethyl, phenethyl, and heteroaryl(C1-8)alkanyl wherein the heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein the phenyl in any phenyl-containing substituent is optionally substituted with one hydroxyl group.
20. The compound according to claim 1 wherein R3 is selected from the group consisting of hydrogen, methyl, methylbutenyl, propenyl, benzyl, phenethyl, and heteroaryl(C1-8)alkanyl wherein the heteroaryl is selected from the group consisting of imidazolyl, furanyl, pyridinyl, thienyl, and thiazolyl.
21. The compound according to claim 1 wherein R3 is selected from the group consisting of hydrogen, methyl, 3-methyl-2-butenyl, 2-propenyl, benzyl, 2-phenethyl, pyridin-2-ylmethyl, fur-3-ylmethyl, thiophene-2-ylmethyl, 1H-imidazol-2-ylmethyl, and thiazol-2-ylmethyl.
22. The compound according to claim 1 wherein R3 is hydrogen, methyl, allyl, or heteroarylmethyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, and thienyl.
23. The compound according to claim 1 wherein R4 is one to three substituents independently selected from the group consisting of hydrogen; C1-6alkanyl; C1-6alkanyloxy; C6-10arylamino wherein C6-10aryl is optionally substituted with one to three substitutents independently selected from the group consisting of C1-6alkanyl; C1-6alkoxy, halogen, and hydroxy; formylamino; pyridinylamino; aminocarbonyl;
C1-6alkanylaminocarbonyl; C1-6alkanylcarbonylamino; halogen; hydroxy;
C6-10aryl; chromanyl; chromenyl; furanyl; imidazolyl; indazolyl; indolyl;
indolinyl; isoindolinyl; isoquinolinyl; isothiazolyl; isoxazolyl;
naphthyridinyl; oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl; pyridinyl;
pyrimidinyl; pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl; quinoxalinyl;
tetrazolyl; thiazolyl; and thienyl.
C1-6alkanylaminocarbonyl; C1-6alkanylcarbonylamino; halogen; hydroxy;
C6-10aryl; chromanyl; chromenyl; furanyl; imidazolyl; indazolyl; indolyl;
indolinyl; isoindolinyl; isoquinolinyl; isothiazolyl; isoxazolyl;
naphthyridinyl; oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl; pyridinyl;
pyrimidinyl; pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl; quinoxalinyl;
tetrazolyl; thiazolyl; and thienyl.
24. The compound according to claim 1 wherein R4 is one to two substituents independently selected from the group consisting of hydrogen, C1-4alkanyl, C1-4alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, and hydroxy.
25. The compound according to claim 1 wherein R4 is one to two substituents independently selected from the group consisting of hydrogen, methyl, methoxy, bromo, fluoro, .alpha.'- or .beta.'-phenyl, .alpha.'- or .beta.'-pyridinyl, .alpha.'- or .beta.'-furanyl, and hydroxy.
26. The compound according to claim 1 wherein R4 is one to two substituents independently selected from the group consisting of hydrogen, methyl, phenyl, bromo, fluoro, methoxy, aminocarbonyl, chloro and hydroxy.
27. The compound according to claim 1 wherein R4 is hydrogen, .alpha.'-methoxy, or .alpha.'-hydroxy.
28. The compound according to claim 1 wherein R4 is hydrogen and Y is O.
29. The compound according to claim 1 wherein R4 is .alpha.'-hydroxy and Y is 0.
30. The compound according to claim 1 wherein R4 is .alpha.'-hydroxy and Y is S.
31. The compound according to claim 1 wherein R4 is hydrogen and Y is S.
32. The compound according to claim 1 wherein R5 is one to two substituents independently selected from the group consisting of hydrogen and halogen.
33. The compound according to claim 1 wherein R5 is hydrogen.
34. The compound according to claim 1 wherein A is -(CH2)2-3-.
35. The compound according to claim 1 wherein A is -(CH2)2-.
36. The compound according to claim 1 wherein Y is O.
37. The compound according to claim 1 wherein Y is S.
38. The compound according to claim 1 wherein Z is O, NH, N(C1-6alkanyl), N(OH), N(OC1-6alkanyl), or N(phenyl).
39. The compound according to claim 1 wherein Z is O, NH, or N(OH).
40. The compound according to claim 1 wherein Z is O or NH.
41. The compound according to claim 1 wherein G is -C(Z)N(R1)R2, phenyl, or a heterocycle selected from the group consisting of tetrazolyl, oxadizolyl, furyl, quinolinyl, thienyl, or pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1-8alkanyl, C1-8alkanyloxy, hydroxy(C1-8)alkanyl, carboxy(C1-8)alkanyl, C1-8alkanylcarbonylamino, halogen, hydroxy, cyano, oxo, thioxo, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-8alkanylthio, aminocarbonyl, aminothiocarbonyl, C1-8alkanylaminocarbonyl, di(C1-8alkanyl)aminocarbonyl, and C1-6alkanyloxycarbonylamino;
R1 is C1-4 alkanyl, or hydrogen;
R2 is hydrogen or C1-4alkanyl optionally substituted with phenyl;
or R1 and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl ring optionally substituted with hydroxy;
Z is NH or oxygen;
R3 is pyridinyl(C1-8)alkanyl, furyl(C1-8)alkanyl, C1-8 alkanyl, hydrogen, C2-8 alkenyl, thienyl(C1-8)alkanyl, imidazolyl(C1-8)alkanyl, phenyl(C1-8)alkanyl, or thiazolyl(C1-8)alkanyl;
R4 is hydrogen, C1-6 alkanyl, C1-6 alkanyloxy, hydroxy, halogen, aminocarbonyl, or phenyl;
R5 is hydrogen;
A is CH2CH2;
Y is O or S;
Z is O or NH; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
R1 is C1-4 alkanyl, or hydrogen;
R2 is hydrogen or C1-4alkanyl optionally substituted with phenyl;
or R1 and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl ring optionally substituted with hydroxy;
Z is NH or oxygen;
R3 is pyridinyl(C1-8)alkanyl, furyl(C1-8)alkanyl, C1-8 alkanyl, hydrogen, C2-8 alkenyl, thienyl(C1-8)alkanyl, imidazolyl(C1-8)alkanyl, phenyl(C1-8)alkanyl, or thiazolyl(C1-8)alkanyl;
R4 is hydrogen, C1-6 alkanyl, C1-6 alkanyloxy, hydroxy, halogen, aminocarbonyl, or phenyl;
R5 is hydrogen;
A is CH2CH2;
Y is O or S;
Z is O or NH; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
42. The compound according to claim 41 wherein G is -C(Z)N(R1)R2;
tetrazolyl; oxadiazolyl optionally substituted with oxo; furyl; quinolinyl;
thienyl; phenyl optionally substituted with (C1-8)alkanylcarbonylamino; or pyridinyl.
tetrazolyl; oxadiazolyl optionally substituted with oxo; furyl; quinolinyl;
thienyl; phenyl optionally substituted with (C1-8)alkanylcarbonylamino; or pyridinyl.
43. The compound according to claim 41 wherein Y is O.
44. The compound according to claim 41 wherein Y is S.
45. The compound according to claim 41 wherein when R1 and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl ring optionally substituted with hydroxy, Z is oxygen
46. The compound according to claim 1 wherein:
G is -C(Z)N(R1)R2; tetrazolyl;oxadiazolyl optionally substituted with oxo;
phenyl optionally substituted with (C1-8)alkanylcarbonylamino; or pyridinyl;
R1 is C1-4 alkanyl, or hydrogen;
R2 is hydrogen or C1-4 alkanyl optionally substituted with phenyl;
or R1 and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl ring optionally substituted with hydroxyl;
Z is NH or oxygen;
R3 is pyridinyl(C1-8)alkanyl, furyl(C1-8)alkanyl, C1-8 alkanyl, hydrogen, C2-8 alkenyl, thienyl(C1-8)alkanyl, imidazolyl(C1-8)alkanyl, phenyl(C1-8)alkanyl, or thiazolyl(C1-8)alkanyl;
R4 is hydrogen, .alpha.'-hydroxy, or .alpha.'-methoxy;
R5 is hydrogen;
A is CH2CH2;
Y is O or S;
Z is O or NH; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
G is -C(Z)N(R1)R2; tetrazolyl;oxadiazolyl optionally substituted with oxo;
phenyl optionally substituted with (C1-8)alkanylcarbonylamino; or pyridinyl;
R1 is C1-4 alkanyl, or hydrogen;
R2 is hydrogen or C1-4 alkanyl optionally substituted with phenyl;
or R1 and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl ring optionally substituted with hydroxyl;
Z is NH or oxygen;
R3 is pyridinyl(C1-8)alkanyl, furyl(C1-8)alkanyl, C1-8 alkanyl, hydrogen, C2-8 alkenyl, thienyl(C1-8)alkanyl, imidazolyl(C1-8)alkanyl, phenyl(C1-8)alkanyl, or thiazolyl(C1-8)alkanyl;
R4 is hydrogen, .alpha.'-hydroxy, or .alpha.'-methoxy;
R5 is hydrogen;
A is CH2CH2;
Y is O or S;
Z is O or NH; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
47. The compound according to claim 46 wherein Y is O.
48. The compound according to claim 46 wherein Y is S.
49. The compound according to claim 1 wherein:
G is -C(Z)N(R1)R2, 1H-tetrazol-4-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 2-methylcarbonylaminophenyl, pyridin-3-yl or pyridin-4-yl, R1 is hydrogen, ethyl, or methyl, R2 is methyl, ethyl, phenethyl, or hydrogen;
or R1 and R2 taken together with the nitrogen to which they are attached form pyrrolidin-1-yl, 3-hydroxypyrrolidin-1-yl, or 3-(S)-hydroxypyrrolidin-1-yl;
Z is NH or oxygen, R3 is pyridin-2-ylmethyl, fur-3-ylmethyl, methyl, hydrogen, 3-methyl-2-butenyl, thiophene-2-ylmethyl, 2-propenyl, 1H-imidazol-2-ylmethyl, 2-phenethyl, thiazol-2-ylmethyl, benzyl, R4 is hydrogen, .alpha.'-methoxy, or .alpha.'-hydroxy, R5 is hydrogen A is CH2CH2;
Y is O or S;
Z is O or NH; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof
G is -C(Z)N(R1)R2, 1H-tetrazol-4-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 2-methylcarbonylaminophenyl, pyridin-3-yl or pyridin-4-yl, R1 is hydrogen, ethyl, or methyl, R2 is methyl, ethyl, phenethyl, or hydrogen;
or R1 and R2 taken together with the nitrogen to which they are attached form pyrrolidin-1-yl, 3-hydroxypyrrolidin-1-yl, or 3-(S)-hydroxypyrrolidin-1-yl;
Z is NH or oxygen, R3 is pyridin-2-ylmethyl, fur-3-ylmethyl, methyl, hydrogen, 3-methyl-2-butenyl, thiophene-2-ylmethyl, 2-propenyl, 1H-imidazol-2-ylmethyl, 2-phenethyl, thiazol-2-ylmethyl, benzyl, R4 is hydrogen, .alpha.'-methoxy, or .alpha.'-hydroxy, R5 is hydrogen A is CH2CH2;
Y is O or S;
Z is O or NH; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof
50. A compound of Formula (I):
wherein:
G is independently selected from -C(Z)N(R1)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, tetrahydropyrimidinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1-8alkanyl, C1-8alkanyloxy, hydroxy(C1-8)alkanyl, carboxy(C1-8)alkanyl, C1-8alkanylcarbonylamino, halogen, hydroxy, cyano, oxo, thioxo, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-8alkanylthio, aminocarbonyl, aminothiocarbonyl, C1-8alkanylaminocarbonyl, di(C1-8alkanyl)aminocarbonyl, and C1-6alkanyloxycarbonylamino;
provided that when G is pyridin-3-yl or thien-3-yl and R3 is hydrogen, R4 is other than hydrogen;
R1 is hydrogen or C1-4alkanyl;
R2 is selected from the group consisting of hydrogen; C1-4alkanyl; phenyl;
and C1-6cycloalkanyl; wherein C1-4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-4alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, C1-8alkanylaminocarbonyl, di(C1-8alkanyl)aminocarbonyl, and phenoxy;
and wherein any phenyl-containing substituent of R2 and C1-6cycloalkanyl substituents of R2 are optionally substituted with one to three substituents independently selected from the group consisting of C1-8alkanyl, C1-8alkanyloxy, trifluoromethyl, phenyl, fluoro, hydroxy, C1-8alkanylthio, C1-8alkanylsulfonyl, and C1-8alkanylsulfonylamino; or R1 and R2 taken together with the nitrogen to which they are attached form a 5-7 membered heterocycloalkyl wherein said heterocycloalkyl is optionally substituted with one to three substituents independently selected from the group consisting of C1-8alkanyl, hydroxy(C1-8)alkanyl, and hydroxy;
R3 is selected from the group consisting of hydrogen, C1-8alkanyl, C2-8alkenyl, C2-8alkynyl, C1-8alkanyloxy(C1-8)alkanyl, C1-8alkanylthio(C1-8)alkanyl, hydroxyC1-8alkanyl, thioformyl, phenylimino(C1-8)alkanyl, phenyl(C1-8)alkanyl, and heteroaryl(C1-8)alkanyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indolyl, indolinyl, isoquinolinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein phenyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyloxy and hydroxy; or optionally, when phenyl and heteroaryl are optionally substituted with two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the moiety is selected from -O(CH2)1-3O-;
R4 is one to three substituents independently selected from the group consisting of hydrogen; C1-6alkanyl; C1-6alkanyloxy; C6-10arylamino wherein C6-10aryl is optionally substituted with one to three substitutents independently selected from the group consisting of C1-6alkanyl;
C1-6alkoxy, halogen, and hydroxy; formylamino; pyridinylamino;
aminocarbonyl; C1-6alkanylaminocarbonyl; C1-6alkanylcarbonylamino;
halogen; hydroxy; C6-10aryl; chromanyl; chromenyl; furanyl; imidazolyl;
indazolyl; indolyl; indolinyl; isoindolinyl; isoquinolinyl; isothiazolyl;
isoxazolyl; naphthyridinyl; oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl;
pyridinyl; pyrimidinyl; pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl;
quinoxalinyl; tetrazolyl; thiazolyl; and thienyl;
R5 is one to two substituents independently selected from the group consisting of hydrogen and halogen;
A is CH2CH2;
Y is O or S;
Z is O, NH, N(C1-6alkanyl), N(OH), N(OC1-6alkanyl), or N(phenyl); and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
wherein:
G is independently selected from -C(Z)N(R1)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, tetrahydropyrimidinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1-8alkanyl, C1-8alkanyloxy, hydroxy(C1-8)alkanyl, carboxy(C1-8)alkanyl, C1-8alkanylcarbonylamino, halogen, hydroxy, cyano, oxo, thioxo, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-8alkanylthio, aminocarbonyl, aminothiocarbonyl, C1-8alkanylaminocarbonyl, di(C1-8alkanyl)aminocarbonyl, and C1-6alkanyloxycarbonylamino;
provided that when G is pyridin-3-yl or thien-3-yl and R3 is hydrogen, R4 is other than hydrogen;
R1 is hydrogen or C1-4alkanyl;
R2 is selected from the group consisting of hydrogen; C1-4alkanyl; phenyl;
and C1-6cycloalkanyl; wherein C1-4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-4alkanyloxy, hydroxy, fluoro, chloro, cyano, aminocarbonyl, C1-8alkanylaminocarbonyl, di(C1-8alkanyl)aminocarbonyl, and phenoxy;
and wherein any phenyl-containing substituent of R2 and C1-6cycloalkanyl substituents of R2 are optionally substituted with one to three substituents independently selected from the group consisting of C1-8alkanyl, C1-8alkanyloxy, trifluoromethyl, phenyl, fluoro, hydroxy, C1-8alkanylthio, C1-8alkanylsulfonyl, and C1-8alkanylsulfonylamino; or R1 and R2 taken together with the nitrogen to which they are attached form a 5-7 membered heterocycloalkyl wherein said heterocycloalkyl is optionally substituted with one to three substituents independently selected from the group consisting of C1-8alkanyl, hydroxy(C1-8)alkanyl, and hydroxy;
R3 is selected from the group consisting of hydrogen, C1-8alkanyl, C2-8alkenyl, C2-8alkynyl, C1-8alkanyloxy(C1-8)alkanyl, C1-8alkanylthio(C1-8)alkanyl, hydroxyC1-8alkanyl, thioformyl, phenylimino(C1-8)alkanyl, phenyl(C1-8)alkanyl, and heteroaryl(C1-8)alkanyl wherein heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, indolyl, indolinyl, isoquinolinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein phenyl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyloxy and hydroxy; or optionally, when phenyl and heteroaryl are optionally substituted with two substituents attached to adjacent carbon atoms, the two substituents together form a single fused moiety; wherein the moiety is selected from -O(CH2)1-3O-;
R4 is one to three substituents independently selected from the group consisting of hydrogen; C1-6alkanyl; C1-6alkanyloxy; C6-10arylamino wherein C6-10aryl is optionally substituted with one to three substitutents independently selected from the group consisting of C1-6alkanyl;
C1-6alkoxy, halogen, and hydroxy; formylamino; pyridinylamino;
aminocarbonyl; C1-6alkanylaminocarbonyl; C1-6alkanylcarbonylamino;
halogen; hydroxy; C6-10aryl; chromanyl; chromenyl; furanyl; imidazolyl;
indazolyl; indolyl; indolinyl; isoindolinyl; isoquinolinyl; isothiazolyl;
isoxazolyl; naphthyridinyl; oxazolyl; pyrazinyl; pyrazolyl; pyridazinyl;
pyridinyl; pyrimidinyl; pyrrolyl; quinazolinyl; quinolinyl; quinolizinyl;
quinoxalinyl; tetrazolyl; thiazolyl; and thienyl;
R5 is one to two substituents independently selected from the group consisting of hydrogen and halogen;
A is CH2CH2;
Y is O or S;
Z is O, NH, N(C1-6alkanyl), N(OH), N(OC1-6alkanyl), or N(phenyl); and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
51. A compound of Formula (I):
wherein:
G is selected from -C(Z)N(R1)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1-4alkanyl, C1-4alkanyloxy, hydroxy(C1-4)alkanyl, carboxy(C1-4)alkanyl, C1-4alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-8alkanylthio, aminocarbonyl, aminothiocarbonyl, C1-8alkanylaminocarbonyl, and di(C1-8alkanyl)aminocarbonyl;
R1 is selected from the group consisting of hydrogen, methyl, ethyl, and propyl;
R2 is selected from the group consisting of hydrogen, C1-4alkanyl, phenyl, and C1-6cycloalkanyl; wherein C1-4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1-4alkanyloxy, hydroxy, fluoro, aminocarbonyl, C1-8alkanylaminocarbonyl, di(C1-8alkanyl)aminocarbonyl, and phenoxy;
and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyl, C1-6alkanyloxy, fluoro, hydroxy, and C1-6alkanylthio; or R1 and R2 taken together with the nitrogen to which they are attached form pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from the group consisting of C1-3alkanyl and hydroxy;
R3 is selected from the group consisting of hydrogen, methyl, allyl, 2-methyl-allyl, propynyl, hydroxyethyl, methylthioethyl, methoxyethyl, thioformyl, phenyliminomethyl, phenethyl, and heteroaryl(C1-8)alkanyl wherein the heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein the phenyl in any phenyl-containing substituent is optionally substituted with one hydroxyl group;
R4 is one to two substituents independently selected from the group consisting of hydrogen, C1-4alkanyl, C1-4alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, and hydroxy;
R5 is hydrogen;
A is CH2CH2;
Y is O or S;
Z is O, NH, or N(OH); and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
wherein:
G is selected from -C(Z)N(R1)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, imidazolinyl, thienyl, pyrazolyl, pyrimidinyl, triazinyl, isothiazolyl, isoxazolyl, oxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1-4alkanyl, C1-4alkanyloxy, hydroxy(C1-4)alkanyl, carboxy(C1-4)alkanyl, C1-4alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, amino, C1-6alkanylamino, di(C1-6alkanyl)amino, C1-8alkanylthio, aminocarbonyl, aminothiocarbonyl, C1-8alkanylaminocarbonyl, and di(C1-8alkanyl)aminocarbonyl;
R1 is selected from the group consisting of hydrogen, methyl, ethyl, and propyl;
R2 is selected from the group consisting of hydrogen, C1-4alkanyl, phenyl, and C1-6cycloalkanyl; wherein C1-4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1-4alkanyloxy, hydroxy, fluoro, aminocarbonyl, C1-8alkanylaminocarbonyl, di(C1-8alkanyl)aminocarbonyl, and phenoxy;
and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyl, C1-6alkanyloxy, fluoro, hydroxy, and C1-6alkanylthio; or R1 and R2 taken together with the nitrogen to which they are attached form pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from the group consisting of C1-3alkanyl and hydroxy;
R3 is selected from the group consisting of hydrogen, methyl, allyl, 2-methyl-allyl, propynyl, hydroxyethyl, methylthioethyl, methoxyethyl, thioformyl, phenyliminomethyl, phenethyl, and heteroaryl(C1-8)alkanyl wherein the heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein the phenyl in any phenyl-containing substituent is optionally substituted with one hydroxyl group;
R4 is one to two substituents independently selected from the group consisting of hydrogen, C1-4alkanyl, C1-4alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, and hydroxy;
R5 is hydrogen;
A is CH2CH2;
Y is O or S;
Z is O, NH, or N(OH); and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
52. The compound according to claim 51 wherein G is -C(Z)N(R1)R2, phenyl, or a heterocycle selected from the group consisting of imidazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxathiadiazolyl, thienyl, isothiazolyl, isoxazolyl, isoxadiazolyl, and pyridinyl; wherein phenyl and the heterocycles of G are optionally substituted with one to three substituents independently selected from the group consisting of C1-4alkanyl, C1-4alkanyloxy, hydroxy(C1-4)alkanyl, C1-4alkanylcarbonylamino, hydroxy, cyano, oxo, thioxo, and aminocarbonyl.
53. The compound according to claim 51 wherein G is -C(Z)N(R1)R2, 2-methylcarbonylaminophenyl, 2-aminocarbonyl-phenyl, 1H-tetrazol-4-yl, 2-methyl-tetrazol-5-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 4H-[1,2,4]-oxadiazol-5-thioxo-3-yl, 4H-[1,2,4]thiadiazol-5-oxo-3-yl, [1,2,3,5]oxathiadiazol-2-oxo-4-yl, or pyridin-3-yl.
54. The compound according to claim 51 wherein G is -C(Z)N(R1)R2, 1H-tetrazol-4-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 2-methylcarbonylaminophenyl, pyridin-3-yl or pyridin-4-yl.
55. The compound according to claim 51 wherein R2 is selected from the group consisting of hydrogen, C1-4alkanyl and phenyl; wherein C1-4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1-4alkanyloxy, hydroxy, fluoro, and phenoxy; and wherein any phenyl-containing substituent is optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyl, C1-6alkanyloxy, fluoro, and hydroxy; or R1 and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from C1-3alkanyl or hydroxy; and R3 is a substituent selected from the group consisting of benzo[1,3]dioxol-5-ylmethyl, carbamimidoyl, 1-H-imidazol-4-ylmethyl, phenyliminomethyl, 1-prop-2-ynyl, thioformyl, 2-hydroxyphenyl-methyl, hydroxy-ethyl, methoxy-ethyl, 2-methyl-allyl, 2-methyl-but-2-enyl, allyl, furan-3-ylmethyl, H, Me, methylthioethyl, phenethyl, pyridin-2-yl methyl, and thiophen-2-yl methyl.
56. The compound according to claim 51 wherein R1 is hydrogen, ethyl, or methyl; R2 is methyl, ethyl, phenethyl, or hydrogen; or R1 and R2 taken together with the nitrogen to which they are attached form pyrrolidin-1-yl, 3-hydroxypyrrolidin-1-yl, or 3-(S)-hydroxypyrrolidin-1-yl.
57. A compound of Formula (I):
wherein:
G is selected from -C(Z)N(R1)R2, 2-methylcarbonylaminophenyl, 2-aminocarbonyl-phenyl, 1H-tetrazol-4-yl, 2-methyl-tetrazol-5-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 4H-[1,2,4]-oxadiazol-5-thioxo-3-yl, 4H-[1,2,4]thiadiazol-5-oxo-3-yl, [1,2,3,5]oxathiadiazol-2-oxo-4-yl, or pyridin-3-yl;
R1 is hydrogen, methyl, or ethyl;
R2 is selected from the group consisting of hydrogen, C1-4alkanyl and phenyl; wherein C1-4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1-4alkanyloxy, hydroxy, fluoro, and phenoxy; and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyl, C1-6alkanyloxy, fluoro, and hydroxy; or R1 and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from C1-3alkanyl or hydroxy;
R3 is selected from the group consisting of hydrogen, methyl, allyl, 2-methyl-allyl, propynyl, hydroxyethyl, methylthioethyl, methoxyethyl, thioformyl, phenyliminomethyl, phenethyl, and heteroaryl(C1-8)alkanyl wherein the heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein the phenyl in any phenyl-containing substituent is optionally substituted with one hydroxyl group;
R4 is one to three substituents independently selected from the group consisting of hydrogen, C1-4alkanyl, C1-4alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, and hydroxy;
R5 is hydrogen;
A is CH2CH2;
Y is O or S;
Z is O or NH; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
wherein:
G is selected from -C(Z)N(R1)R2, 2-methylcarbonylaminophenyl, 2-aminocarbonyl-phenyl, 1H-tetrazol-4-yl, 2-methyl-tetrazol-5-yl, 4H-[1,2,4]-oxadiazol-5-oxo-3-yl, 4H-[1,2,4]-oxadiazol-5-thioxo-3-yl, 4H-[1,2,4]thiadiazol-5-oxo-3-yl, [1,2,3,5]oxathiadiazol-2-oxo-4-yl, or pyridin-3-yl;
R1 is hydrogen, methyl, or ethyl;
R2 is selected from the group consisting of hydrogen, C1-4alkanyl and phenyl; wherein C1-4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1-4alkanyloxy, hydroxy, fluoro, and phenoxy; and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyl, C1-6alkanyloxy, fluoro, and hydroxy; or R1 and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from C1-3alkanyl or hydroxy;
R3 is selected from the group consisting of hydrogen, methyl, allyl, 2-methyl-allyl, propynyl, hydroxyethyl, methylthioethyl, methoxyethyl, thioformyl, phenyliminomethyl, phenethyl, and heteroaryl(C1-8)alkanyl wherein the heteroaryl is selected from the group consisting of benzo[1,3]dioxolyl, imidazolyl, furanyl, pyridinyl, thienyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl; wherein the phenyl in any phenyl-containing substituent is optionally substituted with one hydroxyl group;
R4 is one to three substituents independently selected from the group consisting of hydrogen, C1-4alkanyl, C1-4alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, and hydroxy;
R5 is hydrogen;
A is CH2CH2;
Y is O or S;
Z is O or NH; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
58. The compound according to claim 31 wherein R2 is a substituent selected from the group consisting of hydrogen, C1-4alkanyl and phenyl;
wherein C1-4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1-4alkanyloxy, hydroxy, and 2,6-dimethyl-phenoxy; and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyl, C1-6alkanyloxy, fluoro, and hydroxy; or R1 and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from C1-3alkanyl or hydroxy.
wherein C1-4alkanyl is optionally substituted with one to three substituents independently selected from the group consisting of phenyl, C1-4alkanyloxy, hydroxy, and 2,6-dimethyl-phenoxy; and wherein any phenyl-containing substituent of R2 is optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkanyl, C1-6alkanyloxy, fluoro, and hydroxy; or R1 and R2 taken together with the nitrogen to which they are attached form a pyrrolidinyl or piperidinyl ring wherein said pyrrolidinyl or piperidinyl is optionally substituted with a substituent selected from C1-3alkanyl or hydroxy.
59. The compound according to claim 31 wherein R3 is a substituent selected from the group consisting of benzo[1,3]dioxol-5-ylmethyl, carbamimidoyl, 1-H-imidazol-4-ylmethyl, phenyliminomethyl, 1-prop-2-ynyl, thioformyl, 2-hydroxyphenyl-methyl, hydroxy-ethyl, methoxy-ethyl, 2-methyl-allyl, 2-methyl-but-2-enyl, allyl, furan-3-ylmethyl, H, Me, methylthioethyl, phenethyl, pyridin-2-yl methyl, and thiophen-2-ylmethyl; and R4 is one to two substituents independently selected from the group consisting of hydrogen, C1-4alkanyl, C1-4alkanyloxy, halogen, phenyl, furanyl, imidazolyl, indazolyl, indolyl, indolinyl, isoindolinyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, and hydroxy.
60. The compound according to claim 31 wherein R3 is a substituent selected from the group consisting of benzo[1,3]dioxol-5-ylmethyl, carbamimidoyl, 1-H-imidazol-4-yl methyl, phenyliminomethyl, 1-prop-2-ynyl, thioformyl, 2-hydroxyphenyl-methyl, hydroxyethyl, methoxyethyl, allyl, furan-3-yl methyl, H, Me, methylthioethyl, and phenethyl; R4 is one to two substituents independently selected from the group consisting of hydrogen, methyl, methoxy, bromo, fluoro, .alpha.'- or .beta.'-phenyl, .alpha.'- or .beta.'-pyridinyl, .alpha.'- or .beta.'-furanyl, and hydroxy.
61. The compound according to claim 31 wherein R3 is a substituent selected from the group consisting of H, benzo[1,3]dioxol-5-ylmethyl, 1-H-imidazol-4-yl methyl, furan-3-ylmethyl, pyridin-2-ylmethyl, and phenyliminomethyl; and R4 is a substituent independently selected from the group consisting of hydrogen, methyl, methoxy, bromo, fluoro, .alpha.'- or .beta.'-phenyl, .alpha.'- or .beta.'-pyridinyl, .alpha.'- or .beta.'-furanyl, and hydroxy.
62. A compound of Formula (I):
selected from the group consisting of:
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is 1H-imidazol-2-yl-methyl; R4 is .alpha.'-hydroxy; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is furan-3-yl-methyl; R4 is .alpha.'-hydroxy; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is .alpha.'-hydroxy; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is .alpha.'-methoxy; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is pyridin-2-yl-methyl; R4 is H; R5 is H; Y is O; A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is furan-3-yl-methyl; R4 is H; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is thien-2-yl-methyl; R4 is H; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is benzyl; R4 is H; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is pyridin-3-yl; R3 is furan-3-yl methyl;
is H; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is furan-2-yl methyl; R4 is H; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is .alpha.'-methyl; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is .alpha.'-phenyl; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is H; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is H; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is .beta."-bromo; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is H; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is .alpha.'-chloro; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is .beta."-fluoro; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is 2-methylcarbonylamino-phenyl; R3 is H; R4 is H; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is pyrrolidin-1-yl; R3 is H; R4 is H; R5 is H;
Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is furan-3-yl-methyl; R4 is H; R5 is H; Y is O; and A is -CH2CH2-; and a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is furan-3-yl-methyl; R4 is H; R5 is H; Y is O; and A is -CH2CH2-.
selected from the group consisting of:
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is 1H-imidazol-2-yl-methyl; R4 is .alpha.'-hydroxy; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is furan-3-yl-methyl; R4 is .alpha.'-hydroxy; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is .alpha.'-hydroxy; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is .alpha.'-methoxy; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is pyridin-2-yl-methyl; R4 is H; R5 is H; Y is O; A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is furan-3-yl-methyl; R4 is H; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is thien-2-yl-methyl; R4 is H; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is benzyl; R4 is H; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is pyridin-3-yl; R3 is furan-3-yl methyl;
is H; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is furan-2-yl methyl; R4 is H; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is .alpha.'-methyl; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is .alpha.'-phenyl; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is H; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is H; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is .beta."-bromo; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is H; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is .alpha.'-chloro; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is H; R4 is .beta."-fluoro; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is 2-methylcarbonylamino-phenyl; R3 is H; R4 is H; R5 is H; Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is pyrrolidin-1-yl; R3 is H; R4 is H; R5 is H;
Y is O; and A is -CH2CH2-;
a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is furan-3-yl-methyl; R4 is H; R5 is H; Y is O; and A is -CH2CH2-; and a compound of Formula (I) wherein G is N,N-diethylaminocarbonyl; R3 is furan-3-yl-methyl; R4 is H; R5 is H; Y is O; and A is -CH2CH2-.
63. A compound according to claim 1 that is:
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
(3-Hydroxy-pyrrolidin-1-yl)-[10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-methanone;
10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid methyl-phenethyl-amide;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine;
Endo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine;
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-N,N-diethyl-10H-phenoxazine-3-carboxamidine;
Endo-N,N-Diethyl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxamidine;
Endo-N, N-Diethyl-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxamidine;
Endo-3-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one;
endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid amide;
Endo-3-[10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one;
Endo-3-[10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one;
10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-10H-phenoxazine-3-carboxylic acid diethylamide;
6-Methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
6-Hydroxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
6-Methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine;
N,N-Diethyl-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxamidine;
3-[10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one;
10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenothiazine;
N-{2-[10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide;
10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-3-pyridin-3-yl-10H-phenothiazine;
3-Pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine;
10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-3-pyridin-4-yl-10H-phenothiazine;
3-Pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine; or 3-Pyridin-4-yl-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine.
10-(8-Methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
(3-Hydroxy-pyrrolidin-1-yl)-[10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-methanone;
10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid methyl-phenethyl-amide;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine;
Endo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine;
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-N,N-diethyl-10H-phenoxazine-3-carboxamidine;
Endo-N,N-Diethyl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxamidine;
Endo-N, N-Diethyl-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxamidine;
Endo-3-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one;
endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid amide;
Endo-3-[10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one;
Endo-3-[10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one;
10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-10H-phenoxazine-3-carboxylic acid diethylamide;
6-Methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
6-Hydroxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
6-Methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine;
N,N-Diethyl-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxamidine;
3-[10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one;
10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenothiazine;
N-{2-[10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide;
10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-3-pyridin-3-yl-10H-phenothiazine;
3-Pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine;
10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-3-pyridin-4-yl-10H-phenothiazine;
3-Pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine; or 3-Pyridin-4-yl-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine.
64. A compound according to claim 1 that is:
N-{2-[10-(8-Allyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide;
N-{2-[10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide;
N-(2-{10-[8-(1H-Imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenothiazin-3-yl}-phenyl)-acetamide;
N-{2-[10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide;
10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenothiazine;
N-{2-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide;
10-(8-Allyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenothiazine;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine;
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine;
Endo-3-Pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;
Endo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine;
Endo-3-Pyridin-3-yl-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;
Endo-3-Pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;
Endo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;
Endo-3-Pyridin-4-yl-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;
Exo-3-(3-Pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester;
Exo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine;
Exo-3-Pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;
Exo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine;
Exo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;
Exo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;
Exo-3-Pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;
Exo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;
Exo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine;or Exo-3-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one;
N-{2-[10-(8-Allyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide;
N-{2-[10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide;
N-(2-{10-[8-(1H-Imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenothiazin-3-yl}-phenyl)-acetamide;
N-{2-[10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide;
10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenothiazine;
N-{2-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-phenyl}-acetamide;
10-(8-Allyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenothiazine;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine;
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine;
Endo-3-Pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;
Endo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine;
Endo-3-Pyridin-3-yl-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;
Endo-3-Pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;
Endo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;
Endo-3-Pyridin-4-yl-10-(8-thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;
Exo-3-(3-Pyridin-3-yl-phenoxazin-10-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester;
Exo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine;
Exo-3-Pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;
Exo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine;
Exo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;
Exo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;
Exo-3-Pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;
Exo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;
Exo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine;or Exo-3-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one;
65. A compound according to claim 1 that is:
[10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-pyrrolidin-1-yl-methanone;
[10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-pyrrolidin-1-yl-methanone;
{10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenothiazin-3-yl}-pyrrolidin-1-yl-methanone;
[10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-(3-hydroxy-pyrrolidin-1-yl)-methanone;
(3-Hydroxy-pyrrolidin-1-yl)-[10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-methanone;
{10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenothiazin-3-yl}-(3-methyl-pyrrolidin-1-yl)-methanone;
[10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-pyrrolidin-1-yl-methanone;
(3-Hydroxy-pyrrolidin-1-yl)-[10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-methanone;
10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carboxylic acid ethylamide;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Thiazol-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Pyridin-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-[8-(1H-Imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Pyridin-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide; or Exo-10-(8-Thiazol-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide.
[10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-pyrrolidin-1-yl-methanone;
[10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-pyrrolidin-1-yl-methanone;
{10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenothiazin-3-yl}-pyrrolidin-1-yl-methanone;
[10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-(3-hydroxy-pyrrolidin-1-yl)-methanone;
(3-Hydroxy-pyrrolidin-1-yl)-[10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-methanone;
{10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenothiazin-3-yl}-(3-methyl-pyrrolidin-1-yl)-methanone;
[10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-pyrrolidin-1-yl-methanone;
(3-Hydroxy-pyrrolidin-1-yl)-[10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazin-3-yl]-methanone;
10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carboxylic acid ethylamide;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Thiazol-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Pyridin-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-[8-(1H-Imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Pyridin-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide; or Exo-10-(8-Thiazol-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide.
66. A compound according to claim 1 that is:
Exo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-[8-(1H-Imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-3-yl-10H-phenoxazin-4-ol;
Endo-7-Pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-4-ol;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-3-pyridin-3-yl-10H-phenoxazine;
Endo-6-Methoxy-3-pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-4-yl-10H-phenoxazin-4-ol;
Endo-7-Pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-4-ol;
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-4-yl-10H-phenoxazin-4-ol;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-3-pyridin-4-yl-10H-phenoxazine;
Endo-6-Methoxy-3-pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;
Endo-6-Methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;
Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide;
Endo-N-{2-[10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide;
Endo-N-{2-[10-(8-Thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide;
Endo-N-{2-[10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide;
Exo-N-{2-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide;
Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-hydroxy-10H-phenoxazin-3-yl]-phenyl}-acetamide;
Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-10H-phenoxazin-3-yl]-phenyl}-acetamide;
10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenothiazine;
10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenothiazine;
10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenothiazine;
N,N-Diethyl-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carboxamidine;
N,N-Diethyl-10-(8-pyridin-2-yl methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carboxamidine;
10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenothiazine;
N,N-Diethyl-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carboxamidine;
10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-3-pyridin-3-yl-10H-phenothiazine;
10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-3-yl-10H-phenothiazin-4-ol;
6-Methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carboxylic acid diethylamide;
10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-10H-phenothiazine-3-carboxylic acid diethylamide; or 10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-hydroxy-10H-phenothiazine-3-carboxylic acid diethylamide.
Exo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-[8-(1H-Imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-3-yl-10H-phenoxazin-4-ol;
Endo-7-Pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-4-ol;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-3-pyridin-3-yl-10H-phenoxazine;
Endo-6-Methoxy-3-pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-4-yl-10H-phenoxazin-4-ol;
Endo-7-Pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-4-ol;
Endo-10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-4-yl-10H-phenoxazin-4-ol;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-3-pyridin-4-yl-10H-phenoxazine;
Endo-6-Methoxy-3-pyridin-4-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine;
Endo-6-Methoxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-4-yl-10H-phenoxazine;
Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide;
Endo-N-{2-[10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide;
Endo-N-{2-[10-(8-Thiophen-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide;
Endo-N-{2-[10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide;
Exo-N-{2-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-phenyl}-acetamide;
Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-hydroxy-10H-phenoxazin-3-yl]-phenyl}-acetamide;
Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-10H-phenoxazin-3-yl]-phenyl}-acetamide;
10-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenothiazine;
10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenothiazine;
10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenothiazine;
N,N-Diethyl-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carboxamidine;
N,N-Diethyl-10-(8-pyridin-2-yl methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carboxamidine;
10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenothiazine;
N,N-Diethyl-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carboxamidine;
10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-3-pyridin-3-yl-10H-phenothiazine;
10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-3-yl-10H-phenothiazin-4-ol;
6-Methoxy-10-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-carboxylic acid diethylamide;
10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-methoxy-10H-phenothiazine-3-carboxylic acid diethylamide; or 10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-hydroxy-10H-phenothiazine-3-carboxylic acid diethylamide.
67. A compound according to claim 1 that is:
Endo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
10-(8-Pyridin-2-yl methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenothiazine;
Endo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine;
Endo-3-[10-(8-Pyridin-2-yl methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one;
Endo-10-[8-(1H-Imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-7-Pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-4-ol;
Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-hydroxy-10H-phenoxazin-3-yl]-phenyl}-acetamide;
Endo-10-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
6-Hydroxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Pyridin-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-4-yl-10H-phenoxazin-4-ol;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-3-yl-10H-phenoxazin-4-ol; or Endo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine.
Endo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
10-(8-Pyridin-2-yl methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenothiazine;
Endo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-(1H-tetrazol-5-yl)-10H-phenoxazine;
Endo-3-[10-(8-Pyridin-2-yl methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-3-yl]-4H-[1,2,4]oxadiazol-5-one;
Endo-10-[8-(1H-Imidazol-2-ylmethyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-[8-(3-Methyl-but-2-enyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-7-Pyridin-3-yl-10-(8-pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazin-4-ol;
Endo-N-{2-[10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-6-hydroxy-10H-phenoxazin-3-yl]-phenyl}-acetamide;
Endo-10-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
6-Hydroxy-10-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Endo-10-(8-Pyridin-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide;
Exo-10-(8-Pyridin-2-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-4-yl-10H-phenoxazin-4-ol;
Endo-10-(8-Aza-bicyclo[3.2.1]oct-3-yl)-7-pyridin-3-yl-10H-phenoxazin-4-ol; or Endo-10-(8-Furan-3-ylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3-pyridin-3-yl-10H-phenoxazine.
68. A composition comprising the dextrorotatory enantiomer of a compound according to claim 1 wherein said composition is substantially free from the levorotatory isomer of said compound.
69. A composition comprising the levororotatory enantiomer of a compound according to claim 1 wherein said composition is substantially free from the dextrorotatory isomer of said compound.
70. A composition comprising the exo isomer of a compound according to claim 1 wherein said composition is substantially free from the endo isomer of said compound.
71. A composition comprising the endo isomer of a compound according to claim 1 wherein said composition is substantially free from the exo isomer of said compound.
72. A pharmaceutical composition comprising a compound, salt or solvate according to any of claims 1 admixed with a pharmaceutically acceptable carrier, excipient or diluent.
73. A veterinary composition comprising a compound, salt or solvate according to claim 1 admixed with a veterinarily acceptable carrier, excipient or diluent.
74. A pharmaceutical composition comprising a compound, salt or solvate according to claim 46 admixed with a pharmaceutically acceptable carrier, excipient or diluent.
75. A veterinary composition comprising a compound, salt or solvate according to claim 46 admixed with a veterinarily acceptable carrier, excipient or diluent.
76. A pharmaceutical composition comprising a compound, salt or solvate according to claim 49 admixed with a pharmaceutically acceptable carrier, excipient or diluent.
77. A veterinary composition comprising a compound, salt or solvate according to claim 49 admixed with a veterinarily acceptable carrier, excipient or diluent.
78. A pharmaceutical composition comprising a compound, salt or solvate according to claim 50 admixed with a pharmaceutically acceptable carrier, excipient or diluent.
79. A veterinary composition comprising a compound, salt or solvate according to claim 50 admixed with a veterinarily acceptable carrier, excipient or diluent.
80. A pharmaceutical composition comprising a compound, salt or solvate according to claim 51 admixed with a pharmaceutically acceptable carrier, excipient or diluent.
81. A veterinary composition comprising a compound, salt or solvate according to claim 51 admixed with a veterinarily acceptable carrier, excipient or diluent.
82. A pharmaceutical composition comprising a compound, salt or solvate according to claim 57 admixed with a pharmaceutically acceptable carrier, excipient or diluent.
83. A veterinary composition comprising a compound, salt or solvate according to claim 57 admixed with a veterinarily acceptable carrier, excipient or diluent.
84. A pharmaceutical composition comprising a compound, salt or solvate according to claim 62 admixed with a pharmaceutically acceptable carrier, excipient or diluent.
85. A veterinary composition comprising a compound, salt or solvate according to claim 62 admixed with a veterinarily acceptable carrier, excipient or diluent.
86. A pharmaceutical composition comprising a compound, salt or solvate according to claim 63 admixed with a pharmaceutically acceptable carrier, excipient or diluent.
87. A veterinary composition comprising a compound, salt or solvate according to claim 63 admixed with a veterinarily acceptable carrier, excipient or diluent.
88. A pharmaceutical composition comprising a compound, salt or solvate according to claim 64 admixed with a pharmaceutically acceptable carrier, excipient or diluent.
89. A veterinary composition comprising a compound, salt or solvate according to claim 64 admixed with a veterinarily acceptable carrier, excipient or diluent.
90. A pharmaceutical composition comprising a compound, salt or solvate according to claim 65 admixed with a pharmaceutically acceptable carrier, excipient or diluent.
91. A veterinary composition comprising a compound, salt or solvate according to claim 65 admixed with a veterinarily acceptable carrier, excipient or diluent.
92. A pharmaceutical composition comprising a compound, salt or solvate according to claim 66 admixed with a pharmaceutically acceptable carrier, excipient or diluent.
93. A veterinary composition comprising a compound, salt or solvate according to claim 66 admixed with a veterinarily acceptable carrier, excipient or diluent.
94. A pharmaceutical composition comprising a compound, salt or solvate according to claim 67 admixed with a pharmaceutically acceptable carrier, excipient or diluent.
95. A veterinary composition comprising a compound, salt or solvate according to claim 67 admixed with a veterinarily acceptable carrier, excipient or diluent.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63831504P | 2004-12-22 | 2004-12-22 | |
US60/638,315 | 2004-12-22 | ||
PCT/US2005/046691 WO2006069276A2 (en) | 2004-12-22 | 2005-12-21 | TRICYCLIC ō-OPIOID MODULATORS |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2591963A1 true CA2591963A1 (en) | 2006-06-29 |
Family
ID=36481352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002591963A Abandoned CA2591963A1 (en) | 2004-12-22 | 2005-12-21 | Tricyclic o-opioid modulators |
Country Status (17)
Country | Link |
---|---|
US (3) | US7439239B2 (en) |
EP (1) | EP1833826B1 (en) |
JP (1) | JP2008525482A (en) |
KR (1) | KR20070092293A (en) |
CN (1) | CN101115751A (en) |
AT (1) | ATE432279T1 (en) |
AU (1) | AU2005319060A1 (en) |
BR (1) | BRPI0518563A2 (en) |
CA (1) | CA2591963A1 (en) |
DE (1) | DE602005014671D1 (en) |
EA (1) | EA011674B1 (en) |
IL (1) | IL184064A0 (en) |
MX (1) | MX2007007626A (en) |
NI (1) | NI200700163A (en) |
NO (1) | NO20073776L (en) |
WO (1) | WO2006069276A2 (en) |
ZA (1) | ZA200706029B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4810423B2 (en) | 2003-06-27 | 2011-11-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Tricyclic delta opioid regulator |
BRPI0513075A (en) * | 2004-08-05 | 2008-04-22 | Janssen Pharmaceutica Nv | tricyclic gamma-opioid modulators |
EP1833826B1 (en) * | 2004-12-22 | 2009-05-27 | Janssen Pharmaceutica N.V. | Tricyclic delta-opioid modulators |
CN101119992A (en) * | 2004-12-22 | 2008-02-06 | 詹森药业有限公司 | Tricyclic delta-opioid modulators |
WO2006069275A1 (en) * | 2004-12-22 | 2006-06-29 | Janssen Pharmaceutica N.V. | Tricyclic delta-opioid modulators |
EP1846400A2 (en) * | 2005-01-06 | 2007-10-24 | Janssen Pharmaceutica N.V. | Tricyclic delta-opioid modulators |
JP2008543866A (en) * | 2005-06-16 | 2008-12-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Tricyclic opioid modulator |
CA2615774C (en) | 2005-07-21 | 2014-12-09 | Rensselaer Polytechnic Institute | Large substituent, non-phenolic opioids |
JP5524181B2 (en) * | 2008-04-24 | 2014-06-18 | アラーガン インコーポレイテッド | Substituted gamma lactams as therapeutic agents |
BR112012011443A2 (en) * | 2009-10-30 | 2020-09-08 | Janssen Pharmaceutica N. V. | phenylamine-2-phenoxy-4-substituted as modulators of the delta opioid receptor. |
IT1396951B1 (en) * | 2009-12-18 | 2012-12-20 | Neuroscienze Pharmaness S C A R L | PHARMACEUTICAL COMPOUNDS |
JP5872585B2 (en) * | 2010-12-22 | 2016-03-01 | パーデュー、ファーマ、リミテッド、パートナーシップ | Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof |
JP5981992B2 (en) | 2011-06-29 | 2016-08-31 | アルカーメス,インコーポレイテッド | Peripherally acting opioid compounds |
JP6154025B2 (en) * | 2012-12-24 | 2017-06-28 | ニューロガストルクス,インコーポレイテッド | Method for treating GI tract disorders |
US9844554B2 (en) | 2014-06-24 | 2017-12-19 | Neurogastrx, Inc. | Prodrugs of metopimazine |
US10836757B1 (en) | 2020-04-02 | 2020-11-17 | Neurogastrx, Inc. | Polymorphic forms of metopimazine |
CN114236024B (en) * | 2021-12-07 | 2023-12-29 | 江苏宝众宝达药业股份有限公司 | Method for simultaneously measuring content of 4-fluoro-3-nitronitrile and isomer thereof |
CN114334022B (en) * | 2021-12-31 | 2022-11-18 | 杭州剂泰医药科技有限责任公司 | Solubility prediction model of compound molecule and application |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2368006A (en) * | 1943-10-07 | 1945-01-23 | Searle & Co | Heterocyclic tertiary amines |
FR1159125A (en) * | 1953-03-27 | 1958-06-23 | Promonta Chem Fab | Process for preparing phenyl-thiazine derivatives having as basic substituent a heterocyclic ring containing a nitrogen atom |
US2901478A (en) * | 1957-02-11 | 1959-08-25 | Promonta Chem Fab | Phenothiazine compounds |
US3179665A (en) * | 1959-12-16 | 1965-04-20 | Wander Ag Dr A | 9-(n-ethyl and n-propyl piperidyl-3'-methyl)-thioxanthenes |
DE1159954B (en) * | 1961-11-25 | 1963-12-27 | Boehringer & Soehne Gmbh | Process for the production of new 10- (alkoxypiperidinopropyl) -phenthiazines and their salts |
DE1670118A1 (en) | 1966-07-22 | 1970-11-05 | Boehringer Mannheim Gmbh | Process for the preparation of new derivatives of 6,11-dihydro-dibenz [b, e] oxepins and their salts |
US3470188A (en) * | 1967-01-05 | 1969-09-30 | Smithkline Corp | 9-cycloalkyl-lower alkyl-piperidylidene derivatives of xanthenes and thioxanthenes |
NL6818027A (en) * | 1968-01-09 | 1969-07-11 | ||
GB1250534A (en) | 1969-03-03 | 1971-10-20 | ||
US3987042A (en) * | 1969-03-03 | 1976-10-19 | Claude Gueremy | Phenothiazine derivative |
US3931232A (en) * | 1974-06-24 | 1976-01-06 | Smithkline Corporation | 3-Alkyl xanthene compounds |
US4086350A (en) * | 1974-11-06 | 1978-04-25 | Smithkline Corporation | Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms |
ZA756550B (en) | 1974-11-06 | 1976-09-29 | Smithkline Corp | Pharmaceutical compositions and method of producing antipsychotic activity without extrapyramidal symptoms |
US4285956A (en) | 1978-05-12 | 1981-08-25 | Kefalas A/S | Xanthene and thioxanthene derivatives, compositions thereof and treatment therewith |
US4356184A (en) * | 1980-06-04 | 1982-10-26 | G. D. Searle & Co. | Anti-allergic or antihypertensive 1-piperidinylmethyl benzenamines |
US4666907A (en) * | 1983-10-05 | 1987-05-19 | Merck Frosst Canada, Inc. | Phenothiazine and derivatives and analogs and use as leukotriene biosynthesis inhibitors |
US4777177A (en) * | 1984-10-19 | 1988-10-11 | Ciba-Geigy Corporation | Pesticidal thioxanthen-9-ylidenepiperidines |
FR2689013B1 (en) * | 1992-03-30 | 1995-05-05 | Rhone Poulenc Rorer Sa | New therapeutic application of phenothiazine derivatives. |
ZA978792B (en) * | 1996-10-04 | 1998-04-06 | Novo Nordisk As | N-substituted azaheterocyclic compounds. |
TW548271B (en) | 1996-12-20 | 2003-08-21 | Astra Pharma Inc | Novel piperidine derivatives having an exocyclic double bond with analgesic effects |
SE9604786D0 (en) * | 1996-12-20 | 1996-12-20 | Astra Pharma Inc | New compounds |
US6040318A (en) * | 1997-06-25 | 2000-03-21 | Novo Nordisk A/S | Tricycle substituted with azaheterocyclic carboxylic acids |
WO1999000376A1 (en) | 1997-06-25 | 1999-01-07 | Novo Nordisk A/S | Novel heterocyclic compounds |
AU2009799A (en) | 1997-12-24 | 1999-07-19 | Ortho-Mcneil Pharmaceutical, Inc. | 4-(aryl(piperidin-4-yl)) aminobenzamides which bind to the delta-opioid receptor |
US6306876B1 (en) * | 1999-12-22 | 2001-10-23 | Ortho-Mcneil Pharmaceutical, Inc. | 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivatives |
EP1263758A2 (en) | 2000-03-03 | 2002-12-11 | Ortho-McNeil Pharmaceutical, Inc. | 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
WO2001072303A1 (en) * | 2000-03-29 | 2001-10-04 | Research Triangle Institute | Selective ligands for the delta opioid receptor |
WO2002036573A2 (en) | 2000-10-31 | 2002-05-10 | Rensselaer Polytechnic Institute | 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents |
WO2002048122A2 (en) | 2000-12-14 | 2002-06-20 | Ortho-Mcneil Pharmaceutical, Inc. | Benzamidine derivatives |
JP4566459B2 (en) * | 2001-06-07 | 2010-10-20 | 株式会社日立製作所 | Display device |
US6601009B2 (en) * | 2001-07-12 | 2003-07-29 | Yahoo Inc | Method and system of automatic bandwidth detection |
EP1306376A1 (en) | 2001-10-25 | 2003-05-02 | Biofrontera Pharmaceuticals AG | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist |
US7060711B2 (en) * | 2001-10-25 | 2006-06-13 | Biofrontera Bioscience Gmbh | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist |
EP1321169A1 (en) | 2001-12-18 | 2003-06-25 | Biofrontera Pharmaceuticals AG | Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament |
EP1538906A2 (en) | 2002-09-18 | 2005-06-15 | Fmc Corporation | Insecticidal tricyclic derivatives |
US20040082612A1 (en) | 2002-10-15 | 2004-04-29 | Baxter Ellen W | Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives |
MXPA05011163A (en) | 2003-04-15 | 2005-12-14 | Pfizer Prod Inc | 3-benzhydrylidene-8-aza-bicyclo[3.2.1]octane derivatives with opioid receptor activity. |
JP4810423B2 (en) * | 2003-06-27 | 2011-11-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Tricyclic delta opioid regulator |
US7372923B2 (en) * | 2003-12-19 | 2008-05-13 | Infineon Technologies Ag | Method for equalization of a payload signal, taking into account an interference source |
BRPI0513075A (en) * | 2004-08-05 | 2008-04-22 | Janssen Pharmaceutica Nv | tricyclic gamma-opioid modulators |
DE102004055057A1 (en) * | 2004-11-15 | 2006-05-24 | Infineon Technologies Ag | Protection for integrated sensor circuit output from overvoltage, reverse polarity and supply line faults, includes semiconductor switch operating in accordance with limiting potentials |
EP1833826B1 (en) | 2004-12-22 | 2009-05-27 | Janssen Pharmaceutica N.V. | Tricyclic delta-opioid modulators |
WO2006069275A1 (en) | 2004-12-22 | 2006-06-29 | Janssen Pharmaceutica N.V. | Tricyclic delta-opioid modulators |
CN101119992A (en) | 2004-12-22 | 2008-02-06 | 詹森药业有限公司 | Tricyclic delta-opioid modulators |
EP1846400A2 (en) | 2005-01-06 | 2007-10-24 | Janssen Pharmaceutica N.V. | Tricyclic delta-opioid modulators |
JP2008543866A (en) * | 2005-06-16 | 2008-12-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Tricyclic opioid modulator |
-
2005
- 2005-12-21 EP EP05855276A patent/EP1833826B1/en active Active
- 2005-12-21 CA CA002591963A patent/CA2591963A1/en not_active Abandoned
- 2005-12-21 KR KR1020077016697A patent/KR20070092293A/en not_active Application Discontinuation
- 2005-12-21 DE DE602005014671T patent/DE602005014671D1/en active Active
- 2005-12-21 JP JP2007548493A patent/JP2008525482A/en not_active Withdrawn
- 2005-12-21 MX MX2007007626A patent/MX2007007626A/en unknown
- 2005-12-21 AU AU2005319060A patent/AU2005319060A1/en not_active Abandoned
- 2005-12-21 AT AT05855276T patent/ATE432279T1/en not_active IP Right Cessation
- 2005-12-21 BR BRPI0518563-7A patent/BRPI0518563A2/en not_active IP Right Cessation
- 2005-12-21 CN CNA2005800479922A patent/CN101115751A/en active Pending
- 2005-12-21 WO PCT/US2005/046691 patent/WO2006069276A2/en active Application Filing
- 2005-12-21 US US11/313,635 patent/US7439239B2/en not_active Expired - Fee Related
- 2005-12-21 EA EA200701355A patent/EA011674B1/en not_active IP Right Cessation
-
2007
- 2007-06-19 IL IL184064A patent/IL184064A0/en unknown
- 2007-06-22 NI NI200700163A patent/NI200700163A/en unknown
- 2007-07-19 NO NO20073776A patent/NO20073776L/en not_active Application Discontinuation
- 2007-07-20 ZA ZA200706029A patent/ZA200706029B/en unknown
-
2008
- 2008-10-09 US US12/248,150 patent/US7652005B2/en not_active Expired - Fee Related
-
2009
- 2009-11-20 US US12/622,548 patent/US20100093709A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2005319060A1 (en) | 2006-06-29 |
ATE432279T1 (en) | 2009-06-15 |
KR20070092293A (en) | 2007-09-12 |
MX2007007626A (en) | 2008-01-28 |
US20090042871A1 (en) | 2009-02-12 |
EP1833826B1 (en) | 2009-05-27 |
WO2006069276A2 (en) | 2006-06-29 |
EA011674B1 (en) | 2009-04-28 |
EP1833826A2 (en) | 2007-09-19 |
DE602005014671D1 (en) | 2009-07-09 |
US20100093709A1 (en) | 2010-04-15 |
IL184064A0 (en) | 2007-10-31 |
CN101115751A (en) | 2008-01-30 |
WO2006069276A3 (en) | 2006-08-10 |
NI200700163A (en) | 2008-02-04 |
NO20073776L (en) | 2007-09-21 |
JP2008525482A (en) | 2008-07-17 |
US20060135763A1 (en) | 2006-06-22 |
BRPI0518563A2 (en) | 2008-11-25 |
US7439239B2 (en) | 2008-10-21 |
US7652005B2 (en) | 2010-01-26 |
ZA200706029B (en) | 2008-12-31 |
EA200701355A1 (en) | 2008-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1833826B1 (en) | Tricyclic delta-opioid modulators | |
US7982042B2 (en) | Thiozanthene derivatives as delta-opioid modulators | |
US20060135522A1 (en) | Tricyclic delta-opioid modulators | |
US7432257B2 (en) | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | |
US7553850B2 (en) | Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators | |
US7589104B2 (en) | Tricyclic-bridged piperidinyline derivatives as §-opioid modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |